DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
A Toxicological Profile for Tin and Tin Compounds, Draft for Public Comment was released in September 2003. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance’s toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance’s relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance’s health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

__________________________
Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and Disease Registry
*Legislative Background*

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children

Other Sections of Interest:

Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178
E-mail: atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAsQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Carolyn Harper, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Llados, Ph.D.
Gary Diamond, Ph.D.
Lara L. Chappell, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

A peer review panel was assembled for tin. The panel consisted of the following members:

1. Michael Aschner, Ph.D., Wake Forest University School of Medicine, Winston-Salem, North Carolina;
2. Olen Brown, Ph.D., University of Missouri-Columbia, Columbia, Missouri; and
3. Bruce Jarnot, Ph.D., DABT, American Petroleum Institute, Washington, DC.

These experts collectively have knowledge of tin's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
# CONTENTS

**DISCLAIMER** ................................................................. ii  
**UPDATE STATEMENT** ...................................................... iii  
**FOREWORD** ................................................................... v  
**QUICK REFERENCE FOR HEALTH CARE PROVIDERS** ........ vii  
**CONTRIBUTORS** ................................................................ ix  
**PEER REVIEW** ................................................................... xi  
**LIST OF FIGURES** ............................................................. xvii  
**LIST OF TABLES** ............................................................... xix  

1. PUBLIC HEALTH STATEMENT ............................................... 1  
1.1 WHAT ARE TIN AND TIN COMPOUNDS? ................................. 1  
1.2 WHAT HAPPENS TO TIN AND TIN COMPOUNDS WHEN THEY ENTER THE ENVIRONMENT? ............................................................. 2  
1.3 HOW MIGHT I BE EXPOSED TO TIN AND TIN COMPOUNDS? ........ 3  
1.4 HOW CAN TIN AND TIN COMPOUNDS ENTER AND LEAVE MY BODY? .......... 4  
1.5 HOW CAN TIN AND TIN COMPOUNDS AFFECT MY HEALTH? ............. 5  
1.6 HOW CAN TIN AND TIN COMPOUNDS AFFECT CHILDREN? ............... 6  
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TIN AND TIN COMPOUNDS? .......................................................... 7  
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TIN AND TIN COMPOUNDS? ................................. 8  
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? ........................................... 8  
1.10 WHERE CAN I GET MORE INFORMATION? ............................... 10  

2. RELEVANCE TO PUBLIC HEALTH ........................................... 11  
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TIN AND TIN COMPOUNDS IN THE UNITED STATES ................................. 11  
2.2 SUMMARY OF HEALTH EFFECTS ........................................ 12  
2.3 MINIMAL RISK LEVELS .......................................................... 16  

3. HEALTH EFFECTS ................................................................. 23  
3.1 INTRODUCTION ................................................................. 23  
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE ........ 23  
3.2.1 Inhalation Exposure ......................................................... 24  
3.2.1.1 Death ........................................................................ 25  
3.2.1.2 Systemic Effects ............................................................. 30  
3.2.1.3 Immunological and Lymphoreticular Effects ......................... 34  
3.2.1.4 Neurological Effects ...................................................... 34  
3.2.1.5 Reproductive Effects ...................................................... 35  
3.2.1.6 Developmental Effects ................................................... 36  
3.2.1.7 Cancer ....................................................................... 36  
3.2.2 Oral Exposure ................................................................. 36  
3.2.2.1 Death ........................................................................ 36  
3.2.2.2 Systemic Effects ............................................................. 114  
3.2.2.3 Immunological and Lymphoreticular Effects ......................... 131  
3.2.2.4 Neurological Effects ...................................................... 135
### 3.4 TOXICOKINETICS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4.1 Absorption</td>
<td>168</td>
</tr>
<tr>
<td>3.4.1.1 Inhalation Exposure</td>
<td>171</td>
</tr>
<tr>
<td>3.4.1.2 Oral Exposure</td>
<td>171</td>
</tr>
<tr>
<td>3.4.1.3 Dermal Exposure</td>
<td>173</td>
</tr>
<tr>
<td>3.4.2 Distribution</td>
<td>173</td>
</tr>
<tr>
<td>3.4.2.1 Inhalation Exposure</td>
<td>175</td>
</tr>
<tr>
<td>3.4.2.2 Oral Exposure</td>
<td>175</td>
</tr>
<tr>
<td>3.4.2.3 Dermal Exposure</td>
<td>179</td>
</tr>
<tr>
<td>3.4.2.4 Other Routes of Exposure</td>
<td>179</td>
</tr>
<tr>
<td>3.4.3 Metabolism</td>
<td>180</td>
</tr>
<tr>
<td>3.4.4 Elimination and Excretion</td>
<td>181</td>
</tr>
<tr>
<td>3.4.4.1 Inhalation Exposure</td>
<td>181</td>
</tr>
<tr>
<td>3.4.4.2 Oral Exposure</td>
<td>182</td>
</tr>
<tr>
<td>3.4.4.3 Dermal Exposure</td>
<td>183</td>
</tr>
<tr>
<td>3.4.4.4 Other Routes of Exposure</td>
<td>183</td>
</tr>
<tr>
<td>3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models</td>
<td>186</td>
</tr>
<tr>
<td>3.5 MECHANISMS OF ACTION</td>
<td>191</td>
</tr>
<tr>
<td>3.5.1 Pharmacokinetic Mechanisms</td>
<td>191</td>
</tr>
<tr>
<td>3.5.2 Mechanisms of Toxicity</td>
<td>193</td>
</tr>
<tr>
<td>3.5.3 Animal-to-Human Extrapolations</td>
<td>196</td>
</tr>
<tr>
<td>3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS</td>
<td>197</td>
</tr>
<tr>
<td>3.7 CHILDREN’S SUSCEPTIBILITY</td>
<td>202</td>
</tr>
<tr>
<td>3.8 BIOMARKERS OF EXPOSURE AND EFFECT</td>
<td>205</td>
</tr>
<tr>
<td>3.8.1 Biomarkers Used to Identify or Quantify Exposure to Tin and Tin Compounds</td>
<td>206</td>
</tr>
<tr>
<td>3.8.2 Biomarkers Used to Characterize Effects Caused by Tin and Tin Compounds</td>
<td>206</td>
</tr>
<tr>
<td>3.9 INTERACTIONS WITH OTHER CHEMICALS</td>
<td>207</td>
</tr>
<tr>
<td>3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE</td>
<td>209</td>
</tr>
<tr>
<td>3.11 METHODS FOR REDUCING TOXIC EFFECTS</td>
<td>209</td>
</tr>
<tr>
<td>3.11.1 Reducing Peak Absorption Following Exposure</td>
<td>210</td>
</tr>
<tr>
<td>3.11.2 Reducing Body Burden</td>
<td>210</td>
</tr>
<tr>
<td>3.11.3 Interfering with the Mechanism of Action for Toxic Effects</td>
<td>210</td>
</tr>
<tr>
<td>3.12 ADEQUACY OF THE DATABASE</td>
<td>211</td>
</tr>
<tr>
<td>3.12.1 Existing Information on Health Effects of Tin and Tin Compounds</td>
<td>211</td>
</tr>
<tr>
<td>3.12.2 Identification of Data Needs</td>
<td>214</td>
</tr>
<tr>
<td>3.12.3 Ongoing Studies</td>
<td>226</td>
</tr>
</tbody>
</table>
4. CHEMICAL AND PHYSICAL INFORMATION ................................................................. 227
   4.1 CHEMICAL IDENTITY ............................................................................................ 227
   4.2 PHYSICAL AND CHEMICAL PROPERTIES ............................................................... 227

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL ............................................ 243
   5.1 PRODUCTION ........................................................................................................... 243
   5.2 IMPORT/EXPORT .................................................................................................... 246
   5.3 USE ....................................................................................................................... 246
   5.4 DISPOSAL .............................................................................................................. 248

6. POTENTIAL FOR HUMAN EXPOSURE ........................................................................ 249
   6.1 OVERVIEW ............................................................................................................. 249
   6.2 RELEASES TO THE ENVIRONMENT ..................................................................... 253
      6.2.1 Air .................................................................................................................... 253
      6.2.2 Water ................................................................................................................. 254
      6.2.3 Soil ..................................................................................................................... 255
   6.3 ENVIRONMENTAL FATE .......................................................................................... 256
      6.3.1 Transport and Partitioning ................................................................................ 256
      6.3.2 Transformation and Degradation ........................................................................ 259
         6.3.2.1 Air ................................................................................................................ 259
         6.3.2.2 Water .......................................................................................................... 259
         6.3.2.3 Sediment and Soil ....................................................................................... 260
   6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT ........................... 260
      6.4.1 Air .................................................................................................................... 261
      6.4.2 Water ................................................................................................................. 261
      6.4.3 Sediment and Soil ............................................................................................ 265
      6.4.4 Other Environmental Media .......................................................................... 269
   6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ............................. 282
   6.6 EXPOSURES OF CHILDREN ................................................................................... 284
   6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .................................... 285
   6.8 ADEQUACY OF THE DATABASE .......................................................................... 286
      6.8.1 Identification of Data Needs ............................................................................. 286
      6.8.2 Ongoing Studies ............................................................................................... 289

7. ANALYTICAL METHODS .............................................................................................. 291
   7.1 BIOLOGICAL MATERIALS .................................................................................... 292
   7.2 ENVIRONMENTAL SAMPLES ................................................................................. 292
   7.3 ADEQUACY OF THE DATABASE .......................................................................... 297
      7.3.1 Identification of Data Needs ............................................................................. 298
      7.3.2 Ongoing Studies ............................................................................................... 299

8. REGULATIONS AND ADVISORIES .......................................................................... 301

9. REFERENCES .............................................................................................................. 309

10. GLOSSARY ................................................................................................................. 371
LIST OF FIGURES

3-1. Levels of Significant Exposure to Tributyltins—Inhalation............................................................... 28
3-2. Levels of Significant Exposure to Inorganic Tin—Oral................................................................. 48
3-3. Levels of Significant Exposure to Dibutyltins—Oral................................................................. 59
3-4. Levels of Significant Exposure to Dioctyltins—Oral................................................................. 66
3-5. Levels of Significant Exposure to Triphenyltins—Oral............................................................... 77
3-6. Levels of Significant Exposure to Triethyltins—Oral................................................................. 83
3-7. Levels of Significant Exposure to Trimethyltins—Oral............................................................... 90
3-8. Levels of Significant Exposure to Tributyltins—Oral................................................................. 107
3-9. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance ................................................................. 186
3-11. Existing Information on Health Effects of Inorganic Tin Compounds........................................ 210
3-12. Existing Information on Health Effects of Organotin Compounds ........................................... 211
6-1. Frequency of NPL Sites with Tin Contamination ........................................................................ 250
6-2. Frequency of NPL Sites with Organotin Contamination............................................................ 251
### LIST OF TABLES

3-1. Levels of Significant Exposure to Tributyltins—Inhalation ............................................................... 26
3-2. Levels of Significant Exposure to Inorganic Tin—Oral ................................................................. 37
3-3. Levels of Significant Exposure to Dibutyltins—Oral ..................................................................... 52
3-4. Levels of Significant Exposure to Dioctyltins—Oral ......................................................................... 62
3-5. Levels of Significant Exposure to Triphenyltins—Oral ..................................................................... 68
3-6. Levels of Significant Exposure to Triethyltins—Oral ........................................................................ 80
3-7. Levels of Significant Exposure to Trimethyltins—Oral ..................................................................... 85
3-8. Levels of Significant Exposure to Tributyltins—Dermal ................................................................. 92
3-9. Levels of Significant Exposure to Tributyltins—Dermal ................................................................. 153
3-10. Genotoxicity of Inorganic Tin Compounds In Vitro ........................................................................... 162
3-11. Genotoxicity of Organotin Compounds In Vitro ............................................................................... 163
3-12. Genotoxicity of Organotin Compounds In Vivo ............................................................................... 168
3-13. Mean Tin Levels in Human Tissues ............................................................................................... 172
4-1. Chemical Identity of Tin and Tin Compounds .................................................................................. 228
4-2. Physical and Chemical Properties of Tin and Tin Compounds ........................................................ 237
5-1. Current U.S. Manufacturers of Selected Tin Compounds ................................................................ 244
6-1. Conversion Between Mass on a Tin Basis to Mass on an Organotin Cation Basis ......................... 262
6-2. Organotin Levels in Sediment ........................................................................................................ 267
6-3. Tin Levels in Food ............................................................................................................................ 270
6-4. Tributyltin (TBT) Levels in Food ..................................................................................................... 272
6-5. Tin and Organotin Levels in Human Tissues and Fluids ................................................................. 277
6-6. Ongoing Studies on Organotin Compounds ..................................................................................... 290
7-1. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Biological Materials .......................................................... 293
7-2. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Environmental Samples .......................................................... 295

8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds ........................................ 302
1. PUBLIC HEALTH STATEMENT

This public health statement tells you about tin and tin compounds and the effects of exposure to them.

The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term federal clean-up activities. Tin and organotin compounds have been found in at least 214 and 8, respectively, of the 1,662 current or former NPL sites. Although the total number of NPL sites evaluated for these substances is not known, the possibility exists that the number of sites at which tin and organotin compounds are found may increase in the future as more sites are evaluated. This information is important because these sites may be sources of exposure and exposure to these substances may harm you.

When a substance is released either from a large area, such as an industrial plant, or from a container, such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, eating, or drinking the substance, or by skin contact.

If you are exposed to tin and tin compounds, many factors will determine whether you will be harmed. These factors include the dose (how much), the duration (how long), and how you come in contact with them. You must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.

1.1 WHAT ARE TIN AND TIN COMPOUNDS?

Tin is a soft, white, silvery metal that is insoluble in water. Tin metal is used to line cans for food, beverages, and aerosols. It is present in brass, bronze, pewter, and some soldering materials.
Tin is a metal that can combine with other chemicals to form various compounds. When tin is combined with chlorine, sulfur, or oxygen, it is called an inorganic tin compound. Inorganic tin compounds are found in small amounts in the earth's crust. They are also present in toothpaste, perfumes, soaps, coloring agents, food additives, and dyes.

Tin also can combine with carbon to form organotin compounds. These compounds are used in making plastics, food packages, plastic pipes, pesticides, paints, wood preservatives, and rodent (rats and mice) repellants.

There can be tin metal as well as inorganic and organic tin compounds in the air, water, and soil near places where they are naturally present in the rocks, mined, manufactured, or used. In general, organic tin compounds are from human-made sources and do not occur naturally in the environment. The time each tin compound stays in air, water, or soil differs from compound to compound.

Further information on the properties and uses of tin and its compounds and how they behave in the environment is found in Chapters 4, 5, and 6.

1.2 WHAT HAPPENS TO TIN AND TIN COMPOUNDS WHEN THEY ENTER THE ENVIRONMENT?

Tin is a component of many soils. Tin may be released in dusts from wind storms, roads, and farming activities. Gases, dusts, and fumes containing tin may be released from smelting and refining processes, burning of waste, and burning of fossil fuels (coal or oil). Particles in the air containing tin may be transported by wind or washed out of the air by rain or snow. Tin binds to soils and to sediments in water and is generally regarded as being relatively immobile in the environment. Tin cannot be destroyed in the environment. It can only change its form or become attached or separated from particles in soil, sediment, and water.

Organic tin compounds stick to soil, sediment, and particles in water. Organic tin compounds can be degraded (by exposure to sunlight and by bacteria) into inorganic tin compounds. In
water, organic tin compounds are mostly attached to particles in water. Organic tin compounds may also settle out of the water into sediments and may remain unchanged for years. Organic tin compounds may be taken up into the tissues of animals that live in water containing these compounds.

1.3 HOW MIGHT I BE EXPOSED TO TIN AND TIN COMPOUNDS?

Tin is present in the air, water, soil, and landfills and is a normal part of many plants and animals that live on land and in water. Tin is also present in the tissues of your body. There is no evidence that tin is an essential element for humans.

Since tin is naturally found in soils, it will be found in small amounts in foods. Tin concentrations of vegetables, fruits and fruit juices, nuts, dairy products, meat, fish, poultry, eggs, beverages, and other foods not packaged in metal cans are generally less than 2 parts per million (ppm) (1 ppm = 1 part of tin in a million parts of food by weight). Tin concentrations in pastas and breads have been reported to range from less than 0.003 to 0.03 ppm. You can be exposed to tin when you eat food or drink juice or other liquids from tin-lined cans. Canned food from lacquered tin-lined cans contains less than 25 ppm of tin since the lacquer prevents the food from reacting with the tin. Food from unlacquered tin-lined cans contains up to 100 ppm of tin since the reaction of the food with the can causes some of the tin to dissolve in the contents of the can. Greater than 90% of tin-lined cans used for food today are lacquered. Only light colored fruit and fruit juices are packed in unlacquered tin-lined cans, since tin helps maintain the color of the fruit. Tin concentrations in food also increase if food is stored in opened cans. Stannous fluoride, a tin-containing compound, is added to toothpaste.

You can also be exposed to higher-than-normal levels of tin if you work in a factory that makes or uses tin. Because tin compounds have many uses, you can be exposed by breathing in tin dusts or fumes or getting tin compounds on your skin. Tin compounds can also be spilled accidentally. If you live near a hazardous waste site, you could be exposed by breathing dusts, touching materials, or drinking water contaminated with tin.
1. PUBLIC HEALTH STATEMENT

Humans are usually exposed to tin at far less than 1 ppm from air and water. The amounts in air and water near hazardous waste sites could be higher.

Young children sometimes eat soil during play. While most soil contains about 1 ppm tin, some soils may contain as much as 200 ppm tin. Assuming that children eat 200 mg of soil per day, exposure to tin from eating soil would be low.

You may be exposed to organic tin compounds (mainly butyltin compounds) by eating seafood from coastal waters or from contact with household products that contain organotin compounds, (polyurethane, plastic polymers, and silicon-coated baking parchment paper). Organic tin compounds have been detected in drinking water in Canada where pipes made of polyvinyl chloride (PVC), which contain organic tin compounds, are used in the distribution of drinking water.

Additional information on how you can be exposed to tin compounds is given in Chapter 6.

1.4 HOW CAN TIN AND TIN COMPOUNDS ENTER AND LEAVE MY BODY?

Tin can enter your body when you eat contaminated food or drink contaminated water, when you touch or eat soil that has tin in it, or when you breathe tin-containing fumes or dusts. Tin compounds can enter your body from nearby hazardous waste sites by exposure to contaminated air, water, and soil. When you eat tin in your food, very little leaves the gastrointestinal tract and gets into your bloodstream. Most tin travels through the intestines and leaves your body in the feces. Some leaves your body in the urine. If you breathe air containing tin dust or fumes, some of the tin could be trapped in your lungs, but this does not affect your breathing if it is a small amount. If you swallow some metallic tin particles, they will leave your body in the feces. Very little tin can enter the body through unbroken skin. Your body can rid itself of most inorganic tin in weeks, but some can stay in your body for 2–3 months. Inorganic tin compounds leave your body very quickly; most are gone within a day. Very small amounts of tin stay in some tissues of your body, like the bones, for longer periods of time.
Further information on how tin enters and leaves your body is given in Chapter 3.

1.5 HOW CAN TIN AND TIN COMPOUNDS AFFECT MY HEALTH?

Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find ways for treating persons who have been harmed.

One way to learn whether a chemical will harm people is to determine how the body absorbs, uses, and releases the chemical. For some chemicals, animal testing may be necessary. Animal testing may also help identify health effects such as cancer or birth defects. Without laboratory animals, scientists would lose a basic method for getting information needed to make wise decisions that protect public health. Scientists have the responsibility to treat research animals with care and compassion. Scientists must comply with strict animal care guidelines because laws today protect the welfare of research animals.

Because inorganic tin compounds usually enter and leave your body rapidly after you breathe or eat them, they do not usually cause harmful effects. However, humans who swallowed large amounts of inorganic tin in research studies suffered stomachaches, anemia, and liver and kidney problems. Studies with inorganic tin in animals have shown similar effects to those observed in humans. There is no evidence that inorganic tin compounds affect reproductive functions, produce birth defects, or cause genetic changes. Inorganic tin compounds are not known to cause cancer.

Inhalation (breathing in), oral (eating or drinking), or dermal exposure (skin contact) to some organotin compounds has been shown to cause harmful effects in humans, but the main effect will depend on the particular organotin compound. There have been reports of skin and eye irritation, respiratory irritation, gastrointestinal effects, and neurological problems in humans exposed for a short period of time to high amounts of certain organotin compounds. Some neurological problems have persisted for years after the poisoning occurred. Lethal cases have been reported following ingestion of very high amounts. Studies in animals have shown that certain organotins mainly affect the immune system, but a different type primarily affects the
nervous system. Yet, there are some organotins that exhibit very low toxicity. Exposure of pregnant rats and mice to some organotin compounds has reduced fertility and caused stillbirth, but scientists still are not sure whether this occurs only with doses that are also toxic to the mother. Some animal studies also suggested that reproductive organs of males may be affected. There are no studies of cancer in humans exposed to organotin compounds. Studies of a few organotins in animals suggest that some organotin compounds can produce cancer. On the basis of no data in humans and questionable data from a study in rats, EPA has determined that one specific organotin, tributyltin oxide, is not classifiable as to human carcinogenicity; that is, it is not known whether or not it causes cancer in humans.

More information on the health effects of tin in humans and animals is found in Chapter 3.

1.6 HOW CAN TIN AND TIN COMPOUNDS AFFECT CHILDREN?

This section discusses potential health effects in humans from exposures during the period from conception to maturity at 18 years of age.

Children can be exposed to tin compounds (inorganic or organic) in the same manner as adults: through the diet or by contact with contaminated soil at or near hazardous waste sites where these compounds are found. Some children eat significant amounts of dirt (a behavior called pica), which may lead to increased exposure if the soil is contaminated. In addition, children can be exposed if family members work with tin compounds and bring home tin residues in their clothing or tools.

There are no studies on health effects in children exposed to tin compounds. However, it is reasonable to assume that children would exhibit the same type of health effects observed in exposed adults. We do not know whether children are more susceptible to the effects of exposure to tin and tin compounds than adults. There are no reports of adverse developmental effects in humans exposed to tin or its compounds, or of inorganic tin in animals. Studies in animals have shown that organotin compounds can cross the placenta and reach the fetus. Exposure of rodents to some organotins during pregnancy has produced birth defects in the
newborn animals. The results of several studies suggest that this may occur only at high exposure levels that cause maternal toxicity, but further research is needed to clarify this issue. One study found that rats whose mothers were exposed to tributyltin during pregnancy showed altered performance in some neurological tests conducted when they were young adults. Another study, also with tributyltin, found that exposure during gestation, lactation, and post-lactation affected some developmental landmarks in female rats. There are no reports of tin or tin compounds in human breast milk, and there is no direct evidence in animals of transfer of these compounds to the young through nursing.

More information regarding children’s health and tin and related compounds can be found in Section 3.7.

1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TIN AND TIN COMPOUNDS?

If your doctor finds that you have been exposed to substantial amounts of tin and tin compounds, ask whether your children might also have been exposed. Your doctor might need to ask your state health department to investigate.

Children living near waste sites containing tin and tin compounds are likely to be exposed to higher than normal environmental levels of tin through breathing, touching soil, and eating contaminated soil. You should discourage your children from eating dirt. Make sure they wash their hands frequently and before eating. Discourage your children from putting their hands in their mouths. Some toothpastes and other dental products contain stannous fluoride, a tin containing compound. Children should be watched carefully when using these products and should not swallow these products.

Because tin is naturally found in the environment at low levels, we cannot avoid being exposed to it. The major route of exposure to tin is from eating or drinking canned products. Reducing the amount of canned products you eat or drink may reduce your exposure to tin. Since tin concentrations in food increase if food is stored in opened cans, you can reduce your exposure by
storing unused portions of canned foods in a separate container. You may be exposed to organic tin compounds by eating seafood from areas that may be contaminated with organic tin compounds or from contact with household products that contain organotin compounds (polyurethane, plastic polymers, and silicon-coated baking parchment paper). Reducing the amount of seafood that you eat from areas that may be contaminated with organic tin compounds and reducing contact with household products that contain organic tin compounds may reduce your exposure to organic tin compounds. If you are accidentally exposed to large amounts of tin or tin compounds, consult a physician immediately.

1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TIN AND TIN COMPOUNDS?

There are tests to measure tin and organotin compounds in your blood, urine, feces, and body tissues. Normally, small amounts of tin are found in the body because of the daily exposure to small amounts in the food. Therefore, the available tests cannot tell you when you were exposed or the exact amount of tin to which you were exposed, but can help determine if you were exposed to an amount of tin or tin compounds unusually high in the near past. This information can be used to locate the source of exposure.

Tests for tin and related compounds are not routinely performed at a doctor’s office because they require special equipment, but the doctor can take samples and send them to a testing laboratory.

Further information on how tin can be measured in exposed humans is presented in Chapter 7.

1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?

The federal government develops regulations and recommendations to protect public health. Regulations can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic substances. Recommendations provide valuable
guidelines to protect public health, but cannot be enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop recommendations for toxic substances.

Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes these not-to-exceed levels differ among federal organizations because they used different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other factors.

Recommendations and regulations are also updated periodically as more information becomes available. For the most current information, check with the federal agency or organization that provides it. Some regulations and recommendations for tin and tin compounds include the following:

Several government agencies and the Congress have acted to protect human health by regulating tin compounds. The EPA has limited the use of certain organotin compounds in paints. OSHA has established workplace exposure limits of 0.1 milligrams per cubic meter of air (mg/m³) for organotin compounds and 2 mg/m³ for inorganic tin compounds, except oxides. NIOSH recommends workplace exposure limits of 2 mg/m³ for inorganic tin compounds, except for tin oxides, and 0.1 mg/m³ for organotins, except tricyclohexyltin hydroxide. NIOSH states that a concentration of tricyclohexyltin hydroxide of 25 mg/m³ should be considered as immediately dangerous to life or health. The FDA regulates the use of some organic tin compounds in coatings and plastic food packaging. The FDA also has set limits for the use of tin, as stannous chloride, as an additive for food.

Additional information on governmental regulations and guidelines regarding tin and compounds is found in Chapter 8 and Table 8-1.
WHERE CAN I GET MORE INFORMATION?

If you have any more questions or concerns, please contact your community or state health or environmental quality department, or contact ATSDR at the address and phone number below.

ATSDR can also tell you the location of occupational and environmental health clinics. These clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous substances.

Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by e-mail at atsdric@cdc.gov, or by writing to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road NE
Mailstop F-32
Atlanta, GA 30333
Fax: 1-770-488-4178

Organizations for-profit may request copies of final Toxicological Profiles from the following:

National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
Web site: http://www.ntis.gov/
2. RELEVANCE TO PUBLIC HEALTH

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TIN AND TIN COMPOUNDS IN THE UNITED STATES

Tin is a naturally occurring element. It is a silver-white, malleable, and somewhat ductile metal. The earth's crust contains about 2–3 ppm tin, comprising 0.0006% of the earth's crust. Major uses of tin include cans and containers, electrical, construction, and transportation. Industrially important tin compounds can be categorized as inorganic (those without a tin-carbon bond) and organic (those having a tin-carbon bond). Inorganic tin compounds are used in the glass industry, and also serve as the base for the formulation of colors, as catalysts, and in perfumes and soaps. The major commercial applications for organotin compounds are as polyvinyl chloride (PVC) heat stabilizers, biocides, catalysts, agrochemicals, and glass coatings.

Tin may be released to the environment from natural and anthropogenic sources. Tin is a component of many soils and tin and inorganic tin compounds may be released by weathering and agricultural activities. Releases of tin to the environment may also occur from the production and use of tin and tin compounds. Tin is generally regarded as being relatively immobile in the environment. In general, organotin compounds are released to the environment through their production and use. Tributyltin and triphenyltin enter the environment directly from their use as antifouling paints and as pesticides. To a lesser extent, organotin compounds may also enter the environment by leaching from consumer products and from the disposal of products containing organotin compounds in landfills. Organotin compounds are generally found to partition to soils and sediments.

Occupational exposure to tin may be significant in some industrial environments. Ambient environmental levels of tin are generally quite low, except in the vicinity of pollution sources. Human exposure to tin may occur by inhalation, ingestion, or dermal absorption. Dermal absorption is a significant route of occupational exposure for certain organotin compounds. The average daily tin intake of an adult in the United States was estimated at 4.003 mg (4 mg from food and 0.003 mg from air), and with undetectable levels contributed by drinking water. The most important source for exposure to tin is from food, especially canned food products. Tin-lined cans used to package food are the most important contributor to dietary tin intake. There was a significant correlation between the amount of canned food consumed and the concentration of tin in the diet. People eating a high percentage of their diet from
canned foods will be exposed to higher amounts of tin than people eating more fresh foods. Tin concentrations in foods will depend on whether they are packaged in lacquer tin-lined cans or unlacquered cans. Mean tin concentrations ranging from <1 to 1,000 mg/kg have been found in foods packaged in unlacquered or partially lacquered cans, while the average tin concentration in foods in lacquered cans has been reported to be 0–6.9 mg/kg. More than 90% of tin-lined cans used for food today are lacquered. Only light colored fruit and fruit juices are packed in unlacquered cans, since tin helps maintain the color of the product.

Data on human exposure to organotin compounds are more limited. Potential exposure for the general population to organotin compounds would be expected to exist for butyltin compounds, phenyltin compounds, and di- and monomethyltin, according to available monitoring data. In a market basket study in Japan, daily intakes of tributyltin and triphenyltin in Japan were estimated to be 6.9 and 5.4 μg, respectively, in 1991 and 6.7 and 1.3 μg, respectively, in 1992, with 95% of the daily intakes of tributyltin and triphenyltin coming from the fish, mollusks, and crustaceans food group. Mono- and dimethyltin and mono- and dibutyltin compounds have been detected in drinking water in Canada where PVC pipes, containing these organotin compounds, are used in the distribution of drinking water. It has been demonstrated that butyltin compounds in siliconized baking parchment can be transferred to food baked on this type of baking parchment. Organotin compounds were found in household dust in a United Kingdom study. Monitoring data were not found to indicate whether the general population is exposed to other organotin compounds, such as trimethyltin and triethyltin.

2.2 SUMMARY OF HEALTH EFFECTS

Most of the information on the health effects of inorganic and organic tin in humans comes from studies of individuals exposed at work, volunteers exposed to controlled amounts, and accidental or intentional exposures. Except for the studies in volunteers, exposure characterization in the reports on humans is generally lacking. Numerous studies have been conducted on the effects of tin and related compounds in a variety of animal species (primarily rodents) mostly following ingestion by the oral route.

Humans chronically exposed to inorganic tin (e.g., stannic oxide dust or fumes) manifest a benign form of pneumoconiosis known as stannosis, which involves mainly the lower respiratory system. Gastrointestinal effects, such as nausea, vomiting, and diarrhea have been reported in subjects ingesting food items contaminated with inorganic tin. Based on the available studies in humans, there is no
2. RELEVANCE TO PUBLIC HEALTH

evidence that inorganic tin affects reproduction or development in humans or that it is a neurotoxin, immunotoxin, mutagenic, or carcinogenic agent in humans. A relatively limited number of studies in animals have not clearly established potential target organs for inorganic tin toxicity. Of the effects described, hematological signs of anemia and gastrointestinal distension appear to be best identified as tin-related. No adverse reproductive or developmental effects of inorganic tin were reported in a small number of studies available. Tin affects the metabolism of other metals such as copper, zinc, and iron; therefore, if the pharmacokinetics of these metals is altered, it is difficult to ascertain whether a specific effect is caused by exposure to tin itself or is due to fluctuations in tissue levels of other metals. Bioassays for carcinogenicity of inorganic tin have been negative.

Cases of lethality have been reported after acute inhalation exposure to a mixture of vapors of trimethyltin and dimethyltin organotins and after acute oral ingestion of trimethyltin. In addition, approximately 100 deaths occurred in France in 1954 following ingestion of a proprietary drug that seemed to have been contaminated with ethyltin triiodide, triethyltin iodide, or tetraethyltin. Deaths occurred after exposure to an estimate dose of 3 g triethyltin iodide over a period of 6–8 weeks. Those affected showed neurological signs and symptoms such as headache, photophobia, altered consciousness, and convulsions. These appeared about 4 days after intoxication and, in individuals who recovered, continuous headaches and weakness persisted for at least 4 years. Additional cases of accidental or intentional acute inhalation, oral, or dermal intoxication with trimethyltin or triphenyltin also have included adverse neurological effects that persisted for a long time (years in some cases) after the poisoning episode. Organotins also are known to be skin and eye irritants in humans.

There are no studies that evaluated whether organotin compounds cause developmental or reproductive alterations in humans or cancer. Limited inhalation data from intermediate-duration studies in animals indicate that organotins can produce lung alterations, irritation of the respiratory airways, skin, and eyes, and liver and kidney effects. In contrast to the limited inhalation database, an extensive oral database indicates that trimethyltin and triethyltin compounds are primarily neurotoxic, whereas tributyltin, dibutyltin, and dioctyltin are essentially immunotoxic. Hepatic and hematological effects also have been described in animals treated orally with organotins. Triphenyltin, dibutyltin, and tributyltin, when administered during pregnancy, have induced developmental and reproductive effects in rodents. However, it remains unclear whether these effects occur only at doses that induce maternal toxicity. Studies of genotoxic activity of organotin compounds have given mixed results depending on the specific compound and test system. Dibutyltin acetate, triphenyltin hydroxide, and tributyltin oxide have been tested for carcinogenicity in long-term bioassays. The first two compounds produced no evidence of
carcinogenicity in Fischer-344 rats and B6C3F₁ mice, whereas the results for tributyltin oxide in Wistar rats were considered questionable by the EPA and led to a carcinogenic classification of “not classifiable as to human carcinogenicity” or, to a group of substances for which there is “inadequate information to assess carcinogenic potential,” according to updated guidelines. Additional studies with higher doses of triphenyltin hydroxide in Wistar rats and NMRI mice showed increased incidence of pituitary cancer in female rats and of liver cancer in female mice.

A greater detailed discussion of immunological, neurological, reproductive/developmental, and hematological effects of tin and compounds follows. The reader is referred to Section 3.2, Discussion of Health Effects by Route of Exposure, for additional information on other health effects.

**Immunological and Lymphoreticular Effects.** There are no studies that evaluated whether environmental concentrations of tin or organotin compounds alter immunocompetence in humans. However, acute exposure of rats to higher concentrations (generally ≥2 mg/kg/day) of tributyltins and other organotins have caused immune alterations. The effect is characterized by reduced thymus weight and size and lymphocyte depletion. Dialkyltins appear to directly interfere with proliferation of thymocytes, a cytostatic effect, whereas tributyltin oxide has a direct and selective toxic action on lymphocytes in the thymus. Long-term studies with tributyltin oxide in rats have demonstrated alterations in parameters of specific and nonspecific resistance at the relatively low dose level of 0.25 mg/kg/day. Although no adverse immunological effects have been described in humans exposed to tin and compounds, the high sensitivity exhibited by the rat thymus and the impairment in resistance to infection suggest that similar responses might occur in humans exposed to these chemicals at high concentrations or for long periods of time.

**Neurological Effects.** While adverse neurological effects have been described in animals following oral exposure to various organotin compounds, triethyltins and trimethyltins are by far the most potent neurotoxins of the organotins and have been the most extensively studied in experimental animals. The results from animal studies have confirmed the findings reported in cases of accidental or intentional exposure to trimethyltin and triethyltin in humans. Triethyltin produces brain and spinal cord swelling, which is characterized by accumulation of fluid between myelin layers, splitting of the myelin sheets, and formation of intramyelin vacuoles. This was observed in fatal cases that occurred from a massive accidental intoxication episode in France in 1954 and similar results have been reproduced in animal studies exposed to doses ≥1 mg/kg/day. Individuals affected in the French case showed neurological signs and symptoms such as headache, photophobia, altered consciousness, and convulsions. These
appeared about 4 days after intoxication and, in individuals who recovered, recurrent headaches and weakness persisted for at least 4 years. Studies in animals have confirmed the reversibility of some of the neurological effects. Trimethyltin produces neuronal necrosis, particularly in the hippocampus and other structures in the limbic system, and this has been demonstrated in humans and in animals. Studies in animals have described neuronal necrosis in the neocortex, pyriform cortex, hippocampal formation, basal ganglia, brain stem, spinal cord, and dorsal root ganglia after single doses of \( \geq 1 \) mg/kg. The morphological changes that occur in the brain translate into behavioral alterations, such as aggression (both in humans and in animals), memory loss, and unresponsiveness. Some neurological symptoms can last for years. No population group has been identified that has undergone long-term exposure to low levels of trimethyltin or triethyltin, and no monitoring data are available to evaluate current exposures of the general population, but it is unlikely that adverse neurological effects would occur in humans exposed to environmental levels of organotins.

Reproductive/Developmental Effects. There are no data regarding reproductive/developmental effects of inorganic or organic tin compounds in humans. Two early studies found no adverse reproductive/developmental effects of inorganic tin in rodents. Much of the information available regarding reproductive/developmental effects of organotins in animals comes from studies conducted in the 1990s. Numerous studies have been conducted with tributyltin, triphenyltin, and dibutyltin which have been shown to cause pregnancy failure, preimplantation loss, postimplantation loss, resorptions, and fetal death. The highest incidence of resorptions and postimplantation losses occurred when the chemicals were administered on gestation days 7–9. Doses that induced these effects were generally \( > 3 \) mg/kg/day. Implantation loss has been attributed to a suppression of uterine decidualization caused by decreased levels of serum progesterone. Organotins have also proved to be embryotoxic and teratogenic, including in studies in vitro using cultured rat embryos. The most commonly seen malformation was cleft palate and other facial malformations. For dibutyltin dichloride, the highest incidence of malformations occurred when dosing on gestation day 8. A key issue in evaluating reproductive/developmental effects has been to ascertain whether the effects occur secondary to maternal toxicity or occur in the absence of maternal toxicity (generally assessed by clinical observations and alterations in body weight gain). Thus far, a conclusive answer has not been provided. Male rats exposed to 10 mg tributylin/kg/day for 10 days had histologic alterations in the seminal vesicles and epididymis and reduced sperm counts, but except for these findings, reproductive effects of organotins in males have not been well studied. Two multigeneration studies in rats with tributyltin chloride showed slight alterations in developmental landmarks in male and female animals suggesting a possible endocrine modulatory role for this compound in laboratory rats. Results from studies in vitro show that some organotins can alter the
activities of enzymes involved in the synthesis of sex hormones in mammals, which can alter the androgens/estrogens balance and affect sexual maturation. However, further studies are necessary to establish the relevancy of these findings to human exposures.

Hematological Effects. No data were located regarding hematological effects of inorganic tin or organotins in humans. Tin affects the metabolism of a number of essential minerals such as iron, copper, zinc, calcium, and selenium by mechanisms that are not totally clear, but which could involve altered absorption and/or retention. Studies in animals have shown that excess dietary tin reduces serum iron and copper levels. Thus, as expected, feeding a diet with excess tin to rats produced signs of anemia, which was reversed by enriching the diet with iron and/or copper. It is reasonable to assume that individuals with low levels of iron or copper may be at risk of developing signs of anemia if at the same time they consume excessive amounts of tin.

Organotin compounds have produced hematological effects in laboratory animals. In a 13-week study with dibutyltin dichloride in rats, the most sensitive end point was hemoglobin concentration which was depressed at a dose of 5.7 mg/kg/day, but not at 3.4 mg/kg/day. Long-term studies with tributyltin oxide in rats also have produced decreased hemoglobin concentrations. Since there was an indication of increased young erythrocytes and decreased serum iron concentrations, it was suggested that exposure to tributyltin oxide disrupts hemoglobin synthesis by interfering with iron uptake or by promoting iron loss. Exposure of rats to dioctyltin dichloride also reduced hemoglobin concentration in rats in a 6-week dietary study. Whether signs of anemia occur in humans exposed to environmental levels of organotin compounds is not known and, although plausible, this seems unlikely due to their relatively low environmental levels.

2.3 MINIMAL RISK LEVELS

Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for tin and tin compounds. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of adverse effects (noncancerogenic) over a specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for
2. RELEVANCE TO PUBLIC HEALTH

acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure.

Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an example, acute inhalation MRLs may not be protective for health effects that are delayed in development or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to assess levels of significant human exposure improve, these MRLs will be revised.

Inhalation MRLs

No inhalation MRLs were derived for inorganic tin or organic tin compounds since adequate experimental data were not available by this route of exposure.

Oral MRLs

Inorganic Tin. Acute oral data for inorganic tin were limited to an early reproductive/developmental study in rodents exposed during gestation (FDA 1972) and a study in which rats and mice were given either a single dose of stannous chloride or were treated for 14 days (NTP 1982). The NTP studies were pilot studies of limited scope designed primarily to establish dose levels to be tested in longer-term studies. Although the FDA (1972) study provided adequate information on embryotoxicity and teratogenicity of tin chloride, it is unknown whether sensitive end points for inorganic tin, such as hematological parameters, were affected in the dams because no evaluations were conducted. The intermediate-duration database is based on a limited number of studies, but a 13-week study in rats provided sufficient information for derivation of an intermediate oral MRL for tin (De Groot et al. 1973). No chronic-duration MRL was derived for inorganic tin because the lowest dose tested, 0.7 mg Sn/kg/day as stannous chloride, reduced survival in rats in a 42-month drinking water study (Schroeder et al. 1968).

- An MRL of 0.3 mg/kg/day has been derived for intermediate-duration oral exposure (15–364 days) to inorganic tin.

The intermediate-duration MRL was based on a NOAEL of 32 mg Sn/kg/day (as stannous chloride) for hematological effects in Wistar rats fed the test material in the diet for 13 weeks (De Groot et al. 1973).
The diet provided doses of approximately 0, 9.5, 32, 95, and 315 mg/kg/day. End points monitored included survival, body weight, food intake, hematology (hemoglobin, hematocrit, total erythrocytes, total and differential leukocytes), serum chemistry (transaminases, alkaline phosphatase, bilirubin), urinalysis, organ weights (nine organs), and gross and microscopic pathology. Tin in the standard diet was not determined, but the concentrations of calcium, phosphorus, iron, copper, and zinc were known. The highest dietary level tested caused reduced food consumption and abdominal distension on week 1. At week 8, loss of body weight occurred in males and females and one male died. At week 9, another three males died and the group was discontinued. Rats in the 95 mg/kg/day group showed poor appetite and abdominal distension the first 2 weeks; this was associated with decreased food consumption, but they continued growing. At termination, no significant differences in body weight were seen. Food consumption was also low in the 32 mg/kg/day group but only for week 1. Hemoglobin concentration was significantly reduced starting at week 4 in the 95 and 315 mg/kg/day groups (about 12 and 20%, respectively), and at week 4 in the 32 mg/kg/day males (3% reduction). Terminal hemoglobin and hematocrit were significantly reduced only in high-dose treated males (6 and 4%, respectively). Tin had no noticeable effect on osmotic resistance of the erythrocytes or on the number of reticulocytes. Serum alkaline phosphatase was significantly decreased at termination in both sexes, but there was no significant effect on transaminases or in bilirubin concentration. Terminal urine samples were unremarkable, as were relative organ weights. Rats from the high-dose group (315 mg/kg/day) that had to be terminated early showed distended intestines, slight edema of the pancreas, and grayish-brown livers. The high-dose rats had moderate testicular degeneration, severe pancreatic atrophy, spongy white matter in the brain, acute bronchopneumonia, enteritis, and liver changes characterized by homogeneous appearance of the liver cell cytoplasm and mild proliferation of the bile duct epithelium. In the 95 mg/kg/day group, treatment-related effects included bile duct epithelium proliferation and homogeneous cytoplasm at termination. Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability) to the NOAEL of 32 mg/kg/day yields an intermediate-duration MRL of 0.3 mg/kg/day for inorganic tin. The 95 mg/kg/day dose level is considered a minimal LOAEL based on the unknown biological significance of a 12% reduction in hemoglobin concentration.

Derivation of oral MRLs was considered for the following organotin compounds: tributyltin, triethyltin, trimethyltin, triphenyltin, dibutyltin, and dioctyltin. These are the organotins that have been subject to the most studies. Of these, relevant and adequate information was found only for tributyltin, for which an intermediate-duration MRL and a chronic-duration MRL were derived, and for dibutyltin, for which an intermediate-duration oral MRL was derived.
Dibutyltin. One of the lowest-observed-adverse-effect levels (LOAELs) for acute oral exposure to dibutyltin was 3.8 mg/kg/day for a reproductive effect in rats, a significant increase in postimplantation loss per litter, a serious LOAEL (Ema and Harazono 2000). The highest NOAEL below that LOAEL was 2.5 mg/kg/day for developmental effects in rats (Ema et al. 1991b), which is very near the serious LOAEL. The chronic-duration database was limited to the NCI (1978a) study in which a relatively low dose, 6.7 mg/kg/day caused significant early mortality in rats. An intermediate-duration oral MRL was derived for dibutyltin dichloride.

- An MRL of 0.005 mg/kg/day has been derived for intermediate-duration oral exposure (15–364 days) to dibutyltin dichloride.

The intermediate-duration oral MRL of 0.005 mg/kg/day for dibutyltin dichloride is based on a LOAEL of 5 mg/kg/day for immunological effects in rats (Seinen et al. 1977b). Groups of male weanling Wistar rats were fed diets containing 0, 50, or 150 ppm of the test material (>98% pure) for 4–6 weeks. Based on a body weight of 0.2 kg, it can be estimated that these levels provided doses of dibutyltin dichloride of approximately 0, 5, and 15 mg/kg/day (EPA 1988e). End points examined included body weight and parameters of humoral and cellular immune responses. The humoral immune response was assessed by measuring antibody formation against SRBC and *E. coli* lipopolysaccharide. The cellular immune response was assessed by examining allograft rejection. Final body weight after 4 weeks of exposure was not significantly altered relative to controls, but it was 28% lower than controls in the high-dose group after 6 weeks of exposure. Allograft rejection time was significantly delayed in the high-dose group relative to controls. In the tests for humoral response, the number of antibody-producing cells per million spleen cells was not affected, but the number per whole spleen was significantly decreased in a dose-related manner. This response was associated with a decreased hemagglutination titer in the high-dose group. The antibody titers against *E. coli* lipopolysaccharide were slightly but not significantly lower in treated groups than in controls. The dose of 5 mg/kg/day is the study LOAEL based on the reduction in hemagglutinating antibodies against SRBC. Applying an uncertainty factor of 1,000 (10 for animal to human extrapolation, 10 for use of a LOAEL, and 10 for species variability) to the LOAEL of 5 mg/kg/day yields an intermediate-duration oral MRL of 0.005 mg/kg/day for dibutyltin dichloride.

Dioctyltin. Only one acute-duration study was available that provided limited information on systemic effects and on effects on the immune system (Seinen et al. 1977a). Intermediate-duration studies focused mainly on the immune system and a relatively low dose tested, approximately 7 mg/kg/day, caused significantly mortality in guinea pigs after 4–5 weeks of treatment (Seinen et al. 1977b). No chronic-duration studies were located.
**Triphenyltin.** Most acute-duration studies provide information on reproductive and developmental effects and NOAELs and LOAELs are around 3–6 mg/kg/day. A dose level of 4.7 mg/kg/day was a serious reproductive LOAEL in rats (Ema et al. 1997b). An intermediate-duration study reported high lethality (100%) in rats at approximately 23 mg/kg/day, but did not report whether deaths occurred at lower dose levels tested (NCI 1978b). That study also reported that the lowest dose tested, approximately 5 mg/kg/day, caused 25% reduction in body weight gain, a serious effect. High lethality was observed in rats in a chronic-duration study with the lowest dose level tested, 0.4 mg/kg/day (Tennekes et al. 1989b). A study in dogs, available in summary form only, found no significant effects of triphenyltin hydroxide on a wide range of end points at doses of up to 0.62 mg/kg/day in the diet for up to 52 weeks (Sachsse et al. 1987).

**Triethyltin.** Most dose levels of triethyltin caused serious effects (primarily neurological) both in acute and intermediate duration oral studies. The highest NOAEL in an acute study was 2 mg/kg/day for neurological effects in a study by Snoeij et al. (1985), but that same dose level was a serious LOAEL for body weight in rats in that same study and caused ataxia and paralysis in a different study (Magee et al. 1957). The highest intermediate LOAEL was 0.66 mg/kg/day for body weight in rats (Purves et al. 1991), but 1.4 mg/kg/day was lethal to rats (Smith 1973) and 0.7–0.8 mg/kg/day were serious neurological LOAELs (Eto et al. 1971; Purves et al. 1991; Reiter et al. 1980). No chronic-duration studies were located.

**Trimethyltin.** Most acute- and intermediate-duration studies of trimethyltin described serious neurological effects occurring at the lowest dose levels tested. The highest acute-duration NOAEL was 0.7 mg/kg/day for neurological effects in rats (Snoeij et al. 1985), but 1 mg/kg/day was a serious neurological LOAEL (self-mutilating and aggressive behavior) in rats (Bouldin et al. 1981). Doses ≥2 mg/kg/day were lethal (Brown et al. 1984; Nolan et al. 1990; Snoeij et al. 1985). In the few intermediate-duration studies available, the lowest LOAEL was 0.05 mg/kg/day for impaired performance of rat pups in a learning task, but there was no dose-response relationship (Noland et al. 1982). No chronic-duration studies were located.

**Tributyltin.** The lowest LOAEL in acute-duration studies was 1 mg/kg/day and caused hyperactivity and dysfunction of spatial learning performance in adult rats whose mothers were exposed during pregnancy; no other dose levels were tested (Gardlung et al. 1991). This developmental effect is considered serious, which precludes its use for MRL derivation. The highest NOAEL below this LOAEL is 0.25 mg/kg/day.
for reduction in maternal serum thyroxine levels in a developmental study in rats (Adeeko et al. 2003). Since no other maternal end points were monitored in the study, it seems inappropriate to use this NOAEL as basis for an acute oral MRL for tributyltin. Another relatively low dose, 2.5 mg/kg/day for 6 days, caused significant weight loss in rats, a serious effect (Yallapragada et al. 1991). Intermediate- and chronic-duration oral MRLs were derived for tributyltin.

- An MRL of 0.0003 mg/kg/day has been derived for intermediate-duration oral exposure (15–364 days) to tributyltin oxide.

The intermediate-duration oral MRL of 0.0003 mg/kg/day for tributyltin oxide is based on a NOAEL of 0.025 mg/kg/day for immunological effects in rats (Vos et al. 1990). Groups of male Wistar rats were fed a diet containing 0, 0.5, 5, or 50 ppm tributyltin oxide (95.3% pure) for 4.5–6 months. This diet provided approximately 0, 0.025, 0.25, and 2.5 mg/kg/day of the test material. Parameters of specific resistance evaluated included immunoglobulin M (IgM) and immunoglobulin G (IgG) response to ovalbumin and delayed-type hypersensitivity (DTH) response to ovalbumin and tuberculin after 6 months of treatment; resistance to *Trichinella spiralis* infection after 5.5 months; mitogenic response of thymus and spleen cells after 4.5 months; and surface marker analysis of mesenteric lymph nodes after 6 months. Parameters of nonspecific resistance examined included clearance of *Listeria monocytogenes* from the spleen after injection at 5 months and natural cell-mediated cytotoxicity of spleen and peritoneal cells after 4.5 months. Neither body weight nor spleen weight were significantly altered after 4.5 months of treatment, but thymus weight was reduced by 17% relative to controls in the high-dose group. Neither the IgM nor IgG response to ovalbumin and *T. spiralis* was altered after 5.5 months of exposure. The immunoglobulin E (IgE) responses to *T. spiralis*, as determined by the passive cutaneous anaphylaxis reaction, was suppressed in a dose-related manner (significant in the mid- and high-dose groups). The DTH reactions to ovalbumin and tuberculin were not significantly altered after 6 months of dosing. There was an increase in the number of larvae *T. spiralis* in muscle after infection in the mid- and high-dose groups after 5.5 months of exposure to the test material. No significant effect was observed on the response of spleen cells to T- and B-mitogens after 4.5 months. The cell surface marker analysis of mesenteric lymph node cells showed a reduction in the relative count of T-lymphocytes and an increase in the percentage of B-lymphocytes in the mid- and high-dose groups after 6 months of treatment. The in vivo clearance of *L. monocytogenes* was impaired in the high-dose group after 5 months of treatment. Treatment with tributyltin oxide did induce a consistent effect on the natural killer cell activity of spleen and peritoneal cells after 4.5 months of exposure (decreased with low dose, increased with mid dose, and decreased with high dose). Based on the depression of IgE titers and increased *T. spiralis* in muscle after 5.5 months of exposure to tributyltin oxide, the study LOAEL is 0.25 mg/kg/day and the NOAEL is
0.025 mg/kg/day. Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for intraspecies variability) to the NOAEL yields an intermediate-duration oral MRL of 0.0003 mg/kg/day.

- An MRL of 0.0003 mg/kg/day has been derived for chronic-duration oral exposure (365 days or more) to tributyltin oxide.

The chronic-duration oral MRL of 0.0003 mg/kg/day for tributyltin oxide is based on a NOAEL of 0.025 mg/kg/day for immunological effects in rats (Vos et al. 1990). Groups of male Wistar rats were fed a diet containing 0, 0.5, 5, or 50 ppm tributyltin oxide (95.3% pure) for 18 months. This diet provided approximately 0, 0.025, 0.25, and 2.5 mg/kg/day of the test material. Parameters of specific resistance evaluated included IgM and IgG response to sheep red blood cells (SRBC) after 16 months; IgM and IgG response to ovalbumin and DTH response to ovalbumin and tuberculin after 15 months of treatment; resistance to *T. spiralis* infection after 16.5 months; mitogenic response of thymus and spleen cells after 16.5 months; and surface marker analysis of mesenteric lymph nodes after 18 months. Parameters of nonspecific resistance examined included clearance of *L. monocytogenes* from the spleen after injection at 17 months and natural cell-mediated cytotoxicity of spleen and peritoneal cells after 16 months. No information was provided regarding body weight or weight of the thymus and spleen weights at termination. Exposure to tributyltin oxide did not affect the primary IgM or the secondary response to SRBC after 16 months of dosing. Neither the IgM nor IgG response to ovalbumin and *T. spiralis* were altered after 15 months of exposure, but the IgE responses to *T. spiralis*, as determined by the passive cutaneous anaphylaxis reaction, were suppressed in a dose-related manner (significant in the mid- and high-dose groups). The DTH reactions to ovalbumin and tuberculin were not significantly altered after 16 months of dosing. There was an increase in the number of larvae *T. spiralis* in muscle after infection in the mid- and high-dose groups after 16.5 months of exposure to the test material. No significant effect was observed on the response of spleen cells to T- and B-mitogens after 16 months. The cell surface marker analysis of mesenteric lymph node cells showed a reduction in the relative count of T-lymphocytes and an increase in the percentage of B-lymphocytes in the mid- and high-dose groups after 18 months of treatment. The *in vivo* clearance of *L. monocytogenes* was impaired in the high-dose group after 17 months of treatment. Treatment with tributyltin oxide for 16 months significantly reduced the natural killer cell activity of spleen and peritoneal cells, but there was no clear dose-response relationship. Based on the depression of IgE titers and increased *T. spiralis* in muscle after 16.5 months of exposure to tributyltin oxide, the study LOAEL is 0.25 mg/kg/day and the NOAEL is 0.025 mg/kg/day. Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for intraspecies variability) to the NOAEL yields a chronic-duration oral MRL of 0.0003 mg/kg/day.
3. HEALTH EFFECTS

3.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of tin and tin compounds. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

Because there is such a large number of inorganic tin and organotin compounds, only the most widely studied compounds and those that present the greatest potential for human exposure have been selected for the discussion of health effects. In addition to primary studies, review articles and government reports are occasionally provided in order to assist the reader in understanding more fully the toxicology of the tin compounds.

3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).

Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a
considerable amount of judgment may be required in establishing whether an end point should be classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is considered to be important because it helps the users of the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not the effects vary with dose and/or duration, and place into perspective the possible significance of these effects to human health.

The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures may differ depending on the user's perspective. Public health officials and others concerned with appropriate actions to take at hazardous waste sites may want information on levels of exposure associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.

Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of tin compounds are indicated in Table 3-5 and Figure 3-5.

A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.

### 3.2.1 Inhalation Exposure

Little information has been published regarding the effects of inhaled inorganic tin or organotin compounds on human health. Reports of human occupational exposures often involve multiple chemicals and lack details on actual exposure concentrations and conditions. Some reports of humans must also be regarded as anecdotal. The older animal literature (from the 1950s) includes inhalation studies that are lacking in description of methods and in reporting of experimental findings. However, it is still possible to characterize some aspects of tin toxicity due to inhalation of inorganic tin and organotin compounds. Exposure levels of the inhaled organotin compounds are expressed as milligrams per cubic meter (mg/m³) of the specific tin compound unless otherwise noted. Doses are not expressed as doses of tin due to the
covalent bond between the tin and the organic moiety. There are no data for specific inorganic tin compounds. Calculations of parts per million (ppm) values are included where appropriate. Table 3-1 and Figure 3-1 summarize available quantitative information on health effects that have been observed in animals after inhalation exposure to tributyltins. Exposure levels are expressed as ppm in Table 3-1 and Figure 3-1. A table and figure are not presented for inorganic tin compounds due to limitations of the available studies.

3.2.1.1 Death

**Inorganic Tin Compounds.** No studies were located regarding lethality in humans or animals after inhalation exposure to inorganic tin compounds.

**Organotin Compounds.** Deaths have been reported in humans following exposure to organotins. One of six workers died 12 days following exposure to a mixture of half dimethyltin and half trimethyltin chloride vapor that occurred during the cleaning of a caldron at a chemical plant. Maximum exposure was a total of 1.5 hours over a 3-day working period (Rey et al. 1984). No estimates of exposure levels were given. The symptoms preceding death included excretion of high levels of tin in the urine, respiratory depression, and coma. More uncertain is the report of a female worker who died following a drenching with triphenyltin chloride, diphenyltin dichloride, and other unidentified compounds. No estimates of exposure levels were given. Death was apparently caused by renal failure 12 days after exposure (NIOSH 1976). No other studies were located regarding lethality in humans after inhalation exposure to organotin compounds.

A 4-hour LC$_{50}$ of 77 mg/m$^3$ for tributyltin oxide (as total particles) was described by Schweinfurth and Gunzel (1987) in a summary of acute studies; the LC$_{50}$ for particles with a diameter of <10 μm was 65 mg/m$^3$. The summary also indicates that a concentration of 20 mg/m$^3$ of an aerosol of tributyltin oxide was lethal to guinea pigs within 1 hour of exposure. Lethality in mice was observed following single or repeated daily exposures to a butyltin mixture (81.2% tributyltin bromide and 3.7% dibutyltin dibromide) together with other unidentified compounds (15.1%) (Igarashi 1959). The concentration was 5.65 mg tin/m$^3$ (1.16 ppm) as the butyltin mixture for different durations of exposure. The tributyltin bromide concentration was 1.1 ppm and that for dibutyltin bromide was 0.06 ppm. For a 2-day, 8-hour/day exposure, approximately 80–90% of the exposed mice died. Despite the observation of other signs of toxicity (see Section 3.2.1.2) the exposure of the mice to multiple compounds confound the interpretation of the data.
### Table 3-1 Levels of Significant Exposure to Tributyltins - Inhalation

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL</th>
<th>Less Serious (ppm)</th>
<th>Serious (ppm)</th>
<th>Reference Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Mouse (NS)</td>
<td>6 d 7 hr/d</td>
<td>Cardio</td>
<td>0.42</td>
<td></td>
<td>0.42</td>
<td>(blood congestion)</td>
<td>Igarashi 1959 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td></td>
<td></td>
<td>0.42</td>
<td>(glomerular swelling, tubular epithelial lesions)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td></td>
<td></td>
<td>0.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reproductive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Rat (NS)</td>
<td>10 d 5 hr/d</td>
<td></td>
<td></td>
<td>0.39</td>
<td>(40% decrease in reproduction)</td>
<td></td>
<td>Iwamoto 1960 TBT</td>
</tr>
<tr>
<td><strong>INTERMEDIATE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Rat (NS)</td>
<td>95 d 6 hr/d</td>
<td>Resp</td>
<td>0.3</td>
<td>(lung hyperemia, catarrhal bronchitis)</td>
<td></td>
<td></td>
<td>Gohike et al 1969 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td></td>
<td></td>
<td>0.3</td>
<td>(minor fatty degeneration)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ocular</td>
<td></td>
<td></td>
<td>0.3</td>
<td>(inflamed eyes, nostrils)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Rat (NS)</td>
<td>80 d</td>
<td>Resp</td>
<td>0.39</td>
<td>(bronchitis edema)</td>
<td>0.39</td>
<td>(myocardial atrophy)</td>
<td>Iwamoto 1960 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td></td>
<td></td>
<td>0.39</td>
<td>(myocardial atrophy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td></td>
<td></td>
<td>0.39</td>
<td>(atrophy, necrosis)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td></td>
<td></td>
<td>0.39</td>
<td>(swelling and congestion)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td></td>
<td></td>
<td>0.39</td>
<td>(splenic hyperplasia, thickened sheaths)</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (ppm)</td>
<td>Less Serious (ppm)</td>
<td>Serious (ppm)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td>5</td>
<td>Rat (NS)</td>
<td>80 d</td>
<td></td>
<td></td>
<td>0.39</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reproductive

5

The number corresponds to entries in Figure 3-1.

Cardio = cardiovascular; d = day(s); Derm = dermal; hr = hour(s); LC50 = lethal concentration, 50% kill; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; Resp = respiratory
Figure 3-1 Levels of Significant Exposure to Tributyltins - Inhalation

Acute (≤14 days)
Figure 3-1 Levels of Significant Exposure to Tributyltins - Inhalation (Continued)

Intermediate (15-364 days)

Systemic

ppm

Respiratory  Cardiovascular  Hepatic  Renal  Ocular  Other  Reproductive

0.1

0.5

1

• 4r  • 4r  • 4r  • 4r  • 4r  • 4r  • 5r

0.3 0.3 0.3 0.3 0.3 0.3

c-Cat - Humans  d-Dog  e-Mouse  f-Ferret  g-Guinea Pig  h-Rabbit  i-Hamster  j-Pigeon  k-Monkey  l-Other

LD50/LC50

Minimal Risk Level

for effects

other than Cancer
3. HEALTH EFFECTS

In rats exposed nose-only for 29–32 days for 4 hours to doses of 0, 0.03 (vapor), 0.16 (vapor), or 2.8 (aerosol) mg/m³ of tributyltin oxide 5 days/week for 21–24 treatments, the mortality in the high-dose group was 5/10 males and 6/10 females (Schweinfurth and Gunzel 1987); no toxicity was noticed in the groups exposed to vapors. Little detail was presented in this brief summary.

3.2.1.2 Systemic Effects

No studies were located regarding cardiovascular, hematological, or musculoskeletal effects in humans or animals after inhalation exposure to inorganic tin or organotin compounds.

The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

Respiratory Effects.

**Inorganic Tin Compounds.** Stannic oxide dust or fumes produce a benign form of pneumoconiosis, known as stannosis, in humans (Cutter et al. 1949; Dundon and Hughes 1950; Pendergrass and Pryde 1948). The workers exhibiting this pulmonary condition had industrial exposures ranging from 15 to 20 years. No exposure levels were included in the case reports. In all cases, chest x-rays of the workers showed discrete opaque shadows throughout the lungs, attributed to stannic oxide deposits. However, there was no impairment of pulmonary function or systemic disease. It also has been reported that x-rays of tin foundry workers confirmed more than 150 cases of stannosis by 1959 (Stewart and Lassiter 2001).

No studies were located regarding respiratory effects in animals after inhalation exposure to inorganic tin compounds.

**Organotin Compounds.** Respiratory depression requiring artificial ventilation occurred in three of six chemical workers. The exposure duration was a total of 1.5 hours over a 3-day working-period to a mixture containing half dimethyltin and half trimethyltin chloride (Rey et al. 1984). Although the two surviving workers, who were the most severely affected, developed permanent neurological disabilities, respiratory problems did not persist.
3. HEALTH EFFECTS

Tributyltin oxide has been implicated in producing irritation of the upper respiratory tract and chest irritation, tightness, and pain in workers using a rubber material containing tributyltin oxide. Exposure conditions were not described. No changes were observed in pulmonary function tests (NIOSH 1976).

Wax and Dockstader (1995) reported that all members of a family of five (two adults and three children) complained of sore throat, burning nose, and wheezing 24 hours after a room in their home had been painted with a paint containing tributyltin oxide for mildew control. Cough and difficulty in breathing, characterized by inspiratory discomfort, were observed in a man a few hours after inhaling an unspecified amount of powdered trimethyltin chloride (Saary and House 2002). Shortness of breath and chest discomfort was still present 20 days after the exposure.

Inflammatory changes consisting of hyperemia and bronchitis were observed in the respiratory system of rabbits exposed to 4–6 mg/m$^3$ (0.30–0.45 ppm) tributyltin chloride for 95 days (Gohlke et al. 1969). Histopathology, consisting of severe bronchitis and vascular and alveolar edema, was seen in rats exposed to 2 mg tin/m$^3$ (0.41 ppm) as a mixture of tributyltin bromide (0.39 ppm), dibutyltin dibromide (0.02 ppm), and hydrocarbon impurities for 80 days (Iwamoto 1960). Since these were terminal histopathological evaluations only, it is not known whether the changes were reversible or would have produced functional impairment in the animals if exposure had continued.

Information summarized by Schweinfurth and Gunzel (1987) indicate that a single 4-hour exposure of rats to aerosols of tributyltin oxide produced signs of irritation such as nasal discharge, lung edema and congestion.

**Gastrointestinal Effects.**

**Inorganic Tin Compounds.** No studies were located regarding gastrointestinal effects in humans or in animals after inhalation exposure to inorganic tin compounds.

**Organotin Compounds.** Very limited information is available in humans. Wax and Dockstader (1995) reported that nausea and vomiting occurred among all the members of a family of five who were exposed at home to tributyltin oxide contained in paint for mildew control. Saary and House (2002) reported that a man who inhaled powdered trimethyltin chloride complained of substernal and epigastric burning with flatulence a few hours after exposure. The abdominal pain still persisted 2 months after exposure.
Hematological Effects.

Inorganic Tin Compounds. No studies were located regarding hepatic effects in humans or in animals after inhalation exposure to inorganic tin compounds.

Organotin Compounds. Data concerning hepatic effects of organotins in humans and animals are limited.

Autopsy of a chemical worker who died following exposure to a combination of methyltin salts (see Section 3.2.1.1) revealed massive fatty degeneration of liver cells and necrosis (Rey et al. 1984).

Fatty degeneration was observed at necropsy in animals killed after a 95-day exposure period to 4–6 mg/m³ (0.30–0.45 ppm) tributyltin chloride (Gohlke et al. 1969). Histopathology, consisting of atrophy and slight necrosis of the liver, was seen in rats exposed to 2 mg tin/m³ (0.41 ppm) as a mixture of tributyltin bromide (0.39 ppm), dibutyltin dibromide (0.02 ppm), and hydrocarbon impurities for up to 80 days as part of a study of reproductive function (Iwamoto 1960). Atrophy of the liver cells increased with exposure duration in the females. Some recovery was apparent if exposure to tin was stopped prior to sacrifice. The longer the duration of exposure, the less complete the recovery.

Renal Effects.

Inorganic Tin Compounds. No studies were located regarding renal effects in humans and animals after inhalation exposure to inorganic tin compounds.

Organotin Compounds. Data concerning renal effects of organotins in humans and animals are limited.

Autopsy of the one chemical worker who died following exposure to the combination of the methyltin salts (see Section 3.2.1.1) revealed shock kidneys (i.e., proximal tubule degeneration), which represents serious tubule damage (Rey et al. 1984). The other five exposed men had high tin concentrations in the urine with the highest levels occurring in the most severely affected.

Inhalation exposure of mice to a concentration of 5.65 mg tin/m³ (1.16 ppm) as a mixture of tributyltin bromide (1.1 ppm), dibutyltin dibromide (0.06 ppm), and hydrocarbon impurities for 7 hours/day over 6 days produced pathological changes in the kidney (Igarashi 1959). Necropsy of animals revealed slight
3. HEALTH EFFECTS

degenerative changes in the glomeruli, convoluted tubules, and collecting tubules as well as extra-
medullary hematopoiesis. More extensive kidney pathology was observed in rats exposed to 2 mg tin/m³
(0.41 ppm) as a mixture of tributyltin bromide (0.39 ppm) and dibutyltin dibromide (0.02 ppm) for
2 hours/day for 80 days. Kidney damage consisted of extensive congestion and swelling of the renal
tubular epithelium (Iwamoto 1960).

Dermal Effects.

Inorganic Tin Compounds. Contact with inorganic tin salts produces mild irritation of the skin and
mucous membranes (WHO 1980). However, no specific studies were located regarding dermal effects in
humans and animals after inhalation exposure to inorganic tin compounds.

Organotin Compounds. No studies were located regarding dermal effects in humans after inhalation
exposure to organotin compounds. Occupational exposure produces such effects as discussed in
Section 3.2.3.1.

Dermal effects were observed during inhalation studies in mice that were exposed to a butyltin mixture
(30 parts tributyltin bromide to 1 part dibutyltin dibromide) and consisted of reddening of the skin and
dilatation of the blood vessels of the nose, feet, and tail (Igarashi 1959). These effects may have been
caused by direct contact with the chemical.

Ocular Effects.

Inorganic Tin Compounds. No information was located regarding ocular effects in humans following
exposure to inorganic tin compounds.

Organotin Compounds. Inflamed eyes and nasal mucous membranes were observed in the last month of
a 95-day inhalation study of tributyltin chloride in female rats (Gohlke et al. 1969). The animals were
exposed to concentrations of 4–6 mg/m³ (0.30–0.45 ppm) for 6 hours/day, 5 days/week.
3. HEALTH EFFECTS

3.2.1.3 Immunological and Lymphoreticular Effects

No studies were located regarding immunological effects in humans or animals after inhalation exposure to inorganic tin or organotin compounds. However, some lymph node atrophy was observed in rats exposed to a butyltin mixture for 14 days (Iwamoto 1960).

3.2.1.4 Neurological Effects

Inorganic Tin Compounds. No studies were located regarding neurological effects in humans or in animals after inhalation exposure to inorganic tin compounds.

Organotin Compounds. A study by Rey et al. (1984) provides some information on neurobehavioral changes in humans after exposure to organotin compounds (dimethyltin dichloride and trimethyltin chloride). The study describes the cases of six chemical workers exposed to methyltins primarily by inhalation who experienced headache, tinnitus, deafness, impaired memory, disorientation, aggressiveness, psychotic and other severe neuropsychiatric behavior, syncope, and loss of consciousness as symptoms of exposure; one subject died. The two surviving workers with the highest urinary tin levels exhibited fixed neurological effects which were not resolved more than 6 years after exposure. The remaining three survivors returned to work, but had memory loss, which persisted for 6 months. Similar cases have been reported by other investigators. Fortemps et al. (1978) reported that two chemists who had been intermittently exposed to vapors of dimethyltin dichloride and trimethyltin chloride for about 3 months abruptly developed a status of mental confusion with generalized epileptic seizures. Before the acute episode, the subjects had complained of headaches, pain in various organs, and psychological disturbances such as memory defects, vigilance loss, insomnia, anorexia, and disorientation. Both patients recovered completely following removal from exposure. Ross et al. (1981) examined 22 male workers 1 month following exposure to trimethyltin spillage (presumable inhalation and dermal exposure occurred) and compared the frequency of neurological symptoms between those who suffered high exposure with those with lower exposure. Those highly exposed showed a significantly higher incidence of nonspecific symptoms such as forgetfulness, fatigue and weakness, loss of motivation, and specific symptoms such as bouts of depression and attacks of rage and temper compared to those with lower exposure. Some symptoms persisted for at least 3 years following the accident. Yanofsky et al. (1991) and Feldman et al. (1993) described the case of a 23-year-old male who was accidentally exposed to vapors of a trimethyltin compound and 72 hours later exhibited delirium, spatial disorientation, perseveration, inappropriate affect, and memory loss. Urine and serum assays for tin showed
considerably elevated concentrations of trimethyltin when tested 3 weeks following the accident. Five months after the accident, the man experienced complex partial seizures that required him to take anticonvulsant medication for 7 years. Four years after exposure, tests revealed persistent memory defects, cognitive dysfunction, and dysphoria. Saary and House (2002) described the case of a man who worked in a chemistry laboratory and inhaled an undetermined amount of powdered trimethyltin chloride on a single occasion. Within 3 hours of exposure he felt agitated and he later developed a headache, dizziness, and twitching of the right eye and cheek. Two months after exposure, he continued experiencing twitching of his eyelids and arms and complained of suffering short-term memory problems and difficulty retaining new information.

No relevant studies were located regarding neurological effects in animals after inhalation exposure to organotin compounds. It was reported that no histopathological changes were observed in the brains of mice following a 6-day inhalation exposure to 2.12 mg tin/m$^3$ (0.44 ppm) as a mixture of tributyltin bromide (0.42 ppm), dibutyltin dibromide (0.02 ppm), and hydrocarbon impurities (Igarashi 1959).

### 3.2.1.5 Reproductive Effects

**Inorganic Tin Compounds.** No studies were located regarding reproductive effects in humans or animals after inhalation exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding reproductive effects in humans after inhalation exposure to organotin compounds.

A study in rats was conducted to assess reproductive effects of a mixture of tributyltin bromide (81.2%) with other compounds such as dibutyltin dibromide (Iwamoto 1960). The rats were exposed to 2 mg tin/m$^3$ (0.41 ppm) for acute- and intermediate-duration exposures (equivalent to 0.39 ppm tributyltin bromide and 0.02 ppm dibutyltin dibromide). Pregnancy rates were markedly reduced after 4 weeks to 3 months of exposure, but returned to near control rates when exposure was discontinued. Histopathological evaluations were made in separate studies of different exposure durations (14–80 days) followed by recovery periods. No changes were seen in males, but atrophy of the glandular uterus was observed as early as 14 days of exposure in females. All effects were reversed during the recovery period. Although a mixture of butyltin compounds was used and the results were not clearly reported, this study suggests that some impairment of female reproductive functions may occur after inhalation of these compounds.
3.2.1.6 Developmental Effects

No studies were located regarding developmental effects in humans or animals after inhalation exposure to inorganic tin or organotin compounds.

3.2.1.7 Cancer

No studies were located regarding cancer effects in humans and animals after inhalation exposure to inorganic tin or organotin compounds.

3.2.2 Oral Exposure

In contrast to the limited information on the inhalation toxicity of tin compounds (Section 3.2.1), there are considerable more data regarding the effects of oral exposure to organotin compounds, particularly in animal studies. Although there is less information concerning health effects produced by oral exposure to inorganic tin compounds, the data from animal studies allow some characterization of health effects of these compounds. Dosages are expressed as milligrams of tin per kilogram of body weight per day (mg tin/kg/day) as the specific inorganic tin compound fed or administered orally. Table 3-2 and Figure 3-2 summarize available quantitative information on health effects that have been observed in animals after oral exposure to inorganic tin compounds. Similar information for organotin compounds is given in Tables 3-3 through 3-8 and Figures 3-3 through 3-8. In order to be consistent with most studies in the literature, dosages are expressed as mg/kg/day of the specific organotin compound rather than as a tin equivalent.

3.2.2.1 Death

*Inorganic Tin Compounds.* No studies were located regarding lethality in humans after oral ingestion of inorganic tin compounds.

In animals, the lowest oral dose that produced deaths in rats following a single gavage administration was 473 mg/kg body weight stannous chloride (NTP 1982). However, all rats survived doses up to 945 mg/kg/day when the compound was fed in the diet for 14 days (NTP 1982). For mice, the lowest oral
### Table 3-2 Levels of Significant Exposure to Inorganic Tin - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposur e/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rat (Fischer-344)</td>
<td>once (GW)</td>
<td></td>
<td></td>
<td>473 F (1/5 females died on day 3)</td>
<td>NTP 1982</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Mouse (B6C3F1)</td>
<td>once (GW)</td>
<td></td>
<td></td>
<td>378 (1/5 males and 1/5 females died on day 3)</td>
<td>NTP 1982</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Mouse (B6C3F1)</td>
<td>14 d 7 d/wk (F)</td>
<td></td>
<td>1229</td>
<td>(males and females gained less weight than those in the lowest dose group)</td>
<td>NTP 1982</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Rat (Wistar)</td>
<td>10 d Gd 6-15 1 x/d (GW)</td>
<td></td>
<td>31 F</td>
<td></td>
<td>FDR 1972</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Mouse (CD-1)</td>
<td>10 d Gd 6-15 1 x/d (GW)</td>
<td></td>
<td>31 F</td>
<td></td>
<td>FDR 1972</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Hamster (Golden Syrian)</td>
<td>5 d Gd 6-10 1 x/d (GW)</td>
<td></td>
<td>31 F</td>
<td></td>
<td>FDR 1972</td>
<td>SnCl₂</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>7</td>
<td>Rat (Wistar)</td>
<td>10 d Gd 6-15 1 x/d (GW)</td>
<td></td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td>FDRL 1972</td>
</tr>
<tr>
<td>8</td>
<td>Mouse (CD-1)</td>
<td>10 d Gd 6-15 1 x/d (GW)</td>
<td></td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td>FDRL 1972</td>
</tr>
<tr>
<td>9</td>
<td>Hamster (Golden Syrian)</td>
<td>5 d Gd 6-10 1 x/d (GW)</td>
<td></td>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td>FDRL 1972</td>
</tr>
</tbody>
</table>

**INTERMEDIATE EXPOSURE**

**Death**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Rat (Wistar)</td>
<td>13 wk 7 d/wk (F)</td>
<td></td>
<td>315</td>
<td>(4/10 males died)</td>
<td>DeGroot et al. 1973</td>
<td>SnCl2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Systemic**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>325</td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
<td>Sn3(PO4)2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>98</td>
<td>325</td>
<td>(slightly distended small and large intestine)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>33</td>
<td>98</td>
<td>(decreased hemoglobin and hematocrit)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>325</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>33</td>
<td>98</td>
<td>(30% decreased body weight gain in males)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>LOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference Chemical Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Rat (Wistar)</td>
<td>13 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>440</td>
<td></td>
<td></td>
<td>DeGroot et al. 1973 SnO</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>440</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>440</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>440</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>440</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rat (Wistar)</td>
<td>13 wk ad libitum (F)</td>
<td>Cardio</td>
<td>315</td>
<td></td>
<td></td>
<td>DeGroot et al. 1973 SnCl2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>32 b</td>
<td>95</td>
<td>(abdominal distension)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>32</td>
<td>95</td>
<td>(reduced hemoglobin concentration)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>32</td>
<td>95</td>
<td>(bile duct epithelium proliferation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>315</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>315</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>95</td>
<td>315</td>
<td>(weight loss)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>32</td>
<td>95</td>
<td>(14% reduced food consumption on week 2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
<td>Sn(Cl8H33O2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>390</td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
<td>SnO2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>390</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>390</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>390</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>390</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>-------------------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td>16</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SnSO4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>28</td>
<td>83</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>83</td>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>28</td>
<td>83</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>220</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>22</td>
<td>66</td>
<td></td>
<td></td>
<td></td>
<td>SnC4-H406</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>66</td>
<td>220</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>220</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>22</td>
<td>66</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>285</td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>29</td>
<td>86 (decreased hemoglobin and hematocrit)</td>
<td></td>
<td>SnC204</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>29</td>
<td>86 (bile duct hyperplasia, homogenous cell cytoplasm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>285</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>29</td>
<td>86 (18-25% decreased body weight gain and decreased food intake)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>315</td>
<td></td>
<td></td>
<td></td>
<td>DeGroot et al. 1973</td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>95</td>
<td>315</td>
<td>(slightly distended small and large intestines)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>32</td>
<td>95</td>
<td>(decreased hemoglobin and hematocrit)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>32</td>
<td>95</td>
<td>(bile duct hyperplasia, homogeneous cell cytoplasm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>315</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>32</td>
<td>95</td>
<td>(30% decreased body weight gain and decreased food intake)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| 20            | Rat (Wistar)     | 4 wk 7 d/wk (F)                    |        |                  |       |                          |                   |           |               |
|               |                  |                                    | Cardio | 390              |       |                          |                   | DeGroot et al. 1973 | SnS          |
|               |                  |                                    | Hemato | 117              | 390   | (significant increase in hematocrit in males) |                   |           |               |
|               |                  |                                    | Hepatic| 390              |       |                          |                   |           |               |
|               |                  |                                    | Renal  | 390              |       |                          |                   |           |               |
|               |                  |                                    | Bd Wt  | 390              |       |                          |                   |           |               |</p>
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Rat (Wistar)</td>
<td>4 wk ad libitum (F)</td>
<td>Gastro</td>
<td>7.9 M (increased intestinal length)</td>
<td></td>
<td></td>
<td>Janssen et al. 1985</td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.9 M (decreased hemoglobin concentration)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bd Wt 7.9 M (17% reduction in final body weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Mouse (B6C3F1)</td>
<td>13 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>2457</td>
<td></td>
<td></td>
<td>NTP 1982</td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gastro 157 311 (gross distention of the cecum)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemato 2457</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatic 2457</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Renal 2457</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bd Wt 157 (11.7% decreased body weight gain in males)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Rabbit (NS)</td>
<td>4 mo 1 x/d (G)</td>
<td>Hemato</td>
<td>10 F (transient hemolytic anemia)</td>
<td></td>
<td></td>
<td>Chmielnicka et al.1993</td>
<td>SnCl2</td>
</tr>
</tbody>
</table>
### Table 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reproductive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Rat (Sprague-Dawley)</td>
<td>20 d Gd 0-20 ad libitum (F)</td>
<td></td>
<td>56 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Theuer et al. 1971</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SnF2</td>
</tr>
<tr>
<td>25</td>
<td>Rat (Sprague-Dawley)</td>
<td>20 d Gd 0-20 ad libitum (F)</td>
<td></td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Theuer et al. 1971</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NaSn2Cl5</td>
</tr>
<tr>
<td><strong>Developmental</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Rat (Sprague-Dawley)</td>
<td>20 d Gd 0-20 ad libitum (F)</td>
<td></td>
<td>56 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Theuer et al. 1971</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SnF2</td>
</tr>
<tr>
<td>27</td>
<td>Rat (Sprague-Dawley)</td>
<td>20 d Gd 0-20 ad libitum (F)</td>
<td></td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Theuer et al. 1971</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NaSn2Cl5</td>
</tr>
<tr>
<td><strong>CHRONIC EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Rat (Long-Evans)</td>
<td>42 mo 7 d/wk (W)</td>
<td></td>
<td>0.7 (decreased longevity in females by 11%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schroeder et al. 1968</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SnCl2</td>
</tr>
</tbody>
</table>
Table 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Rat (Fischer-344)</td>
<td>105 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>63</td>
<td>63</td>
<td></td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>63</td>
<td></td>
<td></td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>63</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Rat (Long-Evans)</td>
<td>42 mo 7 d/wk (W)</td>
<td>Hepatic</td>
<td>0.7 (fatty degeneration)</td>
<td>0.7 (tubular degeneration, vacuolization)</td>
<td>0.7 (11-16% decreased body weight, compared to controls)</td>
<td>Schroeder et al. 1968</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>0.7</td>
<td></td>
<td></td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Mouse (B6C3F1)</td>
<td>105 wk 7 d/wk (F)</td>
<td>Cardio</td>
<td>164</td>
<td></td>
<td></td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>164</td>
<td></td>
<td></td>
<td>SnCl2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>164</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>164</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>32</td>
<td>Mouse (albino)</td>
<td>18 mo 7 d/wk (W)</td>
<td>Bd Wt</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-2.

b Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.3 mg/kg/day; the MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability).

Cardio = cardiovascular; d = day(s); Derm = dermal; (F) = feed; (GW) = gavage in water; Gastro = gastrointestinal; Hemato = hematological; LOAEL = lowest-observed-adverse-effect level; M = males; mo = month(s); NOAEL = no-observed-adverse-effect level; SnC2O4 = stannous oxalate; SnC4H4O6 = stannous tartrate; Sn(C18H33O2)2 = stannous oleate; SnCl2 = stannous chloride; SnO2 = stannic oxide; Sn2O7N2 = stannous nitrate; Sn3(PO4)2 = stannous orthophosphate; SnS = stannous sulfide; SnSO4 = stannous sulfate; (W) = water; wk = week(s)
Figure 3-2 Levels of Significant Exposure to Inorganic Tin - Oral

Acute (≤14 days)

mg/kg/day

Death

Systemic

Reproductive

Developmental

1r

2m

3m

6s

5m

4r

9s

8m

7r

c-Cat - Humans
d-Dog - Monkeys
r-Rat - Mouse
p-Pig - Rabbit
q-Cow - Sheep
f-Ferret - Others
n-Mink - Other Animals
O Cancer Effect Level-Animals
O LOAEL, More Serious-Animals
O LOAEL, Less Serious-Animals
O NOAEL - Animals

O Cancer Effect Level-Humans
O LOAEL, More Serious-Humans
O LOAEL, Less Serious-Humans
O NOAEL - Humans

MLD50/LC50
Minimal Risk Level
for effects
other than Cancer

3. HEALTH EFFECTS

TIN AND TIN COMPOUNDS
Figure 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (Continued)
Intermediate (15-364 days)

Systemic

mg/kg/day

Death
Cardiovascular
Gastrointestinal
Hematological
Hepatic

TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS

<table>
<thead>
<tr>
<th>c-Cat</th>
<th>d-Dog</th>
<th>r-Rat</th>
<th>p-Pig</th>
<th>q-Cow</th>
</tr>
</thead>
<tbody>
<tr>
<td>-Humans</td>
<td>-Humans</td>
<td>-Humans</td>
<td>-Humans</td>
<td>-Humans</td>
</tr>
<tr>
<td>f-Ferret</td>
<td>j-Pigeon</td>
<td>o-Gerbil</td>
<td>s-Hamster</td>
<td>g-Guinea Pig</td>
</tr>
<tr>
<td>n-Mink</td>
<td>o-Other</td>
<td>o-Other</td>
<td>o-Other</td>
<td>o-Other</td>
</tr>
</tbody>
</table>

Cancer Effect Level-Animals
Cancer Effect Level-Humans
LD50/LC50
Minimal Risk Level
for effects
other than Cancer
Figure 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (Continued)

Intermediate (15-364 days)

mg/kg/day

Systemic

Renal  Endocrine  Body Weight  Other  Reproductive  Developmental

0.1  1  10  100  1000  10000

22m

12r  11r  15r  16r  18r  19r  20r  13r  22m  11r  13r  14r  15r  16r  17r  18r  13r  19r  24r  26r  22r  27r

c-Cat - Humans  d-Dog - Humans  f-Ferret - Humans  n-Mink - Humans  Cancer Effect Level-Animals

d-Rat - Humans  k-Monkey - Humans  j-Pigeon - Other  o-Gerbil - Other  LOAEL, More Serious-Animals

r-Rat - Humans  m-Mouse - Humans  e-Gerbil - Other  s-Hamster - Other  LOAEL, Less Serious-Animals

p-Pig - Humans  h-Rabbit - Humans  a-Sheep - Humans  g-Guinea Pig - Humans  NOAEL - Animals

q-Cow - Humans  NOAEL - Humans

LD50/LC50 - Minimal Risk Level

Minimal Risk Level for effects other than Cancer

TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS
Figure 3-2 Levels of Significant Exposure to Inorganic Tin - Oral (Continued)

Chronic (≥365 days)

mg/kg/day

Death  Cardiovascular  Gastrointestinal  Hepatic  Renal  Body Weight

31m  31m  31m  31m

29r  29r  29r  29r  29r

28r  30r  30r  30r  30r

TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS

- Humans  f-Ferret  n-Mink  Cancer Effect Level-Animals  Cancer Effect Level-Humans  LD50/LC50
- Monkey  j-Pigeon  o-Gerbil  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Level
- Mouse  h-Rabbit  s-Hamster  LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans  for effects
- Pig  a-Sheep  g-Guinea Pig  NOAEL - Animals  NOAEL - Humans  other than
- Cow  other than
Cancer
### Table 3-3 Levels of Significant Exposure to Dibutyltins - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rat (NS)</td>
<td>3 d 1 x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td>20 F (4/20 deaths 24 hours after dosing)</td>
<td></td>
<td>Alam et al. 1993</td>
<td>DBT</td>
</tr>
<tr>
<td>2</td>
<td>Rat (Wistar)</td>
<td>4 d 1 x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td>50 (death of 30%-50%)</td>
<td></td>
<td>Barnes and Magee 1958</td>
<td>DBT</td>
</tr>
<tr>
<td>3</td>
<td>Rat (Wistar)</td>
<td>Gd 7-15 1 x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td>7.5 F (5 out 12 pregnant rats died)</td>
<td></td>
<td>Ema et al. 1991b</td>
<td>DBT</td>
</tr>
<tr>
<td>4</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td>Gastro</td>
<td>50 (distention of stomach)</td>
<td></td>
<td></td>
<td></td>
<td>Seinen et al. 1977a</td>
<td>DBT</td>
</tr>
<tr>
<td>5</td>
<td>Rat (Wistar)</td>
<td>4 d 1 x/d (GO)</td>
<td>Hepatic</td>
<td>50 (bile duct necrosis)</td>
<td></td>
<td></td>
<td></td>
<td>Barnes and Magee 1958</td>
<td>DBT</td>
</tr>
<tr>
<td>6</td>
<td>Rat (Wistar)</td>
<td>3 d 1 x/d (GO)</td>
<td>Bd Wt</td>
<td>20 F (reduced body weight gain)</td>
<td></td>
<td></td>
<td>40 F (significant body weight loss)</td>
<td>Khaliq et al. 1991</td>
<td>DBT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------</td>
<td>------------------------------------</td>
<td>----------</td>
<td>------------------</td>
<td>------------------</td>
<td>----------------------------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td>Hepatic</td>
<td>7.7</td>
<td>23 (proliferation of bile duct epithelium; periportal fibrosis)</td>
<td>Seinen et al. 1977a</td>
<td>DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>18.3 M (increased serum AST and ALT activities)</td>
<td>Ueno et al. 2003b</td>
<td>DBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Mouse (albino)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>9.2 M</td>
<td>18.3 M (liver damage)</td>
<td>Ueno et al. 1995</td>
<td>DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Mouse (albino)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td></td>
<td>58.6 M (liver necrosis)</td>
<td>Ueno et al. 2003b</td>
<td>DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Gn Pig (Hartley)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>36.6 M</td>
<td></td>
<td>Ueno et al. 2003a</td>
<td>DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Hamster (Golden Syrian)</td>
<td>1 d 1x/d (GO)</td>
<td>Hepatic</td>
<td></td>
<td>30 M (bile duct necrosis)</td>
<td>Jang et al. 1986</td>
<td>DBT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immuno/Lymphoret</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
</tr>
<tr>
<td>Key to Figure</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>14</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>17</td>
</tr>
<tr>
<td>18</td>
</tr>
<tr>
<td>19</td>
</tr>
</tbody>
</table>
Table 3-3 Levels of Significant Exposure to Dibutyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developmental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Rat (Wistar)</td>
<td>Gd 4-7 1 x/d GO</td>
<td></td>
<td>3.8</td>
<td>7.6 (significantly reduced fetal body weight)</td>
<td>Ema and Harazono 2000 DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Rat (Wistar)</td>
<td>Gd 7-15 1 x/d GO</td>
<td></td>
<td>2.5</td>
<td>5 (increased incidence of external and skeletal malformations)</td>
<td>Ema et al. 1991b DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Rat (Wistar)</td>
<td>Gd 7-9 1 x/d GO</td>
<td></td>
<td></td>
<td>20 (increased incidence of malformations)</td>
<td>Ema et al. 1992 DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Rat (Wistar)</td>
<td>Gd 6-15 1 x/d GO</td>
<td></td>
<td>5</td>
<td>10 (slight increase in malformations)</td>
<td>Farr et al. 2001 DBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Rat (Wistar)</td>
<td>Gd 7-17 1 x/d GO</td>
<td></td>
<td>5</td>
<td>10 (increased external and skeletal malformations)</td>
<td>Noda et al. 1992b DBT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-3 Levels of Significant Exposure to Dibutyltins - Oral

(continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTERMEDIATE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Rat (Fischer-344)</td>
<td>90 d ad libitum (F)</td>
<td>Hemato</td>
<td>3.4 M</td>
<td>5.7 F (8% reduced hemoglobin concentration)</td>
<td></td>
<td>Gaunt et al. 1968 DBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>5.7 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>5.7 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>5.7 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>5.7 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Rat (albino)</td>
<td>15 d 1 x/d (GO)</td>
<td>Hepatic</td>
<td>17.5 M (increased heme oxygenase activity, decreased activity of microsomal enzymes)</td>
<td></td>
<td></td>
<td>Mushtaq et al 1981 DBT</td>
</tr>
<tr>
<td>27</td>
<td>Mouse (Swiss-Webster)</td>
<td>4 wk ad libitum (F)</td>
<td>Hepatic</td>
<td>30 M</td>
<td></td>
<td></td>
<td>Seinen et al. 1977a DBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>30 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>30 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>30 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immuno/ Lymphoret</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Rat (Wistar)</td>
<td>4-6 wk ad libitum (F)</td>
<td></td>
<td>b 5 M (depressed humoral response against SRBC)</td>
<td></td>
<td></td>
<td>Seinen et al. 1977b DBT</td>
</tr>
<tr>
<td>29</td>
<td>Mouse (Swiss-Webster)</td>
<td>4 wk ad libitum (F)</td>
<td></td>
<td>30 M</td>
<td></td>
<td></td>
<td>Seinen et al. 1977a DBT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>-------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>30</td>
<td>Mouse (Swiss-Webster)</td>
<td>4 wk ad libitum (F)</td>
<td></td>
<td>29 M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Rat (Fischer-344)</td>
<td>78 wk ad libitum (F)</td>
<td></td>
<td>6.65 M (52% survival at termination compared to 85% in controls)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Mouse (B6C3F1)</td>
<td>78 wk ad libitum (F)</td>
<td></td>
<td>19.76 F (86% survival compared with 95% in controls)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Rat (Fischer-344)</td>
<td>78 wk ad libitum (F)</td>
<td>Resp</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>6.65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Mouse (B6C3F1)</td>
<td>78 wk ad libitum (F)</td>
<td>Resp</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-3 Levels of Significant Exposure to Dibutyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>LOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td></td>
<td></td>
<td>Renal</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>19.76</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-3.

b Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.005 mg/kg/day; The MRL was derived by dividing the LOAEL by an uncertainty factor of 1000 (10 for the use of a LOAEL, 10 for animal to human extrapolation and 10 for human variability).

Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = Female; Gastro = gastrointestinal; gd = gestational day; (GO) = gavage in oil; hemato = hematological; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; Resp = respiratory; x = time(s); wk = week(s)
### Figure 3-3 Levels of Significant Exposure to Dibutyltins - Oral

**Acute (≤14 days)**

<table>
<thead>
<tr>
<th>mg/kg/day</th>
<th>Systemic</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Death</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td></td>
<td>Hepatic</td>
</tr>
<tr>
<td></td>
<td>Body Weight</td>
</tr>
<tr>
<td></td>
<td>Immuno/lymphoc</td>
</tr>
<tr>
<td></td>
<td>Reproductive</td>
</tr>
<tr>
<td></td>
<td>Developmental</td>
</tr>
</tbody>
</table>

**Animals**
- c-Cat: Cancer Effect Level-Animals
- d-Dog: LOAEL, More Serious-Animals
- k-Monkey: NOAEL - Animals
- f-Ferret: Cancer Effect Level-Animals
- j-Pigeon: LOAEL, Less Serious-Animals
- e-Gerbil: NOAEL - Animals
- s-Hamster: Cancer Effect Level-Animals
- g-Guinea Pig: Cancer Effect Level-Humans
- n-Mink: Cancer Effect Level-Humans
- o-Other: LOAEL, Less Serious-Humans
- p-Pig: Cancer Effect Level-Humans
- h-Rabbit: Cancer Effect Level-Humans
- a-Sheep: LD50/LC50; Minimal Risk Level for effects
- m-Mouse: Cancer Effect Level-Humans
- r-Rat: LD50/LC50; Minimal Risk Level for effects
- q-Cow: Cancer Effect Level-Humans
- m-Mouse: Cancer Effect Level-Humans
- h-Rabbit: Cancer Effect Level-Humans
- a-Sheep: Cancer Effect Level-Humans
- g-Guinea Pig: Cancer Effect Level-Humans
- n-Mink: Cancer Effect Level-Humans
- o-Other: LD50/LC50; Minimal Risk Level for effects
- p-Pig: Cancer Effect Level-Humans
- j-Pigeon: Cancer Effect Level-Humans
- e-Gerbil: Cancer Effect Level-Humans
- s-Hamster: Cancer Effect Level-Humans
- f-Ferret: Cancer Effect Level-Humans
- d-Dog: Cancer Effect Level-Humans
- k-Monkey: Cancer Effect Level-Humans
Figure 3-3 Levels of Significant Exposure to Dibutyltins - Oral (Continued)

Intermediate (15-364 days)

mg/kg/day

Systemic

- Hematological
- Hepatic
- Renal
- Endocrine
- Body Weight
- Immuno-Lymphor

Cancer Effect Level - Animals
LOAEL, More Serious - Animals
LOAEL, Less Serious - Animals
NOAEL - Animals

Cancer Effect Level - Humans
LOAEL, More Serious - Humans
LOAEL, Less Serious - Humans
NOAEL - Humans

Minimal Risk Level for effects other than Cancer
LD50/LC50
Figure 3-3 Levels of Significant Exposure to Dibutyltins - Oral (Continued)
Chronic (≥365 days)

mg/kg/day

Death
Respiratory
Cardiovascular
Gastrointestinal
Hepatic
Renal
Endocrine
Dermal
Body Weight

Systemic

Chronic (≥365 days)
Systemic mg/kg/day

100

32m
34m
34m
34m
34m
34m
34m
34m

10

31r
33r
33r
33r
33r
33r
33r
33r

1

Cancer Effect Level: Animals
LOAEL, More Serious: Animals
LOAEL, Less Serious: Animals
NOAEL - Animals

Cancer Effect Level: Humans
LOAEL, More Serious: Humans
LOAEL, Less Serious: Humans
NOAEL - Humans

LD50/LC50: Minimal Risk Level for effects other than Cancer

Animals:
- Humans
- Mink
- Other
- Dogs
- Monkeys
- Pigs
- Cows
- Rabbits
- Minks
- Other

Species:
- Cats
- Ferrets
- Guinea Pigs
- Guinea Pigs
- Guinea Pigs
- Guinea Pigs
- Guinea Pigs

Table 3-4 Levels of Significant Exposure to Dioctyltins - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td>Hepatic</td>
<td>23</td>
<td></td>
<td></td>
<td>Seinen et al. 1977a DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>23</td>
<td></td>
<td></td>
<td>DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>23</td>
<td></td>
<td></td>
<td>DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>7.7 F</td>
<td>23 F (12% reduced final body weight)</td>
<td></td>
<td>Seinen et al. 1977a DOT</td>
</tr>
</tbody>
</table>

**ACUTE EXPOSURE**

**Systemic**

**Immuno/ Lymphoret**

| 2             | Rat (Wistar)     | 2 wk ad libitum (F)                  |                     | 7.7 (over 35% reduction in relative thymus weight; lymphocyte depletion in lymphoid organs) | Seinen et al. 1977a DOT |

**INTERMEDIATE EXPOSURE**

**Death**

| 3             | Gn Pig (Hartley) | 5-7 wk ad libitum (F)                |                     | 7 F (10 of 16 deaths on weeks 4-5) | Seinen et al. 1977b DOT |
### Table 3-4 Levels of Significant Exposure to Dioctyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td>Resp</td>
<td>5.3 F</td>
<td>16 F</td>
<td>(gross changes suggesting chronic respiratory disease)</td>
<td>Seinen and Willems 1976 DOT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>5.3</td>
<td>16 M</td>
<td>(decrease hemoglobin concentration)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>5.3</td>
<td>16 M</td>
<td>(functional changes suggesting renal impairment)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Mouse (BALB/c)</td>
<td>8 wk 1 x/wk (GO)</td>
<td>Hemato</td>
<td>100 F</td>
<td>500 F</td>
<td>(14% reduction in mean hemoglobin concentration)</td>
<td>Miller et al. 1986 DOT</td>
<td></td>
</tr>
</tbody>
</table>

**Systemic**

**DOT**
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Gn Pig (Hartley)</td>
<td>4 wk ad libitum (F)</td>
<td>Gastro</td>
<td>4 M</td>
<td></td>
<td>8 M (abdominal edema)</td>
<td></td>
<td>Seinen et al. 1977a</td>
<td>DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>8 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>8 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>8 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>4 M (13% reduced final body weight)</td>
<td>8 M (43% reduced final body weight)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td></td>
<td></td>
<td>5.3</td>
<td></td>
<td></td>
<td>Seinen and Willems 1976</td>
<td>DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(thymus atrophy; lymphocyte depletion in thymic cortex)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Rat (Wistar)</td>
<td>4-6 wk ad libitum (F)</td>
<td></td>
<td></td>
<td>5 M</td>
<td>(impaired cell-mediated immunity; lymphocyte depletion from thymus)</td>
<td></td>
<td>Seinen et al. 1977b</td>
<td>DOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Mouse (BALB/c)</td>
<td>8 wk 1 x/wk (GO)</td>
<td></td>
<td>100 F</td>
<td></td>
<td></td>
<td>500 F (67% reduction in relative thymus weight)</td>
<td>Miller et al. 1986</td>
<td>DOT</td>
</tr>
<tr>
<td>10</td>
<td>Gn Pig (Hartley)</td>
<td>4 wk ad libitum (F)</td>
<td></td>
<td>4 M</td>
<td></td>
<td></td>
<td>8 M (lymphocyte depletion in thymic cortex)</td>
<td>Seinen et al. 1977a</td>
<td>DOT</td>
</tr>
</tbody>
</table>
Table 3-4 Levels of Significant Exposure to Dioctyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Gn Pig (Hartley)</td>
<td>5-7 wk ad libitum (F)</td>
<td></td>
<td>7 F</td>
<td></td>
<td></td>
<td>Seinen et al. 1977b DOT</td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-4.

Bd Wt = body weight; Endocr = endocrine; (F) = feed; F = Female; Gastro = gastrointestinal; (GO) = gavage in oil; hemato = hematological; Immuno = immunological; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; Resp = respiratory; x = time(s); wk = week(s)
Figure 3-4 Levels of Significant Exposure to Diocytlns - Oral

Acute (≤14 days)

Hepatic
Renal
Endocrine
Body Weight
Immunolymphor

mg/kg/day

100
10
1

Cancer Effect Level-Animals
LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals

Cancer Effect Level-Humans
LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans

LD50/LC50
Minimal Risk Level
for effects
other than
Cancer

c-Cat - Humans
d-Dog - Mink
r-Rat - Other
p-Pig - a-Sheep
g-Guinea Pig
f-Ferret - n-Mink
j-Pigeon - g-Hamster
k-Monkey - j-Hamster
m-Mouse - h-Mouse
e-Gerbil - a-Rabbit
h-Rabbit - g-Rabbit
s-Hamster - f-Ferret
o-Other - j-Pigeon

66 TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS
Figure 3-4 Levels of Significant Exposure to Dioctyltins - Oral (Continued)
Intermediate (15-364 days)

mg/kg/day

Systemic

Death  Respiratory  Gastrointestinal  Hematological  Musculoskeletal  Hepatic  Renal  Endocrine  Dermal  Body Weight  Immuno-Lymphor

Death  Respiratory  Gastrointestinal  Hematological  Musculoskeletal  Hepatic  Renal  Endocrine  Dermal  Body Weight  Immuno-Lymphor

Death  Respiratory  Gastrointestinal  Hematological  Musculoskeletal  Hepatic  Renal  Endocrine  Dermal  Body Weight  Immuno-Lymphor

Death  Respiratory  Gastrointestinal  Hematological  Musculoskeletal  Hepatic  Renal  Endocrine  Dermal  Body Weight  Immuno-Lymphor
| Table 3-5 Levels of Significant Exposure to Triphenyltins - Oral |

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rat (Wistar)</td>
<td>Gd 7-17 1 x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Hamster (Golden Syrian)</td>
<td>once (GO)</td>
<td>Endocr</td>
<td>50 M (hyperglycemia and hypertriglyceridemia)</td>
<td></td>
<td>Ohhira and Matsui 1996</td>
</tr>
<tr>
<td>3</td>
<td>Hamster (Golden Syrian)</td>
<td>once (GO)</td>
<td>Endocr</td>
<td>50 M (increased serum glucose and triglycerides)</td>
<td></td>
<td>Ohhira et al. 1999</td>
</tr>
<tr>
<td>4</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td>6.7 M</td>
<td>20 M (19% reduction in thymus weight)</td>
<td>Snoeij et al. 1985</td>
</tr>
<tr>
<td>5</td>
<td>Rat (Wistar)</td>
<td>Gd 0-3 1 x/d (GO)</td>
<td></td>
<td>3.1 F</td>
<td>4.7 F (infertility and preimplantation loss)</td>
<td>Ema et al. 1997b</td>
</tr>
<tr>
<td>6</td>
<td>Rat (Wistar)</td>
<td>Gd 7-9 1 x/d (GO)</td>
<td></td>
<td>3.1 F</td>
<td>6.3 F (increased resorptions, dead fetuses, and postimplantation loss)</td>
<td>Ema et al. 1999a</td>
</tr>
<tr>
<td>7</td>
<td>Rat (Wistar)</td>
<td>Gd 0-3 1 x/d (GO)</td>
<td></td>
<td>3.1 F</td>
<td>4.7 F (reduced uterine weight and serum progesterone)</td>
<td>Ema et al. 1999b</td>
</tr>
</tbody>
</table>

**ACUTE EXPOSURE**

**Death**

1. 9 F (mortality in pregnant rats)

**Systemic**

2. 50 M (hyperglycemia and hypertriglyceridemia)

3. 50 M (increased serum glucose and triglycerides)

**Immunoo/ Lymphoret**

4. 6.7 M (19% reduction in thymus weight)

**Reproductive**

5. 3.1 F

6. 3.1 F

7. 3.1 F
### Table 3-5 Levels of Significant Exposure to Triphenyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Rat (Wistar)</td>
<td>Gd 7-17 1 x/d (GO)</td>
<td>3 F</td>
<td></td>
<td>6 F   (fetal resorption)</td>
<td>Noda et al. 1991b</td>
<td>TPT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Developmental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Rat (Wistar)</td>
<td>Gd 0-3 1 x/d (GO)</td>
<td>3.1</td>
<td>4.7 (reduced fetal body weight)</td>
<td>Ema et al. 1997b</td>
<td>TPT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Rat (Wistar)</td>
<td>Gd 13-15 1 x/d (GO)</td>
<td>6.3</td>
<td>9.4 (decreased body weight of live fetuses)</td>
<td>Ema et al. 1999a</td>
<td>TPT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INTERMEDIATE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Rat (Fischer- 344)</td>
<td>7 wk ad libitum (F)</td>
<td></td>
<td>23.2 (10/10 rats died)</td>
<td>NCI 1978b</td>
<td>TPT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Mouse (B6C3F1)</td>
<td>7 wk ad libitum (F)</td>
<td></td>
<td>60 (10/10 died)</td>
<td>NCI 1978b</td>
<td>TPT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rat (Fischer- 344)</td>
<td>7 wk ad libitum (F)</td>
<td>Bd Wt</td>
<td>5 (25% reduction in body weight gain)</td>
<td>NCI 1978b</td>
<td>TPT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-5 Levels of Significant Exposure to Triphenyltins - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Rabbit (New Zealand)</td>
<td>70 d ad libitum (F)</td>
<td>Hepatic</td>
<td>8.7 M</td>
<td>17.4 M (hypertrophy of smooth endoplasmic reticulum)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>8.7 M</td>
<td>17.4 M (slight vacuolization of tubular epithelium)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1.7 M</td>
<td>8.7 M (more than 10% reduction in final body weight)</td>
<td>17.4 M (more than 20% reduction in final body weight)</td>
<td></td>
</tr>
<tr>
<td>Immuno/ Lymphoret</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Rat (Wistar)</td>
<td>3-4 wk (F)</td>
<td></td>
<td>1.25 M</td>
<td>(changes in immune response)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Rabbit (New Zealand)</td>
<td>70 d ad libitum (F)</td>
<td></td>
<td>8.7 M</td>
<td>17.4 M (depletion of lymphocytes in thymic cortex)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CHRONIC EXPOSURE

#### Death

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th></th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Rat (Wistar)</td>
<td>104 wk ad libitum (F)</td>
<td></td>
<td>0.4 F</td>
<td>(51% survival vs. 75% in controls)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Mouse (B6C3F1)</td>
<td>78 wk ad libitum (F)</td>
<td></td>
<td>4.88 M</td>
<td>(74% survival vs. 95% in controls)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>19</td>
<td>Mouse (Hybrid)</td>
<td>80 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tennekes et al. 1989a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20.16 F (50% survival vs. 74% in controls)</td>
<td></td>
<td></td>
<td>TPT</td>
</tr>
<tr>
<td>20</td>
<td>Rat (Fischer-344)</td>
<td>78 wk ad libitum (F)</td>
<td>Resp</td>
<td>3.75</td>
<td></td>
<td></td>
<td>NCI 1978b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>3.75</td>
<td></td>
<td></td>
<td>TPT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>3.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------</td>
<td>------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>21</td>
<td>Rat (Wistar)</td>
<td>104 wk (F)</td>
<td>Cardio</td>
<td>6.2 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>6.2 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>6.2 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>6.2 F</td>
<td>0.4 F (bile duct proliferation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>6.2 F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>0.4 1.3</td>
<td>0.4 F (cystoid lesions and hyperplasia of the pituitary)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ocular</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Rat (Wistar)</td>
<td>52 wk (F)</td>
<td>Cardio</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>0.4 1.3</td>
<td>1.3</td>
<td>(significant decrease in hemoglobin and hematocrit in females; increased prothrombin time in males)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>0.4 F</td>
<td></td>
<td>(bile duct proliferation)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>0.4 1.3</td>
<td>1.3</td>
<td>(cystoid pituitary lesions)</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>Exposure System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>23 (B6C3F1)</td>
<td>Mouse</td>
<td>78 wk ad libitum (F)</td>
<td>Resp</td>
<td>9.75</td>
<td></td>
<td></td>
<td>NCI 1978b TPT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>9.75</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-5 Levels of Significant Exposure to Triphenyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Mouse (Hybrid)</td>
<td>80 wk ad libitum (F)</td>
<td>Cardio</td>
<td>20.16</td>
<td>4.56 F</td>
<td>Tennekes et al. 1989a</td>
<td>TPT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>20.16 F</td>
<td>4.56 F</td>
<td>15.24 M (35-40% increase relative liver weight)</td>
<td>TPT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>20.16</td>
<td></td>
<td></td>
<td>(skin lesions, females more sensitive than males)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ocular</td>
<td>20.16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>4.56 F</td>
<td></td>
<td></td>
<td>(11% reduced final body weight)</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td>25</td>
<td>Dog (Beagle)</td>
<td>52 wk (F)</td>
<td>Resp</td>
<td>0.62</td>
<td></td>
<td>Sachsse et al 1987</td>
<td>TPT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dermal</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ocular</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>0.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Rat (Wistar)</td>
<td>52 wk (F)</td>
<td></td>
<td>0.3 M (reduction in serum immunoglobulins IgG1, IgG2a, IgG2C, IgA, and increase in IgM)</td>
<td>Tennekes et al. 1989b</td>
<td>TPT</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Rat (Wistar)</td>
<td>104 wk (F)</td>
<td></td>
<td>6.2 F</td>
<td></td>
<td>Tennekes et al. 1989b</td>
<td>TPT</td>
</tr>
<tr>
<td>28</td>
<td>Mouse (Hybrid)</td>
<td>80 wk (F)</td>
<td></td>
<td>15.24 (decreased levels of serum immunoglobulins)</td>
<td>Tennekes et al. 1989a</td>
<td>TPT</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-5 Levels of Significant Exposure to Triphenyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Rat (Wistar)</td>
<td>104 wk (F)</td>
<td></td>
<td></td>
<td></td>
<td>0.3 M (Leydig cell hypertrophy and tubular atrophy)</td>
<td></td>
<td>Tennekes et al. 1989b</td>
</tr>
<tr>
<td>30</td>
<td>Rat (Wistar)</td>
<td>104 wk (F)</td>
<td></td>
<td></td>
<td></td>
<td>1.6 CEL (pituitary tumors)</td>
<td></td>
<td>Tennekes et al. 1989b</td>
</tr>
<tr>
<td>31</td>
<td>Rat (Wistar)</td>
<td>104 wk (F)</td>
<td></td>
<td></td>
<td></td>
<td>5.2 F CEL (testicular tumors)</td>
<td></td>
<td>Tennekes et al. 1989b</td>
</tr>
<tr>
<td>32</td>
<td>Mouse</td>
<td>80 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td>15.24 F CEL (hepatocellular carcinoma)</td>
<td></td>
<td>Tennekes et al. 1989a</td>
</tr>
</tbody>
</table>

**a** The number corresponds to entries in Figure 3-5.

Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; (GW) = gavage in water; hemato = hematological; Immuno = immunological; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; Resp = respiratory; x = time(s); wk = week(s)
Figure 3-5  Levels of Significant Exposure to Triphenyltins - Oral

Acute (≤14 days)

mg/kg/day

Death  Endocrine  Immuno/Lymph  Reproductive  Developmental

3. HEALTH EFFECTS

TIN AND TIN COMPOUNDS
Figure 3-5 Levels of Significant Exposure to Triphenyltins - Oral (Continued)

Intermediate (15-364 days)

mg/kg/day

Systemic

Death  Hepatic  Renal  Body Weight  Immuno/Lymph

100

11r

12m

14h  14h  14h  16h

10

14h  14h  14h  16h

1

14h  15r

3. HEALTH EFFECTS

TIN AND TIN COMPOUNDS

c-Cat d-Dog r-Rat p-Pig q-Cow
-Humans k-Monkey m-Mouse n-Harbor
f-Ferret j-Pigeon e-Gerbil s-Hamster g-Guinea Pig

n-Mink o-Other

◆ Cancer Effect Level-Animals ◆ Cancer Effect Level-Humans
◆ LOAEL, More Serious-Animals ▲ LOAEL, More Serious-Humans
◆ LOAEL, Less Serious-Animals ▲ LOAEL, Less Serious-Humans
◆ NOAEL - Animals △ NOAEL - Humans

■ LD50/LC50

; Minimal Risk Level

; for effects

; other than

; Cancer
Figure 3-5 Levels of Significant Exposure to Triphenyltins - Oral (Continued)

Chronic (≥365 days)

Systemic

mg/kg/day

Death  Respiratory  Cardiovascular  Gastrointestinal  Hematological  Musculoskeletal  Hepatic  Renal  Endocrine  Dermal  Ocular  Body Weight  Immune/Lymphoid  Reproductive  Cancer *

- 19m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 24m  ○ 32m

- 18m  ○ 21r  ○ 22r  ○ 21r  ○ 21r  ○ 21r  ○ 21r  ○ 22r  ○ 21r  ○ 21r  ○ 21r  ○ 27r  ○ 31r

- 17r  ○ 22r  ○ 22r  ○ 22r  ○ 22r  ○ 21r  ○ 21r  ○ 22r  ○ 22r  ○ 26r  ○ 29r

* Doses represent the lowest dose tested per study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer endpoint.
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Route</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Exposure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td>6.7 M (3/10 died, none in controls)</td>
<td>Snoeij et al. 1985</td>
<td>TET</td>
</tr>
<tr>
<td>2</td>
<td>Rat (CD)</td>
<td>2 wk 2 x/wk (GW)</td>
<td></td>
<td></td>
<td></td>
<td>3 M (4/10 rats died after third dose)</td>
<td>Squibb et al. 1980</td>
<td>TET</td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td>Bd Wt</td>
<td></td>
<td>0.7 M (13% reduction in final body weight)</td>
<td>2 M (30% reduction in final body weight)</td>
<td>Snoeij et al. 1985</td>
<td>TET</td>
</tr>
<tr>
<td>4</td>
<td>Rat (CD)</td>
<td>2 wk 2 x/wk (GW)</td>
<td>Bd Wt</td>
<td></td>
<td></td>
<td>3 M (significant body weight loss)</td>
<td>Squibb et al. 1980</td>
<td>TET</td>
</tr>
<tr>
<td>5</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td>Bd Wt</td>
<td></td>
<td></td>
<td>0.5 M (body weight loss)</td>
<td>Yallapragada et al. 1991</td>
<td>TET</td>
</tr>
<tr>
<td><strong>Neurological</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Rat (Sprague-Dawley)</td>
<td>once (GW)</td>
<td></td>
<td></td>
<td></td>
<td>3 M (significant disruption of normal spontaneous activity)</td>
<td>Kernan et al. 1991</td>
<td>TET</td>
</tr>
<tr>
<td>7</td>
<td>Rat (albino)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td>2 (ataxia, paralysis of hind limbs)</td>
<td>Magee et al. 1957</td>
<td>TET</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td>8</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td>2 M</td>
<td>6.7 M (brain edema)</td>
<td>Snoeij et al. 1985</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Rat (CD)</td>
<td>2 wk 2 x/wk (GW)</td>
<td></td>
<td>1 M</td>
<td>1 M (reduced grip strength and startle responsiveness)</td>
<td>Squibb et al. 1980</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td></td>
<td>1 M</td>
<td>1.5 M (hind limb paralysis)</td>
<td>Yallapragada et al. 1991</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td><strong>INTERMEDIATE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Rat (albino)</td>
<td>3 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td>Magee et al. 1957</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Rat (Wistar)</td>
<td>11 wk (W)</td>
<td></td>
<td></td>
<td>1.4 (death)</td>
<td>Smith 1973</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rat (Sprague-Dawley)</td>
<td>90 d ad libitum (W)</td>
<td>Bd Wt</td>
<td>0.66 M</td>
<td></td>
<td>Purves et al. 1991</td>
<td>TET</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rat (CD)</td>
<td>4 wk (W)</td>
<td>Bd Wt</td>
<td></td>
<td>0.8 M (50% decrease in body weight)</td>
<td>Reiter et al. 1980</td>
<td>TET</td>
<td></td>
</tr>
</tbody>
</table>
Table 3-6 Levels of Significant Exposure to Triethyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Rat (Sprague-Dawley)</td>
<td>3 mo ad libitum (W)</td>
<td></td>
<td></td>
<td>0.7</td>
<td>(brain edema; changes in brain lipid composition)</td>
<td>Eto et al. 1971</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Rat (Osborne-Mendel)</td>
<td>22 d ad libitum (W)</td>
<td></td>
<td></td>
<td>2.8</td>
<td>(motor dysfunction, splitting of peripheral myelin sheaths and edema of brain)</td>
<td>Graham and Gonatas 1973</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Rat (Sprague-Dawley)</td>
<td>90 d ad libitum (W)</td>
<td>0.26 M</td>
<td></td>
<td>0.66 M (significant increase in brain spongiosis)</td>
<td>Purves et al. 1991</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Rat (CD)</td>
<td>4 wk ad libitum (W)</td>
<td></td>
<td>0.4 M (diminished maze activity and startle response)</td>
<td>0.8 M (paralysis)</td>
<td>Reiter et al. 1980</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Rat (Long-Evans)</td>
<td>3 wk ad libitum (W)</td>
<td></td>
<td></td>
<td>4.2 M (hind limb paralysis followed by recovery; demyelination in spinal cord and peripheral nerves)</td>
<td>Richman and Bienkamper 1984</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-6.

Bd Wt = body weight; d = day(s); (F) = feed; (GO) = gavage in oil; (GW) = gavage in water; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); NOAEL = no-observed-adverse-effect; x = time(s); (W) = drinking water; wk = week(s)
Figure 3-6 Levels of Significant Exposure to Triethyltins - Oral

Acute (≤14 days)

mg/kg/day

Death

Systemic

Body Weight

Neurological

Cancer Effect Level - Animals

LOAEL, More Serious

LOAEL, Less Serious

NOAEL

Cancer Effect Level - Humans

LOAEL, More Serious

LOAEL, Less Serious

NOAEL

LD50/LC50

Minimal Risk Level for effects other than Cancer

Animals

Humans

C-Cat - Humans

d-Dog - k-Mouse

r-Rat - m-Mouse

p-Pig - h-Rabbit

q-Cow - a-Sheep

f-Ferret - n-Mink

e-Gerbil - o-Other

- Cancer Effect Level - Animals

- LOAEL, More Serious - Animals

- NOAEL - Animals

- Cancer Effect Level - Humans

- LOAEL, More Serious - Humans

- NOAEL - Humans

- LD50/LC50

- Minimal Risk Level for effects other than Cancer
Figure 3-6  Levels of Significant Exposure to Triethyltins - Oral (Continued)

Intermediate (15-364 days)

mg/kg/day

Systemic

Death

Body Weight

Neurological

0.1

1

10

0.1

Cancer Effect Level - Animals
- LOAEL, More Serious
- LOAEL, Less Serious
- NOAEL

Cancer Effect Level - Humans
- LOAEL, More Serious
- LOAEL, Less Serious
- NOAEL

LD50/LC50

Minimal Risk Level

for effects

other than

Cancer
### Table 3-7 Levels of Significant Exposure to Trimethyltins - Oral

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rat (albino)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>7 M (4 out 10 rats died)</td>
<td></td>
<td>Alessandri et al. 1994 TMT</td>
</tr>
<tr>
<td>2</td>
<td>Rat (Long- Evans) (G)</td>
<td>once</td>
<td></td>
<td></td>
<td></td>
<td>5 (fatal seizures after 4 doses)</td>
<td></td>
<td>Bouldin et al. 1981 TMT</td>
</tr>
<tr>
<td>3</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>12.6 M (LD50)</td>
<td></td>
<td>Brown et al. 1979 TMT</td>
</tr>
<tr>
<td>4</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td></td>
<td></td>
<td>2 M (2/10 deaths, none in controls)</td>
<td></td>
<td>Snoeij et al. 1985 TMT</td>
</tr>
<tr>
<td>5</td>
<td>Hamster (NS)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>4 F (death within 4 days of dosing)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
</tr>
<tr>
<td>6</td>
<td>Primate (NS)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>3.75 M (4/11 died within 3 days of dosing)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
</tr>
<tr>
<td>7</td>
<td>Gerbil (NS)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>3 F (death within 2-7 days of dosing)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
</tr>
</tbody>
</table>

**Note:**
- **Key & Figure:** Indicate the key figure and the species (strain) used in the experiment.
- **Exposure/Duration/Frequency:** Specify the exposure duration, frequency, and route.
- **System:** Indicate the system used for the experiment.
- **NOAEL (mg/kg/day):** No observed adverse effect level.
- **LOAEL:** Lowest observed adverse effect level.
- **Less Serious:** Adverse effects less severe.
- **Serious:** Severe adverse effects.
- **Reference:** Cite the reference for the study.
Table 3-7 Levels of Significant Exposure to Trimethyltin—Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Gerbil (Mongolian)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>4 (death within days of dosing)</td>
<td>Nolan et al. 1990</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td>9</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td>Renal</td>
<td></td>
<td></td>
<td>3 M (slightly dilated proximal tubules and impaired organ function)</td>
<td>Opacka and Sparrow 1985</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td>10</td>
<td>Rat (Long-Evans) (GW)</td>
<td>once (GW)</td>
<td>Renal</td>
<td></td>
<td></td>
<td>12.25 M (severe kidney tubule damage)</td>
<td>Robertson et al. 1987</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12.25 M (significant weight loss)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td>Bd Wt</td>
<td></td>
<td></td>
<td>1.5 M (reduced body weight gain)</td>
<td>Yallapragada et al. 1991</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td>12</td>
<td>Rat (Long-Evans)</td>
<td>14 d 1 x/d (G)</td>
<td></td>
<td></td>
<td></td>
<td>1 (self-mutiliating and highly aggressive behavior)</td>
<td>Bouldin et al. 1981</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td>13</td>
<td>Rat (Long-Evans)</td>
<td>once (G)</td>
<td></td>
<td></td>
<td></td>
<td>6 M (morphological damage to sensory neurons)</td>
<td>Chang and Dyer 1983</td>
<td>TMT</td>
<td>TMT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Rat (Long- Evans) (GW)</td>
<td>once</td>
<td></td>
<td></td>
<td>7.5 M (neuronal damage; mainly olfactory cortex, fascia dentata)</td>
<td>Chang et al 1983</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Rat (Sprague-Dawley)</td>
<td>once</td>
<td>(GW)</td>
<td></td>
<td>9 M (progressive degeneration of hippocampal cells; impaired learning)</td>
<td>Ishida et al. 1997</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Rat (Long- Evans) (GW)</td>
<td>once</td>
<td></td>
<td></td>
<td>8 F (significant damage to hippocampal structures)</td>
<td>Kutscher 1992</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Rat (Sprague-Dawley)</td>
<td>once</td>
<td>(G)</td>
<td></td>
<td>9 M (aggressive behavior and biochemical changes in brain areas)</td>
<td>Nishimura et al. 2001</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td>0.7 M</td>
<td>2 M (neuronal degeneration in hippocampus and pyriform cortex)</td>
<td>Snoeij et al. 1985</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Rat (Sprague-Dawley)</td>
<td>once</td>
<td>(GW)</td>
<td></td>
<td>9 M (loss of pyramidal cells in hippocampus and impaired learning)</td>
<td>Tsutsumi et al. 2002</td>
<td>TMT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL (mg/kg/day)</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------------------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td></td>
<td>0.75 M (hyperexcitability; reduced brain calmodulin activity)</td>
<td></td>
<td>Yallapragada et al. 1991 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Mouse (BALB/c)</td>
<td>once (GW)</td>
<td></td>
<td>3 M (neuronal damage; mainly hippocampal, fascia dentata)</td>
<td></td>
<td>Chang et al 1983 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Hamster (NS)</td>
<td>once (GO)</td>
<td></td>
<td>4 F (whole body tremors)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Primate (NS)</td>
<td>once (GO)</td>
<td></td>
<td>3 M (ataxia; neuronal degeneration in brain areas)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Gerbil (NS)</td>
<td>once (GO)</td>
<td></td>
<td>3 F (tremors, prostration, hippocampal degeneration)</td>
<td></td>
<td>Brown et al. 1984 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Gerbil (Mongolian)</td>
<td>once (GO)</td>
<td></td>
<td>3.5 (prostration, tremors and ataxia; histopathological changes in the CNS)</td>
<td></td>
<td>Nolan et al. 1990 TMT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### INTERMEDIATE EXPOSURE

#### Systemic

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Rat (Wistar)</td>
<td>25 d ad libitum (F)</td>
<td>Bd Wt</td>
<td>0.8</td>
<td></td>
<td>Allen et al. 1994</td>
</tr>
</tbody>
</table>

#### Neurological

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Rat (Wistar)</td>
<td>25 d ad libitum (F)</td>
<td></td>
<td></td>
<td>0.8 (aggressive behavior; cell necrosis in the hippocampus, pyriform cortex, amygdala, and olfactory tuberculum)</td>
<td>Allen et al. 1994</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Rat (Long-Evans)</td>
<td>26 d 1 x/2d (G)</td>
<td></td>
<td></td>
<td>1 (tremors and seizures in pups; neuronal necrosis in hippocampus)</td>
<td>Bouldin et al. 1981</td>
</tr>
</tbody>
</table>

#### Developmental

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Rat (Sprague-Dawley)</td>
<td>56 d ad libitum (W)</td>
<td></td>
<td>0.05 M (significant decrease in extinction learning ability)</td>
<td></td>
<td>Noland et al. 1982</td>
</tr>
</tbody>
</table>

---

a The number corresponds to entries in Figure 3-7.

Bd Wt = body weight; d = day(s); (F) = feed; F = Female; (G) = gavage; (GO) = gavage in oil; (GW) = gavage in water; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; x = time(s); (W) = drinking water; wk = week(s)
Figure 3-7 Levels of Significant Exposure to Trimethyltins - Oral

Acute (≤14 days)
Figure 3-7 Levels of Significant Exposure to Trimethyltins - Oral (Continued)

Intermediate (15-364 days)

- Body Weight
- Systemic
- Neurological
- Developmental

mg/kg/day

- c-Cat - Humans
- d-Dog
- r-Rat
- p-Pig
- q-Cow
- f-Ferret
- n-Mink
- o-Other
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals

- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans

- LD50/LC50
- Minimal Risk Level
- for effects
- other than Cancer

- 26r
- 27r
- 28r
- 29r
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACUTE EXPOSURE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rat (Sprague-Dawley)</td>
<td>3 d 1 x/d (GO)</td>
<td></td>
<td></td>
<td>37.5 M (6/50 died)</td>
<td></td>
<td></td>
<td>Elsabbagh et al. 2002</td>
<td>TBT</td>
</tr>
<tr>
<td>2</td>
<td>Rat (albino)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td>148 M (LD50 in corn oil)</td>
<td></td>
<td></td>
<td>Elsea and Paynter 1958</td>
<td>TBT</td>
</tr>
<tr>
<td>3</td>
<td>Rat (albino)</td>
<td>once (GW)</td>
<td></td>
<td></td>
<td>194 M (LD50 in aqueous suspension)</td>
<td></td>
<td></td>
<td>Elsea and Paynter 1958</td>
<td>TBT</td>
</tr>
<tr>
<td>4</td>
<td>Mouse (Hybrid)</td>
<td>Gd 6-17 1 x/d (GO)</td>
<td></td>
<td></td>
<td>27 F (3/40 pregnant mice died, none in controls)</td>
<td></td>
<td></td>
<td>Faqi et al. 1997</td>
<td>TBT</td>
</tr>
<tr>
<td>5</td>
<td>Hamster (Golden Syrian)</td>
<td>once (GO)</td>
<td></td>
<td></td>
<td>149.6 M (2-week LD50; 172 mg/kg in females)</td>
<td></td>
<td></td>
<td>Takagi et al. 1992</td>
<td>TBT</td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Rat (Sprague-Dawley)</td>
<td>11 d Gd 8-19 1 x/day (GO)</td>
<td>Endocr</td>
<td>0.25 F</td>
<td>2.5 F (reduced serum thyroxine)</td>
<td></td>
<td></td>
<td>Adeeko et al. 2003</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>2.5 F</td>
<td>10 F (18% reduced body weight gain)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Rat (Long-Evans)</td>
<td>Gd 6-20 1 x/d (GO)</td>
<td>Bd Wt</td>
<td>5 F</td>
<td>10 F (20% decrease in body weight gain)</td>
<td></td>
<td></td>
<td>Crofton et al. 1989</td>
<td>TBT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Reference Chemical Form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>--------</td>
<td>-------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td>Endocr</td>
<td>60 M</td>
<td></td>
<td>Raffray and Cohen 1993 TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td></td>
<td>30 M (body weight loss 48 hours after dosing)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>58.6 M (increased serum AST and ALT activities)</td>
<td></td>
<td>Ueno et al. 2003b TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td>Bd Wt</td>
<td>1.5 M</td>
<td>2.5 M (significant weight loss)</td>
<td>Yallapragada et al. 1991 TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Mouse (albino)</td>
<td>Gd 6-15 (GO)</td>
<td>Bd Wt</td>
<td>5 F (18% reduction in body weight gain)</td>
<td></td>
<td>Baroncelli et al. 1995 TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Mouse (albino)</td>
<td>Gd 6-15 (GO)</td>
<td>Hemato</td>
<td>20 F</td>
<td></td>
<td>Karrer et al. 1995 TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Mouse (albino)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>39 M</td>
<td>58.6 M (liver damage)</td>
<td>Ueno et al. 1995 TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Mouse (albino)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td></td>
<td>58.6 M (liver necrosis)</td>
<td>Ueno et al. 2003b TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Gn Pig (Hartley)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>117.2 M</td>
<td></td>
<td>Ueno et al. 2003a TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-8 Levels of Significant Exposure to Tributyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Gn Pig (Hartley)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>58.6</td>
<td>M</td>
<td></td>
<td>Ueno et al. 2003b</td>
</tr>
<tr>
<td>17</td>
<td>Hamster (Golden Syrian)</td>
<td>once (GO)</td>
<td>Hepatic</td>
<td>29.6</td>
<td>(bile duct dilation and inflammatory damage)</td>
<td></td>
<td>Takagi et al. 1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bd Wt</td>
<td></td>
<td>66.7 F</td>
<td>100 F (13% decrease in final body weight)</td>
<td></td>
<td>TBT</td>
</tr>
</tbody>
</table>

**Immuno/ Lymphoret**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Rat (Wistar)</td>
<td>once (GO)</td>
<td></td>
<td>30 M</td>
<td>(significant decrease in relative and absolute thymus weight)</td>
<td></td>
<td>Raffray and Cohen 1993</td>
</tr>
<tr>
<td>19</td>
<td>Rat (Fischer-344)</td>
<td>10 d 1 x/d (GO)</td>
<td></td>
<td>1.25 M</td>
<td>2.5 M (enhanced primary immune response to SRBC; significant decrease in thymus weight)</td>
<td>Smialowicz et al. 1989</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TBT</td>
</tr>
<tr>
<td>20</td>
<td>Rat (Fischer-344)</td>
<td>10 d 1 x/d (GO)</td>
<td></td>
<td>2.5 M</td>
<td>5 M (enhanced immune response to SRBC immunization; reduced T cells)</td>
<td>Smialowicz et al. 1990</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TBT</td>
</tr>
<tr>
<td>21</td>
<td>Rat (Wistar)</td>
<td>2 wk ad libitum (F)</td>
<td></td>
<td>2 M</td>
<td>6.7 M (lymphocyte depletion in the thymus)</td>
<td>Snoeij et al. 1985</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TBT</td>
</tr>
</tbody>
</table>
### Table 3-8 Levels of Significant Exposure to Tributyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neurological</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Rat (Sprague-Dawley)</td>
<td>3 d 1 x/d (GO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Rat (Wistar)</td>
<td>once (G)</td>
<td></td>
<td></td>
<td>6.3 M (decreased dark-phase spontaneous motor activity)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Elsabbagh et al. 2002</td>
<td>TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Rat (Sprague-Dawley)</td>
<td>6 d 1 x/d (GO)</td>
<td></td>
<td></td>
<td>1.5 M</td>
<td>2.5 M (slight tremors and weakness)</td>
<td></td>
<td>Yallapragada et al. 1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reproductive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Rat (Sprague-Dawley)</td>
<td>11 d Gd 8-19 1 x/day (GO)</td>
<td></td>
<td></td>
<td>10 F</td>
<td></td>
<td></td>
<td>Adeekoo et al. 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Rat (Wistar)</td>
<td>3 d Gd 7-9 Gd 10-12 Gd 13-15 (GO)</td>
<td></td>
<td></td>
<td></td>
<td>25 F (significant increase in resorptions and post-implantation loss)</td>
<td></td>
<td>Ema et al. 1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Rat (Wistar)</td>
<td>Gd 9 once (GO)</td>
<td></td>
<td></td>
<td></td>
<td>100 F (significant increase in post-implantation loss)</td>
<td></td>
<td>Ema et al. 1997a</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Route</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL (mg/kg/day)</td>
<td>Reference Chemical Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>-------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Rat (Wistar)</td>
<td>4 d Gd 0-3 (GO)</td>
<td></td>
<td>8.1 F</td>
<td>16.3 F (significant increase in pregnancy failure)</td>
<td>Harazono et al. 1998 TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Rat (Wistar)</td>
<td>11 d Gd 7-17 (GO)</td>
<td></td>
<td>8 F</td>
<td>16 F (increased fetal deaths and resorptions)</td>
<td>Noda et al. 1991a TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Rat (Sprague-Dawley)</td>
<td>10 d 1 x/d (GO)</td>
<td></td>
<td>5 M</td>
<td>10 M (histologic alterations of seminal vesicles and epididymis)</td>
<td>Yu et al. 2003a TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Rat (Sprague-Dawley)</td>
<td>10 d 1 x/d (GO)</td>
<td></td>
<td>5 M</td>
<td>10 M (reduced sperm counts)</td>
<td>Yu et al. 2003b TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Mouse (albino)</td>
<td>Gd 6-15 (GO)</td>
<td></td>
<td></td>
<td>5 F (increased early parturitions and number of resorptions)</td>
<td>Baroncelli et al. 1995 TBT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Mouse (albino)</td>
<td>10 d Gd 6-15 1x/d (GO)</td>
<td></td>
<td>23.4 F</td>
<td>35 F (decreased number of implantations and living fetuses)</td>
<td>Davis et al 1987 TBT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3-8 Levels of Significant Exposure to Tributyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Mouse (Hybrid)</td>
<td>Gd 6-17 1 x/d (GO)</td>
<td></td>
<td>27 F</td>
<td></td>
<td></td>
<td>Faqì et al. 1997</td>
</tr>
<tr>
<td>35</td>
<td>Rat (Sprague-Dawley)</td>
<td>11 d Gd 8-19 1 x/day (GO)</td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td>Adeeko et al. 2003</td>
</tr>
<tr>
<td>36</td>
<td>Rat (Long-Evans)</td>
<td>Gd 6-20 1 x/d (GO)</td>
<td></td>
<td>5 F</td>
<td></td>
<td>10 F (decreased pup survival)</td>
<td>Crofton et al. 1989</td>
</tr>
<tr>
<td>37</td>
<td>Rat (Wistar)</td>
<td>3 d Gd 7-9 Gd 10-12 Gd 13-15 (GO)</td>
<td></td>
<td>25</td>
<td>(significant increase in incidence of cleft palate when TBTC was given on Gd 13-15)</td>
<td>Ema et al. 1995</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Rat (Wistar)</td>
<td>Gd 9 once (GO)</td>
<td></td>
<td>100</td>
<td>(significant increase in incidence of cleft palate)</td>
<td>Ema et al. 1997a</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 6-20 1 x/d (G)</td>
<td></td>
<td>1</td>
<td>(hyperactivity and impaired learning)</td>
<td>Gardlung et al. 1991</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Rat (Wistar)</td>
<td>4 d Gd 0-3 (GO)</td>
<td></td>
<td>8.1 16.3</td>
<td>(significantly reduced fetal weight)</td>
<td>Harazono et al. 1998</td>
<td></td>
</tr>
</tbody>
</table>

TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS
<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Rat (Wistar)</td>
<td>11 d Gd 7-17 (GO)</td>
<td></td>
<td>8</td>
<td>16</td>
<td>(significant increase in cleft palate incidence)</td>
<td>Noda et al. 1991a</td>
<td>TBT</td>
</tr>
<tr>
<td>42</td>
<td>Mouse (albino)</td>
<td>Gd 6-15 1 x/d (GO)</td>
<td></td>
<td>20 F</td>
<td>40 F (approximately 21% lower fetal weight)</td>
<td>Baroncelli et al. 1990</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Mouse (albino)</td>
<td>Gd 6-15 (GO)</td>
<td></td>
<td>10 F</td>
<td>20 F (significant increase in postnatal mortality)</td>
<td>Baroncelli et al. 1995</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Mouse (albino)</td>
<td>10 d Gd 6-15 1x/d (GO)</td>
<td></td>
<td></td>
<td>11.7 F (cleft plate and other bone abnormalities)</td>
<td>Davis et al 1987</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Mouse (Hybrid)</td>
<td>Gd 6-17 1 x/d (GO)</td>
<td></td>
<td>13.5</td>
<td>27</td>
<td>(significant increased incidence of cleft palate)</td>
<td>Faqí et al. 1997</td>
<td>TBT</td>
</tr>
</tbody>
</table>

**INTERMEDIATE EXPOSURE**

**Death**

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>46</td>
<td>Rat (Wistar)</td>
<td>5 wk 3 d/wk (GW)</td>
<td></td>
<td>8</td>
<td>(unspecified number of deaths on week 3)</td>
<td>Attaíru et al. 1991</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>47</strong></td>
<td>Monkey (Cynomolgus)</td>
<td>22 wk 6 d/wk (GW)</td>
<td>Hemato</td>
<td>0.16 M</td>
<td></td>
<td></td>
<td>Karrer et al. 1992</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>0.16 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>48</strong></td>
<td>Rat (Sprague-Dawley)</td>
<td>26 wk 5 x/wk (GO)</td>
<td>Endocr</td>
<td>3 M</td>
<td>6 M (33% increase in adrenal relative weight and 26% of the hypophysis)</td>
<td></td>
<td>Funahashi et al. 1980</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>3 M</td>
<td>6 M (13% decrease in final body weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>49</strong></td>
<td>Rat (Sprague-Dawley)</td>
<td>19 d Gd 0-19 1 x/day (GO)</td>
<td>Endocr</td>
<td>2.5 F</td>
<td>10 F (decreased serum T4 and T3)</td>
<td></td>
<td>Adeeko et al. 2003</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td></td>
<td>20 F (25% reduced weight gain)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>50</strong></td>
<td>Rat (Wistar)</td>
<td>30 d ad libitum (F)</td>
<td>Hepatic</td>
<td>2.5 M</td>
<td></td>
<td></td>
<td>Bressa et al. 1991</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>2.5 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>----------------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------</td>
<td>--------------------------</td>
<td>-------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>51</td>
<td>Rat (Fischer-344)</td>
<td>6 wk ad libitum (F)</td>
<td>Hepatic</td>
<td>16</td>
<td></td>
<td>(cholangitis with biliary retention)</td>
<td></td>
<td>Carthew et al. 1992 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>16 M (27% reduced final body weight relative to controls)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Rat (Wistar)</td>
<td>6 wk 7 d/wk (F)</td>
<td>Endocr</td>
<td>1 M (decreased serum insulin levels)</td>
<td>4 M</td>
<td>(decreased thyroxine, thyroid stimulating hormone and insulin; increased leutinizing hormone)</td>
<td></td>
<td>Krajnc et al 1984 TBT</td>
</tr>
<tr>
<td>53</td>
<td>Rat (Wistar)</td>
<td>4 wk ad libitum (F)</td>
<td>Hemato</td>
<td>0.25</td>
<td>4</td>
<td>(abnormalities in all hematological components)</td>
<td></td>
<td>Krajnc et al 1984 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>1</td>
<td>4</td>
<td>(slight atrophy of hematocytes)</td>
<td>16 (liver necrosis and bile duct hyperplasia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>1</td>
<td>4 (10% lower final body weight)</td>
<td>16 (weight loss)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td>Bd Wt</td>
<td>4 M</td>
<td></td>
<td></td>
<td></td>
<td>Van Loveren et al 1990 TBT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/ Duration/ Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>--------------------------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td>Bd Wt</td>
<td>8 M</td>
<td></td>
<td></td>
<td>Vandebriel et al. 1998</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Rat (Sprague-Dawley)</td>
<td>28 d ad libitum (F)</td>
<td>Hemato</td>
<td>5</td>
<td></td>
<td></td>
<td>Verdier et al. 1991</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>5</td>
<td></td>
<td></td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Mouse (BALB/c)</td>
<td>30 d ad libitum (F)</td>
<td>Bd Wt</td>
<td>25 M</td>
<td></td>
<td></td>
<td>Konno et al. 2001</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td><strong>Immuno/ Lymphoret</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Rat (Wistar)</td>
<td>30 d ad libitum (F)</td>
<td></td>
<td>0.5 M (partial atrophy of mesenteric lymph nodes)</td>
<td></td>
<td></td>
<td>Bressa et al. 1991</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Rat (Fischer-344)</td>
<td>6 wk ad libitum (F)</td>
<td></td>
<td>16 (22-28% reduced relative thymus weight)</td>
<td></td>
<td></td>
<td>Carthew et al. 1992</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Rat (Sprague-Dawley)</td>
<td>26 wk 5x/wk (GO)</td>
<td></td>
<td>3 M (30% decreased relative thymus weight)</td>
<td></td>
<td></td>
<td>Funahashi et al. 1980</td>
<td></td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>NOAEL (mg/kg/day)</td>
<td>LOAEL</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>-------------</td>
</tr>
<tr>
<td>61</td>
<td>Rat (Wistar)</td>
<td>4 wk 7 d/wk (F)</td>
<td>0.25</td>
<td></td>
<td>1 (17% decrease thymus weight)</td>
<td>4 (35% decreased thymus weight)</td>
<td>Krajnc et al. 1984</td>
<td>TBT</td>
</tr>
<tr>
<td>62</td>
<td>Rat (Fischer-344)</td>
<td>3 wk 3x/wk (GO)</td>
<td></td>
<td></td>
<td>5 M (significant reduction in thymus weight; reduced lymphoproliferative response to mitogen Con A).</td>
<td>10 M (approximately 45% reduction in thymus weight)</td>
<td>Smialowicz et al. 1989</td>
<td>TBT</td>
</tr>
<tr>
<td>63</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td>0.5</td>
<td></td>
<td>1 M (reduced natural killer cell activity)</td>
<td></td>
<td>Van Loveren et al. 1990</td>
<td>TBT</td>
</tr>
<tr>
<td>64</td>
<td>Rat (Wistar)</td>
<td>6 wk ad libitum (F)</td>
<td>2 M</td>
<td></td>
<td>8 M (25% reduced thymus weight)</td>
<td></td>
<td>Vandebriel et al. 1998</td>
<td>TBT</td>
</tr>
<tr>
<td>65</td>
<td>Rat (Sprague-Dawley)</td>
<td>28 d ad libitum (F)</td>
<td>0.5</td>
<td></td>
<td>5 (slight impairment in host resistance to Listeria monocytogenes)</td>
<td></td>
<td>Verdier et al. 1991</td>
<td>TBT</td>
</tr>
<tr>
<td>66</td>
<td>Rat (Wistar)</td>
<td>4.5-6 mo ad libitum (F)</td>
<td>0.025 M</td>
<td></td>
<td>0.25 M (altered parameters of both specific and nonspecific immunocompetence)</td>
<td></td>
<td>Vos et al. 1990</td>
<td>TBT</td>
</tr>
<tr>
<td>Key to Figure</td>
<td>Species (Strain)</td>
<td>Exposure/Duration/Frequency (Route)</td>
<td>System</td>
<td>NOAEL (mg/kg/day)</td>
<td>Less Serious (mg/kg/day)</td>
<td>Serious (mg/kg/day)</td>
<td>Reference</td>
<td>Chemical Form</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Reproductive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Rat (Sprague-Dawley)</td>
<td>19 d Gd 0-19 1 x/day (GO)</td>
<td></td>
<td>10</td>
<td>20 (post-implantation loss; decreased litter size)</td>
<td></td>
<td>Adeeko et al. 2003</td>
<td>TBT</td>
</tr>
<tr>
<td>68</td>
<td>Rat (Wistar)</td>
<td>42 d Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>10 F</td>
<td></td>
<td></td>
<td>Ogata et al. 2001</td>
<td>TBT</td>
</tr>
<tr>
<td>69</td>
<td>Rat (Wistar)</td>
<td>42 d Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>10 M</td>
<td></td>
<td></td>
<td>Omura et al. 2001</td>
<td>TBT</td>
</tr>
<tr>
<td>70</td>
<td>Mouse (ICR)</td>
<td>4 wk 2 x/wk (GW)</td>
<td></td>
<td>2 M</td>
<td>10 M (reduced sperm counts)</td>
<td></td>
<td>Kamasaka et al. 2002</td>
<td>TBT</td>
</tr>
<tr>
<td><strong>Developmental</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>Rat (Sprague-Dawley)</td>
<td>19 d Gd 0-19 1 x/day (GO)</td>
<td></td>
<td>0.25 M (increased anogenital distance)</td>
<td></td>
<td></td>
<td>Adeeko et al. 2003</td>
<td>TBT</td>
</tr>
<tr>
<td>72</td>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-21 Ld 1-21 Pid 1-60 (GO)</td>
<td></td>
<td>0.025</td>
<td>0.25 (decreased pup's liver and thymus weight)</td>
<td></td>
<td>Cooke et al. 2004</td>
<td>TBT</td>
</tr>
</tbody>
</table>
Table 3.8 Levels of Significant Exposure to Tributyltins - Oral

<table>
<thead>
<tr>
<th>Key to Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System (mg/kg/day)</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-21 Ld 1-21 (F)</td>
<td>F</td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>Makita et al. 2003</td>
<td></td>
</tr>
<tr>
<td>Rat (Wistar)</td>
<td>Ld 1-21 (F)</td>
<td></td>
<td>0.25</td>
<td>2.5</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>Rat (Wistar)</td>
<td>Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>Makita et al. 2004</td>
<td></td>
</tr>
<tr>
<td>Rat (Wistar)</td>
<td>Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>Ogata et al. 2001</td>
<td></td>
</tr>
<tr>
<td>Rat (Sprague-Dawley)</td>
<td>Gd 8-21 Ld 1-21 (F)</td>
<td></td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>Ohta et al. 2004</td>
<td></td>
</tr>
<tr>
<td>Rat (Wistar)</td>
<td>Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>TBT</td>
<td></td>
</tr>
<tr>
<td>Rat (Wistar)</td>
<td>Gd 1-21 Ld 1-21 (F)</td>
<td></td>
<td>0.4 M</td>
<td>2 F (slight reduction in pup weight)</td>
<td>TBT</td>
<td></td>
</tr>
</tbody>
</table>

Exposure to Tributyltin Compounds

3. HEALTH EFFECTS
### Table 3-8 Levels of Significant Exposure to Tributyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>LOAEL</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>Rat (Wistar)</td>
<td>106 wk ad libitum (F)</td>
<td>Resp</td>
<td>2.5 F</td>
<td></td>
<td>2.5 F (decreased hemoglobin and hematocrit after 12 months)</td>
<td></td>
<td>Wester et al. 1990</td>
<td>TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cardio</td>
<td>2.5 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastro</td>
<td>2.5 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hemato</td>
<td>0.25 F</td>
<td>2.1 M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Musc/skel</td>
<td>2.5 F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic</td>
<td>0.25 F</td>
<td>2.1 M</td>
<td>(29% increase in absolute liver weight; increased serum liver transaminases)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal</td>
<td>0.19 M</td>
<td>2.1 M</td>
<td>(29% increase in absolute kidney weight)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endocr</td>
<td>0.19 M</td>
<td>2.1 M</td>
<td>(decreased thyroid follicular epithelial cell height)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bd Wt</td>
<td>0.19 M</td>
<td>2.1 M</td>
<td>(decreased body weight from week 67 onward)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>79</td>
<td>Rat (Wistar)</td>
<td>18 mo ad libitum (F)</td>
<td>Immuno/Lymphoret</td>
<td>0.025 M</td>
<td>0.25 M</td>
<td>(altered parameters of both specific and nonspecific immunocompetence)</td>
<td></td>
<td>Vos et al. 1990</td>
<td>TBT</td>
</tr>
</tbody>
</table>
### Table 3-8 Levels of Significant Exposure to Tributyltins - Oral (continued)

<table>
<thead>
<tr>
<th>Key to Figure</th>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL (mg/kg/day)</th>
<th>Less Serious (mg/kg/day)</th>
<th>Serious (mg/kg/day)</th>
<th>Reference Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>Rat (Wistar)</td>
<td>106 wk ad libitum (F)</td>
<td></td>
<td></td>
<td>2.1 M (significant changes in serum immunoglobulin levels)</td>
<td></td>
<td>Wester et al. 1990 TBT</td>
</tr>
</tbody>
</table>

a The number corresponds to entries in Figure 3-8.

b Used to derive an intermediate-duration minimal risk level (MRL) of 0.0003 mg/kg/day; The MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability).

c Used to derive a chronic-duration minimal risk level (MRL) of 0.0003 mg/kg/day; The MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability).

Bd Wt = body weight; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; (GW) = gavage in water hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); NOAEL = no-observed-adverse-effect level; Resp = respiratory; x = time(s); wk = week(s)
Figure 3-8 Levels of Significant Exposure to Tributyltins - Oral

Acute (≤14 days)

mg/kg/day

Death Hematological Hepatic Endocrine Body Weight Immunolympho Neurological Reproductive Developmental

1000
100
10
1
0.1

Death Hematological Hepatic Endocrine Body Weight Immunolympho Neurological Reproductive Developmental

1000
100
10
1
0.1

Key:
- Cancer Effect Level-Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Animals
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Animals
- LOAEL, Less Serious-Humans
- NOAEL - Animals
- NOAEL - Humans
- LD50/LC50 Minimal Risk Level for effects other than Cancer

Animals:
- c-Cat - Humans
- d-Dog
- e-Gerbil
- f-Ferret
- g-Guinea Pig
- h-Rabbit
- j-Pigeon
- k-Monkey
- l-Lamb
- m-Mouse
- n-Mink
- o-Other

3. HEALTH EFFECTS

TIN AND TIN COMPOUNDS

- Humans
- LD50/LC50 Minimal Risk Level for effects other than Cancer
Figure 3-8  Levels of Significant Exposure to Tributyltins - Oral (Continued)

Acute (≤14 days)

mg/kg/day

Developmental

- Humans
  - Cancer Effect Level - Humans
    - LOAEL, More Serious-Humans
    - LOAEL, Less Serious-Humans
    - NOAEL - Humans
  - LD50/LC50
    - Minimal Risk Level
    - for effects
    - other than Cancer

- Animals
  - Cancer Effect Level - Animals
    - LOAEL, More Serious-Animals
    - LOAEL, Less Serious-Animals
    - NOAEL - Animals
  - LOAEL, More Serious-Animals
  - LOAEL, Less Serious-Animals
  - NOAEL - Animals

- Other
  - Cancer Effect Level - Other
  - LOAEL, More Serious-Other
  - LOAEL, Less Serious-Other
  - NOAEL - Other

- Mink
  - Cancer Effect Level - Mink
  - LOAEL, More Serious-Mink
  - LOAEL, Less Serious-Mink
  - NOAEL - Mink

- Mouse
  - Cancer Effect Level - Mouse
  - LOAEL, More Serious-Mouse
  - LOAEL, Less Serious-Mouse
  - NOAEL - Mouse

- Rat
  - Cancer Effect Level - Rat
  - LOAEL, More Serious-Rat
  - LOAEL, Less Serious-Rat
  - NOAEL - Rat

- Dog
  - Cancer Effect Level - Dog
  - LOAEL, More Serious-Dog
  - LOAEL, Less Serious-Dog
  - NOAEL - Dog

- Monkey
  - Cancer Effect Level - Monkey
  - LOAEL, More Serious-Monkey
  - LOAEL, Less Serious-Monkey
  - NOAEL - Monkey

- Pigeon
  - Cancer Effect Level - Pigeon
  - LOAEL, More Serious-Pigeon
  - LOAEL, Less Serious-Pigeon
  - NOAEL - Pigeon

- Gerbil
  - Cancer Effect Level - Gerbil
  - LOAEL, More Serious-Gerbil
  - LOAEL, Less Serious-Gerbil
  - NOAEL - Gerbil

- Guinea Pig
  - Cancer Effect Level - Guinea Pig
  - LOAEL, More Serious-Guinea Pig
  - LOAEL, Less Serious-Guinea Pig
  - NOAEL - Guinea Pig

- Mink
  - Cancer Effect Level - Mink
  - LOAEL, More Serious-Mink
  - LOAEL, Less Serious-Mink
  - NOAEL - Mink

- Ferret
  - Cancer Effect Level - Ferret
  - LOAEL, More Serious-Ferret
  - LOAEL, Less Serious-Ferret
  - NOAEL - Ferret

- Guinea Pig
  - Cancer Effect Level - Guinea Pig
  - LOAEL, More Serious-Guinea Pig
  - LOAEL, Less Serious-Guinea Pig
  - NOAEL - Guinea Pig

- Other
  - Cancer Effect Level - Other
  - LOAEL, More Serious-Other
  - LOAEL, Less Serious-Other
  - NOAEL - Other
Figure 3-8 Levels of Significant Exposure to Tributyltins - Oral (Continued)
Intermediate (15-364 days)

Systemic

mg/kg/day

Death Hematological Hepatic Renal Endocrine Body Weight Immuno-Lymphor Reproductive Developmental

Cancer Effect Level-Animals
LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals

Cancer Effect Level-Humans
LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans

LD50/LC50: Minimal Risk Level for effects other than Cancer

Animals:
c-Cat - Humans
d-Dog
d-Rat
m-Mouse
j-Pigeon
n-Other

Animals:
e-Gerbil
f-Ferret
h-Rabbit
s-Hamster

Animals:
g-Guinea Pig
k-Monkey
l-Monkey
m-Mouse
n-Mink

Other:
o-Other

C-Other
n-Other

0.1
1
10
100

0.0001
0.001
0.01
0.1
1
10
100
Figure 3-8 Levels of Significant Exposure to Tributyltins - Oral (Continued)
Intermediate (15-364 days)
Figure 3-8 Levels of Significant Exposure to Tributyltins - Oral (Continued)

Chronic (≥365 days)

mg/kg/day

Respiratory Cardiovascular Gastrointestinal Hematological Musculoskeletal Hepatic Renal Endocrine Body Weight Immuno/Lymphor

0.0001 0.001 0.01 0.1 1 10

Cancer Effect Level-Animals
LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
Cancer Effect Level-Humans
LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
LD50/LC50
Minimal Risk Level for effects other than Cancer

- Humans
- Ferret
- Mink
- Other
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans
- LD50/LC50
- Minimal Risk Level for effects other than Cancer

- Animals
- Dog
- Monkey
- Pigeon
- Other
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans
- LD50/LC50
- Minimal Risk Level for effects other than Cancer

- Animals
- Rat
- Mouse
- Gerbil
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans
- LD50/LC50
- Minimal Risk Level for effects other than Cancer

- Animals
- Pig
- Rabbit
- Hamster
- Guinea Pig
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans
- LD50/LC50
- Minimal Risk Level for effects other than Cancer

- Animals
- Cow
- Sheep
- Guinea Pig
- Cancer Effect Level-Animals
- LOAEL, More Serious-Animals
- LOAEL, Less Serious-Animals
- NOAEL - Animals
- Cancer Effect Level-Humans
- LOAEL, More Serious-Humans
- LOAEL, Less Serious-Humans
- NOAEL - Humans
- LD50/LC50
- Minimal Risk Level for effects other than Cancer
dose producing death following a single gavage administration was 378 mg tin/kg as stannous chloride (NTP 1982). All mice survived the 14-day feeding of the compound up to dietary levels of 2,457 mg/kg/day. These studies were performed in order to set doses for the chronic bioassay of stannous chloride in rats and mice (see Section 3.2.2.8).

In intermediate-duration studies (4 or 13 weeks), rats were fed various inorganic tin compounds. A single female (1/10) died during week 11 with after receiving doses of 795 mg tin/kg/day as stannous chloride. A total of four males receiving doses of 315 mg/kg/day died during weeks 8 and 9 leading to discontinuation of this dose (De Groot et al. 1973).

The results of the chronic bioassays showed somewhat lower survival of high-dose male rats (63 mg tin/kg/day as stannous chloride) compared to the controls. In mice, survival of control males was affected more than the dosed groups (82 and 164 mg tin/kg/day), but survival of the female dosed groups was affected less than the controls (NTP 1982). No explanation was provided for the apparent lower survival among control male mice.

Reliable LOAEL values for lethality in animals in each duration category are recorded in Table 3-2 and plotted in Figure 3-2.

Organotin Compounds. The oral administration of a proprietary drug, Stalinon, resulted in the deaths of about 100 people in France from an estimated 1,000 who had been treated for osteomyelitis, anthrax, and acne. Most of the 10 or more accounts of this 1954 tragedy are published in the French literature, but a summary can be found in WHO (1980). The primary ingredients in Stalinon were diethyltin diiodide (15 mg/capsule) and linoleic acid (100 mg/capsule). It has been proposed that the deaths were caused by triethyltin iodide, which was present as an impurity from the manufacturing process. An estimate of 70 mg of triethyltin has been calculated as the toxic dose for humans ingesting this compound over an 8-day period (Barnes and Stoner 1959). A review by Boyer (1989) states that deaths occurred after exposure to an estimate dose of 3 g triethyltin iodide over a period of 6–8 weeks. However, many confounding variables in the reporting of this poisoning episode weaken the validity of these estimates. Kreyberg et al. (1992) described the case of a woman who ingested an unknown amount of trimethyltin and died 6 days after consuming the chemical; the main pathological findings were confined to the nervous system.
Lethal doses for monoorganotins ranging from 1,500 to more than 6,000 mg/kg have been reported for rodents suggesting that these compounds have relatively low toxicity (Pelikan and Cerny 1970).

Acute-duration studies with dibutyltins have described lethal doses in rats between 20 and 50 mg/kg administered by gavage (Alam et al. 1993; Barnes and Magee 1958). In a 2-week dietary study, a dose of approximately 23 mg/kg/day was lethal to 6 out of 20 rats during the second week of the study (Seinen et al. 1977a). In a developmental study, daily gavage doses of 7.5 mg/kg/day administered on gestation days (Gds) 7–15 killed 5 out of 12 rats with a mean time of 8 days (Ema et al. 1991b). Long-term treatment (78-week study) with dibutyltin diacetate significantly decreased survival in rats and mice at the termination of the study (NCI 1978a). A dose of 7 mg dioctyltin dichloride/kg/day in the food was lethal to 10 out of 16 guinea pigs after 4–5 weeks of treatment (Seinen et al. 1977b).

In male albino rats, the oral LD$_{50}$ for tributyltin oxide was 148 mg/kg when the chemical was administered by gavage in corn oil and 194 mg/kg when administered as an aqueous suspension (Elsea and Paynter 1958). Three consecutive daily doses of 37.5 mg of tributyltin oxide/kg killed 6 out of 50 rats (Elsabbagh et al. 2002). In pregnant mice, a dose of 27 mg/kg of tributyltin oxide administered during gestation was lethal to 3 out of 40 mice; no deaths occurred in controls (Faqi et al. 1997). Takagi et al. (1992) calculated a 2-week LD$_{50}$ of approximately 150 mg/kg for tributyltin chloride in male hamsters and 172 mg/kg in females.

Numerous studies provide information on the lethal effects of trimethyltin. In general, lethal doses, mostly in acute-duration studies, are below 10 mg/kg. For example, Brown et al. (1979) calculated an oral LD$_{50}$ of 12.6 mg/kg in rats following a single gavage dose; most deaths occurred 2–5 days after dosing. Other studies have reported lethal single doses in rats of 5 mg/kg (Bouldin et al. 1981) and 7 mg/kg (Alessandri et al. 1994). In a 2-week dietary study, doses of 2 mg/kg/day were lethal to 2 out of 10 rats and doses of ≥6.7 mg/kg/day killed 10/10 rats in a few days (Snoeij et al. 1985). Three female hamsters that received a single dose of 4 or 5 mg/kg showed whole body tremors and were almost moribund when killed 4 days after dosing (Brown et al. 1984). In the same study, a single dose of 3.75 mg/kg of trimethyltin chloride killed 4 out of 11 marmoset monkeys within 3 days of dosing (Brown et al. 1984). Single doses of 3–4 mg/kg were lethal to gerbils within a few days of treatment (Brown et al. 1984; Nolan et al. 1990).

Triethyltins are also highly toxic. In a 2-week study, doses of 6.7 mg/kg/day in the diet were lethal to 3 out of 10 rats, but no lethality occurred with doses of 2 mg/kg/day (Snoeij et al. 1985). In an additional
2-week study, rats were gavaged with triethyltin bromide in water twice/week and a dose of 3 mg/kg killed 4 out of 10 rats after the third dose (Squibb et al. 1980). Four out of six rats died during the third week on a diet that provided 2 mg/kg/day of triethyltin hydroxide (Magee et al. 1957) and in an 11-week drinking water study with triethyltin sulfate in rats at dose levels of 1.4 mg/kg/day; deaths occurred after 4 weeks (Smith 1973).

An extensive listing of LD$_{50}$ values for organotin compounds in several animal species can be found in Smith (1978) and WHO (1980).

Reliable LOAEL values for lethality, and LD$_{50}$ values in each species and duration category are recorded in Tables 3-3 through 3-8 and plotted in Figures 3-3 through 3-8.

### 3.2.2.2 Systemic Effects

No studies were located regarding musculoskeletal, or ocular effects in humans or animals after oral exposure to inorganic tin or organotin compounds.

The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2 for inorganic tin compounds. Similar information is given in Tables 3-3 through 3-8 and Figures 3-3 through 3-8 for organotin compounds.

**Respiratory Effects.**

**Inorganic Tin Compounds.** No studies were located regarding respiratory effects in humans or in animals after oral exposure to inorganic tin compounds.

**Organotin Compounds.** No histopathological alterations were observed in the lungs, bronchi, and trachea from rats and mice fed diets that provided up to 6.7 and 19.8 mg/kg/day of dibutyltin diacetate, respectively, for 78 weeks (NCI 1978a) or up to 3.8 and 9.8 mg/kg/day, respectively, of triphenyltin hydroxide for 78 weeks (NCI 1978b). Beagle dogs dosed with up to 0.62 mg triphenyltin hydroxide/kg/day for up to 52 weeks did not show any gross or microscopic alterations in the respiratory tract (Sachsse et al. 1987). Similar results were reported for rats dosed with up to 2.5 mg/kg/day of tributyltin oxide for 106 weeks (Wester et al. 1990). In a 6-week dietary study with dioctyltin dichloride
in rats, Seinen and Willems (1976) reported that rats dosed with approximately 16 mg/kg/day had grayish areas in the lungs at termination, suggesting chronic respiratory disease, and that three rats that died early in the study showed severe pneumonic alterations. No further relevant information was located.

**Cardiovascular Effects.**

*Inorganic Tin Compounds.* No studies were located regarding cardiovascular effects in humans after oral exposure to inorganic tin compounds.

In a feeding study in rats, at dietary levels ranging from <10 to 315 mg/kg/day as stannous chloride for 13 weeks, relative heart weights of males were higher than those of controls (De Groot et al. 1973). This effect was not dose-dependent and there were no associated histopathological findings. By itself, the significance of the observation is not clear. In a 4-week exposure to the same doses, there were no changes in heart weights (De Groot et al. 1973).

*Organotin Compounds.* No studies were located regarding cardiovascular effects in humans after oral exposure to organotin compounds.

No gross or microscopic alterations were observed in the heart of rats dosed with up to 5.7 mg dibutyltin dichloride/kg/day for 90 days (Gaunt et al. 1968). In a chronic-duration study, no histopathological alterations were observed in the hearts of rats and mice fed diets that provided up to 6.7 and 19.8 mg/kg/day of dibutyltin diacetate, respectively, for 78 weeks (NCI 1978a). Similar findings regarding the heart were reported in chronic-duration studies with triphenyltin hydroxide in rats and mice dosed with up to 6.2 and 20 mg/kg/day, respectively, for 78–106 weeks (NCI 1978b; Tennekes et al. 1989a, 1989b). Also, no cardiovascular effects were reported in dogs administered up to 0.62 mg triphenyltin hydroxide/kg/day for up to 52 weeks (Sachsse et al. 1987).

Dietary treatment of rats with up to 16 mg dioctyltin dichloride/kg/day for 6 weeks (Seinen and Willems 1976) or up to 2.5 mg tributyltin oxide/kg/day for 106 weeks (Wester et al. 1990) did not induce gross or microscopic alterations in the heart.
Gastrointestinal Effects.

**Inorganic Tin Compounds.** There are several accounts of people who experienced gastrointestinal effects such as diarrhea, gastrointestinal pain, nausea, or gastroenteritis after ingestion of various foods stored in tin cans (WHO 1980, 2003). Doses ranged from 250 to 1,000 mg tin/kg body weight. Recent studies by Boogaard et al. (2003) showed that tin levels up to approximately 270 ppm in canned food caused no adverse effects in healthy humans.

Data from studies in animals show that inorganic tin compounds can cause adverse gastrointestinal effects. Slightly distended small and large intestines were observed at necropsy of rats fed for 4 weeks diets containing 315–325 mg tin/kg/day as either stannous chloride or stannous orthophosphate. However, there were no histopathological changes (De Groot et al. 1973). In a 13-week study by the same investigators, doses of ≥95 mg Sn/kg/day as stannous chloride caused abdominal distension in rats during the first 2 weeks of the study, doses of 32 mg/kg/day caused no significant effects. Rats dosed with 315 mg/kg/day, which had to be terminated prematurely, showed distended intestines and slight ascites.

In another study, effects on the morphology and on absolute and relative weights of the gastrointestinal tract were evaluated after feeding rats dietary levels of 7.9 and 15.9 mg tin/kg/day stannous chloride for 4 weeks. Feed restriction was also studied in an attempt to distinguish between tin effects and the effects of decreased food intake and poor growth (Janssen et al. 1985). Increased relative weights of the stomach, cecum, and colon were observed at the lowest tin dose, but were apparently caused by diminished food intake since these changes were present in the pair fed controls as well as in the tin exposed animals. On the other hand, increases in the weight and length of the small intestines were observed to be independent of food consumption and thus a consequence of the exposure to stannous chloride. There was also an increase in the villus length, a decrease in the number of villi per unit surface, an increase in villus cell turnover, and changes in villi morphology in the intestines of the treated rats. Although similar changes of the intestinal villi were reported in another study (Dreef-van der Meulen et al. 1974), there are not enough data at this time to verify the intestinal changes as adverse.

Mice fed 311–2,457 mg tin/kg/day as stannous chloride for 13 weeks showed gross distention of the cecum and reddened gastric mucosa at necropsy but no compound-related histopathological changes (NTP 1982). Similar findings were observed in rats fed 120–236 mg tin/kg/day (NTP 1982). However,
no such changes were observed in rats fed 32 or 63 mg tin/kg/day or mice fed 82 or 164 mg tin/kg/day as stannous chloride during a 105-week study (NTP 1982).

Organotin Compounds. Limited information is available regarding gastrointestinal effects in humans after oral exposure to organotin compounds. Nausea and vomiting were reported in more than 70% of the individuals intoxicated presumably with triethyltin in a massive accidental poisoning episode in France in 1954 (WHO 1980). Abdominal pain, diarrhea, nausea, and vomiting have been reported in cases of oral intoxication with triphenyltin (Lin and Hsueh 1993; Lin et al. 1998; Wu et al. 1990).

Stomach distention was observed in rats 24 hours after a single dose of 50 mg dibutyltin dichloride/kg (Barnes and Magee 1958). The duodenum was also examined in many rats, but no changes were evident. Chronic studies with dibutyltin diacetate in rats and mice did not report any significant alterations in the gastrointestinal tract from rats or mice dosed with up to 6.7 and 19.8 mg/kg/day of the test material, respectively, for 78 weeks (NCI 1978a).

Histopathological evaluation of the gastrointestinal tract (at six different levels) from rats dosed with up to approximately 16 mg dioctyltin dichloride/kg/day did not reveal any significant alterations (Seinen and Willems 1976).

Single doses of 500 mg/kg of various tributyltin salts (chloride, acetate, benzoate, oleate) produced hemorrhages in the digestive tract of mice (Pelikan and Cerny 1968). Similar gross changes in the gastrointestinal tract were seen in another study in mice treated with much higher doses (4,000 mg/kg) of monobutyltin trichloride and other monobutyltin salts (Pelikan and Cerny 1970). No gastrointestinal alterations were observed in rats treated with up to 2.5 mg tributyltin oxide/kg/day for 106 weeks (Wester et al. 1990).

No treatment-related alterations in the gastrointestinal tract were reported in rats, mice, and dogs in chronic-duration studies with triphenyltin hydroxide (NCI 1978b; Sachsse et al. 1987; Tennekes et al. 1989a, 1989b). Rats were dosed with up to 6.2 mg/kg/day and mice were dosed with up to 20 mg/kg/day; the dogs were dosed with up to 0.62 mg/kg/day.
Hematological Effects.

**Inorganic Tin Compounds.** No studies were located regarding hematological effects in humans after oral exposure to inorganic tin compounds.

Data from 4-week feeding studies in rats showed some hematological changes (De Groot et al. 1973). A significant increase was observed in the hematocrit of male, but not in female, rats fed a dietary level of 395 mg tin/kg/day as stannous sulfide. Both sexes of rats fed tin at dietary levels ranging from 68 to 325 mg tin/kg/day as the chloride, orthophosphate, sulfate, oxalate, and tartrate showed anemia. The signs of anemia were decreased hematocrit, total erythrocytes, and hemoglobin levels. Lower mean corpuscular volume and hemoglobin concentrations were seen at the highest doses (225–325 mg tin/kg/day). In 13-week studies, stannic oxide produced no hematological changes in rats (De Groot et al. 1973). However, dietary levels of ≥7.9 mg tin/kg/day as stannous chloride produced decreased hematological values in rats with 4-week exposures (Janssen et al. 1985). It is possible that the mineral content of the diet had an effect on the results of these studies since the no effect levels (22–440 mg Sn/kg/day) for hematological effects in studies with diets adequate in copper and iron (De Groot et al. 1973; Dreef-van der Meulen et al. 1974) exceeded the LOAEL (7.9 mg/kg/day) from the work by Janssen et al. (1985) with diets that contained only one fifth as much iron and copper. Iron and copper are key nutrients in hematopoiesis; deficiencies in these elements are associated with microcytic anemias characterized by low hemoglobin and hematocrit values. It is suggested that the poor iron and copper nutrition in the Janssen et al. (1985) work was a predisposing factor, which amplified the adverse effects of tin on hematological parameters. This hypothesis is supported by studies in which the dietary concentrations of copper, tin, and iron were varied (De Groot 1973). High levels of copper and iron (well above dietary requirements) added to semipurified diets containing up to 75 mg/kg/day tin almost completely prevented hematological changes. Transient hemolytic anemia also was reported in rabbits treated daily by gavage with 10 mg tin/kg (as stannous chloride), the only dose tested, for 4 months (Chmielnicka et al. 1993). However, no information was provided in that study regarding the trace mineral composition of the diet. The NOAEL of 32 mg/kg/day for tin, as stannous chloride, in the 13-week study by De Groot et al. (1973) was used to derive an intermediate-duration oral MRL for inorganic tin.

**Organotin Compounds.** No studies were located regarding hematological effects in humans after oral exposure to organotin compounds.
3. HEALTH EFFECTS

Treatment of Fischer-344 rats with 5–6 mg dibutyltin dichloride/kg/day in the diet for up to 13 weeks produced a slight, but significant decrease in hemoglobin concentration in females after 6 weeks and in males after 13 weeks (Gaunt et al. 1968). This decrease was not associated with reductions of other erythrocyte parameters or with a reticulocytosis. Lower doses of approximately 3 mg/kg/day caused no significant effect. Differential leukocyte counts were not altered by treatment with dibutyltin dichloride.

Decreased hemoglobin and hematocrit values, lowered mean corpuscular volume and hemoglobin mass, and decreased leucocytes were observed in rats fed a diet that provided approximately 4 and 16 mg/kg/day tributyltin oxide for 4 weeks (Krajnc et al. 1984). Erythrocytes were reduced, and spherocytes and Howell-Jolly body-containing erythrocytes were increased in the 16 mg/kg/day group only. However, a study in Sprague-Dawley rats found no significant alterations in a complete set of hematological parameters following treatment with approximately 5 mg tributyltin oxide/kg/day for 28 days (Verdier et al. 1991). The reason for the discrepancy between these two studies is unknown. In a 2-year bioassay in Wistar rats, hematological determinations were made in weeks 13 and 53, and at termination (Wester et al. 1990). Significant hematological effects restricted to the high-dose males (dosed with approximately 2.1 mg/kg/day) were seen only at 12 months, and consisted of decreased hemoglobin, hematocrit, and mean corpuscular hemoglobin levels, and mean corpuscular volume (also at 3 months. In females, there was an indication of increased young erythrocytes at 3 and 12 months, but the doses were not indicated. Leucocytes were decreased in high-dose males (24 months) and females (12 and 24 months). In a 22-week gavage study in Cynomolgus monkeys, treatment with doses of tributyltin oxide of 0.16 mg/kg/day (only dose level tested) decreased total leukocytes in weeks 8–10 at weeks 16–20 (Kerr et al. 1992). The biological significance of this finding is unknown.

In a 6-week dietary study with dioctyltin dichloride in male and female Wistar rats, hematological investigations conducted on blood collected at termination included hemoglobin concentration and total and differential leukocyte counts (Seinen and Willems 1976). Doses of approximately 16 mg/kg/day significantly decreased hemoglobin concentration in males, but there was no effect on total or differential leukocyte counts; the NOAEL for hemoglobin concentration was approximately 5.3 mg/kg/day. A study in female Balb/c mice treated by gavage with 500 mg dioctyltin dichloride/kg once per week for 8 weeks reported a 14% reduction in hemoglobin concentration at termination but no significant alterations in red or white blood cell counts (Miller et al. 1986). A dose of 100 mg/kg had no significant effect on hemoglobin concentration.
Triphenyltin hydroxide at a dose of 1.3 mg/kg/day caused a transient decrease in hemoglobin and hematocrit values at 26 and 52 weeks in female rats, but not in the males (Tennekes et al. 1989b). These changes were not apparent at 78 and 104 weeks (Tennekes et al. 1989b), nor were they seen in dogs given the same compound at doses of approximately 0.62 mg/kg/day for up to 42 weeks (Sachsse et al. 1987).

**Musculoskeletal Effects.**

**Inorganic Tin Compounds.** No studies were located regarding musculoskeletal effects in humans or animals following oral exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding musculoskeletal effects in humans following oral exposure to organotin compounds. Treatment of rats with up to 16 mg dioctyltin dichloride/kg/day for 6 weeks did not induce histopathological alterations in skeletal muscle (Seinen and Willems 1976). No treatment-related alterations in skeletal muscles were observed in a 104-week study in rats dosed with up to 6.2 mg triphenyltin hydroxide/kg/day or in mice dosed with up to 9.8 mg triphenyltin hydroxide/kg/day (Tennekes et al. 1989a, 1989b). Beagle dogs dosed with up to 0.62 mg triphenyltin hydroxide/kg/day for up to 52 weeks showed no gross or microscopic alterations in skeletal muscle or in the sternum bone (Sachsse et al. 1987). Similar findings were reported in a 106-week study with tributyltin oxide in rats dosed with to 2.5 mg/kg/day of the chemical (Wester et al. 1990).

**Hepatic Effects.**

**Inorganic Tin Compounds.** No studies were located regarding hepatic effects in humans after oral exposure to inorganic tin compounds.

Hepatic effects have been observed following intermediate and chronic oral exposure of rats. Data from a 4-week feeding study in Wistar rats showed some histopathological changes (De Groot et al. 1973). Both sexes fed tin as the chloride, orthophosphate, sulfate, oxalate, and tartrate had histopathological changes in the liver. The cytoplasm exhibited a clear homogeneous appearance, which suggested a disappearance of the cellular organelles and impaired cell function at the highest dietary level of 226–325 mg/kg/day and to a lesser extent at a level of 68–98 mg tin/kg/day (the doses varied with the tin compound used). A slight but definite oval cell type hyperplasia of the bile ducts was also apparent. Changes in organ weights were inconsistent. The authors suggested that the changes in liver cell morphology were due, in
3. HEALTH EFFECTS

part, to the reduced food intake and resultant impaired weight gain. These changes were apparent in the animals with the poorest weight gains.

In a 13-week study in Wistar rats, histopathological changes were observed in the livers of both sexes at a dietary level of 315 mg tin/kg/day as stannous chloride, but in only a few rats at 95 mg tin/kg/day (De Groot et al. 1973). The changes were a homogeneous appearance of the cell cytoplasm and mild proliferation of the bile duct epithelium. Organ weights were not affected. In another 13-week study, similar changes were seen in the livers of rats fed a diet that was gradually increased to a final level of 252 mg tin/kg/day as stannous chloride (Dreef-van der Meulen et al. 1974).

No hepatic effects were reported in Fischer-344 rats and B6C3F1/N mice fed stannous chloride for either 14 days or 13 weeks (NTP 1982). The highest dietary levels were 236 mg tin/kg/day as stannous chloride for rats and 2,457 mg tin/kg/day for mice. Considering the extremely high doses used, it is surprising that hepatic changes were not observed.

Limited hepatic changes were seen following chronic oral exposure of rats and mice to stannous chloride. In a drinking water study at 0.7 mg tin/kg/day as stannous chloride for life, 80 rats were evaluated for hepatic and other health effects (Schroeder et al. 1968). There was a significant increase in fatty degeneration of the liver in the tin-exposed rats. Thirty-eight percent of the control rats had liver lesions, whereas 68% of the tin-exposed rats had liver lesions. Degeneration and necrosis, as well as fatty changes moderate to severe, were found in 55% of the control rats with lesions and in 65% of the tin-exposed rats with lesions. Although similar hepatic effects were reported in the 105-week chronic bioassay of stannous chloride in rats and mice, the findings were not dose-related and comparable in treated and control animals (NTP 1982).

Organotin Compounds. Liver impairment, as judged by increased serum levels of transaminases, was described in two cases of acute oral intoxication with triphenyltin (Lin et al. 1998; Wu et al. 1990). Hepatitis also was reported in three subjects who ingested between 20 and 50 grams of a preparation containing 45% triphenyltin acetate (Lin and Hsueh 1993). No further relevant information was located.

Hepatic and bile duct effects were observed following acute and intermediate oral exposures of animals to organotin compounds. A single dose of dibutyltin dichloride of 50 mg/kg produced inflammation of the common bile duct of Wistar rats (Barnes and Magee 1958). Severe hepatic injury occurred in rats following three consecutive doses of 50 mg dibutyltin dichloride/kg/day; this treatment was lethal to
some rats in 6–10 days. The main features of the bile-duct injury included thickening, inflammation, and dilatation of the proximal duct. Histologically, the epithelium of the wall was replaced by granulomatous tissue. In cases in which the bile duct was perforated, severe peritonitis and fatty necrosis were seen. Multiple yellow infarcts developed in lobes of the liver, followed by inflammation of the portal blood vessels. In some cases, there was complete necrosis of the bile ducts. In rats examined 6–12 months after receiving the three doses of dibutyltin, the bile duct was shorter and thicker than normal and there was wall fibrosis in the adjacent pancreas, and in the portal tracts of the liver. Seinen et al. (1977a) noticed proliferation of the bile duct epithelium and periportal fibrosis in Wistar rats fed a diet that provided approximately 23 mg/kg/day of dibutyltin dichloride for 2 weeks; doses of 7.7 mg/kg/day caused no significant effect. Bile duct necrosis also was seen in Syrian hamsters treated with a single dose of 30 mg/kg (Jang et al. 1986). Bile duct necrosis also occurred in mice, but not in rabbits or guinea pigs (20–50 mg/kg dose ranges) (Barnes and Magee 1958). No adverse hepatic effects (histopathology and serum transaminases) were reported in Fischer-344 rats dosed with up to 5.7 mg dibutyltin dichloride/kg/day for 90 days (Gaunt et al. 1968). In variance with the findings of bile duct necrosis in mice reported by Barnes and Magee (1958), Seinen et al. (1977a) did not observe histological changes in the liver from Swiss mice dosed with dibutyltin dichloride in doses of up to 30 mg/kg/day for 4 weeks; however, it is unclear whether the bile duct was examined. No microscopic alterations were reported in the liver from Fischer-344 rats or B6C3F1 mice treated with dibutyltin diacetate in doses of up to 6.7 and 20 mg/kg/day, respectively, for 78 weeks (NCI 1978a).

A significant increase in serum levels of ornithine carbamyl transferase (used as index of hepatotoxicity) was observed in albino mice gavaged once with 58 mg tributyltin chloride/kg (Ueno et al. 1994). The increase was first apparent 24 hours after dosing. Parallel experiments with dibutyltin dichloride and monobutyltin trichloride showed that the hepatotoxicity potency followed the order: dibutyltin > tributyltin > monobutyltin (Ueno et al. 1994). Monobutyltin was not hepatotoxic. Further studies by the same group of investigators showed that the liver toxicity of tributyltin chloride could be prevented by pretreatment of the mice with the cytochrome P-450 inhibitor SKF-525 (Ueno et al. 1995, 1997). Conversely, pretreatment with the P-450 inducer phenobarbital (PB) increased the toxicity of tributyltin chloride. These results suggest that the liver toxicity of tributyltin is due to a metabolite, most likely dibutyltin. Comparative studies with tributyltin and dibutyltin in mice and guinea pigs showed the mice to be much more sensitive to the hepatotoxicity of tri- and dibutyltin dichloride than guinea pigs (Ueno et al. 2003a), and this was correlated with differential inhibition of mitochondrial respiration in the two species. Additional experiments suggested that the difference in susceptibility between mice and guinea pigs might be due to the high affinity of butyltins, particularly dibutyltin, for hepatic mitochondria in
mice containing higher levels of sulphhydril groups relative to guinea pigs. In a three species comparison, the susceptibilities followed the order: mice > rats > guinea pigs (Ueno et al. 2003b). Kinetic studies showed that the differences in susceptibility appeared to be partly due to differences in metabolism of tributyltin and in the distribution of dibutyltin within cell organelles. In hepatocytes of mice treated with dibutyltin chloride, 41% of the dibutyltin was found in organelles compared to 27% in rats and 9% in guinea pigs (Ueno et al. 2003b).

A single dose of 29.6 mg tributyltin chloride/kg (lowest dose tested) induced bile duct changes in Syrian hamsters consisting of adhesion in the liver, pancreas, and duodenum, and severe inflammation (Takagi et al. 1992). In a separate experiment, following a single dose of 44.4 mg/kg of tributyltin, the maximum concentrations of tributyltin and dibutyltin appeared in the liver 1 day after treatment and rapidly decreased thereafter. The concentration of dibutyltin was 10 times higher than that of tributyltin 1 day after dosing (Takagi et al. 1992). By day 14, neither compound could be detected in the liver, and aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-guanosine triphosphate (GTP), and alkaline phosphatase activities were not significantly different than control. These results suggest that dibutyltin has an important role in the hepatotoxicity of tributyltin. In a 4-week feeding study in Wistar rats, doses of approximately 16 mg tributyltin oxide/kg/day induced hepatic changes consisting of liver necrosis and bile duct hyperplasia (Krajnc et al. 1984). Slight atrophy of the hepatocytes was seen at 4 mg/kg/day and no significant alterations were seen at 1 mg/kg/day. Consistent with these observations, no microscopic changes were observed in the livers of Sprague-Dawley rats treated with \( \leq 5 \) mg tributyltin oxide/kg/day for 28 days (Verdier et al. 1991). Cholangitis with biliary retention was reported in Fischer-344 rats dosed with tributyltin oxide at 16 mg/kg/day for 6 weeks (Carthew et al. 1992). In a 2-year bioassay with tributyltin oxide in Wistar rats, liver effects were restricted to high-dose rats (2.1 mg/kg/day) and consisted of slight bile duct changes (hyperplasia, cellular hypertrophy, minimal mononuclear cell infiltration) observed at 12 months, increased serum AST and ALT activities at 24 months, and an approximate 30% increase in absolute liver weight at termination; no histopathologic alterations were seen at 24 months (Wester et al. 1990). The NOAEL was 0.25 mg/kg/day.

No hepatotoxicity was seen in dogs exposed through the diet to up to 0.62 mg triphenyltin hydroxide/kg/day for up to 52 weeks (Sachsse et al. 1987). Hypertrophy of the smooth endoplasmic reticulum was reported in New Zealand rabbits exposed to approximately 17.4 mg triphenyltin acetate/kg/day via the diet for 70 days (Dacasto et al. 1994a). A dose-related trend towards portal sclerosis and bile duct proliferation was observed in Wistar rats given doses of 0.3–6.2 mg/kg/day.
triphenyltin hydroxide for 52 and 104 weeks; there was no corresponding increase in liver weight (Tennekes et al. 1989b). The dose-related trend was stronger in females (p<0.0005) than in males (p<0.005). However, no liver pathology was reported in Fischer-344 rats dose with the same compound in doses of up to 3.8 mg/kg/day for 78 weeks (NCI 1978b). In NMRI mice, this same compound was associated with a 35–40% increase in relative liver weight and nodular hyperplasia at doses of 15.2 mg/kg/day for males and 20.2 mg/kg/day for females but not at lower doses (Tennekes et al. 1989a). No significant liver alterations were reported in B6C3F1 mice in the 78-week bioassay with triphenyltin hydroxide (NCI 1978b).

Studies with dioctyltin dichloride showed no significant histopathologic alterations in the livers from rats treated in the diet with doses of approximately 23 mg/kg/day for 2 weeks (Seinen et al. 1977a) or 16 mg/kg/day for 6 weeks (Seinen and Willems 1976), or in guinea pigs treated with 8 mg/kg/day for 4 weeks (Seinen et al. 1977a). No significant changes in liver weight were reported in mice gavaged with up to 500 mg/kg/day once per week for 8 weeks, but no other liver end points were evaluated (Miller et al. 1986).

Renal Effects.

*Inorganic Tin Compounds.* No studies were located regarding renal effects in humans after oral exposure to inorganic tin compounds.

Histopathological changes in the kidneys were reported in Wistar rats that received dietary levels up to approximately 315 mg tin/kg/day as stannous chloride for 13 weeks (De Groot et al. 1973). The changes included large protein-like droplets in renal tubular epithelial cells. This appears to be a common finding in the strain of rats used in this study and did not appear to be related to tin exposure. The authors also mentioned the absence of calcareous deposits in the high-dose level female rats. This appears to be an unusual finding since these deposits are commonly seen with the species of rats used in the study. However, the toxicological significance of these kidney findings is not clear.

In another 13-week study, Wistar rats that were fed the compound up to a maximum level of 252 mg tin/kg/day as stannous chloride showed increased relative kidney weights (Dreef-van der Meulen et al. 1974). The protein-like droplets and calcareous deposits, which are common in the rat strains used, were present in the controls but were absent in the tin-fed animals. The absence of calcareous deposits in the females confirms the observations of De Groot et al. (1973), but the relevance of these finding to
compound toxicity is unclear. The organ weight change itself, in the absence of histopathological or other
effects, is usually not considered a toxic effect.

Renal changes have been evaluated following chronic oral exposure of rats and mice to stannous chloride
and the studies were described under Hepatic Effects. Vacuolar changes in the proximal convoluted
tubules of the kidney were significantly increased in rats administered stannous chloride, compared with
controls (Schroeder et al. 1968). However, in 14-day, 13-week, and 105-week studies of stannous
chloride in rats and mice, no treatment-related nonneoplastic renal changes were reported (NTP 1982).

Organotin Compounds. Acute nephropathy was reported in three subjects who ingested between 20 and
50 grams of a preparation containing 45% triphenyltin acetate (Lin and Hsueh 1993). No further
information was located regarding renal effects in humans after oral exposure to organotin compounds.

Treatment of rats with up to 5.7 mg dibutyltin dichloride/kg/day for 90 days (Gaunt et al. 1968) or mice
with up to 30 mg dibutyltin dichloride/kg/day (Seinen et al. 1977a) for 4 weeks did not induce any
significant gross or microscopic alterations in the kidneys. Also, no significant renal effects were
reported in rats or mice dosed with up to 6.7 or 19.8 mg dibutyltin diacetate/kg/day, respectively, for
78 weeks (NCI 1978a).

Rats dosed with up to approximately 23 mg dioctyltin dichloride/kg/day for 2 weeks showed no
significant histopathological alterations in the kidneys at termination (Seinen et al. 1977a). However,
treatment with approximately 16 mg/kg/day for 6 weeks produced signs of slight impairment of renal
function (decreased specific gravity of the urine, increased BUN), but no histopathologic alterations were
noticed (Seinen and Willems 1976). No significant alterations were observed in the kidneys from guinea
pigs treated with up to 8 mg dioctyltin dichloride/kg/day for 4 weeks (Seinen et al. 1977a).

Administration of a single dose of 4,000 mg/kg of tributyltin laureate to mice caused gross renal changes
observed at necropsy 24 hours later (Pelikan and Cerny 1970). The kidneys were light red and slightly
enlarged, and histopathological findings included steatosis of the renal cortical tubular epithelium and
hyperemia of the renal medulla. In an intermediate-duration study, treatment of rats with doses of
2.5 mg/kg/day of tributyltin chloride in the diet for 30 days did not cause any gross kidney alterations
(Bressa et al. 1991). A significant increase (29–33%) in absolute kidney weight was observed in male
and female rats dosed with approximately 2 mg tributyltin oxide/kg/day for 2 years (Wester et al. 1990).
Increased urine production, seen after 3, 12, and 24 months of treatment, suggested a decreased renal
The renal effects of trimethyltin chloride were examined in male Wistar rats (Opacka and Sparrow 1985). Gavage administration of single doses (3, 6, or 10 mg/kg) of the tin compound significantly increased urine production over an observation period of 3 days; this effect was dose-related. Water consumption was significantly increased in the high-dose group beginning the first 24 hours after dosing. Histopathological examinations of the kidneys showed changes ranging from slight vacuolization of the proximal tubular cells with loss of brush borders at 3 mg/kg to extensive vacuolar degeneration with tubular dilation and evidence of regeneration in the 10 mg/kg dose-group. Severe nephrotoxicity was also reported in Long-Evans rats treated once with a dose of approximately 12 mg trimethyltin chloride/kg (Robertson et al. 1987). This dose was lethal to 16 out of 43 rats. Examination of the kidneys from surviving animals showed hyaline droplet inclusions, attenuated brush border, basolateral vacuolization, and eosinophilic granular casts in the proximal tubule cells. These lesions could be detected as early as 2 days after dosing and were partially reversed during the 14-day observation period following treatment. Maximum severity was observed 7–11 days after treatment.

Triphenyltin hydroxide did not induce morphological or functional alterations in the kidney from rats, mice, or dogs given doses of 0.6–20 mg/kg/day for up to 104 weeks (NCI 1978b; Sachsse et al. 1987; Tennekes et al. 1989a, 1989b).

**Endocrine Effects.**

**Inorganic tin compounds.** No studies were located regarding endocrine effects in humans following exposure to inorganic tin compounds.

In a study in rats, there were no treatment-related alterations in the gross or microscopic appearance of the thyroid following dietary administration of up to 315 mg tin/kg/day as stannous chloride for 13 weeks (De Groot et al. 1973). No further relevant information was located.

**Organotin compounds.** No information was located regarding endocrine effects in humans following oral exposure to organotin compounds.
Treatment of rats with up to 5.7 mg dibutyltin dichloride/kg/day for 13 weeks did not induce any significant alterations in absolute or relative weight of the pituitary, thyroid, or adrenals or gross or microscopic appearance of these organs (Gaunt et al. 1968). Similar findings were reported for the adrenals of mice treated with up to 30 mg dibutyltin dichloride/kg/day for 4 weeks (Seinen et al. 1977a). Chronic-duration studies with dibutyltin diacetate also found no significant histopathological alterations in endocrine glands from rats and mice treated with doses of up to 6.7 and 19.8 mg/kg/day, respectively, for 78 weeks (NCI 1978a).

Dietary exposure of rats to up to 23 mg dioctyltin dichloride/kg/day for 2 weeks had no significant effect on the weight or morphological appearance of the adrenals (Seinen et al. 1977a). Similar lack of effects was reported in the adrenals, thyroid, and pituitary glands from rats exposed to doses of up to 16 mg/kg/day via the diet for 6 weeks (Seinen and Willems 1976). In contrast, guinea pigs exposed for 4 weeks to 8 mg/kg/day showed a 50% increase in relative adrenal weight, suggesting that an increase of glucocorticoids may have been indirectly responsible for the thymus atrophy observed in this study (Seinen et al. 1977a). No significant effects were seen at 4 mg/kg/day.

Administration of a single gavage dose of 60 mg tributyltin oxide/kg to Wistar rats had no significant effect on the weight of the adrenals (Raffray and Cohen 1993). Treatment of male Fischer-344 rats with a single dose of 100 mg/kg of tributyltin oxide increased serum cortisol levels and induced adrenal hypertrophy (Funahashi et al. 1980). It also caused changes consistent with activation of both secretion and synthesis of ACTH, and to subsequent adrenal hypertrophy. Serum levels of thyroxine (T4) and thyrotrophin (TSH) were markedly reduced, but the intensity of TSH cells staining was increased, suggesting that tributyltin oxide inhibited TSH release, which caused thyroid hypofunction. Since the decrease in circulating T4 was much more pronounced than that of TSH, Funahashi et al. (1980) suggested that tributyltin oxide has a direct effect on the thyroid. Most acute effects appeared to be reversible within 14 days. Treatment of rats with ≥6 mg/kg/day for 26 weeks increased adrenals and hypophysis weight and caused signs of thyroid hypofunction (Funahashi et al. 1980). In a study by Krajnc et al. (1984), Wistar rats were fed diets that provided approximately 0, 1, or 4 mg tributyltin oxide/kg/day for 6 weeks. Treatment with 4 mg/kg/day significantly decreased serum levels of T4 and TSH, whereas luteinizing hormone (LH) was significantly increased. Both exposure levels decreased insulin levels in serum; however, the results of a glucose tolerance test were unremarkable, suggesting that the decrease in serum insulin may have been due to a marked decrease in feed intake. No significant changes were measured in concentrations of follicle-stimulating hormone (FSH) and corticosterone. Release of TSH after administration of thyrotropin-releasing hormone (TRH) was slightly reduced at
4 mg/kg/day, but release of both LH and FSH were enhanced. Light microscopy revealed flattening of the epithelial lining of the thyroid follicles at 4 mg/kg/day, but not at lower doses. In the pituitary, treatment with 4 mg/kg/day tributyltin oxide reduced the number of TSH-immunoreactive cells and the staining intensity, increased the number of cells staining for LH, and had no significant effect in the staining for GH-, FSH-, or ACTH-producing cells. Krajnc et al. (1984) concluded that their results suggested that treatment with tributyltin oxide for 6 weeks did not stimulate the pituitary-adrenal axis. In a 2-year dietary study with tributyltin oxide in Wistar rats, no significant alterations were observed at 12 and 24 months in serum levels of TSH, LH, FSH, insulin, T4, or free thyroxine (FT4) with a dose level of up to 2.1 mg/kg/day (Wester et al. 1990). However, decreased thyroid follicular epithelial cell height was observed at 12 and 24 months. Treatment of pregnant rats with ≥10 mg tributyltin chloride/kg/day on Gds 0–19 significantly reduced serum T4 and T3, and treatment with ≥2.5 mg/kg/day on Gds 8–19 significantly reduced only T4 (measurements were conducted on Gd 20) (Adeeko et al. 2003).

No significant gross or microscopic alterations were seen in the adrenal, thyroid, and parathyroid glands of dogs dosed with up to 0.62 mg triphenyltin hydroxide/kg/day in the diet for up to 52 weeks (Sachsse et al. 1987). Triphenyltin hydroxide caused dose-related cystoid changes in the pars intermedia of the pituitary gland from male and female Wistar rats administered this compound for 52 or 104 weeks at doses of 0.3–6.2 mg/kg/day (Tennekes et al. 1989b). At the highest dose, up to 40% of the males and 80% of the females were affected at 52 weeks. At the end of 104 weeks, 72.3% of the high dose males and 55.6% of the females exhibited the cystoid changes. The lower incidence in females at 104 weeks was related to a high early mortality from fatal pituitary adenomas (see Section 3.2.2.7). However, no significant histopathological alterations were observed in endocrine organs from male or female Fischer-344 rats treated with up to 3.8 mg/kg/day of the test material in the diet for 78 weeks (NCI 1978b). Also, chronic treatment of mice with up to 20 mg triphenyltin oxide/kg/day did not result in histopathological alterations in endocrine glands (NCI 1978b; Tennekes et al. 1989a).

Studies conducted by Ohhira and coworkers showed that administration of a single dose of 50 mg of triphenyltin chloride/kg produced transient hyperglycemia and hypertriglyceridemia in hamsters but not in rats (Ohhira and Matsui 1996). Kinetic studies showed that hamsters accumulated significantly more triphenyltin in the pancreas than did rats, and peak levels of triphenyltin in the pancreas correlated well with peak levels of glucose in plasma. Additional studies by these investigators showed that pretreatment of hamsters with the cytochrome P-450 inducer phenobarbital (PB) suppressed the diabetogenic effects of triphenyltin compared to PB-untreated hamsters (Ohhira et al. 1999). Pretreatment with the CYP1A and 2A inducers β-naphthoflavone and 3-methylcholanthrene, respectively, was not as effective as
pretreatment with PB in preventing the organotin-induced hyperglycemia and hypertriglyceridemia. On
the other hand, pretreatment with the P-450 inhibitor, SKF-525A, increased the diabetogenic effects of
triphenyltin (Ohhira et al. 2000). Overall, these findings suggested that the hyperglycemic toxicity of
triphenyltin is due primarily to accumulation of the parent compound, triphenyltin, in the pancreas.

Dermal Effects.

**Inorganic Tin Compounds.** No studies were located regarding dermal effects in humans or animals after
oral exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding dermal effects in humans after oral exposure
to organic tin compounds.

Administration of dibutyltin diacetate to rats (6.7 mg/kg/day) and mice (19.8 mg/kg/day) for 78 weeks did
not cause any significant alteration in the skin (NCI 1978a). Similar findings were reported in rats dosed
with up to 16 mg dioctyltin dichloride/kg/day for 6 weeks (Seinen and Willems 1976).

No skin alterations were observed in rats dosed with up to 3.8 mg dibutyltin diacetate/kg/day for
78 weeks or in mice dosed with up to 9.8 mg/kg/day for the same duration (NCI 1978b). In female mice,
a dose of 20.2 mg/kg/day triphenyltin hydroxide administered for 80 weeks was associated with dermal
sores and burn-like lesions, and was sometimes accompanied by hair loss (Tennekes et al. 1989a). These
lesions were present primarily in the cervical area of the back, but were also identified on the head, ears,
forelimb, and abdomen. Males were affected to a much lesser extent than the females. No skin lesions
were associated with the chronic administration of triphenyltin hydroxide to rats or dogs (Sachsse et al.
1987; Tennekes et al. 1989b).

Ocular Effects.

**Inorganic Tin Compounds.** No studies were located regarding ocular effects in humans or animals after
oral exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding ocular effects in humans after oral exposure
to organic tin compounds. The only information available in animals is that no ophthalmologic
alterations were observed in rats treated with up to 6.2 mg triphenyltin hydroxide/kg/day or in mice dosed
with up to 20.2 mg/kg/day of the same compound for 80–104 weeks and examined at 6, 12, and 18 months (Tennekes et al. 1989a, 1989b). Dogs dosed with up to 0.62 mg triphenyltin hydroxide/kg/day for up to 2 weeks also exhibited no gross or histologic alterations in the eyes (Sachsse et al. 1987).

### Body Weight Effects.

**Inorganic Tin Compounds.** Reductions in body weight, food intake, and water consumption were observed in oral studies of inorganic tin compounds. Decreases in body weights and reduced food intake were recorded in studies in which stannous chloride and other inorganic tin (≥7.9 mg tin/kg/day) compounds were administered to rats for acute and intermediate durations (De Groot et al. 1973; Janssen et al. 1985). This was usually accompanied by reduced food consumption. However, these parameters were comparable between control and treated rats fed stannous chloride during chronic studies (NTP 1982; Schroeder et al. 1968). The findings appear to suggest direct action of some inorganic tin compounds on growth and food intake after acute- and intermediate-duration dosing but not during chronic dosing. When assessing effects of inorganic tin on growth, it is important to monitor the status of some essential minerals such as zinc, since reduced growth is a common symptom of zinc deficiency and excess dietary tin reduces zinc absorption (Greger and Johnson 1981; Johnson and Greger 1982).

**Organotin Compounds.** Reduced body weight gain and even body weight loss have been reported in numerous studies with organotins following various exposure durations. In some cases, but not all, information on food and water consumption was also provided. Rats treated once daily for 3 days with 40 mg dibutyltin laureate/kg/day lost weight, and a dose level of 20 mg/kg/day significantly reduced body weight gain (Khaliq et al. 1991). In a 2-week dietary study in rats, a dose level of 23 mg/kg/day of dibutyltin dichloride reduced final body weight by 20%, a lower dose of 7.7 mg/kg/day was without significant effect (Seinen et al. 1977a). No significant effect on body weight was reported in a 90-day dietary study in rats dosed with up to 57 mg/kg/day of dibutyltin dichloride (Gaunt et al. 1968). Mice treated for 4 weeks with up to 30 mg/kg/day of dibutyltin dichloride also showed no treatment-related effects on body weight (Seinen et al. 1977a). Chronic-duration studies with dibutyltin diacetate did not report significant differences in body weight between treated and control groups of rats and mice treated with up to 6.7 and 19.8 mg/kg/day, respectively, for 78 weeks (NCI 1978a).

Doses of 23 mg/kg/day of dioctyltin dichloride for 2 weeks reduced final body weight in rats by approximately 12% relative to controls; the NOAEL was 7.7 mg/kg/day (Seinen et al. 1977a). A 7–9% reduction in final weight was seen in a 6-week dietary study in rats that received doses of up to
16 mg/kg/day of dioctyltin dichloride (Seinen and Willems 1976). Since food consumption was practically unaffected, the authors suggested that the treatment slightly lowered food efficiency. Guinea pigs seemed more susceptible to treatment with dioctyltin dichloride since a 4-week treatment with 8 mg/kg/day caused a 43% reduction in final body weight and half that dose reduced it by 13% (Seinen et al. 1977a).

Single-dose studies with tributyltin oxide and chloride reported reduced weight gain and weight loss that became noticeable 48 hours following doses of 30–50 mg/kg (Ema et al. 1991a; Raffray and Cohen 1993). Significant weight loss was also reported in rats following 6 days of treatment with 2.5 mg/kg/day of tributyltin bromide (Yallapragada et al. 1991). A single dose of 100 mg/kg of tributyltin chloride produced a 13% reduction in body weight in hamsters 2 weeks after dosing (Takagi et al. 1992). Intermediate-duration studies with tributyltins have reported alterations in body weight in the range of 2.5–16 mg/kg/day (Bressa et al. 1991; Funahashi et al. 1980; Krajnc et al. 1984). In a 106-week study, body weights of rats were unaffected up to week 67, at which time, body weights of high-dose males (2.1 mg/kg/day) began to decrease (Wester et al. 1990); no quantitative data were provided.

Acute studies with triethyltin reported weight loss with doses ≥0.5 mg/kg/day (Yallapragada et al. 1991), and significant weight loss was reported in an intermediate-duration study with doses of 0.8 mg/kg/day in drinking water (Reiter et al. 1980). The lowest dose of trimethyltin that caused weight loss in rats in an acute study was 2.5 mg/kg/day (Yallapragada et al. 1991).

Intermediate-duration studies with triphenyltins reported a 25% reduction in body weight gain in rats following 7 weeks on a diet that provided 5 mg/kg/day of triphenyltin hydroxide (NCI 1978b). Rabbits also experienced a significant reduction in final weight gain following 70 days of treatment with approximately 17 mg triphenyltin acetate/kg (Dacasto et al. 1994a). Triphenyltin hydroxide was also associated with reduced body weight in male NMRI mice following 80 weeks on a diet that provided 15.2 mg/kg/day of the chemical (Tennekes et al. 1989a). No significant alterations in body weight gain were reported in dogs dosed with up to 0.62 mg triphenyltin hydroxide/kg/day for up to 52 weeks (Sachsse et al. 1987).

3.2.2.3 Immunological and Lymphoreticular Effects

Inorganic Tin Compounds. No studies were located regarding immunological effects in humans after oral exposure to inorganic tin compounds.
The only information available regarding effects in animals is that from a study by De Groot et al. (1973), which observed no significant histological alterations in the thymus and spleen from rats fed a diet that provided up to 440 mg Sn/kg/day as stannous oxide or up to 315 mg Sn/kg/day as stannous chloride for 13 weeks.

**Organotin Compounds.** No studies were located regarding immunological effects in humans after oral exposure to organotin compounds.

Numerous studies have shown that the lymphoreticular system, specifically the thymus, is the main target for some organotin compounds. For example, in Wistar rats fed diets that provided approximately 7.7 mg of dibutyltin dichloride/kg/day (the lowest dose tested) for 2 weeks, there was approximately a 50% reduction in relative thymus weight accompanied by lesser reductions in the relative weight of the spleen and popliteal lymph nodes (Seinen et al. 1977a). All treated rats showed marked lymphocyte depletion in the thymus, particularly the thymic cortex, but no signs of cell destruction could be seen. Rats dosed with 23 mg/kg/day showed almost complete depletion of lymphocytes. In addition to the thymus, lymphocyte depletion was evident in thymus-dependent areas of the spleen and popliteal nodes. Similar results were obtained with dioctyltin dichloride (Seinen and Williams 1977a). A 4-week dosing with dioctyltin dichloride followed by an 8-week period on a control diet showed that the effects on the thymus were completely reversed within 2 weeks after treatment ceased. Similar experiments conducted with diethyltin dichloride and dipropyltin dichloride showed similar but less pronounced effects. In contrast, dimethyltin dichloride, didodecyltin dibromide, dioctadecyltin dibromide, monoocetylthn trichloride, triocetylthn chloride, and tetraocetylthn did not induce atrophy of the lymphoid organs (Seinen et al. 1977a). Functional changes occurring in conjunction with the loss thymus weight and cellularity included a depression in the humoral response to immunization with sheep red blood cells (SRBC) in rats dosed with approximately 5 mg of dibutyltin dichloride/kg/day for 4–6 weeks and a significant delay in an allograft response at 15 mg/kg/day (Seinen et al. 1977b). Rats treated similarly with a 5 mg/kg/day dioctyltin dichloride exhibited a depressed delayed-type hypersensitivity (DTH) to tuberculin, a cell-mediated immunity parameter. Seinen et al. (1977b) also showed that the immune effects were more pronounced in rats exposed in the developmental phase of the lymphoid system. The immune effects of these organotin compounds were not induced by stress-related release of glucocorticoids, since adrenalectomy did not prevent the reduction in thymus weight (Seinen and Willem 1976). In addition, relative adrenal weight was unaffected in these studies and there were no histological signs of hyperactivity in the adrenal cortex.
(Seinen and Willems 1976). The findings of Seinen et al. (1977b) with dibutyltin dichloride in rats were used as basis for derivation of an intermediate-duration oral MRL for dibutyltin dichloride.

In contrast to rats, the immune functions of Swiss mice were unaffected by exposure to up to approximately 30 mg dibutyltin dichloride/kg/day for 4 weeks (Seinen et al. 1977a), and neither were the immune functions of guinea pigs treated with approximately 7 mg dioctyltin dichloride/kg/day for 5–7 weeks (Seinen et al. 1977b). However, exposure of Hartley guinea pigs to higher doses of dioctyltin dichloride for 4 weeks caused a reduction of the size of the thymus and its relative weight by about 37% compared with controls, and a marked depletion of lymphocytes in the thymic cortex (Seinen et al. 1977a). Treatment of Balb/c mice with a much higher dose of 500 mg dioctyltin dichloride/kg by gavage once per week for 8 weeks caused a reduction in relative thymus weight of approximately 67% relative to controls, and no significant changes occurred at 100 mg/kg (Miller et al. 1986).

Snoeij et al. (1985) studied the effects of a series of triorganotins in Wistar rats fed the compounds in the diet for 2 weeks. At doses of approximately 20 mg/kg/day, tripropyltin chloride, tributyltin chloride, and triphenyltin chloride induced a reduction in relative thymus weight of 47, 61, and 19%, respectively, relative to controls, and caused reduction of cellularity in the thymus. These effects were completely reversed within 2 weeks. Trihexyltin chloride was less effective, whereas trioctyltin chloride was ineffective. Trimethyltin chloride and triethyltin chloride were primarily neurotoxic (see Section 3.2.2.4).

In a 70-day dietary study in New Zealand rabbits, a dose of approximately 17.4 mg triphenyltin acetate/kg/day caused blurring of the demarcation between cortex and medulla of the thymus and depletion of lymphocytes in the cortex (Dacasto et al. 1994a). Also, lymph nodes showed decreased cellularity in the thymic-dependent areas.

A chronic-duration dietary study with dibutyltin dichloride did not report histopathological alterations in lymphoid tissues of Fischer-344 rats and B6C3F1 mice following treatment with doses of up to 6.7 and 19.8 mg/kg/day, respectively, for 78 weeks (NCI 1978a, 1978b). Long-term studies with triphenyltin hydroxide reported a reduction in serum immunoglobulins in Wistar rats following treatment with a dose of 0.3 mg/kg/day and higher for 52 weeks (Tennekes et al. 1989b), and in NMRI mice following administration of 15.2 mg/kg/day for 80 weeks (Tennekes et al. 1989a). No histopathological effects were observed in lymphoid tissues from Fischer-344 rats or B6C3F1 mice administered up to 3.8 and 9.8 mg of triphenyltin hydroxide/kg/day, respectively, for 78 weeks (NCI 1978a, 1978b), or in dogs dosed with up to 0.62 mg/kg/day for 52 weeks (Sachsse et al. 1987). No tests of immunocompetence were conducted in any of these long-term studies.
Several additional acute- and intermediate-duration studies with tributyltin hydroxide (and also oxide) have reported decreased weight in lymphoid organs (Bressa et al. 1991; Carthew et al. 1992; Funahashi et al. 1980; Krajnc et al. 1984; Raffray and Cohen 1993; Smialowicz et al. 1989, 1990; Vandebriel et al. 1998; Vos et al. 1990). Other immune parameters such as the primary immune response to SRBC and lymphoproliferative responses to stimulation with mitogens were affected by exposure to tributyltin oxide (Smialowicz et al. 1989, 1990). Furthermore, comparative 3-week studies in adult and preweanling Fischer-344 rats showed that younger animals were more sensitive to the immunosuppressive effects of tributyltin oxide than mature rats (Smialowicz et al. 1989). A 4.5–6-month dietary study in male Wistar rats showed that doses of 0.25 mg tributyltin oxide/kg/day, or higher, altered both parameters of specific resistance and nonspecific resistance (Vos et al. 1990). Neither the IgM nor the IgG response to ovalbumin and *T. spiralis* were altered after 5.5 months, but the IgE responses to *T. spiralis* was suppressed in a dose-related manner (significant at ≥0.25 mg/kg/day). The DTH reactions to ovalbumin and tuberculin were not significantly altered after 6 months of dosing. There also was an increased number of larvae of *T. spiralis* in muscle after infection at ≥0.25 mg/kg/day after 5.5 months of exposure to the test compound. There was no significant effect on the response of spleen cells to T- and B-mitogens after 4.5 months of treatment. The cell surface marker analysis of mesenteric lymph node cells showed a reduction in the relative count of T-lymphocytes and an increase in the percentage of B-lymphocytes at ≥0.25 mg/kg/day after 6 months. The *in vivo* clearance of *L. monocytogenes* was impaired at 2.5 mg/kg/day after 5 months of treatment. Treatment with tributyltin oxide for 4.5 months had no significant effect on natural killer cell activity of spleen and peritoneal cells. No significant effects were seen at 0.025 mg/kg/day and this dose, the study NOAEL, was used to derive an intermediate-duration oral MRL for tributyltin oxide. The same tests conducted after groups of rats had been on the experimental diets for 15–16.5 months yielded similar results and a LOAEL was defined at 0.25 mg/kg/day for depression of IgE titers and increased *T. spiralis* larvae in muscle after 16.5 of dosing; the NOAEL was 0.025 mg/kg/day and was used to derive a chronic-duration oral MRL for tributyltin oxide.

In another 2-year study of tributyltin oxide in Wistar rats, doses of 2.1–2.5 mg/kg/day significantly increased serum immunoglobulin A (IgA) after 12 and 24 months in males and females, decreased IgG in females after 3 and 13 months, and increased IgM after 3, 12, and 24 months (Wester et al. 1990). There were no histopathological changes in the thymus or lymph nodes, but the spleen showed decreased hemosiderin content after 12 months of exposure in males and females. No significant effects were seen with doses of approximately 0.2 mg/kg/day.
The highest NOAEL values and all reliable LOAEL values for immunological effects in each species and duration category are recorded in Tables 3-3 through 3-8 and plotted in Figures 3-3 through 3-8 for organotin compounds.

3.2.2.4 Neurological Effects

Inorganic Tin Compounds. No studies were located regarding neurological effects in humans after oral exposure to inorganic tin compounds.

In the studies of systemic and other effects of inorganic tin compounds in animals (Sections 3.2.2.1 and 3.2.2.2), clinical signs of neurotoxicity or behavioral changes were not noted. However, central nervous system effects in animals consisting of ataxia, muscular weakness, and depression have apparently been associated with oral exposure to the inorganic compounds (WHO 1980). Histopathological examinations of rats fed levels of 315 mg tin/kg/day as stannous chloride for 8–9 weeks revealed a spongy state of the white matter of the brain (De Groot et al. 1973). However, the treatment of these animals was terminated at 9 weeks because of the number of rats that were dead or moribund. It is, accordingly, difficult to determine if the tissue changes observed were due to a direct effect of tin on the brain or were secondary to the poor health of the animals. There were no other neurological changes reported and the meaning of the finding is not clear.

Organotin Compounds. Death and intoxication resulting from the Stalinon incidents are described in Section 3.2.2.1. Stalinon contained diethyltin diodide and an undetermined amount of triethyltin iodide. It has been proposed that the effects were caused by triethyltin iodide, which was present as an impurity from the manufacturing process (WHO 1980). Symptoms in the affected persons appeared suddenly, about 4 days following ingestion of the drug, and included vertigo, intense headache, photophobia, altered consciousness, visual impairment, and convulsions. Sensory disturbances, hypoflexia, and loss of sphincter control were common observations. Deaths occurred after 4–10 days as the result of deep coma, or more frequently, acute intracranial hypertension. Autopsies revealed diffuse edema in central nervous system white matter (Foncin and Gruner 1979). Kreyberg et al. (1992) described the neuropathological effects associated with a fatal case of trimethyltin intoxication. A few hours after the intoxication, the patient experienced tinnitus, lightheadedness, aggression, and episodes of unresponsiveness. The patient died of multiorgan failure six days after consumption of the chemical. Postmortem examination revealed generalized chromatolysis of the neurons in the brain, spinal cord, and
spinal ganglia. There was recent neuronal necrosis in the fascia dentata of the hippocampus and spinal ganglia, and also in the pyramidal cell layer of the hippocampus, cerebral cortex, basal ganglia, and Purkinje cell layer of the cerebellum. Kreyberg et al. (1992) noted that some of these changes could have been caused by an anoxic episode shortly before death. Ultrastructurally, there was marked accumulation of lysosomal dense bodies and disorganization of the granular endoplasmic reticulum in the neurons.

Acute intoxication with an unknown amount of triphenyltin produced severe ataxia, dysmetria, nystagmus, and blurring of vision in a 23-year-old male (Wu et al. 1990). Twelve days later, the patient developed disturbance of consciousness and confusion that lasted for 2 months. Electrophysiological tests revealed a delayed sensorimotor polyneuropathy due to axonal degeneration and demyelination. Lin et al. (1998) described an additional case of triphenyltin intoxication in a 19-year-old female who presented with spontaneous involuntary movement of the hands, facial twitching, diplopia, drowsiness, giddiness, vertigo, bidirectional nystagmus, impairment of calculations ability, and disorientation to people, time, and places. No seizures occurred, but 12 days after the poisoning episode the electroencephalogram (EEG) showed mild cortical dysfunction. Follow-up of the patient showed complete recovery within a year.

The effects associated with oral exposure of animals to triorganotins, particularly trimethyltin and triethyltin, have been described in a number of studies conducted mostly in rats. End points that have been monitored include neurochemistry, neurophysiology, and behavior. While the main target of both trimethyltins and triethyltin is the nervous system, exposure to trimethyltin is characterized by neuronal necrosis, particularly in the hippocampus, whereas triethyltin treatment causes primarily intramyelinic edema. Rats dosed in the food with approximately 2 mg triethyltin oxide/kg/day (only dose level tested) for 2 weeks had ataxia and paralysis of the hind limbs (Magee et al. 1957). Necropsy revealed swelling in the brain and spinal cord with compression of structures. Microscopic examination revealed interstitial edema of the white matter in all sections of the central nervous system; neurons of the brain and spinal cord seemed not to be affected. Rats that survived the treatment for 2 weeks followed by doses of 1 mg/kg/day for 6 weeks and then 4 months on a normal diet did not show evidence of the characteristic edema or obvious loss of myelinated fibers. Similar results were reported by in Osborne-Mendel rats dosed with approximately 2.8 mg triethyltin sulfate/kg/day in the drinking water for 22 days (Graham and Gonatas 1973). Signs of motor dysfunction were evident between the 10th and 17th day of intoxication. There was also greater involvement of the anterior than the posterior nerve roots, both of which showed more intramyelinic vacuole formation and splitting than did the sciatic nerve. Older rats appeared more susceptible than younger rats. Exposure of Sprague-Dawley rats to approximately 0.7–1.4 mg triethyltin
3. HEALTH EFFECTS

sulfate/kg/day in the water for 3 months caused mild brain edema as early as day 10 (Eto et al. 1971). After 30 days, there was a noticeable decrease in the amount of stainable myelin. In the treated rats, the yield of myelin per brain was reduced by half, but the isolated myelin appeared morphologically normal. Analysis of whole brains showed decreased proteolipid protein and total lipid, particularly galactolipids. Eto et al. (1971) hypothesized that treatment with triethyltin causes nonspecific chemical abnormalities in the myelin sheath undergoing secondary degeneration. Some Wistar rats treated with approximately 1.4 mg triethyltin sulfate/kg/day in the water developed weakness and paralysis after 4 weeks of treatment and some died (Smith 1973). Necropsy showed edema of the brain and spinal cord.

In a 2-week dietary study with several trialkyltin compounds in male Wistar rats, Snoeij et al. (1985) observed that triethyltin chloride and trimethyltin chloride were neurotoxic (cerebral edema and neuronal necrosis, respectively), whereas tripropyltin chloride, tributyltin chloride, and triphenyltin were mainly immunotoxic (see Section 3.2.2.4), trihexyltin chloride was slightly immunotoxic, and trioctyltin chloride was not toxic at the doses tested.

In addition to examination of the morphological effects of triethyltin, behavioral testing has also been conducted. In male CD rats, no toxic signs were seen during treatment with 1 mg triethyltin bromide/kg/day twice per week (1, 2, or 3 mg/kg/day) for 2 weeks (Squibb et al. 1980). However, grip strength (hindlimb and forelimb) was significantly reduced during the second week of treatment at 2 mg/kg even during a week free of treatment. Four weeks after treatment ceased, limb strength had returned to normal (1 and 2 mg/kg). Startle responsiveness was significantly reduced at 1 and 2 mg/kg, beginning the first week of treatment, but recovered in the posttreatment period. Two weeks after start of treatment, all treated groups showed edema of the white matter in the central nervous system but none was seen in the sciatic nerve. There appeared to be no neuronal damage. Partial recovery of the lesions was seen 4 weeks after treatment ceased. In another drinking water study, repeated doses of triethyltin bromide (0.4–0.8 mg/kg/day) produced performance decrements in a series of behavioral toxicity tests in rats (Reiter et al. 1980). The effects were rapid in onset, but were reversible 1 month after exposure was discontinued. Such findings correlate well with effects on the myelin sheath (i.e., demyelination).

The neurotoxicity of trimethyltin has been examined in numerous acute-duration studies and in a smaller number of intermediate-duration studies. Bouldin et al. (1981) conducted a detailed analysis of the morphological effects of trimethyltin hydroxide in adult and neonatal Long-Evans rats. Both groups were dosed with 1 mg/kg, the adults once a day for 14 days, and the neonates once every other day for 26 days. Adult rats became self-mutilating and highly aggressive after 10–12 days, whereas the neonates exhibited
spontaneous tremors and seizures, and were reactive to noise but were not aggressive. The major finding in both groups was neuronal necrosis in the neocortex, pyriform cortex, hippocampal formation, basal ganglia, brain stem, spinal cord, and dorsal root ganglia. The neurons of the hippocampal formation and pyriform cortex were most vulnerable to the effects of trimethyltin. Bouldin et al. (1981) also observed that acute high doses affected preferentially neurons of the fascia dentata, whereas longer-term low doses affected the neurons of Ammon’s horn. Ultrastructurally, the changes were characterized by cytoplasmic accumulations of dense-core vesicles and tubules, autophagic vacuoles, and polymorphic dense bodies both in acute and chronic intoxications in both mature and immature rats. Light- or electron-microscopy provided no evidence of neuronal necrosis in the hippocampal formation or pyriform cortex of neonatal or adult rats exposed to dimethyltin, diethyltin, tripropyltin, tributyltin, tricyclohexyltin, or triphenyltin (Bouldin et al. 1981).

Chang et al. (1983) conducted a comparative study in two strains of rats (Long-Evans and Sprague-Dawley) and mice (Balb/c and C57BL/6). All groups were dosed once, mice with 3 mg/kg and rats with 7.5 mg/kg trimethyltin chloride. Mice showed signs of intoxication earlier than rats and more prominent hippocampal lesions than rats. Long-Evans rats showed signs of intoxication earlier than Sprague-Dawley rats (3 days vs. 5 days). Furthermore, while mice showed most lesions in the hippocampal fascia dentata, rats showed more prominent neuronal damage in the olfactory cortex and hippocampal Ammon’s horn. Trimethyltin also has been shown to induce neuronal damage in sensory neurons of the central and peripheral nervous system (Chang and Dyer 1983). These investigators found that a single gavage dose of 6 mg/kg of trimethyltin chloride produced extensive damage in the retina, inner ear, pyriform cortex, olfactory tubercle, and dorsal root ganglia of rats. Inner ear damage was already evident 72 hours after dosing and extensive destruction was apparent 15–30 days after treatment. Small neurons in the olfactory cortex (pyriform cortex and olfactory tubercle) also degenerated rapidly after treatment with trimethyltin. Fifteen days after exposure, there was extensive destruction of the pyriform cortex and olfactory cortex. No necrotic changes were seen in the dorsal root ganglia, but electron microscopy showed accumulation of lysosomes and formation of myeloid bodies both in the cell bodies and axons. Hypertrophy and hyperplasia of the neuronal mitochondria were seen 30 days after treatment; these changes were thought to represent a compensatory response.

The neurological effects of trimethyltin also have been studied in other species. Brown et al. (1984) conducted studies with trimethyltin chloride in hamsters, marmosets, and gerbils. Hamsters receiving a single dose of 4 or 5 mg/kg showed whole-body tremors and were almost moribund when sacrificed at 4 days. These animals showed neuronal necrosis and chromatolysis primarily in the hippocampus but
also in the pyriform cortex, amygdala, neocortex, and various brain stem nuclei. Motor neurons of the cervical spinal cord were also involved. The brains of hamsters treated with 1 mg/kg once per week for 5 weeks were normal and those of animals treated similarly for 7 weeks showed neuronal degeneration confined to the hippocampus. The marmoset monkeys were gavaged with single doses (3–4.5 mg/kg) or two doses (3 plus 3 mg/kg or 3 plus 1.5 mg/kg) of trimethyltin chloride. Signs of poisoning at 24 hours included fine tremor, diarrhea, and salivation. Two days later, these signs increased to whole body tremor, ataxia, agitation, aggression, and loss of appetite. A dose of 3.75 mg/kg caused prostration at 2–3 days with continuous body tremors and myoclonic jerks of the head and body. No convulsions were seen. One monkey at 3 mg/kg was moribund on day 4, four at 3.75 mg/kg on days 2–3, and one at 4.5 mg/kg on day 1. Two monkeys given 3 mg/kg survived to days 35 and 45. The monkeys that died early showed neuronal necrosis and chromatolysis primarily in the hippocampus but also in the pyriform cortex, amygdala, neocortex, various brain stem nuclei, and retina. Some signs of histopathological alterations were still present in the two monkeys that survived 35 and 45 days. No lesions were seen in the lumbar spinal ganglia or sciatic nerve. Gerbils were gavaged with single doses between 3 and 12 mg/kg of trimethyltin chloride. All dose levels caused lethality. Clinical signs included whole body tremors, prostration, and convulsions. Histopathologic examinations showed neuronal necrosis and chromatolysis primarily in the hippocampus but also in the pyriform cortex, amygdala, neocortex, and various brain stem nuclei. In two animals given 3 mg/kg that survived to 7 and 18 days, the pyramidal cells in the hippocampus were normal.

Less information is available for other organotins. For example, Wistar rats treated once with 6.3 mg tributyltin chloride/kg (the lowest dose level tested) showed no overt signs of toxicity (Ema et al. 1991a). Diurnal activity was higher than in controls on days 1–4 in the groups receiving the highest dose (50 mg/kg). Spontaneous motor activity during the dark phase was significantly decreased, but returned to normal 4 days after dosing. Also, the acquisition of conditioned avoidance responses was significantly impaired at ≥25 mg/kg. An additional acute study reported that a daily dose of 2.5 mg tributyltin bromide/kg for 6 days induced slight tremors and weakness in Sprague-Dawley rats; doses of 1.5 mg/kg caused no adverse effects (Yallapragada et al. 1991). Administration of 37.5 or 75 mg tributyltin oxide/kg/day for 3 days to rats induced significant reductions in serotonin, dopamine, and noradrenaline in whole brain preparations (Elsabbagh et al. 2002). In general, the reductions were dose-related. ATPase activities also were significantly reduced. Histopathological examination of the brains showed hyperemic meningeal and cerebral blood vessels. There were focal hemorrhages in vacuolated myelinated fibers and some neurones showed chromatolysis and others necrosis. The purkinje cells showed degenerative changes. In general, the severity of the effects was dose-related. In a 2-year
bioassay with tributyltin oxide, no histopathologic alterations were observed in the brain and spinal cord from Wistar rats administered dietary doses of up to 2.5 mg/kg/day (Wester et al. 1990).

Rats treated acutely with 20 mg dibutyltin laureate/kg/day for 3 days showed decreased motor activity and learning, but that dose also caused lethality (Alam et al. 1993). In 78-weeks dietary studies with dibutyltin chloride, there was no evidence of adverse gross or microscopic alterations in the brains of Fischer-344 rats and B6C3F1 mice dosed with up 6.7 and 19.8 mg/kg/day, respectively (NCI 1978a). No neurological effects have been observed in chronic-duration studies with triphenyltin hydroxide in rats and mice (NCI 1978b), and dogs (Sachsse et al. 1987).

The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and duration category are recorded in Tables 3-3 through 3-8 and plotted in Figures 3-3 through 3-8 for organotin compounds.

### 3.2.2.5 Reproductive Effects

**Inorganic Tin Compounds.** No studies were located regarding reproductive effects in humans after oral exposure to inorganic tin compounds.

Limited information was found on effects in animals. No reproductive effects (number of corpora lutea and of implantation and resorption sites) were reported in rats, mice, and hamsters administered up to 31 mg tin/kg/day (as stannous chloride) during gestation (Gds 6–15 for rats and mice, Gds 6–10 for hamsters) (FDA 1972). Exposure of rats during Gds 0–20 to up to approximately 45 mg tin/kg/day (as sodium pentachlorostannite) or 56 mg tin/kg/day (as tin fluoride) in the diet had no significant effect on the number of resorptions or placental weight (Theuer et al. 1971). In a 13-week study in rats, dietary levels ranging from 1.5 to 9.2 mg tin/kg/day as stannous chloride caused testicular degeneration (De Groot et al. 1973). Histopathological degeneration was seen in a few animals that were treated for 9 weeks with 315 mg/kg/day and then sacrificed because of their moribund physiological state. The biological significance of the findings is unclear.

**Organotin Compounds.** No studies were located regarding reproductive effects in humans after oral exposure to organotin compounds.
The reproductive effects of some organotin compounds have been studied mostly in rats, although some information in mice is also available. In most studies in rats, the pregnant dams were dosed at various times during pregnancy and sacrifices were conducted on Gd 20. Treatment of pregnant Wistar rats with doses of $\geq 7.5$ mg dibutyltin dichloride/kg/day on Gds 7–15 significantly increased the number of resorptions and dead fetuses per litter and the percentage of postimplantation loss (Ema et al. 1991b). These dose levels also caused rats mortality. Doses of 5 mg/kg/day produced no significant maternal or reproductive effects. In a similar study, doses of 15 mg dibutyltin diacetate/kg/day administered on Gds 7–17 significantly increased the incidence of dead or resorbed fetuses, but a lower dose of 10 mg/kg/day was without significant reproductive effects (Noda et al. 1992). Maternal thymus weight was reduced by 54% with a dose of 5 mg/kg/day and body weight was significantly reduced at 15 mg/kg/day, suggesting that the adverse reproductive effects observed at 15 mg/kg/day may have been secondary to maternal toxicity and that thymic involution, while a sensitive index of maternal toxicity, may be unrelated to the manifestation of reproductive effects. In a more recent study with dibutyltin dichloride administered on Gds 6–15, the highest dose tested, 10 mg/kg/day, was maternally toxic (reduced weight gain and food consumption), but did not significantly affect any reproductive parameter, (i.e., total implantations, mean implantations/litter, total early resorptions, mean early resorptions/litter, total late resorptions, and mean late resorptions/litter) (Farr et al. 2001). Further studies of Ema and coworkers showed that administration of dibutyltin dichloride on Gds 7–9 induced more resorptions and postimplantation losses than when given on Gds 10–12 or 13–15 (Ema et al. 1992). Furthermore, within that 3-day period, Gd 8 was the day of highest susceptibility. Treating rats with $\geq3.8$ mg dibutyltin chloride/kg/day on Gds 4–7 significantly increased the percentage of postimplantation losses/litter and doses of $\geq7.6$ mg/kg/day on Gds 0–3 increased the number and percentage of preimplantation losses (Ema and Harazono 2000). In a subsequent study, Ema et al. (2003) reported that subcutaneous administration of progesterone partially prevented the preimplantation losses induced by dibutyltin and hypothesized that a decline in progesterone is a primary mechanism for the implantation failure induced by dibutyltin. Results from further studies by the same group of investigators suggested that the early embryonic loss induced by dibutyltin is due to inhibition of uterine decidualization, which is caused by inhibition of the development of uterine sensitivity due to decreased serum progesterone levels (Harazono and Ema 2003).

In long-term studies, female Fischer-344 rats fed diets that provided approximately 3.33 and 6.65 mg/kg/day dibutyltin diacetate showed inflammation and hyperplasia of the uterus (NCI 1978a). The frequency with which these changes were observed was greater in the low-dose group than in the high-dose group. However, the tissues from 17 of the 50 high-dose group animals were lost before
3. HEALTH EFFECTS

microscopic examination; therefore, these findings must be regarded as inconclusive. No significant alterations in reproductive organs from B6C3F1 mice were seen in a 78-week bioassay (NCI 1978a).

Studies with tributyltins have provided results similar to those with dibutyltins. Increased fetal deaths and resorptions were seen in rats dosed with 16 mg tributyltin acetate/kg/day on Gds 7–17 (Noda et al. 1991a); this dose levels also caused maternal toxicity (reduced food consumption and body weight gain and 28% reduction in thymus weight). A significant increase in resorptions and in the incidence of postimplantation loss was seen in rats dosed with 25 mg tributyltin chloride/kg/day (the lowest dose tested) on Gds 7–9 relative to controls and to treatments on Gds 10–12 or 13–15 (Ema et al. 1995b). In a subsequent study from the same group, Gd 9 was identified as the most susceptible for postimplantation loss to occur compared to Gds 7, 8, 10–15 (Ema et al. 1997a). In another study, a significant increase in pregnancy failure occurred when dosing with 16.3 mg/kg/day on Gds 0–3, whereas a much higher dose, 65.1 mg/kg/day, was needed to cause pregnancy failure if treatment was done on Gds 4–7 (Harazono et al. 1998). A more recent study reported decreased fertility, increased postimplantation loss, and decreased litter size in rats treated with 20 mg tributyltin chloride/kg/day on Gds 0–19; no such effects were seen at 10 mg/kg/day (Adeeko et al. 2003).

In four studies of similar design in mice (treatment for at least 10 days during gestation) (Baroncelli et al. 1990, 1995; Davis et al. 1987; Faqi et al. 1997), the LOAEL for tributyltins was 5 mg/kg/day for increased early parturitions and resorptions (Baroncelli et al. 1995). A study that evaluated a different type of reproductive parameter showed that treatment of male ICR mice with 10 mg tributyltin oxide/kg 2 times/week for 4 weeks significantly reduced sperm counts to about 70% of controls (Kumasaka et al. 2002). In addition, light microscopy of the testis revealed disorganized seminiferous tubules with vacuolization of Sertoli cells and some loss of germ cells. No effects were seen on spermatogonia, spermatocytes, spermatids, Leydig cells, and the basement membrane of the seminiferous tubules; the study NOAEL was 2 mg/kg/day.

Daily administration of tributyltin chloride (5–20 mg/kg/day) to 35-day-old male rats did not significantly alter the weights of the testes, epididymis, or prostate, but doses of 10 and 20 mg/kg/day significantly decreased seminal vesicle weight in a dose-related manner (Yu et al. 2003a). Doses of 10 and 20 mg/kg/day did not produce morphological alterations in the testes or prostate, but did so in seminal vesicles and epididymis. In rats that underwent the same treatment but were examined 5 weeks after the last dose, the 20 mg/kg/day dose of tributyltin chloride significantly reduced sperm counts recovered from the testes relative to controls (Yu et al. 2003b). Epididymal sperm counts also were significantly reduced
at 10 and 20 mg/kg/day. In general, sperm motility was not significantly altered by treatment with tributyltin.

In 2-generation reproductive studies with tributyltin chloride in male and female Wistar rats, the highest dose tested, 10 mg/kg/day, had no significant effect on the fertility index of females (females with delivery/females copulated) of either the parental generation (P) or the F1 generation (Ogata et al. 2001) or on the copulation index or the fertility index of F1 males (Omura et al. 2001). In a 2-year bioassay with tributyltin oxide in Wistar rats, no histopathological alterations were observed in the ovaries, uterus, testis, or prostate (Wester et al. 1990).

Studies with triphenyltins in which pregnant rats were dosed during most of the pregnancy (Gd 5–17) reported significant increases in resorptions at dose levels of 13 mg/kg/day (only dose level tested) (Chernoff et al. 1990) and 6 mg/kg/day (Noda et al. 1991b); a NOAEL of 3 mg/kg/day was identified in the latter study. Dosing rats with 4.7 mg/kg/day on Gds 0–3 induced pregnancy failure, preimplantation loss and a decrease in the number of implantations per female (Ema et al. 1997b). However, pregnancy failure occurred only at ≥12.5 mg/kg/day and increased implantations losses only at 25 mg/kg/day when the rats were treated on Gds 4–6. It was suggested that preimplantation losses are caused by changes in the development of uterine receptivity induced by triphenyltin (Ema et al. 1999b). Similar to findings with other alkyltins, the most vulnerable dosing period for resorptions and postimplantation losses to occur was Gds 7–9 relative to Gds 10–12 or 13–15 (Ema et al. 1999a). Transient reduced fertility was reported in male rats treated with approximately 5 mg triphenyltin hydroxide/kg/day for up to 64 days (Gaines and Kimbrough 1968). However, because changes in food consumption closely followed the gradual change in fertility and the recovery, it appeared that the decrease in food intake was responsible for the reduced fertility.

Male rats fed triphenyltin hydroxide at doses of ≥5.2 mg/kg/day for 2 years displayed a dose-related increase in Leydig cell hyperplasia (p<0.0005) and tubular atrophy (p=0.004) of the testes (Tennekes et al. 1989b), which was not seen in either rats dosed with up to 9.8 mg/kg/day or mice dosed with up to 3.75 mg/kg/day for 78 weeks (NCI 1978b). Administration of up to 0.62 mg triphenyltin hydroxide/kg/day in the diet for up to 52 weeks to male and female dogs did not produce any significant gross or microscopic changes in the reproductive organs (Sachsse et al. 1987).

The effects of diphenyltin also have been studied. Administration of ≥16.5 mg diphenyltin dichloride/kg/day on Gds 0–3 to rats significantly increased the incidence of pre-implantation losses and
24.8 mg/kg/day also decreased the pregnancy rate (Ema et al. 1999c). Results from a subsequent study showed that the early pregnancy failure was due to suppressed uterine deciduization and reduced serum progesterone levels (Ema and Miyawaki 2002).

No significant alterations in reproductive parameters were observed in rats treated with up to 400 mg monobutyltin trichloride/kg/day on Gds 7–17 (Noda et al. 1992b).

The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species and duration are recorded in Tables 3-3 through 3-8 and plotted in Figures 3-3 through 3-8 for organotin compounds.

3.2.2.6 Developmental Effects

**Inorganic Tin Compounds.** No studies were located regarding developmental effects in humans after oral exposure to inorganic tin compounds.

Limited information is available from studies in animals. Treatment of rats, mice, and hamsters with up to 31 mg tin/kg/day by gavage in water during gestation (Gds 6–15 for mice and rats, Gds 6–10 for hamsters) has no significant effect on fetal weight, the number of live of dead fetuses, and the incidence of external and internal malformations (FDA 1972). Administration of up to approximately 56 mg tin/kg/day (as tin fluoride) or 45 mg tin/kg/day (as sodium pentachlorostannite) to rats on Gds 0–20 had no significant effect on average fetal weight or the number of live fetuses per litter (Theuer et al. 1971).

**Organotin Compounds.** No studies were located regarding developmental effects in humans after oral exposure to organotin compounds.

Several organotins have been evaluated for potential developmental effects in animals. A dose of 5 mg dibutyltin dichloride/kg/day administered by gavage to pregnant Wistar rats on Gds 7–15 significantly increased the incidence of external and skeletal malformations but not of internal malformations (Ema et al. 1991b). Cleft jaw and ankyloglossia were the most frequent malformations. A lower dose of 2.5 mg/kg/day did not cause any significant effect. Since adjusted maternal weight and food consumption during pregnancy were not affected at 5 mg/kg/day, it would appear that the developmental effects occurred in the absence of maternal toxicity. In a similar study in Wistar rats dosed on Gds 7–17, Noda et al. (1992) observed increased external and skeletal malformations at 10 mg/kg/day, but not at
3. HEALTH EFFECTS

5 mg/kg/day. Neither maternal weight nor food consumption were significantly altered at 10 mg/kg/day, but maternal thymus weight was significantly reduced at ≥5 mg/kg/day suggesting that for dibutyltin, a known immunotoxicant (see Section 3.2.2.3), maternal changes in thymus weight may be a better predictor of embryotoxicity and teratogenicity than changes in body weight. In a third study of similar design, Farr et al. (2001) observed a slight increase in malformations at 10 mg/kg/day, a dose level that also reduced maternal weight gain and food consumption, and decreased thymus weight; 5 mg/kg/day was the maternal and developmental NOAEL.

Studies have been conducted to determine the period of highest susceptibility during gestation. For example, Ema et al. (1992) dosed rats with dibutyltin dichloride (20 mg/kg/day) at various times during gestation, after Gd 6, and noticed that the highest incidence of malformations occurred when dosing on Gd 8. No teratogenicity was evident when the rats were treated on Gds 10–12 or 13–15. Fetal weights were most severely decreased when dosing on Gds 7–9. In a more recent study, Ema and Harazono (2000) reported that doses of up to 15.2 mg dibutyltin dichloride/kg/day administered on either Gds 0–3 or 4–7 caused no external malformations.

Doses of 16 mg tributyltin acetate/kg/day administered to pregnant Wistar rats on Gds 7–17 significantly increased the incidence of external malformations, particularly cleft palate and also reduced maternal weight gain and food consumption, and thymus weight by about 28% (Noda et al. 1991a). The developmental NOAEL was 8 mg/kg/day, but even a lower dose, 4 mg/kg/day, reduced maternal thymus weight. A dose of 25 mg tributyltin chloride/kg/day administered on Gds 13–15 caused more external malformations in rats (particularly cleft palate) than when given on Gds 10–12 (Ema et al. 1995b). Single-day treatments from Gd 7 onward showed that the most vulnerable periods for increased external malformations were Gds 11, 12, 13, and 14; a smaller increase also occurred when dosing on Gd 8 (Ema et al. 1997a). As with dibutyltin, doses of up to 16.3 mg tributyltin chloride administered on Gds 0–3 or 4–7 did not cause malformations (Harazono et al. 1998). Doses of tributyltin chloride up to 10 mg/kg/day administered on Gds 8–19 did not significantly affect fetal weight, anogenital distance (male and female pups), or sex ratio, and caused no external malformations (Adeeko et al. 2003). However, 0.25 mg/kg/day and higher doses given on Gds 0–19 significantly increased anogenital distance in male pups and ≥10 mg/kg/day increased the percentage of unfused ossification centers in the sternebrae (Adeeko et al. 2003).

In a 2-generation reproductive toxicity study in female Wistar rats designed to examine the reproductive effects of tributyltin chloride (0.4, 2, 10 mg/kg/day), exposure to the highest dose (10 mg/kg/day)
significantly decreased the percentage of live pups and the birth weight of female pups (Ogata et al. 2001). Gestational body weight was significantly reduced in the high-dose parental (P) and F1 generations. There were no gross malformations. The day of eye opening was significantly delayed in the high-dose F2 pups. Body weights of F1 and F2 high-dose pups were significantly lower than controls for both pre- and postweaning. Anogenital distance was significantly increased in F1 and F2 females on postnatal days (Pnds) 1 and 4 with the high-dose and on Pnd 1 in mid-dose F1. The day of vaginal opening was significantly delayed (6 days) in the high-dose F1 and F2 groups. Analysis of the estrous cycles between Pnds 71 and 92 showed no alterations in F1, but the number of cycles was significantly decreased in the high-dose F2. Also, the percentage of normal cycles was decreased in the high-dose F1 and F2 rats. The NOAEL was 2 mg/kg/day.

A study of similar design was conducted to evaluate the development of reproductive parameters in male Wistar rats (Omura et al. 2001). The doses tested were 0.4, 2, and 10 mg/kg/day. Body weight was significantly reduced in the high-dose F1 pups on Pnds 1, 4, 14, and 21 and in the mid-dose F1 pups on Pnds 14 and 21. Body weight was also reduced in the high-dose F2 pups on Pnds 1, 4, 14, and 21. Anogenital distance and day of testes descent (measured on Pnds 1 and 4) was not significantly altered in F1 or F2 males. The day of eye opening was significantly delayed in the mid- and high-dose F1 males and in the high-dose F2 pups. Postnatal body weight gain, but not food consumption, was significantly depressed in the high-dose F1 and F2 pups. Effects on the weight of the sex organs included: decreased absolute testis weight in all F1 groups (dose-related); decrease absolute epididymis weight in the low- and high-dose F1 groups; decrease absolute testis and epididymis weight in the high-dose F2 groups and in relative prostate weight in the mid- and high-dose F2 groups. The only sperm parameters that were significantly altered were sperm count in the high-dose F2 rats and spermatid count in high-dose F1 rats and the mid- and high-dose F2 rats. Histological examination of the testes revealed minimal alterations in the high-dose F1 groups, but more frequent and severe effects in F2 groups, which were considered abnormal and consisted of vacuolization of the seminiferous epithelium, spermatid retention, and delayed spermiation. Serum testosterone was increased and estradiol was decreased in the high-dose F1; serum estradiol was decreased, and luteinizing hormone (LH) was increased in the high-dose F2. Based on decreased pups weight on Pnds 14 and 21, the authors established the developmental LOAEL at 2 mg/kg/day and the NOAEL at 0.4 mg/kg/day. The changes in sex organ weight were not considered biologically significant.

Tributyltin chloride has also been shown to cause neurodevelopmental effects in rats. Treatment of pregnant Sprague-Dawley rats with 1 mg/kg/day (the lowest dose tested) on Gds 6–20 caused
3. HEALTH EFFECTS

hyperactivity in the offspring when tested on Pnds 60–70 and impaired learning in a radial arm maze test on Pnds 65–68 (Gardlung et al. 1991). No obvious maternal toxicity was noticed and there were effects on the physical development of the offspring. No significant effects were seen on open-field activity (Pnds 120–125) or on performance on a swim-maze test (Pnds 66–70). Also, in rats sacrificed on Pnds 60–70, no significant alterations were found in the levels of noradrenaline in the frontal and occipital cortex, hippocampal formation, and cerebellum; levels of serotonin and metabolites in the frontal cortex, striatum, olfactory tubules, hippocampus, mesencephalon, and cerebellum; and levels of dopamine and its metabolites in the striatum, olfactory tubules, and mesencephalon. Trihexylothin chloride, which was also tested in the study, was much less effective than tributyltin.

Cooke et al. (2004) and Tryphonas et al. (2004) evaluated systemic and immunological parameters in rats that were exposed to tributyltin chloride in utero (Gds 8–21), through the mother’s milk, and directly as young adults until the age of 90 days. The doses tested were 0.025, 0.25, and 2.5 mg/kg/day. Neither body weights nor food consumption was affected in the dams. No effects were observed on litter size, pup's weight at birth, sex ratio, or survival until weaning. Growth of the treated pups after weaning was slightly reduced (<10%) relative to controls and analysis of food consumption and weight gain showed that male pups converted feed into weight gain less effectively than females. No effects were seen on the weights of pup's brain, kidney or adrenals, but there was a decrease in absolute and relative liver weight in 60-day-old females at 0.025 and 2.5 mg/kg/day, a decrease in absolute and relative liver weight in 90-day-old males at 2.5 mg/kg/day, decrease in absolute spleen weight in 30-day-old males at 2.5 mg/kg/day and in relative spleen weight in 60-day-old females at 2.5 mg/kg/day, a decrease in relative thymus weight in 60-day-old females at 0.25 and 2.5 mg/kg/day and in absolute thymus weight in 30-day-old males at 2.5 mg/kg/day. No consistent treatment-related gross or microscopic lesions were observed in dams and pups. Clinical chemistry changes of potential biological importance included a decrease in serum amylase in 90-day-old males at 0.25 and 2.5 mg/kg/day and decreased T4 also in 90-day-old males at 2.5 mg/kg/day. Based on the changes in pup's organ weights and in clinical chemistry parameters, the 0.25 mg/kg/day dose is a LOAEL and 0.025 mg/kg/day a NOAEL. The reduced weight gain of the pups is not considered adverse because the difference with controls was less than 10%.

In the study of immunological parameters (Tryphonas et al. 2004), the only significant change in serum immunoglobulin levels that appeared dose-related was an increase in IgG at 0.25 and 2.5 mg/kg/day in 90-day old males. Flow cytometric analysis of splenocytes showed a significant increase mean percent and absolute NK cell numbers in high-dose 30-day-old males and females, a decrease in the percentage, but not in absolute numbers of CD4+8+ T cells in 60-day old females, and an increase in the percentage
of NK cells in 90-day-old males. The anti-SRBC IgM response was not affected by exposure to tributyltin. No significant alterations were observed in the lymphoproliferative activity of splenocytes in response to mitogen stimulation. The delayed-type hypersensitivity response (DTH) was not affected in 60-day-old females, but 90-day-old males showed a significant trend toward a decrease in DTH response with increasing doses of tributyltin. The assays for *L. monocytogenes* infectivity and NK cell activity did not give dose-related responses. Cytokine levels in serum were not affected. Gross examination of lymphoid tissues was unremarkable. The most consistent histological finding was mild to moderate cortical atrophy of the thymus, characterized by decreased numbers of cortical lymphocytes at 2.5 mg/kg/day at all ages.

In mice, doses of ≥11.7 mg tributyltin oxide/kg/day on Gds 6–15 induced cleft palate and other bone abnormalities and also decreased weight gain in the pregnant mice (Davis et al. 1987). Similar findings were reported by Faqi et al. (1997) following dosing the mice on Gds 6–17 with 27 mg/kg/day, a dose level that also caused maternal toxicity. The developmental and maternal NOAEL was 13.5 mg/kg/day. Doses of up to 20 mg tributyltin oxide/kg/day did not increase the incidence of malformations in pups from dams treated on Gds 6–15, but significant early pup mortality occurred with this dose level (Baroncelli et al. 1995). That same dose level did not significantly alter hematological parameters in the dams, neonates, or pups on Pnds 7, 14, and 21 (Karrer et al. 1995). Absolute and relative thymus weight was reduced in pups on Pnd 7 and increased on Pnd 21 relative to controls; spleen weight was not affected by treatment.

Experiments conducted with triphenyltin chloride in Wistar rats showed that doses of up to 12.5 mg/kg/day administered on either Gds 7–9, 10–12, or 13–15 did not significantly increase the incidence of malformations, but fetal weight was decreased at 9.4 mg/kg/day when dosed on Gds 13–15 (Ema et al. 1999a). No significant effect was seen on the incidence of malformations in doses up to 25 mg/kg/day administered on Gds 4–6 or up to 6.3 mg/kg/day on Gds 0–3; fetal weight was decreased with doses of 4.7 mg/kg/day administered on Gds 0–3 (Ema et al. 1997b). An unpublished study reported that fetal weights were slightly depressed (11%) in the offspring of New Zealand white rabbits that were administered 0.9 mg triphenyltin hydroxide/kg/day by gavage on Gds 6–18 (Rodwell 1987). Delayed ossification of the hyoid bone was also present, but there were no teratogenic effects. Food consumption and maternal weight gain were also significantly reduced at this dose level. The maternal and developmental NOAEL was 0.3 mg/kg/day. No other study in rabbits was identified that could have been used to corroborate or refute these findings.
3. HEALTH EFFECTS

In a study with diphenyltin dichloride, treatment of rats with 16.5 mg/kg/day and higher doses on Gds 0–3 significantly decreased the body weight of the live fetuses, but no significant effect was seen with doses of 8.3 mg/kg/day (Ema et al. 1999c). Treatment with up to 33 mg/kg/day did not alter the sex ratio or induce external malformations.

Monobutyltin trichloride did not induce maternal or developmental effects in rats administered the compound on Gds 7–17 in doses of up to 400 mg/kg/day (Noda et al. 1992).

Trimethyltin chloride (0.05, 0.16, 0.34 mg/kg/day) altered extinction learning ability in 11-day-old rat pups from rats treated for a period that included 14 days premating, gestation, and lactation (Noland et al. 1982). This specific effect (altered extinction learning ability) was dose-related, but no dose-response was evident for other behavioral tests. Tests with monomethyltin trichloride (3.7, 12.5, and 37 mg/kg/day) were inconclusive.

All reliable NOAEL and LOAEL values for developmental effects in each species and duration category are recorded in Tables 3-3 through 3-8 are plotted in Figures 3-3 through 3-8 for organotin compounds.

3.2.2.7 Cancer

Inorganic Tin Compounds. No studies were located regarding cancer effects in humans after oral exposure to inorganic tin compounds.

A carcinogenesis bioassay for stannous chloride was conducted in male and female Fischer-344 rats and B6C3F1/N mice (NTP 1982). Diets containing 32 or 63 mg tin/kg/day as stannous chloride were fed to rats and 82 or 164 mg tin/kg/day to mice for 105 weeks. Aspects of the toxicity of stannous chloride observed during prechronic studies completed prior to the bioassay have been presented in Sections 3.2.2.1 and 3.2.2.2. Tumors occurred at increased incidences in the dosed groups in the bioassay. These included C-cell adenomas of the thyroid in low-dose male rats, lung adenomas in the high-dose male rats, and hepatocellular adenomas and carcinomas and histiocytic lymphomas in both low- and high-dose female mice. However, the authors concluded that the incidences of the tumors relative to the histological control rat and mouse data were similar and were not clearly related to administration of stannous chloride. The possibility that the C-cell tumors in the thyroid may have been related to stannous chloride feeding was not ruled out since the incidence in the low-dose group, but not the high-dose group, was significant by comparison to the controls and to historical controls. Despite the
reservation, the conclusion from the NTP (1982) data was that stannous chloride was not carcinogenic for
male or female rats or mice.

An earlier chronic oral study that evaluated the carcinogenic potential of sodium chlorostannate must be
regarded as flawed for several reasons. The rats were fed on irregular dose schedules and most of the
animals developed pneumonia (Roe et al. 1965). After 1 year, three malignant tumors were identified in
30 rats. Long-term chronic studies of stannous chloride in rats and mice were conducted using a single
low-dose exposure and limited pathology studies (Schroeder and Balassa 1967; Schroeder et al. 1968).
The authors concluded that stannous chloride was not carcinogenic.

**Organotin Compounds.** No studies were located regarding cancer effects in humans after oral exposure
to organotin compounds.

A carcinogenesis bioassay for dibutyltin diacetate was conducted in male and female Fischer-344 rats and
B6C3F1 mice (NCI 1978a). Rats were fed diets that provided approximately 0, 3.33, or 6.65 mg
dibutyltin diacetate/kg/day for 78 weeks followed by a period of no compound administration for
26 weeks. Mice also were fed diets that provided approximately 0, 9.9, or 19.8 mg/kg/day for 78 weeks
followed by a period of no compound administration for 14 weeks. There were no significant increased
tumor incidence in treated groups of rats and mice compared to their respective controls. However,
accidental loss of tissues from the uterus from 17 of the 50 high-dose female rats precluded a complete
evaluation of neoplasms in this organ. Apparently, there were no historical control data available at the
time for evaluation of background versus experimental findings. The general conclusion was that
dibutyltin diacetate was not carcinogenic for male rats and male or female mice under the experimental
conditions of the study. The loss of the tissues prevented reaching a conclusion with regard to the
relationship between dibutyltin diacetate and the occurrence of uterine neoplasms in female rats.

Another organotin compound, triphenyltin hydroxide, was tested in a bioassay using male and female
Fischer-344 rats and B6C3F1 mice (NCI 1978b). The regimen included dietary feeding for 78 weeks
followed by a 26-week observation period. Dosage levels were approximately 0, 1.88, and
3.75 mg/kg/day as triphenyltin hydroxide for rats and 0, 4.88, and 9.75 mg/kg/day for mice. Survival was
affected in male mice, but no other effects were observed in the mice or the rats. The incidence of tumors
seen in treated animals was comparable to controls. Historical control data were apparently not available
at the time for evaluation of background versus experimental findings. The general conclusion was that
3. HEALTH EFFECTS

Triphenyltin hydroxide was not carcinogenic for male and female rats and mice under the experimental conditions of the study.

In contrast to these results, longer-term studies on the carcinogenicity of triphenyltin hydroxide in Wistar rats and NMRI mice, using higher maximum doses, produced tumors in both species (Tennekes et al. 1989a, 1989b). In rats administered doses of 0.3–6.2 mg/kg/day triphenyltin hydroxide in the diet, there was a dose-related increase in pituitary adenomas in the exposed females at 104 weeks. Although the incidence of this lesion was high in the control animals (64.4%), it was even greater in the exposed animals, especially at the two highest dose levels (76.8 and 93.1%, respectively). There was also a dose-related decrease in survival for the females that was related to tumor incidence. Only 23% of the females receiving the highest dose were alive at the termination of the study as opposed to 80% of the males.

The number of males with testicular Leydig cell tumors was increased in animals exposed to 5.2 mg/kg/day triphenyltin hydroxide for 104 weeks (16.7 as opposed to 1.7% in the controls).

Tumors were also present in mice given diets containing 0.9–20.2 mg/kg/day triphenyltin hydroxide. After sacrifice at 80 weeks, examination of the tissue revealed an increased incidence of hepatocellular adenomas in both sexes. These tumors were consistent with the nodular hyperplasia seen in the livers of the treated animals. As was the case with the rat study, the females appeared to be more sensitive to tin treatment than the males. There was a decrease in survival for the females at the highest dose. Only 50% of the females receiving this dose were alive at the termination of the study as opposed to 70% of the males in the same dose group and 74% of the female control animals. The difference between the high-dose treated females and control females was statistically significant.

A 2-year bioassay was conducted with tributyltin oxide in male and female Wistar rats (Wester et al. 1990). The rats were fed a diet that provided 0, 0.019, 0.19, or 2.1 mg/kg/day of tributyltin oxide for males and 0, 0.025, 0.25, or 2.5 mg/kg/day for females. In high-dose males, survival at termination was 40 vs. 60% in controls; in females, it was 54 vs. 74% in controls. There was a significant increase in total pituitary tumors in males and females from the low- and high-dose groups, but not in the mid-dose groups. Also, the total pheochromocytomas (adrenal gland) were significantly increased in high-dose males and females. In addition, the number of parathyroid adenomas was significantly increased in high-dose males. Wester et al. (1990) stated that the increase incidence of some tumors may have been due to hormonal or immunological changes. They further noted that because there is a high spontaneous incidence of these tumors in this strain of rat, the variable incidence in the treated groups, and the absence
of a dose-effect relationship, the significance of the increased incidence is questionable. Based on no human data and questionable data in rats, EPA (IRIS 2005) placed tributyltin oxide in Group D, not classifiable as to human carcinogenicity or, according to updated guidelines (EPA 2003g), in a group for which there is inadequate information to assess carcinogenic potential.

3.2.3 Dermal Exposure

Except for dermal/ocular effects (Section 3.2.3.2) there is no information that describes health effects in humans or animals after dermal exposure to inorganic tin or organotin compounds. Table 3-9 summarizes available quantitative information on health effects that have been observed in animals after dermal exposure to organotin compounds.

3.2.3.1 Death

Inorganic Tin Compounds. No studies were located regarding death in humans or animals after dermal exposure to inorganic tin compounds.

Organotin Compounds. The death of a female worker accidentally drenched in phenyltin and other unidentified compounds was described in Section 3.2.1.1. Second and third degree burns developed 12 hours following the accident (NIOSH 1976).

Dermal LD$_{50}$ values in animals are available for a number of organotin compounds (Smith 1978). A dermal LD$_{50}$ in rabbits was reported to be 11,700 mg/kg bis(tributyltin) oxide (Elsea and Paynter 1958). For rats, an LD$_{50}$ of 605 mg/kg is given (Smith 1978). Despite variations in values for other compounds such as benzoates, naphthenates, and fluorides, the acute dermal toxicity of organotin compounds is generally less than by the oral route. The LD$_{50}$ values for representative species in the acute- and intermediate-duration category are recorded in Table 3-9. Doses are expressed as mg/kg/day of the compounds rather than as doses of tin.
<table>
<thead>
<tr>
<th>Species (Strain)</th>
<th>Exposure/Duration/Frequency (Route)</th>
<th>System</th>
<th>NOAEL</th>
<th>Less Serious</th>
<th>Serious</th>
<th>Reference</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat (albino)</td>
<td>1 d 1x/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>605 mg/kg/day (LD50)</td>
<td>TBT</td>
</tr>
<tr>
<td>Rabbit (albino)</td>
<td>once</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11700 mg/kg/day (LD50)</td>
<td>Elsea and Paynter 1958</td>
</tr>
<tr>
<td>Mouse (BALB/c)</td>
<td>once</td>
<td>Dermal</td>
<td>0.9 F</td>
<td>1.8 F</td>
<td>(skin irritation)</td>
<td></td>
<td>Corsini et al. 1996</td>
</tr>
<tr>
<td>Mouse (C)</td>
<td>once</td>
<td></td>
<td>mg/kg</td>
<td>%volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno/ Lymphoret</td>
<td>once</td>
<td></td>
<td>0.25 F</td>
<td>(contact sensitization)</td>
<td></td>
<td>Stringer et al. 1991</td>
<td></td>
</tr>
<tr>
<td>INTERMEDIATE EXPOSURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>Gm Pig</td>
<td>50 d 1x/d</td>
<td>40 M (LD50)</td>
<td>TBT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit (albino)</td>
<td>90 d 5 d/wk 7 hr/d</td>
<td></td>
<td>68 mg/kg/day (7/10 animals died)</td>
<td>Sheldon 1975</td>
<td>TBT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-9 Levels of Significant Exposure to Tributyltins - Dermal (continued)

<table>
<thead>
<tr>
<th>Species (Strain)</th>
<th>Exposure/ Duration/ Frequency (Route)</th>
<th>System</th>
<th>NOAEL</th>
<th>Less Serious</th>
<th>Serious</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gn Pig (Hartley)</td>
<td>50 d 1 x/d</td>
<td>Renal</td>
<td></td>
<td></td>
<td>10 M mg/kg/day (tubule degeneration)</td>
<td>Mori et al 1984 TBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 M mg/kg/day (decreased body weight)</td>
<td>Sheldon 1975 TBT</td>
</tr>
<tr>
<td>Rabbit</td>
<td>90 d 5 d/wk 7 hr/d</td>
<td>Dermal</td>
<td>14 mg/kg/day</td>
<td>40 M mg/kg/day (severe decrease in body weight)</td>
<td>Sheldon 1975 TBT</td>
<td></td>
</tr>
</tbody>
</table>

Bd Wt = body weight; (C) = capsule; d = day(s); F = Female; (G) = gavage; Gn pig = Guinea pig; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; x = time(s); wk = week(s)
3. HEALTH EFFECTS

3.2.3.2 Systemic Effects

**Inorganic Tin Compounds.** No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, or renal effects in humans or animals after dermal exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, or renal effects in humans after dermal exposure to organotin compounds.

No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, or hepatic effects in animals after dermal exposure to organotin compounds.

The highest NOAEL values and reliable LOAELs are recorded in Table 3-9.

**Hepatic Effects.** Signs of hepatic injury, as judged by increased serum AST and ALT activities, were reported in a case of acute dermal exposure to triphenyltin acetate (Colosio et al. 1991). The patient, a 36-year-old man, spilled powder of a 19% formulation of triphenyltin acetate on exposed skin on his arms. The acute rise in transaminase activities was followed by a gradual decrease for the next 18 days. Twelve days after poisoning, echotomography showed a generalized enlargement of the liver. Three days later, examination of a liver needle biopsy showed slight and nonspecific inflammatory abnormalities. Slight hepatomegaly persisted when the patient was discharged 21 days after poisoning.

**Renal Effects.** Doses of 10 or 40 mg tributyltin oxide/kg/day were applied to the shaved skin of male guinea pigs for 50 days (Mori et al. 1984). Swelling, degeneration, and destruction of tubular epithelium were observed, but there were no changes in the glomerulus. There was also an increased excretion of sodium, chloride, phosphate, glucose, and amino acids in the urine. In serum, the concentrations of phosphate and certain amino acids were low reflecting the excessive loss in the urine. According to the authors, these findings were consistent with a secondary Fanconi syndrome. These renal tubular changes are similar to those seen with inorganic tin compounds after oral exposure (see Section 3.2.2.2) and suggest that the compound was absorbed systemically.
3. HEALTH EFFECTS

Dermal Effects.

**Inorganic Tin Compounds.** No studies were located regarding dermal effects in humans after dermal exposure to inorganic tin compounds.

Stannous fluoride (0.25 and 0.5%) and stannous chloride (1 and 2%) produced leukocyte pustules in rabbit skin along the area adjacent to an abdominal epidermal scratch (Stone and Willis 1968). Infiltration of the tissue with polymorphonuclear and mononuclear leukocytes was present in the absence of pustules at a stannous chloride concentration of 0.5% and a stannous fluoride concentration of 0.1%.

**Organotin Compounds.** It is known that organotins are skin irritants in humans (Sheldon 1975). Direct skin contact with triphenyltin fluoride produced an irritant contact folliculitis in a male worker (Andersen and Petri 1982). Patch tests were performed in human subjects, as well as in guinea pigs and rabbits, but the dermatitis could not be reproduced. An irritant contact dermatitis was also seen in workers using a paint containing tributyltin oxide (Goh 1985). Sensitization was not observed in any of the referenced studies or in a separate study of tributyltin oxide-based paints (Gammeltoft 1978). Lyle (1958) described the following time-course of events in five volunteers who had undiluted tributyltin chloride painted on the skin of the back of the hand. Reddening and swelling of the mouths of the hair follicles appeared after 2–3 hours; this was followed by progressively intense follicular inflammation. The pruritus was confined to the tested area and persisted for 2 or 3 days. Pustules appeared on the second day and remained small until they dried up on the third or fourth day. On the fifth day, resolution was well advanced and, after a week, all that remained was faint punctate erythema with a little perifollicular scaling.

Tributyltin oxide is a severe irritant to the skin in rabbits (Sheldon 1975). By contrast, tributyltin fluoride and triphenyltin fluoride produced only minimal skin irritation (Sheldon 1975). Other acute studies have likewise demonstrated the skin irritating potential of tributyltin oxide and triphenyltin acetate in rats and mice (Corsini et al. 1996a; Klimmer 1969; Pelikan and Cerny 1968).

Dermal exposure of rats to doses of 80 mg/kg of dipropyltin dichloride, diisopropyltin dichloride, or diethyltin dichloride for 5 consecutive days produced necrosis, edema, and inflammation of the skin (Barnes and Stoner 1958). The same dose of dimethyltin dichloride produced dermal necrosis with black scar formation; dibutyltin dichloride produced little superficial damage to the skin and some edema of subcutaneous tissues. Dihexyltin dichloride and dioctyltin dichloride did not produce skin lesions (Barnes and Stoner 1958). In a 90-day repeated-dose dermal study, rabbits developed skin irritation at
3. HEALTH EFFECTS

each of three levels tested (14, 27, and 68 mg/kg/day tributyltin fluoride) (Sheldon 1975). Deaths occurred in 7 of 10 rabbits at 68 mg/kg, but surviving animals eventually returned to normal a few days after exposure was terminated. The authors stated that a dose of 14 mg/kg (65 applications) was a NOAEL despite local irritation at the application sites. In view of the exaggerated daily contact with the rabbit skin, this value seems reasonable since such high levels of daily exposure would not be the case in humans. However, a detailed report of this study was not available for review.

A study in guinea pigs did not find tributyltin oxide to be a contact sensitizer (Schweinfurth and Gunzel 1987).

Ocular Effects.

Inorganic Tin Compounds. No studies were located regarding ocular effects of inorganic tin in humans or animals following dermal exposure.

Organotin Compounds. Lyle (1958) described the case of a worker who was not wearing protective goggles and splashed an unspecified butyltin compound on the face and both eyes were affected. Lachrimation and intense suffusion of the conjunctiva appeared within minutes and, despite immediate lavage, persisted for 4 days. Tributyltin oxide, tributyltin fluoride and triphenyltin fluoride are extreme irritants to rabbits’ eyes (Sheldon 1975).

3.2.3.3 Immunological and Lymphoreticular Effects

Inorganic Tin Compounds. No studies were located regarding immunological and lymphoreticular effects in humans or animals following dermal exposure to inorganic tin.

Organotin Compounds. Colosio et al. (1991) reported that a man who spilled a powder pesticide formulation containing 19% triphenyltin acetate over exposed skin on his arm developed severe genital edema and urticarial eruptions on his trunk. In addition, on day 11 after the accident his serum IgE was elevated. Although patch tests conducted with the entire formulation and with each single component of the formulation gave negative results, the investigators attributed the findings to poisoning with triphenyltin. Tributyltin oxide induced contact sensitization in mice applied the test material for 3 days and challenged with it 3 days later (Stringer et al. 1991). The lowest concentration tested, 0.25% by volume, triggered a positive response.
3.2.3.4 Neurological Effects

_Inorganic Tin Compounds._ No studies were located regarding neurological effects in humans or animals following dermal exposure to inorganic tin.

_Organic Tin Compounds._ The only relevant information is that from the case of a man who spilled a powder pesticide formulation containing 19% triphenyltin acetate on his exposed arms, and 10 days after the accident, his EEG showed alterations consisting of generalized paroxysmal abnormalities and bradyrhythmia (Colosio et al. 1991). Four months after the accident, the EEG showed slight anomalies during hyperpnea.

No studies were located regarding the following effects in humans or animals after dermal exposure to inorganic tin or organotin compounds:

3.2.3.5 Reproductive Effects

3.2.3.6 Developmental Effects

3.2.3.7 Cancer

_Inorganic Tin Compounds._ No studies were located regarding cancer effects in humans or animals after dermal exposure to inorganic tin compounds.

_Organotin Compounds._ No studies were located regarding cancer effects in humans after dermal exposure to organotin compounds.

In a limited evaluation of carcinogenicity, tributyltin fluoride was applied to the shaved backs of male white mice 3 times/week for a period of 6 months. Treated mice received 15 mg of 5 or 10% of the compound in propylene glycol. Hyperplastic skin changes were observed in the 5% group, but not in the 10% group (Sheldon 1975). Carcinogenic effects were not observed in this study, which was only of intermediate duration. No other studies were located regarding cancer effects in animals after dermal exposure to organotin compounds.
3. HEALTH EFFECTS

3.2.4 Other Routes of Exposure

This section provides brief examples of effects of tin compounds that have been studied primarily by exposing the animals by a route other than inhalation, oral, or dermal.

A considerable number of studies have evaluated the developmental effects of both trimethyltin and triethyltin following perinatal exposure by intraperitoneal injection of animals, and some studies have demonstrated that some alterations persist until adulthood. For example, a single intraperitoneal dose of trimethyltin hydroxide (4–6 mg/kg) to rat pups on Pnd 5 reduced growth and impaired performance on rope descent when tested on Pnd 20 and 21 (Ruppert et al. 1983). Motor activity in a figure-eight maze was increased at 57 days of age and at 120 days of age. The response to acoustic startle was decreased during preweaning and as adults. At termination (Pnd 120), whole brain weight and weight of olfactory bulbs decreased at 4, 5, and 6 mg/kg, whereas the hippocampus weight was decreased at 5 and 6 mg/kg. Similar results were obtained following a single intraperitoneal injection of triethyltin bromide (3 or 6 mg/kg) also on Pnd 5 (Reiter et al. 1981). Barone et al. (1995) showed that some behavioral alterations that can be detected on Pnd 23 after a single injection of triethyltin on Pnd 5, which were no longer apparent 3 or 12 months postdosing, became apparent again in 24-month-old rats, suggesting an unmasking effects by the natural aging process.

Chang (1984a, 1984b) did not observe lesions in the hippocampal formation of rats injected intraperitoneally with 6 mg/kg trimethyltin chloride between Pnd 1 and 4, but increasing damage to Ammon’s horn was seen when dosing occurred between the ages of Pnd 5 and 15. This was followed by an apparently reduced sensitivity after Pnd 20. Since the pathological patterns were well-correlated with the development and functional maturity of the hippocampal neurons, Chang (1984a, 1984b, 1990) postulated that the production of lesions, particularly those in subfield CA3, require functionally mature and intact granule cells and their fibers, the mossy fibers. It has also been shown that the day of exposure greatly influences the magnitude of cognitive deficits and neuropathology associated with exposure to triethyltin (Freeman et al. 1994).

Trimethyltin and triethyltin have induced ototoxicity in rodents. A single intraperitoneal injection of 4–6 mg trimethyltin/kg produced a frequency-dependent loss of auditory sensitivity in rats that was severe in the high frequency range (Eastman et al. 1987; Ruppert et al. 1984). Subsequent studies showed that the alterations were long-lasting and consisted of a high-frequency hearing loss characterized by elevated thresholds in the auditory startle response test detected 11 weeks postdosing (Crofton et al. 1990). Thresholds for the brainstem auditory evoked response were also elevated in treated rats 9 weeks
postdosing. Microscopic examination of the cochlea from base to apex showed dead outer hair cells preferentially in regions associated with high-frequency hearing, in a dose-related manner. A study in guinea pigs treated intraperitoneally with a single dose of 2 mg of trimethyltin chloride/kg showed high-frequency impairment, which improved throughout a 6-week period of testing (Fechter and Carlisle 1990). As seen in the rat, hair cell loss occurred in a portion of the cochlea responsible for encoding high-frequency sound. There also was a marked increase in the diameter of the vessels of the stria vascularis (an area containing one of the primary vascular networks in the cochlea) along with signs of atrophy in the stria vascularis. However, since the increases in vessel diameter were not confined to the basal portion of the cochlea, and were greater in the middle and apical regions than in the base, it seemed that the strial pathology was not directly related to hair cell loss or functional impairment. In a different study, both trimethyltin and triethyltin were shown to severely disrupt (increase) the compound action potential (CAP) threshold in guinea pigs within 30–60 minutes of dosing, but had no significant effect on the cochlear microphonic (CM) potential (Clerici et al. 1991). The CAP is generated by the release of neurotransmitters from the inner hair cells and the subsequent depolarization of spiral ganglion cells, whereas CM reflects electromechanical function of the outer hair cells. In a further study, trimethyltin was shown to reduce CAP sensitivity and CM amplitude (Fechter et al. 1992). The effect was relatively broad across test frequencies 6 hours after dosing and gradually became restricted to higher frequencies. The effect of trimethyltin appears to be a direct effect on the cochlea, as disruption of sound-evoked cochlear action potentials can be observed after direct application of trimethyltin to the round window of guinea pigs (Liu and Fechter 1995). The results of these and other studies were thought to be consistent with the hypothesis that trimethyltin disrupts function at the synapse between the inner hair cell and the Type I spiral ganglion cell, possibly by damaging the hair cells or ganglia from uncontrolled production of reactive oxygen species (ROS) (Clerici 1996; Fechter and Liu 1994).

A series of publications from Merkord and coworkers have described the effects of dibutyltin dichloride on the pancreas from rats following intravenous injection of the chemical. Earlier studies described an acute interstitial pancreatitis in rats developing 24 hours after a single dose followed by a more severe pancreatitis with mononuclear cell infiltrates 4–6 days later (Merkord and Hennighausen 1989). In a more recent study, the time-course of the pancreatic alterations was followed for up to 28 days with interim sacrifices at various intervals after a single dose of 6 mg dibutyltin dichloride/kg (Merkord et al. 1997). The findings suggested an initial cytotoxic effect on the biliopancreatic duct epithelium leading to epithelial necrosis with obstruction of the duct. This was followed by hematogenic effects directly injuring pancreatic cells followed by interstitial edema and inflammation. A tendency to a chronic course occurred when the obstruction of the duct and cholestasis persisted. Extending the observation period
showed that an active inflammatory process persisted for up to 60 days after dosing (Sparmann et al. 1997). A study of repeated administration of a slightly lower dose of dibutyltin dichloride (4 mg/kg) at intervals of 3 weeks, reported the development of acute pancreatitis and biliopancreatic lesions after 6 weeks and pancreatic fibrosis and liver lesions after 9–12 weeks (Merkord et al. 2001). In rats followed for up to 1 year after a single injection of 6 mg dibutyltin dichloride/kg, the permanent obstruction of biliopancreatic secretion and chronic cholestasis led to the formation of deposits inside the dilated duct, occasionally with bacterial infiltration and growth. Considerable amounts of tin were detected inside the bacterially infected deposits (Jonas et al. 2002).

3.3 GENOTOXICITY

*In vitro* studies with inorganic tin have provided mixed results (Table 3-10). DNA damage was noted in Chinese hamster ovary cells incubated with stannous chloride in the absence of metabolic activation, but the results for stannic chloride were negative (McLean et al. 1983). Cytogenetic studies also gave positive responses with stannous chloride for chromosomal aberrations and sister chromatid exchanges in Chinese hamster ovary cells with or without metabolic activation (Gulati et al. 1989). Ganguly et al. (1992) incubated peripheral lymphocytes from 27 healthy male volunteers with stannic chloride and observed a significant increase in the frequency of chromosomal aberrations. In K562 cells (a cell line derived from a chronic myelogenic human leukemia), stannous chloride reduced viability and induced DNA damage, as determined by the comet assay (Dantas et al. 2002). The investigators (Dantas et al. 2002) proposed that genetic damage is produced by ROS generated by the reduction of hydrogen peroxide by stannous ions. Earlier research from this group had demonstrated that ROS scavengers and metal-ion chelators could prevent, at least partially, the inactivation of *Escherichia coli* cultures treated with stannous chloride (Dantas et al. 1996). Stannous chloride has also been reported to rapidly convert hydroperoxy thymidine to mutagenic hydroxymethyl deoxyuridine species *in vitro*, suggesting a redox component in the genotoxic potential of stannous chloride *in vivo* (Tofigh and Frenkel 1989).

Table 3-11 presents data on the genotoxicity of organotin compounds in *in vitro* assays. Hamasaki et al. (1993) tested 14 different organotin compounds in two strains of *Salmonella typhimurium*, TA98 and TA100, without metabolic activation. All but dibutyltin dichloride gave negative results in TA98. In TA100, the monobutyltins, dibutyltins, and tributyltin compounds gave positive results. Results from assays in mammalian cells for a number of trialkyl organotins, with and without metabolic activation, showed mostly negative results (Davis et al. 1987; Sasaki et al. 1993). However, other studies have reported elevated incidences of chromosomal aberrations, sister chromatid exchanges, and micronuclei in
### Table 3-10. Genotoxicity of Inorganic Tin Compounds *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>End point</th>
<th>Results With activation</th>
<th>Results Without activation</th>
<th>Form</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prokaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Bacillus subtilis</em></td>
<td>Rec-assay</td>
<td>No data</td>
<td>–</td>
<td>Stannous chloride</td>
<td>Nishioka 1975</td>
</tr>
<tr>
<td><em>B. subtilis</em></td>
<td>Rec-assay</td>
<td>No data</td>
<td>–</td>
<td>Stannic oxide</td>
<td>Nishioka 1975</td>
</tr>
<tr>
<td><em>Salmonella typhimurium TA100, TA98</em></td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Stannic chloride</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>Escherichia coli MBL50</em></td>
<td>DNA damage</td>
<td>No data</td>
<td>+</td>
<td>Stannous chloride</td>
<td>Cabral et al. 1998</td>
</tr>
<tr>
<td><strong>Mammalian cells:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese hamster ovary cells</td>
<td>DNA damage</td>
<td>No data</td>
<td>+</td>
<td>Stannous chloride</td>
<td>McLean et al. 1983</td>
</tr>
<tr>
<td>Chinese hamster ovary cells</td>
<td>DNA damage</td>
<td>No data</td>
<td>–</td>
<td>Stannic chloride</td>
<td>McLean et al. 1983</td>
</tr>
<tr>
<td>Chinese hamster ovary cells</td>
<td>Sister chromatid exchanges</td>
<td>+</td>
<td>+</td>
<td>Stannous chloride</td>
<td>Gulati et al. 1989</td>
</tr>
<tr>
<td>Chinese hamster ovary cells</td>
<td>Chromosomal aberrations</td>
<td>+</td>
<td>+</td>
<td>Stannous chloride</td>
<td>Gulati et al. 1989</td>
</tr>
<tr>
<td>K562 cell line</td>
<td>DNA damage</td>
<td>No data</td>
<td>+</td>
<td>Stannous chloride</td>
<td>Dantas et al. 2002</td>
</tr>
<tr>
<td>Human peripheral lymphocytes</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>+</td>
<td>Stannic chloride</td>
<td>Ganguly et al. 1992</td>
</tr>
</tbody>
</table>

+ = positive result; – = negative result; DNA = deoxyribonucleic acid
### Table 3-11. Genotoxicity of Organotin Compounds *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>Compound</th>
<th>End point</th>
<th>With activation</th>
<th>Without activation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bacillus subtilis</em></td>
<td>TBTO</td>
<td>Rec-assay</td>
<td>No data</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>TBTO</td>
<td>Fluctuation test</td>
<td>No data</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>Salmonella typhimurium</em></td>
<td>TBTO</td>
<td>Plate assay</td>
<td>–</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>S. typhimurium</em></td>
<td>TBTO</td>
<td>Hepatocyte</td>
<td>–</td>
<td>No data</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>S. typhimurium</em></td>
<td>TBTO</td>
<td>Mediated assay</td>
<td>–</td>
<td>No data</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>S. typhimurium</em></td>
<td>TBTO</td>
<td>Fluctuation test</td>
<td>+</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>MBTO</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>MBTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>DBTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>+</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TBTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TBTO</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TeBT</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>MPhTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>DPhTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TPhTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TePhT</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>MMTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>DMTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TMTC</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium TA98</em></td>
<td>TeMT</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>–</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>S. typhimurium</em></td>
<td>MBTO</td>
<td>Reverse mutation</td>
<td>No data</td>
<td>+</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><em>TA100</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 3-11. Genotoxicity of Organotin Compounds *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>Compound</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>With activation</td>
<td>Without activation</td>
<td></td>
</tr>
<tr>
<td><strong>S. typhimurium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA100</td>
<td>MBTC</td>
<td>Reverse mutation</td>
<td>No data +</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>DBTC</td>
<td>Reverse mutation</td>
<td>No data +</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TBTC</td>
<td>Reverse mutation</td>
<td>No data +</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TBTO</td>
<td>Reverse mutation</td>
<td>No data +</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TeBT</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>MPhTC</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>DPhTC</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TPhTC</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TePhT</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>MMTC</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>DMTC</td>
<td>Reverse mutation</td>
<td>No data +</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TMTC</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td>TA100</td>
<td>TeMT</td>
<td>Reverse mutation</td>
<td>No data –</td>
<td>Hamasaki et al. 1993</td>
</tr>
<tr>
<td><strong>Eukaryotic organisms:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Saccharomyces pombe</em></td>
<td>TBTO</td>
<td>Forward mutation</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><em>Saccharomyces cerevisiae</em></td>
<td>TBTO</td>
<td>Mitotic gene conversion</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Mammalian cells:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>8-Azaguanine and ovarian resistance</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>6-Thioguanine resistance</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mouse lymphoma cells</td>
<td>TBTO</td>
<td>6-Thioguanine and Buer resistance</td>
<td>No data</td>
<td>–</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>Sister chromatid exchange</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
### Table 3-11. Genotoxicity of Organotin Compounds *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>Compound</th>
<th>End point</th>
<th>With activation</th>
<th>Without activation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>Chromosomal aberrations</td>
<td>+</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>Inhibition of metabolic cooperation</td>
<td>No data</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTH</td>
<td>Gene mutation</td>
<td>–</td>
<td>–</td>
<td>Oshiro et al. 1991</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTH</td>
<td>Micronucleus</td>
<td>+</td>
<td>–</td>
<td>Oshiro et al. 1991</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTH</td>
<td>Micronucleus</td>
<td>+</td>
<td>+</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTA</td>
<td>Micronucleus</td>
<td>+</td>
<td>–</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTA</td>
<td>Sister chromatid exchange</td>
<td>+</td>
<td>–</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTH</td>
<td>Sister chromatid exchange</td>
<td>+</td>
<td>–</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTC</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTA</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTH</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTC</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>DBTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTF</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTO</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>–</td>
<td>Sasaki et al. 1993</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TMTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TBTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>DMTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>TPhTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
<tr>
<td>Chinese hamster cells</td>
<td>DPhTC</td>
<td>Spindle inhibition</td>
<td>No data</td>
<td>+</td>
<td>Jensen et al. 1991b</td>
</tr>
</tbody>
</table>
### Table 3-11. Genotoxicity of Organotin Compounds *In Vitro*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>Compound</th>
<th>End point description</th>
<th>With activation</th>
<th>Without activation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human peripheral lymphocytes</td>
<td>TMTC</td>
<td>Chromosomal aberrations</td>
<td>No data</td>
<td>+</td>
<td>Ghosh et al. 1991</td>
</tr>
<tr>
<td>Human peripheral lymphocytes</td>
<td>TMTC</td>
<td>Sister chromatid exchange</td>
<td>No data</td>
<td>+</td>
<td>Ganguly et al. 1992</td>
</tr>
<tr>
<td>Human peripheral lymphocytes</td>
<td>TMTC</td>
<td>Micronucleus</td>
<td>No data</td>
<td>+</td>
<td>Ghosh et al. 1990</td>
</tr>
</tbody>
</table>

+ = positive result; – = negative result; DBTC = di-n-butyltin dichloride; DMTC = dimethyltin dichloride; DPhTC = diphenyltin dichloride; MBTC = n-butyltin trichloride; MBTO = mono-n-butyltin oxide; MMTC = methyltin trichloride; MPhtC = phenyltin trichloride; TBTC = tri-n-butyltin chloride; TBTF = tributyltin fluoride; TBTO = bis(tributyltin)oxide; TeBT = tetra-n-butyltin; TeMT = tetramethyltin; TePHT = tetraphenyltin; TMTC = trimethyltin chloride; TPhTA = triphenyltin acetate; TPhTC = triphenyltin chloride; TPhTH = triphenyltin hydroxide
peripheral lymphocytes obtained from healthy individuals and incubated with trimethyltin chloride (Ganguly et al. 1992; Ghosh et al. 1990, 1991). Triphenyltin compounds were positive in tests for induction of micronuclei and sister chromatid exchanges in Chinese hamster cells (Chao et al. 1999; Oshiro et al. 1991).

A limited number of studies have examined the in vivo genotoxic effects of organotins administered in animals (Table 3-12). In vivo micronucleus tests for tributyltin oxide in mice have produced mixed results. Neither tributyltin oxide nor triphenyltin chloride injected in doses up to 100 mg/kg in mice increased the incidence of micronuclei in blood reticulocytes (Yamada and Sasaki 1993). Similar results were reported by Schweinfurth and Gunzel (1987) after administration of a single dose of 125 mg/kg of tributyltin oxide to mice. In contrast, Davis et al. (1987) reported an increase in micronuclei in mice treated with a single dose of 60 mg/kg tributyltin oxide. According to Schweinfurth and Gunzel (1987), the difference between their results and those of Davis et al. (1987) may be due to a higher number of polychromatic erythrocytes per animal that were scored in Schweinfurth and Gunzel (1987). Sagelsdorff et al. (1990) treated male and female rats with a single gavage dose (approximately 3.5 mg/kg) of \(^{14}\)C-dioctyltin dichloride and isolated DNA from thymus and liver 96 hours later to determine possible adduct formation. They detected radioactivity incorporated to all DNA fractions via biosynthesis, but there was no adduct formation. Gavage administration of three doses of 2 mg/kg of triphenyltin acetate to mice or a single dose of 12.5 mg/kg significantly increased the incidence of micronucleated reticulocytes; a similar significant increase occurred following a single dose of 2.5 mg/kg of triphenyltin hydroxide (Chao et al. 1999). Intraperitoneal treatment of mice with 0.25–1 mg/kg of trimethyltin significantly increased the incidence of chromosomal aberrations in mouse bone marrow cells 6–24 hours after dosing (Ganguly 1994).

3.4 TOXICOKINETICS

3.4.1 Absorption

The results of toxicity studies suggest that inorganic tin compounds are not readily absorbed after oral or inhalation exposure and show only limited effects after dermal exposure. Organotin compounds are more readily absorbed than inorganic tin compounds by these three routes of exposure.
### Table 3-12. Genotoxicity of Organotin Compounds *In Vivo*

<table>
<thead>
<tr>
<th>Species (test system)</th>
<th>Compound</th>
<th>End point</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insect system:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Drosophila melanogaster</em></td>
<td>TBTO</td>
<td>Test for sex-linked recessive lethal mutations</td>
<td>–</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td><strong>Mammalian system:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mice</td>
<td>TBTO</td>
<td>Micronucleus test; single dose 60 mg/kg body weight</td>
<td>+</td>
<td>Davis et al. 1987</td>
</tr>
<tr>
<td>Mice</td>
<td>TBTO</td>
<td>Micronucleus test; cytotoxic doses; highest 125 mg/kg body weight</td>
<td>–</td>
<td>Schweinfurth and Gunzel 1987</td>
</tr>
<tr>
<td>Mice</td>
<td>TPhTA</td>
<td>Micronucleus; single 12.5 mg/kg oral dose</td>
<td>+</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td></td>
<td>TPhTH</td>
<td>Micronucleus test; single 2.5 mg/kg oral dose</td>
<td>+</td>
<td>Chao et al. 1999</td>
</tr>
<tr>
<td>Rat</td>
<td>DOTC</td>
<td>Liver and thymus DNA adduct single oral gavage ~3.5 mg/kg</td>
<td>–</td>
<td>Sagelsdorff et al. 1990</td>
</tr>
<tr>
<td>Mice</td>
<td>TMTC</td>
<td>Chromosomal aberrations; three intraperitoneal doses 0.25–1 mg/kg</td>
<td>+</td>
<td>Ganguly 1994</td>
</tr>
<tr>
<td>Mice</td>
<td>TBTO</td>
<td>Micronucleus; single oral dose ≤100 mg/kg</td>
<td>–</td>
<td>Yamada and Sasaki 1993</td>
</tr>
</tbody>
</table>

+ = positive result; – = negative result; DNA = deoxyribonucleic acid; DOTC = dioctyltin dichloride; TBTO = bis(tributyltin)oxide; TMTC = trimethyltin chloride; TPhTA = triphenyltin acetate; TPhTC = triphenyltin chloride; TPhTH = triphenyltin hydroxide
3. HEALTH EFFECTS

3.4.1.1 Inhalation Exposure

No quantitative studies were located regarding absorption in humans or animals after inhalation exposure to inorganic tin or organotin compounds. However, limited data summarized in Section 3.2.1 suggest that absorption of organotins by the inhalation route is possible, as occurred for example in cases for subjects who exhibited serious neurological effects after accidental exposure to vapors of a trimethyltin (Feldman et al. 1993; Fortemps et al. 1978; Rey et al. 1984; Ross et al. 1981; Saary and House 2002; Yanofsky et al. 1991). Dermal exposure may have also occurred in these cases.

3.4.1.2 Oral Exposure

Inorganic Tin Compounds. Johnson and Greger (1982) conducted a balance study in eight healthy adult males, who were placed on diets containing either 0.1 mg Sn/day (basal diet) or 50 mg Sn/day (supplemented with stannous chloride). Subjects were placed on the diets for 20 days and intakes and excretion were measured daily in two 6-day periods (following a 6-day adjustment to the diets). Average fecal excretion was 55% of the daily intake in the basal group and 97% in the supplemented group, suggesting net absorption of 45 and 3%, respectively. Average urinary excretion was 26% of the daily intake in the basal group and 2.4% in the supplemented group. Estimates of absorption in individuals ranged from -4 to 71% of the daily intake in the basal group and from -7 to 9% in the supplemented group. These observations suggest that gastrointestinal absorption of tin, in humans, decreases with increasing dose. An alternative explanation for the differences in absorption of tin in the basal and supplemented diets is that tin naturally incorporated into food may be more readily absorbed than tin added as stannous chloride to food. Consistent with the former explanation are observations from Calloway and McMullen (1966). In this study, nine healthy adults were placed on diets for 24 days consisting of either fresh food (10 mg Sn/day), canned food that had been stored for 20 months at 1 °C (26 mg Sn/day), or canned foods that had been stored for 20 months at 37 °C (163 mg Sn/day). Tin was not detected in the urine in this study, and the amount excreted in the feces was the same as the amount ingested. Thus, net absorption of tin could not be detected at these higher levels of intake, in contrast to the observations made at lower intakes (0.1 mg Sn/day; Johnson and Greger 1982).

Studies conducted in animals suggest that fractional absorption of ingested inorganic Sn[II] is higher, by a factor of approximately 4, than Sn[IV]; however, the associated anion appears to have little or no effect on the absorption fraction. Gastrointestinal absorption was 2.85 and 0.64% of the administered dose, in
3. HEALTH EFFECTS

rats, after a single oral dose of $^{113}$Sn[II]citrate or $^{113}$Sn[IV]citrate (20 mg Sn/kg), respectively (Hiles 1974). Fractional absorption of tin after single oral doses (20 mg Sn/kg) of stannous pyrophosphate ($^{113}$Sn[II]$_2$P$_2$O$_7$), stannous fluoride ($^{113}$Sn[II]F$_2$), or stannic fluoride ($^{113}$Sn[IV]F$_4$) appeared to be similar to that of $^{113}$Sn[II]citrate and $^{113}$Sn[IV]citrate (i.e., <5%), based on comparisons of tissue and excreta levels (Hiles 1974). Furchner and Drake (1976) concluded, from comparisons of tissue retention kinetics after oral gavage and intravenous injection of stannous chloride ($^{113}$SnCl$_2$), that gastrointestinal absorption of Sn[II] was similar (less than 5%) in dogs, mice, rats, and monkeys.

Organotin Compounds. No quantitative estimates of absorption of organotin compounds in humans were located. The detection of butyltin compounds in blood and in postmortem human liver samples indicates that butyltin compounds are absorbed in humans (Kannan et al. 1999; Nielsen and Strand 2002). Also, numerous deaths occurred in a poisoning episode with presumably accidental ingestion of triethyltin in France in 1954 (WHO 1980) indicating that absorption occurred. In addition, Kreyberg et al. (1992) described the case of a woman who ingested an unknown amount of trimethyltin and died 6 days after consuming the chemical.

Methyltin Compounds. Quantitative estimates of absorption of methyltin compounds after ingestion were not located. Tin levels in brain, kidney, and liver were similar in neonatal rats that received oral doses of 1 mg/kg trimethyltin hydroxide (0.66 mg Sn/kg) or triethyltin sulfate (0.44 mg Sn/kg), suggesting that both compounds may be absorbed similarly (Mushak et al. 1982).

Ethyltin Compounds. Rats administered a single oral dose of approximately 25 mg/kg ethyltin trichloride (12 mg Sn/kg) excreted 92% (range 89–95%) of the dose in feces and 1.2% (range 1–2%) in urine, suggesting that at least 8% of the dose had been absorbed (Bridges et al. 1967). This is a minimum estimate of absorption, since absorbed ethyltin compounds are secreted in bile and excreted in feces (see Section 3.4.4.4).

Butyltin Compounds. Mice administered a single oral dose of approximately 180 μmol/kg, respectively, of mono-, di-, or tributyltin (23 mg Sn/kg) excreted, approximately 2, 20, or 35% of the dose in urine within 96 hours following dosing (Ueno et al. 1994). These values are minimum estimates of the absorption of the ingested dose because they do not account for absorbed tin excreted by other routes (e.g., bile-fecal pathway; see Section 3.4.4.4). However, these results indicate that the fraction of an ingested dose of butyltin compounds excreted in urine increases with increasing number of butyl...
moieties, suggesting that more-highly butylated tin compounds may be absorbed to a greater extent (Kimmel et al. 1977).

**Phenyltin Compounds.** Quantitative estimates of absorption of phenyltin compounds after ingestion were not located. Urinary excretion of tin compounds (as total tin) over a 96-hour period following a single oral dose of tri-, di-, or monophenyltin (15.5 mg Sn/kg) was <1% of the administered dose of tin (Ohhira and Matsui 1993a). This is a minimum estimate of the absorbed fraction as it does not account for excretion by other routes or retention of tin.

### 3.4.1.3 Dermal Exposure

**Inorganic Tin Compounds.** No studies were located regarding absorption in humans or animals after dermal exposure to inorganic tin compounds.

**Organotin Compounds.** No studies were located regarding absorption in humans after dermal exposure to organotin compounds.

Quantitative estimates of dermal absorption of organotin compounds in animals were not located. Organotin compounds, including trimethyltin, triethyltin, tributyltin, and triphenyltin, have produced systemic toxicity in animals after dermal exposure, indicating that dermal exposures can result in systemic absorption of tin (Mori et al. 1984; Stoner 1966).

### 3.4.2 Distribution

The human body has been estimated to contain less than 17 mg of tin, with approximately 6 mg in soft tissues and the remaining fraction associated with skeletal tissues (ICRP 1981a). In a survey of tin concentrations in postmortem human tissues collected from several hundred subjects, the highest concentrations occurred in the kidney, liver, lung, and bone (Kehoe et al. 1940; Schroeder et al. 1964; see Table 3-13). Tin was not detected in brain tissue (Kehoe et al. 1940). In kidney and liver, the highest concentrations (kidney 57–60 mg/kg, liver 48–61 mg/kg) were observed at ages 1–10 years; concentrations were 20–40 mg/kg thereafter; tin was not detected in kidney or liver at birth (Schroeder et al. 1964). In the lungs, tin appeared to increase with age, with the highest levels (53–64 mg tin/kg) at ages 51–84 (Schroeder et al. 1964). Although, these data indicate trends in tin accumulation in human tissues, wide variations in tissue concentrations were observed, most likely reflecting variation in
### Table 3-13. Mean Tin Levels in Human Tissues

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Wet weight (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney</td>
<td>0.2–0.78</td>
</tr>
<tr>
<td>Heart</td>
<td>0.2</td>
</tr>
<tr>
<td>Brain</td>
<td>ND</td>
</tr>
<tr>
<td>Liver</td>
<td>0.35–1.0</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.2</td>
</tr>
<tr>
<td>Lung</td>
<td>0.45–1.20</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.1</td>
</tr>
<tr>
<td>Bone</td>
<td>0.5–8.0</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>0.1–0.5</td>
</tr>
</tbody>
</table>

ND = Not detected

*aAdapted from Kehoe et al. 1940; Schroeder et al. 1964*
exposures and, possibly the health/exposure history of the tissue donors (Tipton and Cook 1963; Tipton et al. 1963). Additional information regarding tin and organotin levels in human tissues and fluids is presented in Table 6-5.

When fresh human whole blood was incubated with triethyl$^{113}$Sn tin chloride, the red blood cell:plasma tin ratio was 1.9 (Rose and Aldridge 1968). This ratio was substantially different from the ratio observed in rat blood (19), and similar to that in other rodent species (range, 1–5). Interspecies differences have been attributed to variable binding of tin (or triethyltin) to hemoglobin (Rose 1969) and may also be applicable to trimethyltin, which also shows a pronounced accumulation in rat red blood cells (Brown et al. 1984; see Section 3.4.2.2 for further discussion).

### 3.4.2.1 Inhalation Exposure

No studies were located regarding distribution in humans or animals after inhalation exposure to inorganic tin or organotin compounds.

### 3.4.2.2 Oral Exposure

**Inorganic Tin Compounds.** No studies were located regarding distribution in humans after oral exposure to inorganic tin compounds; however, data are available on tissue levels of tin in general populations (Schroeder et al. 1964; see Section 3.4.2).

Consistent with observations made of the tissue distribution of tin in humans, bone, kidney, and liver are major sites of deposition of tin in rats and mice, after oral administration of inorganic tin compounds (Hiles 1974; NTP 1982; Schroeder et al. 1968; Yamaguchi et al. 1980). Levels of tin in bone, kidney, and liver were 0.02–1% of the administered dose of $^{113}$Sn in rats that received a single oral dose of 20 mg Sn/kg/day as stannous pyrophosphate ($^{113}$Sn[II]$_2$P$_2$O$_7$), stannous fluoride ($^{113}$Sn[II]F$_2$), stannic fluoride ($^{113}$Sn[IV]F$_4$), $^{113}$Sn[II]citrate, or $^{113}$Sn[IV]citrate (Hiles 1974). Levels in blood were 0.01% (or less) of the administered dose. In rats that received 20 mg Sn/kg/day of stannous fluoride ($^{113}$Sn[II]F$_2$) or stannic fluoride ($^{113}$Sn[IV]F$_4$), for a period of 28 days, levels of tin in kidneys and liver were approximately the same as after a single oral dose (Hiles 1974); however, levels in bone were higher after multiple dosing, suggesting slower elimination kinetics of tin from bone, relative to kidney and liver (see Section 3.4.4.4).
Accumulation of tin in bone has also been observed in rats and mice exposed to stannous chloride (Sn(II)Cl₂) (NTP 1982; Yamaguchi et al. 1980). Tissue concentration ratios were approximately 43 for bone:kidney and 32 for bone:liver after 90 days of oral (gavage) doses of stannous chloride; the bone:tissue ratios increased with increasing doses of 0.3, 1, or 3 mg/kg/day (Yamaguchi et al. 1980). Chronic exposures of rats, at much higher doses (60–70 mg/kg/day, 1,000 ppm in diet), resulted in tissue concentration ratios of approximately 0.5 for bone:kidney and 55 for bone:liver; increasing the dose by a factor of approximately 2, resulted in a proportional increase bone:kidney and bone:liver ratios (NTP 1982). Chronic exposures of mice (230–280 mg/kg/day, 1,000 ppm in diet), resulted in tissue concentration ratios of approximately 30 for bone:kidney and 60 for bone:liver (NTP 1982). Bone:kidney and bone:liver ratios, in rats and mice, were similar in female and males (NTP 1982). These studies indicate a dose-dependence and possible species differences (i.e., mice compared to rats) in the tissue distribution of tin after exposures to stannous chloride. However, it should be noted that the dosages administered in the NTP (1982) study resulted in gastrointestinal tract toxicity, which may have affected absorption of administered tin.

Schroeder et al. (1968) chronically exposed rats to 5 ppm stannous chloride in drinking water and found relatively high concentrations of tin in spleen. Tissue concentration ratios (spleen:tissue) were: kidney, 11; liver, 5; heart, 2; and lung, 3. Tin concentrations in brain were approximately twice that of blood in rats exposed to stannous chloride (Sn(II)Cl₂, 100, 250, or 500 mg/L, 63, 156, or 313 mg Sn/L) for up to 18 weeks, and appeared to increase with increasing duration of exposure, suggesting the possibility of accumulation of tin in brain with prolonged exposure to stannous chloride (Savolainen and Valkomen 1986).

Animal studies in which absorbed tin was measured in tissues following parenteral injection of Sn(II)chloride (¹¹³SnCl₂), confirmed the above observations; i.e., that bone, kidney, and liver are major sites of deposition of absorbed Sn(II) (see Section 3.4.4.4).

Tin was not detected in the uterine horns or combined fetuses and placentas in rats following daily ingestion of 20 mg Sn/kg/day as ¹¹³SnF₂, or ¹¹³SnF₄ beginning on the day of conception (Hiles 1974). However, on Gd 21, fetuses of dams administered 20 mg Sn/kg/day as SnF₂ (approximately 100 mg Sn cumulative dose) contained approximately 0.2 μg Sn/g, or approximately 0.2% of the cumulative administered dose (detection limit, 0.1 μg/g). This suggests the possibility that, in the rat, tin administered orally as stannous chloride may be transferred to the fetus.
No studies on transfer of tin to breast milk following oral exposure (or exposure by other routes) to inorganic tin compounds were located.

**Organotin Compounds.** No studies were located regarding distribution in humans after oral exposure to organotin compounds.

**Methyltin Compounds.** Studies conducted in animals indicate that ingested methyltin compounds distribute to soft tissues, with the highest levels usually observed in liver. Species differences in the tissue distribution of trimethyltin have been observed. In marmosets, 1–13 days following a single oral dose of 3–4.5 mg/kg trimethyltin chloride (1.8–2.4 mg Sn/kg), brain:blood concentration ratios ranged from 6 to 10; whereas, in rats, 5 days following an oral dose of 10 mg/kg (6 mg Sn/kg), blood:brain ratios were approximately 38 (Brown et al. 1979, 1984). Mushak et al. (1982) also observed relatively high blood:tissue ratios of tin in neonatal rats that received oral doses of trimethyltin hydroxide (0.66 mg Sn/kg/day, Pnds 2–29): brain, 42; kidney, 22; and liver, 8. Following multiple oral doses of 4 mg/kg (2.4 mg Sn/kg) for 7 days, blood:brain ratios in the rat ranged from 30 to 48 (Brown et al. 1979). The relatively high blood levels of tin in rats, compared to other species, have been attributed to a more pronounced accumulation of trimethyltin in red blood cells. When samples of blood from rats were incubated with trimethyltin, the blood:plasma concentration ratio was approximately 67, compared to approximately 1 in the marmoset, gerbil, and hamster (Brown et al. 1984). The mechanism for the difference has not been elucidated.

**Ethyltin Compounds.** In animals, ingested ethyltin, along with five dealkylation products, distribute to soft tissues, including brain, kidney and liver. In rats, following 5 oral doses of 10 mg/kg/day triethyltin (5.8 mg Sn/kg/day), tissue:blood concentration ratios of triethyltin were approximately: brain, 8; kidney, 4; and liver, 0.5 (Iwai et al. 1982b). Following the same dose of tetraethyltin (5.1 mg Sn/kg/day), both tetra- and triethyltin were detected in tissues, reflecting dealkylation of tetraethyltin (see Section 3.4.3). The brain:blood ratio of tetraethyltin was <1 whereas the brain:blood ratio of triethyltin was >8. In neonatal rats that received oral doses of triethyltin sulfate (0.44 mg Sn/kg/day, Pnds 2–29), tissue:blood tin concentration ratios were: 0.7, brain; kidney, 0.8; liver, 3.4 (Mushak et al. 1982). The higher liver:blood ratio of total tin, compared to that of triethyltin, following ingestion of triethyltin, also may reflect the dealkylation of trimethyltin in the liver (see Section 3.4.3).

**Butyltin Compounds.** Similar to ethyltin compounds, ingested butyltin compounds and their dealkylation products distribute to soft tissues, including brain, kidney, and liver. In rats, following five oral doses of
3. HEALTH EFFECTS

10 mg/kg tributyltin (5.8 mg Sn/kg), tissue:blood concentration ratios of tributyltin were approximately: brain, <1; kidney, 2–4; and liver 1–2 (Iwai et al. 1982b). Following the same dose of tetrabutyltin, tissue:blood concentration ratios of tetrabutyltin were approximately: brain, <1; kidney, 10–12; and liver, 20. In rats given a single oral dose of 40 mg/kg tributyltin fluoride (15 mg Sn/kg), transient elevations in tributyltin, dibutyltin, monobutyltin, and inorganic tin were observed in brain and liver over the 8-day period following the dose, indicating that dealkylation had occurred (Iwai et al. 1981, see Section 3.4.3). In neonatal rats that received oral doses of tributyltin acetate (1.0 mg Sn/kg/day, Pnds 2–29), tissue:blood tin concentration ratios (possibly limited by the detection limit for blood tin) were: brain, 2.6; kidney, 19; and liver, 24 (Mushak et al. 1982).

In rats exposed to tributyltin oxide in the diet (0.25, 1, 4, or 16 mg/kg/day; 0.1, 0.4, 1.6, or 6.4 mg Sn/kg/day) for 4 weeks, total tin in kidney, liver, and brain increased with increasing dosage, and were similar in females and males (Krajnc et al. 1984). Levels in the brain and adipose tissue were 10–20% of the kidney and liver levels.

Twenty-four hours after administration of a single dose of 22 mg dibutyltin diacetate/kg to pregnant rats on Gd 8, dibutyltin and monobutyltin were detected in maternal blood and liver, and in the embryos, indicating placental transfer (Noda et al. 1994). In the embryos, the concentration of dibutyltin was 6–7 times higher than that of monobutyltin. Nakamura et al. (1993) had also detected dibutyltin in fetuses on Gd 18 after administration of the chemical to the pregnant rats on Gd 7–17.

**Phenyltin Compounds.** Studies conducted in animals indicate that ingested phenyltin compounds and dearylated metabolites (see Section 3.4.3) distribute to soft tissues, including brain, kidney, liver, and pancreas. In hamsters and rats, following a single oral dose of 50 mg triphenyltin chloride (15 mg Sn/kg), triphenyltin and dearylated metabolites, including inorganic tin, were detected in brain, blood, kidney, liver and pancreas (Ohhira and Matsui 1996). The highest concentrations of triphenyltin and metabolites were found in liver and kidney. In rats, tissue:blood ratios for triphenyltin, 48 hours after the dose, were approximately: brain, 10; kidney, 21; liver, 17; and pancreas, 4. Similar ratios were observed in hamsters: brain, 9; kidney, 11; liver, 21; and pancreas, 11. In neonatal rats that received oral doses of triphenyltin acetate (0.87 mg Sn/kg/day, Pnds 2–29), tissue:blood tin concentration ratios (based on the detection limit for blood) were: brain, 3; kidney, 6; and liver, 14 (Mushak et al. 1982).
3. HEALTH EFFECTS

In rats, following a single oral dose of 55.4 mg/kg tetraphenyltin (15 mg Sn/kg), tetraphenyltin, and the dearylated metabolites (tri-, di-, and monophenyltin) were detected in kidney and liver (Ohhira and Matsui 2003).

3.4.2.3 Dermal Exposure

No studies were located regarding distribution in humans or animals after dermal exposure to inorganic tin or organotin compounds.

3.4.2.4 Other Routes of Exposure

Inorganic Tin Compounds. Animal studies, in which absorbed tin was measured in tissues following parenteral injection of Sn[II]chloride ($^{113}$SnCl$_2$), confirm observations from oral exposure studies (Section 3.4.2.3) that bone, kidney, and liver are major sites of deposition of absorbed Sn[II] (Furchner and Drake 1976; Hiles 1974). In rats that received an intraperitoneal injection of stannous chloride ($^{113}$Sn[II]Cl$_2$, 0.006 μg/kg), tissue levels (percent of body burden) 1 day after dosing were: bone, 50%; kidney, 3.5%; liver, 6%; and skeletal muscle, 20%; thus, muscle also appears to a major site of deposition of Sn[II] (Furchner and Drake 1976).

Organotin Compounds. Animal studies, in which organotin compounds were administered parenterally confirm observations made following oral exposures; organotin compounds distribute to soft tissues, including brain, kidney, and liver.

Methyltin Compounds. In rats administered a single intraperitoneal dose of 6 mg/kg trimethyltin (4.3 mg Sn/kg), tin distributed to brain, heart, kidney, and liver, with levels in brain (ng/g protein) that were 15–50% of that in other tissues (Cook et al. 1984a). Tin distribution was uniform across the brain regions, cerebellum, medulla-pons, hypothalamus, hippocampus, and striatum (Cook et al. 1984a). Tin in brain, kidney, and liver were lower after a dose of 6 mg/kg trimethyltin (4.3 mg Sn/kg) than after a dose of 6 mg/kg triethyltin (2.5 mg Sn/kg).

Ethyltin Compounds. In rats, 5 days following a single intravenous dose of 10 mg/kg triethyl[$^{113}$Sn]tin chloride (5 mg Sn/kg), tissue:blood tin ratios were: liver, 1.3; kidney, 0.6; brain, 0.2; skeletal muscle, 0.15; and spinal cord, 0.1; levels were similar in brain stem cerebellum, cerebrum, and cortex (Rose and Aldridge 1968). These observations are consistent with those of Cook et al. (1984a): following a single
intraperitoneal dose of 6 mg/kg triethyltin (3.5 mg Sn/kg), similar levels of tin were observed in heart, kidney, and liver, and levels in brain were 15–25% of that of kidney and liver. Increasing the intravenous dose of triethyltin from approximately 0.6 to 5 mg/kg (0.3–2.5 mg Sn/kg) in rats resulted in proportional increases in levels of tin in blood, brain, kidney, and liver, with no evidence of a limitation in capacity for deposition in these tissues (Rose and Aldridge 1968).

Species differences in deposition of tin in red blood cells have been observed following parenterally-administered triethyltin to animals (Rose and Aldridge 1968). In rats, 4–5 hours following a single intravenous dose of 10 mg/kg triethyl\[^{113}\text{Sn}\]tin chloride (5 mg Sn/kg), substantially higher levels of tin in blood (relative to other tissues) were observed, compared to the hamster and guinea pig, although the distribution to other tissues was similar among rodent species. When samples of whole blood from rats were incubated with triethyl\[^{113}\text{Sn}\]tin chloride, the red blood cell:plasma tin concentration ratio was 19; ratios observed in blood from other rodent species were considerably lower (1–5) and, in human blood, the ratio was 1.9, suggesting that the mechanism for the species differences in red blood cell:plasma ratios involved uptake and/or retention of triethyltin (or tin derived from triethyltin) in red blood cells (Rose and Aldridge 1968). Rat hemoglobin bound more \(^{113}\text{Sn}\) when incubated with triethyl\[^{113}\text{Sn}\]tin than hemoglobins isolated from other rodents, or from humans (Rose and Aldridge 1968).

3.4.3 Metabolism

**Inorganic Tin Compounds.** No studies were located in humans or animals on metabolism of inorganic tin after inhalation, oral, or dermal exposure.

**Organotin Compounds.** No studies were located in humans on metabolism after inhalation, oral, or dermal exposure to organotin compounds. Microsomes prepared from human liver dealkylate tributyltin to form di- and monobutyltin metabolites, suggesting that similar pathways may be active in humans, in vivo (Ohhira et al. 2003). This would be consistent with the detection of dibutyltin and monobutyltin in postmortem human liver samples (Nielsen and Strand 2002) and with the more substantial evidence for dealkylation of alkyltins, including butyltins, in various nonhuman species (see below).

**Ethyltin Compounds.** Studies conducted in rats indicate that tetra-, tri- and diethyltin undergo dealkylation to ethyltin compounds (Bridges et al. 1967; Cremer 1958). Dealkylation and hydroxylation of the ethyl moieties are catalyzed by microsomal monoxygenase(s) of liver, and possibly other tissues (Kimmel et al. 1977).
Butyltin Compounds. Studies conducted in rats indicate that tributyltin undergoes dealkylation to di- and monobutyltin compounds (Iwai et al. 1981, 1982; Matsuda et al. 1993; Ueno et al. 1994). The butyl moieties are also oxidized at carbon 3 to yield 3-hydroxybutyl and 3-oxobutyl metabolites; and at carbon 4, to yield the 4-hydroxybutyl and 3-carboxy metabolites (Matsuda et al. 1993). The simple dealkylation products were the principal metabolites detected in blood and brain following a 2 mg/kg oral dose of tributyltin chloride, whereas in kidney and liver, hydroxy-, carboxy-, and oxo-metabolites were the dominant metabolites (Matsuda et al. 1993). Dealkylation and hydroxylation are catalyzed by microsomal monooxygenase(s) (Kimmel et al. 1977; Ohhira et al. 2003). The alkyl products of dealkylation are conjugated with glutathione and further metabolized to mercapturic acid derivatives (Suzuki et al. 1999b).

Phenyltin Compounds. Studies conducted in hamsters and rats indicate that tetra-, tri-, di-, and monophenyltin compounds are dearylated. The dearylated metabolites, including inorganic tin, can be found in kidney and liver after an oral exposure to phenyltin compounds (Ohhira and Matsui 1993a, 1993b, 2003; Ohirra et al. 1996). Dearylation of phenyltin compounds is catalyzed by microsomal monooxygenase(s) in liver, and possibly in other tissues (Ohhira et al. 2003). A recent study of CYP isoforms in rat hepatocytes showed that CYP2B1 had a small metabolic capacity for triphenyltin, but the principal CYP for triphenyltin metabolism in rats was CYP2C6 (Ohhira et al. 2004). Support for this finding was provided by experiments in which anti-rat CYP2C6 antibodies and cimetidine, a selective CYP2C6 inhibitor, inhibited triphenyltin dearylation activity in the hepatic microsomes of rats (Ohhira et al. 2004).

3.4.4 Elimination and Excretion

3.4.4.1 Inhalation Exposure

Inorganic Tin Compounds. No studies were located regarding excretion in humans or animals after inhalation exposure to inorganic tin.

Organotin Compounds. No studies were located regarding excretion in humans or animals after inhalation exposure to inorganic tin, although tin was detected in the urine from a fatal inhalation case described by Rey et al. (1984).
3.4.4.2 Oral Exposure

**Inorganic Tin Compounds.** Feces and urine are major routes of excretion of ingested tin in humans (Calloway and McMullen 1966; Johnson and Greger 1982, see Section 3.4.4.2). In eight healthy adult males who were placed on diets (for 20 days) containing 0.1 mg Sn/day (basal diet) or 50 mg Sn/day (supplemented with stannous chloride), average fecal excretion was 55% of the daily intake in the basal group and 97% in the supplemented group (Johnson and Greger 1982). Average urinary excretion was 26% of the daily intake in the basal group and 2.4% in the supplemented group, suggesting that urine was a major route of excretion of absorbed tin. These and other observations (Calloway and Mullen 1966) also suggest that gastrointestinal absorption of tin in humans may decrease with increasing dose, possibly reflecting a tight homeostatic control of tin absorption (see Section 3.4.1.2).

In dogs, mice, rats, and Rhesus monkeys, tin ingested as Sn[II] or Sn[IV] compounds is excreted primarily in feces; however, urine and bile appear to be major routes of excretion of absorbed Sn[II] (see Section 3.4.4.4). In rats, 48 hours after dosing (20 mg Sn/kg/day), 95% of the administered $^{113}$Sn (as Sn[II], Sn[IV] citrate, Sn[II]$_2$P$_2$O$_7$, Sn[II]F$_2$, or Sn[IV]F$_4$) was recovered in feces, while <1% was detected in urine (Hiles 1974). Similar results were obtained in dogs, mice, rats, and Rhesus monkeys (Furchner and Drake 1976).

Whole body and tissue retention kinetics have been measured in mice, monkeys, rats, and dogs after an oral gavage dose of stannous chloride (Sn[II]Cl$_2$) (Furchner and Drake 1976). Whole-body elimination kinetics of absorbed Sn[II] were similar in all four species and could be described with 1- or 2-compartment models in which 96–100% of the initial body burden is eliminated with a half-time of 0.2–0.4 days. In Rhesus monkeys (dose, 0.0004 μg/kg), approximately 96% of the body burden was eliminated with a half-time of 0.3 days (reflecting mainly excretion of unabsorbed tin in feces), and 4% was eliminated with a half-time of 3 days.

**Organotin Compounds.** No studies were located regarding excretion in humans after oral exposure to organotin compounds.

**Methyltin Compounds.** In rats, after a single oral dose of 3 mg/kg (1.8 mg Sn/kg; Brown et al. 1984), blood concentrations of trimethyltin decreased by one-half in approximately 3 days and, in brain, in approximately 2 (or less) days. Information identifying the relative contributions of various excretory routes for elimination of methyltin compounds was not located.
3. HEALTH EFFECTS

**Ethyltin Compounds.** Studies in rats indicate that urine and feces are the major routes of excretion of ethyltin following oral exposures to ethyltin compounds (Bridges et al. 1967). Over a 3-day period following a single oral dose of approximately 25 mg/kg ethyltin trichloride (12 mg Sn/kg), rats excreted 92% (range 89–95%) of the dose in feces and 1.2% (range 1–2%) in urine (Bridges et al. 1967). Following absorption, ethyltin is excreted predominantly in urine, whereas absorbed diethyltin and triethyltin are excreted to a greater extent in feces (See Section 3.4.4.4).

**Butyltin Compounds.** In mice that received a single oral dose of 1.2 mg/kg tri[14C]butyltin acetate, approximately 16% of the 14C dose was excreted in urine in 5 days, 53% was excreted in feces, and 22% was exhaled as [14C]CO2 (Kimmel et al. 1977). Following a similar dose di[14C]butyltin diacetate the excretion pattern (% of dose) was: urine, 10%; feces, 66%; and carbon dioxide, 7% (Kimmel et al. 1977). In mice, the amount of tin excreted in urine following an oral dose of different butyltins also increased with the number of butyl groups. Five days following a single oral dose of 180 μmol/kg of tri-, di-, or monobutyltin, urinary excretion of tin (percent of dose) was approximately: tributyltin, 5%; dibutyltin, 3%; and butyltin, 0.3% (Ueno et al. 1994). These differences may reflect real differences in urinary excretion of absorbed tin compounds, or greater absorption of the tin compounds having a larger number of butyl groups.

**Phenyltin Compounds.** Information or the rates or relative contributions of various excretory routes for elimination of phenyltin compounds was not located.

**3.4.4.3 Dermal Exposure**

No studies were located regarding excretion in humans or animals after dermal exposure to inorganic tin or organotin compounds.

**3.4.4.4 Other Routes of Exposure**

**Inorganic Tin Compounds.** Studies in which inorganic tin compounds have been parenterally injected into animals have shown that absorbed inorganic tin is excreted in urine and bile. Forty-eight hours after an intravenous injection to rats of 2 mg Sn/kg, as 113Sn [II] citrate, 35% of the administered radioactivity was excreted in urine and approximately 12% was (2 mg Sn/kg, as 113Sn [II] citrate) was excreted in the feces. In bile-duct cannulated rats, 23% was excreted in the urine, 11% in bile, and 2% in the feces. These observations indicate that urine and bile appear to be major routes of excretion of absorbed Sn[II].
3. HEALTH EFFECTS

The biliary contribution to excretion of Sn[IV] was less than that of Sn[II], and after intravenous injection of 2 mg Sn/kg, as $^{113}$Sn [IV] citrate, 40% of the administered radioactivity was excreted in urine and 3% in feces. Following the same intravenous dose administered to rats that had bile duct cannulas, 25% of the administered dose was excreted in urine and 0.5% in bile (Hiles 1974). Urine-feces excretion ratios after intravenous injection of stannous chloride were approximately 10 in dogs, 3 in mice and rats, and 5 in Rhesus monkeys (Furchner and Drake 1976).

Rates of elimination of absorbed inorganic tin have been measured in mice, monkeys, rats, and dogs after intravenous or intraperitoneal injection of stannous chloride (Sn[II]Cl$_2$) (Furchner and Drake 1976). Whole-body elimination kinetics of absorbed Sn[II] were similar in all four species and could be described with similar 4-compartment models. In Rhesus monkeys (dose, 0.0004 μg/kg), approximately 39% of the body burden was eliminated with a half-time of 0.6 days, 11% was eliminated with a half-time of 5 days, 8% eliminated with a half-time of 24 days, and 42% was eliminated with a half-time of 88 days. The pseudo-first order elimination half-times (all components combined) were approximately 7 days in monkeys and 1–2 days in dogs, mice, and rats; the difference reflects the larger contribution of the slow compartment in the monkey (42%) compared to the other three species (20–30%).

Measurements of the elimination kinetics of absorbed Sn[II], from individual tissues in rats (dose, 0.006 μg/kg), suggested that bone was a major contributor to the slowest compartment, comprising approximately 50% of the body burden 1 day after dosing, and approximately 70–75% of the body burden from days 6–113 after dosing. Elimination rates were similar in all soft tissues measured (blood, brain, kidney, liver, spleen). These observations are consistent with the observations of accumulation of tin in bone with repeated exposures to Sn[II] compounds (Hiles 1974; NTP 1982; Yamaguchi et al. 1980).

**Methyltin Compounds.** The elimination kinetics of tin from tissues, following parenteral injection of trimethyltin has been investigated in the rat. Cook et al. (1984a) administered single intraperitoneal doses of 6 mg/kg trimethyltin bromide (4.4 mg Sn/kg) to rats and measured tissue tin over 22 days following the dose. The pseudo-first order elimination half-times for tin were: blood, 10 days; brain, 10 days; heart, 11 days; kidney, 12 days; and liver, 15 days. These rates were slower than those estimated for tin following a dose of triethyltin (Cook et al. 1984a). Ekuta et al. (1998) derived empirical, single-compartment models of the kinetics of $^{14}$C in blood of four inbred mouse strains following single intraperitoneal injections of tri[$^{14}$C]methyltin. Elimination half-times were 28.5 hours (AKR/J), 31.3 hours (BalbcByJ), 30.0 hours (C57Bi6J), and 57.4 hours (DBA/2J).
3. HEALTH EFFECTS

**Ethyltin Compounds.** Following absorption, ethyltin is excreted predominantly in urine, whereas absorbed diethyltin is excreted to a much greater extent in feces. In rats, during the 72-hour period following an intraperitoneal dose of 12.7 mg/kg ethyltin trichloride (6 mg Sn/kg), 73% of the dose was excreted in urine and none in feces; approximately 4% of the dose was secreted into bile (Bridges et al. 1967). Biliary secretion appears to be quantitatively more important in the excretion of absorbed diethyltin, compared to ethyltin. During the 72 hours following an intraperitoneal dose of 10 mg/kg \[^{14}C\]diethyltin dichloride (5 mg Sn/kg), approximately 64% of the administered dose of tin was excreted in feces and 31% in urine (fecal:urine ratio, 2.2); 32% of the administered \[^{14}C\] was excreted in feces and 19% in urine (fecal:urine ratio, 1.8). In rats in which the bile duct had been cannulated, 56% of an intraperitoneal dose of \[^{14}C\]diethyltin was secreted into bile; essentially all of the \[^{14}C\] secreted into bile was identified as diethyltin. Biliary secretion of triethyltin has also been observed in hamsters and guinea pigs, following intraperitoneal injection of 10 mg/kg triethyl\[^{113}Sn\]tin chloride (5 mg Sn/kg) (Rose and Aldridge 1968).

In rats, absorbed tetraethyltin appears to be excreted primarily as the trialkyltin metabolite. During the 3 days following a subcutaneous dose of 10 mg/kg triethyltin in rats, approximately 0.20% of the dose was excreted in urine and 0.08% in feces (urine:feces ratio, 2.5; Iwai et al. 1982b). During the 3 days following a subcutaneous dose of 10 mg/kg tetraethyltin in rats, approximately 0.13% of the dose was excreted in urine and 0.07% in feces (urine:feces ratio, 1.9); however, no tetraethyltin was detected in excreta.

The elimination kinetics of tin from tissues, following parenteral injection of triethyltin has been investigated in the rat. Cook et al. (1984a) administered single intraperitoneal doses of 6 mg/kg triethyltin as the bromide salt (3.5 mg Sn/kg) to rats and measured tissue tin levels over 22 days following the dose. The pseudo-first-order elimination half-times for tin were: blood, 2.5 days; brain, 4.6 days; heart, 3.4 days; kidney, 5.6 days; and liver, 6.1 days. These estimates are consistent with rates of decline in tin levels measured in blood, brain, kidney, and liver 1–5 days following a single intravenous dose of 10 mg/kg triethyl\[^{113}Sn\]tin chloride (5 mg Sn/kg) in rats (Rose and Aldridge 1968).

**Butyltin Compounds.** In rats, absorbed tetrabutyltin appears to be excreted as the trialkyltin metabolite. In rats, during the 3 days following a subcutaneous dose of 10 mg/kg tributyltin, approximately 0.18% of the dose was excreted in urine and 0.04% in feces (urine:feces ratio, 4.5; Iwai et al. 1982b). Following the same subcutaneous dose of tetrabutyltin, approximately 0.12% of the dose was excreted in urine and 0.16% in feces (urine:feces ratio, 0.8); however, no tetrabutyltin was detected in excreta.
3. HEALTH EFFECTS

3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and disposition of chemical substances to quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic end points.

PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 1987; Andersen and Krishnan 1994). These models are biologically and mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to route, between species, and between subpopulations within a species. The biological basis of PBPK models results in more meaningful extrapolations than those generated with the more conventional use of uncertainty factors.

The PBPK model for a chemical substance is developed in four interconnected steps: (1) model representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-specific physicochemical parameters, and species-specific physiological and biological parameters. The numerical estimates of these model parameters are incorporated within a set of differential and algebraic equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations provides the predictions of tissue dose. Computers then provide process simulations based on these solutions.

The structure and mathematical expressions used in PBPK models significantly simplify the true complexities of biological systems. If the uptake and disposition of the chemical substance(s) are
adequately described, however, this simplification is desirable because data are often unavailable for many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, therefore, of great importance, and model validation is essential to the use of PBPK models in risk assessment.

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where doses were higher or were administered in different species. Figure 3-9 shows a conceptualized representation of a PBPK model.

If PBPK models for tin and tin compounds exist, the overall results and individual models are discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.

ICRP (1981b, 2001) Tin Biokinetics Model

Description of the model.

The ICRP (1981b, 2001) model is based on an empirical model developed by Furchner and Drake (1976) (Figure 3-10). The fraction of ingested tin that is absorbed from the gastrointestinal tract (uptake to blood) is assumed to be 0.02. Absorbed tin is assumed to enter the blood from where 50% is immediately transferred to excreta (specific routes not specified in the model), 35% is transferred to bone mineral, and 15% is uniformly distributed to all other tissues. Tin in any tissue or organ is retained with elimination half-times of 4 (20% of tissue burden), 25 (20%), and 400 (60%) days.

ICRP (1981b, 2001) also provides classifications for clearance of inhaled tin compounds in the respiratory tract, for use in the ICRP (1994) inhalation model. Sulphides, oxides, hydroxides, halides, and nitrates of tin, and stannic phosphate are assigned Type M; all other compounds of tin are assigned to Type F. For Type F compounds, rapid 100% absorption is assumed to occur within 10 minutes of material deposition in the bronchi (BB) bronchiole (bb), and alveolar interstitial (AI) regions. Fifty percent of Type F compounds deposited in extrathoracic region transfer to the gastrointestinal tract (ET$_2$). During nose breathing, there is rapid absorption of approximately 25% of the tin deposited in the
3. HEALTH EFFECTS

Figure 3-9. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance

Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Figure 3-10. ICRP (1981b, 2001) Tin Biokinetic Model

*Elimination half-life
extrathoracic region, and 50% absorption during mouth breathing. For Type M compounds, approximately 70% of the tin deposited in AI eventually is transferred to blood and there is rapid absorption of about 10% of the tin deposited in BB and bb, and 5% of tin deposited in ET2. During nose breathing, approximately 2.5% of the deposit in ET is rapidly absorbed and 5% is rapidly absorbed during mouth breathing.

**Validation of the model.**

The extent to which the ICRP model has been validated is not described in ICRP (1981b).

**Risk assessment.**

The model has been used to establish radiation dose equivalents (Sv/Bq) of ingested and inhaled radioactive tin isotopes for ages 1 day to 50 years (ICRP 2001).

**Target tissues.**

The model is designed to calculate intake limits for radioactive tin, based on radiation dose to all major organs, including the bone surfaces, bone marrow, and liver, to which the highest doses would be expected.

**Species extrapolation.**

The model is designed for applications to human dosimetry and cannot be applied to other species without modification.

**Interroute extrapolation.**

The ingestion model (ICRP 1981b, 2001), together with the respiratory tract model (ICRP 1994) are designed to simulate oral and inhalation exposures to tin and cannot be applied to other routes of exposure without modification.
3. HEALTH EFFECTS

3.5 MECHANISMS OF ACTION

3.5.1 Pharmacokinetic Mechanisms

**Absorption.** The mechanism(s) of absorption of inorganic and organotin compounds have not been elucidated. In rats, following five oral doses of 10 mg/kg/day of tetra- or triethyltin, or tetra- or tributyltin, the alkyltin in the gastrointestinal tract tissue was primarily associated with the duodenum and jejunum indicating that these may be sites of absorption (Iwai et al. 1982b). A recent study with the Caco-2 human intestinal cell-line suggested that, in general, butyltins have a low *in vivo* permeability (Azenha et al. 2004). The study also showed that the permeability pattern correlated with the *in vivo* toxicity (trialkyltin > dialkyltin > monoalkyltin). However, the accumulation pattern (dialkyltin > trialkyltin > monoalkyltin) was different than that of permeability, presumably due to the strong affinity of dibutyltin for dithiol groups. Finally, the permeability of monobutyltin and dibutyltin, but not that of tributyltin, was found to be dependent of the paracellular route status.

**Distribution.** Inorganic tin deposits in bone mineral; however, the mechanisms for the uptake and retention in bone have not been elucidated.

Species differences have been demonstrated in the distribution of methyltin and ethyltin compounds within whole blood. Rats show higher red blood cell:plasma concentration ratios than other species, including humans and nonhuman primates (Brown et al. 1984; Rose and Aldridge 1968). Uptake and retention of methyltin and ethyltin in red blood cells has been attributed to binding to hemoglobin; however, the mechanism for the difference has not been elucidated. When hemoglobin from rat red blood cells is incubated with triethyl[\(^{113}\)Sn]tin, radioactivity was bound to hemoglobin with an apparent affinity constant of approximately 3.5x10^5 M\(^{-1}\) (Rose 1969). The pH-dependence of binding is consistent with involvement of histidine residues in hemoglobin (Rose 1969).

The subcellular distribution of tin, following parenterally-administered trimethyltin or triethyltin, has been examined in rats and guinea pigs (Cook et al. 1984a; Rose and Aldridge 1968). Fractionation of brain tissue from animals that received a single intraperitoneal dose of 6 mg/kg trimethyltin (4.3 mg Sn/kg), revealed that tin was associated with the crude mitochondrial and microsomal fractions and, within the crude mitochondrial fraction, tin was associated with myelin, synaptosomes, and mitochondria (Cook et al. 1984b). The concentration in the mitochondrial fraction increased over time, reaching a maximum of 5 days after the dose. Subcellular concentrations of tin were 4–20 times lower after the 6 mg/kg dose of trimethyltin (4.3 mg Sn/kg), compared to the 6 mg/kg dose of triethyltin (2.5 mg Sn/kg).
The subcellular distribution of tin in kidney and liver was similar in rats and guinea pigs following a parenteral dose of triethyltin; however, differences were observed between the distribution in rat brain compared to kidney and liver (Rose and Aldridge 1968). In rats, 2 hours following a single intravenous dose of 10 mg/kg triethyl[113Sn]tin chloride (5 mg Sn/kg), approximately 60% of the 113Sn was associated with the 40,000 x g supernatant (cytosolic) fraction and approximately 13% was associated with the heavy mitochondrial fraction. In brain, approximately 32% was associated with the supernatant fraction and 40% with the heavy mitochondrial fraction. Cook et al. (1984b) also found tin associated with the crude mitochondrial (13,000 x g) fraction of rat brain after a single intraperitoneal dose of 6 mg/kg triethyltin bromide (2.5 mg Sn/kg). Subfractionation of the crude mitochondrial fraction on a Ficoll gradient revealed tin associated with the myelin, synaptosomes, and mitochondria.

In a comparative study with rats, mice, and guinea pigs, the susceptibility to develop liver damage followed the order: mice > rats > guinea pigs (Ueno et al. 2003b). This appeared to be partly due to differences in metabolism of tributyltin and in the distribution of dibutyltin within cell organelles. In hepatocytes of mice treated with dibutyltin chloride, 41% of the dibutyltin was found in organelles compared to 27% in rats and 9% in guinea pigs (Ueno et al. 2003b).

Metabolism. No information on speciation of inorganic tin after absorption was located; therefore, the extent to which Sn[II] and Sn[IV] are interconverted is unknown. The major metabolic pathways for alkyltin compounds include dealkylation and hydroxylation and further oxidation of the alkyl moieties (see Section 3.4.3). These reactions have been found to occur in the microsomal fraction of liver (including human liver), are dependent on reduced nicotinamide adenosine dinucleotide phosphate (NADPH), and are inhibited by carbon monoxide, suggesting involvement of cytochrome P-450 (Kimmel et al. 1977; Ohhira et al. 2003). For triphenyltin, CYP2C6 constitutes the principal CYP for dearylation in hepatic microsomes of rats (Ohhira et al. 2004).

Several studies have examined the involvement of metabolism in the toxicity of some organotin compounds. Cases have been described in which metabolism can either increase or decrease the toxicity of these compounds. For example, studies in hamsters showed that pretreatment of the animals with the cytochrome P-450 inducer, phenobarbital (PB), suppressed the diabetogenic effects of triphenyltin compared to PB-untreated hamsters (Ohhira et al. 1999). Pretreatment with the CYP1A and 2A inducers β-naphthoflavone and 3-methylcholanthrene, was not as effective as PB in preventing the organotin-induced hyperglycemia and hypertriglyceridemia. On the other hand, pretreatment with the
P-450 inhibitor, SKF-525A, increased the diabetogenic effects of triphenyltin (Ohhira et al. 2000). Overall, these findings suggested that the hyperglycemic toxicity of triphenyltin is due primarily to accumulation of the parent compound, triphenyltin, in the pancreas, and not to a metabolite. Studies by Ueno et al. (1995, 1997) showed that the liver toxicity of tributyltin chloride could be prevented by treatment of the mice with the cytochrome P-450 inhibitor SKF-525A and that pretreatment with the P-450 inducer, PB increased the toxicity of tributyltin. These results suggested that the liver toxicity of tributyltin is due to a metabolite, most likely dibutyltin.

**Excretion.** Bile, feces, and urine are major routes of elimination of absorbed inorganic and organotin compounds (see Section 3.4.4.4). Information on the mechanisms of biliary secretion and urinary excretion of tin compounds was not located.

### 3.5.2 Mechanisms of Toxicity

Studies in laboratory animals have shown that exposure to tin and tin compounds can produce a wide array of effects, but it is unknown whether exposure of humans to levels of tin compounds found in the environment will cause similar effects. General mechanisms of neurotoxicity and immunotoxicity of organotin compounds are briefly discussed below, as effects on these two systems may cause the most concern following potential exposures of humans to these substances. Although exposure to toxic amounts of neurotoxic organotins is somewhat unlikely, studies with trimethyltin and triethyltin in animals have shown a very steep dose-response curve for these substances and similar severe effects have been observed following acute high exposure of humans. Exposure to immunotoxic organotins, such as tributyltin, is much more likely because of substances’ use and, environmental prevalence, based on monitoring data.

**Neurotoxicity.** Trimethyltin has been shown to produce degenerative lesions in the hippocampus and associated structures of the limbic system (e.g., dentate gyrus) in nonhuman primates and in several rodent species (see Section 3.2.2.4; Koczyk 1996). The lesions have been characterized as neuronal cell apoptosis and are accompanied with astrocyte swelling and reactive gliosis (Aschner and Aschner 1992; Fiederowicz et al. 2001; Haga et al. 2002; Koczyk and Oderfeld-Nowak 2000; McCann et al. 1996; Monnet-Tschudi et al. 1995a, 1995b). The glial response may be secondary to the primary neuronal lesion or a direct effect of trimethyltin on glial cell activation. Glial cell activation has been observed in primary cultures of rat cortical astrocytes (Mizuhashi et al. 2000a, 2000b; Röhl et al. 2001) and in primary cultures of neuronal/glial cells (including hippocampal cells) at exposures that did not produce changes in
neuronal cells (Figiel and Fiedorowicz 2002; Monet-Tschudi et al. 1995a, 1995b), suggesting direct effects of trimethyltin on microglia. Glial cell activation could contribute to neuronal cell degeneration by local release of pro-inflammatory cytokines, tumor necrosis factor-α, and/or interleukins (Bruccoleri et al. 1998; Harry et al. 2002; Maier et al. 1995; McPherson et al. 2003). Trimethyltin has also been shown to induce apoptosis (and necrosis at higher exposure concentrations) in primary cell cultures of rat neuronal cells and in other cell models, suggesting possible direct effects on neuronal cells (Gunasekar et al. 2001; Jenkins and Barone 2004; Thompson et al. 1996; Viviani et al. 1998). Specific gene products, stannin and calcitonin gene-related peptide, may render neurons more vulnerable to trimethyltin-induced apoptosis (Bulloch et al. 1999; Thompson et al. 1996; Toggas et al. 1992). Astrocyte swelling may be related to perturbation of the regulation of transmembrane potassium (or other solute) gradients (Aschner et al. 1992; Brand et al. 1997).

Numerous functional disturbances, at the cellular level, have been observed in association with the trimethyltin neuropathology. These effects may be contributing mechanisms to the primary lesion or may represent secondary phenomena associated with neuronal cell loss. Trimethyltin has been shown to stimulate the neuronal release of and/or to decrease neuronal cell uptake of neurotransmitters in brain tissue, including aspartate, GABA, glutamate, norepinephrine, and serotonin (Aschner et al. 1992; Costa 1985; Dawson et al. 1995; Doctor et al. 1982; Earley et al. 1992; Gassó et al. 2000; Naalsund and Fonnum 1986; Patterson et al. 1996). Such effects could give rise to imbalances in neuronal inhibition and excitation; however, their contributions as either primary or secondary mechanisms of trimethyltin-induced neuronal degeneration and/or neurological impairment have not been established.

In mice, exposure to trimethyltin decreases the expression of neural cell adhesion molecule (NCAM) and depresses NCAM levels in the hippocampus (Dey et al. 1994, 1997). NCAM functions by establishing intercellular contact between neurons (e.g., synaptogenesis) and in cell migration during the development of the nervous system. In mature mice, NCAM continues to be expressed in the hippocampus, where it appears to function in the acquisition and consolidation of memory. Thus, altered NCAM expression may contribute to trimethyltin-induced impairments in learning and memory.

At doses of trimethyltin that produce loss of hippocampal neurons, expression of several neuropeptides (e.g., dynorphin, enkephalin, neuropeptide Y, somatostatin) and neuropeptide receptors (e.g., neuropeptide Y) are altered in affected areas of the brain (Ishikura et al. 2001, 2002; Sadamatsu et al. 1998; Tsunashima et al. 1998). Altered expression of enkephalin and dynorphin may be contributing mechanisms to trimethyltin-induced brain seizures (Ishikura et al. 2001). Trimethyltin also has been
shown to alter various factors in the lymbic system associated with the pathophysiology of Alzheimer’s disease (Nilsberth et al. 2002).

Triethyltin induces an edema that is largely restricted to brain white matter (intramyelinic edema) in animal models without a prominent gliosis, in contrast to the reactive gliosis observed in trimethyltin toxicity (see Section 3.2.2.4). The mechanism for the intramyelinic edema observed in triethyltin neurotoxicity has not been established. Altered expression of myelin basic protein is an early event in the intralamellar vacuolization that precedes the development of intramyelinic edema (Veronesi et al. 1991a, 1991b). Increased expression of various pro-inflammatory cytokines in affected areas also appears to coincide with vacuolization; these include tumor necrosis factor-α, interleukin-1 β, and monocyte chemoattractant protein 1-α (Mehta et al. 1998). Results from a study with cultured oligodendrocytes, the myelin-forming cells of the central nervous system, suggested that triethyltin causes the onset of programmed cell death in oligodendrocytes, as indicated by DNA fragmentation (Stahnke and Richter-Landsberg 2004). Programmed cell death was accompanied by induction of a heat shock protein, HSP32, an indicator of oxidative stress, and ERK1,2, a signal-regulated kinases known to be activated under conditions similar to those that induce HSP32 transcription.

**Immunotoxicity.** Thymic atrophy produced by certain organotins, such as triphenyltin, tributyltin, dibutyltin, and dioctyltin compounds, involves a decrease in the number of cortical thymocytes, resulting in reduced thymus weight (see Section 3.2.2.3, Seinen and Willems 1976; Seinen et al. 1977a, 1977b). With prolonged exposure, T-cell-mediated immune responses are suppressed (Seinen et al. 1977b). Loss of thymocytes appears to involve suppression of proliferation of immature thymocytes and, at higher dosages, apoptosis of mature thymocytes (Bollo et al. 1996; Raffay and Cohen 1993). These appear to be direct effects on the thymus as both cytotoxicity and apoptosis have been observed in thymocyte cell cultures exposed to di- or tributyltin (Gennari et al. 1997, 2000, 2002a; Raffay et al. 1993; Umebayashi et al. 2004) and triphenyltin (Dacasto et al. 2001; Stridh et al. 1999b). Cytotoxicity of butyltin compounds in thymocyte cultures involves suppression of DNA and protein synthesis (Gennari et al. 2002a; Raffay et al. 1993), and also induction of the expression of genes involved in apoptosis, such as nur77, a transcription factor member of the steroid/thyroid hormone receptor superfamily (Gennari et al. 2002b). An early and, possibly, the initiating event of apoptosis is a rise in cytosolic ionized calcium (Ca²⁺) concentration, caused both by intracellular calcium stores as well as by disruption of calcium transport at the cell membrane (Chow et al. 1992; Corsini et al. 1997; Gennari et al. 2000; Oyama et al. 1991, 1994, 2003). Disruption of the regulation of intracellular calcium levels and, possibly, direct effects on energy metabolism of mitochondria either contributes to or gives rise to the uncontrolled production of reactive
oxygen species, release of cytochrome $c$ to the cytosol, and the proteolytic and nucleolytic cascade of apoptosis (Gennari et al. 2000; Okada et al. 2000). Modification of the cytoskeleton through Ca$^{2+}$-independent disruption of F-actin may also contribute to DNA fragmentation (Chow and Orrenius 1994).

Alkyltin compounds, in particular butyltin compounds, suppress T-cell-mediated immune responses, including antibody formation against foreign antigens, delayed hypersensitivity reactions, and allograft rejection (see Section 3.2.2.3). These effects appear to result from suppression of proliferation of immature thymocytes (CD4$^-$CD8$^-$) which would, otherwise, differentiate into mature T-cells possessing the complete antigen-recognizing T-cell receptor complex, resulting in lower numbers of circulating functional T-cells (Pieters et al. 1994b, 1994c). Suppression of lymphoproliferative responses to T- and B-cell mitogens also has been demonstrated for triphenyltin (Dacasto et al. 1994b, 2001a, 2001b).

Direct effects on lymphocyte function may also contribute certain aspects of immune suppression observed in animals exposed to butyltin compounds, including decreased natural killer cell activity. In vitro, butyltin compounds suppress cytotoxic activity of human natural killer cells that function in the immune response to tumors and virally-infected cells (Whalen et al. 1999, 2000, 2002a, 2003). Mechanisms for suppression of killer cells appear to involve loss of cell surface receptors important for binding to target cells (Odman-Ghazi et al. 2003; Whalen et al. 2002b), possibly secondary to a loss of regulation of intracellular cAMP (Whalen and Loganathan 2001), and disruption of the transcription of genes for the cytotoxic proteins granzyme B and perforin (Thomas et al. 2004), which are proteins contained in granules released by NK cells.

3.5.3 Animal-to-Human Extrapolations

Although information is available to support development of models of toxicokinetics for various tin compounds in rodents and nonhuman primates (e.g., Rhesus monkey, marmoset), evaluation of such models for applications to predicting the toxicokinetics of tin in humans would be highly uncertain because of the near complete lack of observations in humans (see Section 3.12.2). In addition, studies conducted in animals suggest differences between nonhuman primates and rats in certain important features of the toxicokinetics of tin compounds. For example, the elimination kinetics of absorbed inorganic tin occurs more slowly in Rhesus monkeys than in rodents; this difference appears to be the result of a larger fraction of the tin body burden associated with the slowest kinetic compartment (presumably bone) in monkeys. Organotin compounds, in particular methyltin and ethyltin, accumulate
3. HEALTH EFFECTS

in red blood cells to a much greater extent in rats than in other species, including nonhuman primates (Brown et al. 1984; Rose and Aldridge 1968). Also, studies of several rodent species showed different sensitivities to liver toxicity induced by tri- and dibutyltin which were related to the subcellular distribution of dibutyltin in hepatocytes (Ueno et al. 2003a, 2003b). The susceptibilities followed the order: mice > rats > guinea pigs. Another case in which extrapolation from rats or mice to humans may not be appropriate is that represented by the biliary duct necrosis produced by some organotins. Bile duct necrosis following administration of dibutyltin occurred in rats, mice, and hamsters, species which unlike man, have common bile duct systems, but did not occur in rabbits, guinea pigs, hens, and cats, which have separate bile duct and pancreatic duct systems (Boyer 1989; Kimbrough 1976). Thus, some toxicities of organotins in some animal species are not directly extrapolatable to humans.

3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS

Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate terminology to describe such effects remains controversial. The terminology endocrine disruptors, initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the EPA to develop a screening program for “...certain substances [which] may have an effect produced by a naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are similar in structure and action to endogenous estrogen. Although the public health significance and descriptive terminology of substances capable of affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction,
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992).

In recent years, concern has been raised that many pesticides and industrial chemicals are endocrine-active compounds capable of having widespread effects on humans and wildlife (Crisp et al. 1998; Daston et al. 1997; Safe et al. 1997). Particular attention has been paid to the possibility of these compounds mimicking or antagonizing the action of estrogen and exhibiting antiandrogenic properties. Estrogen influences the growth, differentiation, and functioning of many target tissues, including female and male reproductive systems, such as mammary gland, uterus, vagina, ovary, testes, epididymis, and prostate. Another way that endocrine-active compounds can affect development is by acting on thyroid hormones. Thyroid hormones are essential for the normal development of the nervous system, lung, skeletal muscle, and possible other organs. The fetus is dependent on maternal thyroid hormones at least until the fetal thyroid begins to produce T4 and triiodothyronine (T3), which occurs in humans at approximately 16–2 weeks of gestation.

Thus far, there is no evidence that tin and tin compounds are endocrine disruptors in humans at the levels found in the environment.

No studies were located regarding endocrine disruption in humans following exposure to tin or tin compounds or regarding effects in animals following exposure to inorganic tin.

**Inorganic Tin Compounds.** The only relevant information located regarding inorganic tin is that stannous chloride induced the growth of MCF-7 breast cancer cells *in vitro*, decreased the steady-state amount of estrogen receptor protein and mRNA, induced the two estrogen-regulated genes, progesterone receptor and pS2, and activated the estrogen receptor in transient transfection experiments (Martin et al. 2003). Tin exhibited 1/3 to 1/4 the estrogenic potency of estradiol when measured in MCF-7 cells transiently transfected with the luciferase reporter construct.

**Organotin Compounds.** Intermediate- and chronic-oral studies with dibutyltin in rats and mice did not show alterations in the weight or in microscopic appearance of endocrine glands (Gaunt et al. 1968; NCI 1978a; Seinen et al. 1977a). Dibutyltin dichloride, tributyltin chloride, and triphenyltin chloride induced
3. HEALTH EFFECTS

pre- and postimplantation loss and resorptions in rats when administered during pregnancy (Ema et al. 1991b, 1995b, 1997b; Noda et al. 1991a, 1992). In all cases, the highest incidence of effects was observed when the chemicals were administered on Gds 7–9 (Ema et al. 1992, 1997a, 1999a). It was suggested that implantation loss that occurs after dosing the pregnant animals early during gestation is caused by an organotin-induced suppression of the uterine decidual cell response and decrease in progesterone levels (Ema and Miyawaki 2002; Ema et al. 1999b; Harazono and Ema 2000, 2003).

Male ICR mice treated with 10 mg tributyltin oxide/kg 2 times/week for 4 weeks showed significantly reduced sperm counts (Kauasaka et al. 2002). In addition, light microscopy of the testis revealed disorganized seminiferous tubules with vacuolization of Sertoli cells and some loss of germ cells. No effects were seen on spermatogonia, spermatocytes, spermatids, Leydig cells, or the basement membrane of the seminiferous tubules; the study NOAEL was 2 mg/kg/day. A 2-year study with tributyltin oxide did not report histopathological alterations in endocrine glands from male and female rats treated with up to 2.1 mg/kg/day, except for a decrease in thyroid follicular epithelial cell height observed at 12 and 24 months (Wester et al. 1990). However, no significant alterations were observed at 12 and 24 months in serum levels of TSH, LH, FSH, insulin, T4, or FT4. Chronic-duration studies with dibutyltin diacetate found no significant histopathological alterations in endocrine glands from rats and mice treated with dietary doses of up to 6.7 and 19.8 mg/kg/day, respectively, for 78 weeks (NCI 1978a). However, a long-term study with triphenyltin hydroxide reported an increase in Leydig cell hyperplasia and tubular atrophy of the testes in rats dosed with 5.2 mg/kg/day for 2 years (Tennekes et al. 1989b). This was not seen in rats dosed with up to 9.8 mg/kg/day or in mice dosed with up to 3.8 mg/kg/day for 78 weeks (NCI 1978b).

In male Fischer-344 rats treated with a single dose of 100 mg/kg of tributyltin oxide, there was an increase in serum cortisol and adrenal hypertrophy (Funahashi et al. 1980). Tributyltin oxide also significantly reduced serum T4 and TSH, but at the same time increased the stainability of TSH cells, suggesting that tributyltin oxide inhibited TSH release, which caused thyroid hypofunction. Since the decrease in circulating T4 was much more pronounced than that of TSH, Funahashi et al. (1980) suggested that tributyltin oxide also has a direct effect on the thyroid. Most acute effects appeared to be reversible within 14 days. Treatment of rats with ≥6 mg/kg/day for 26 weeks increased adrenal and hypophysis weight and also caused signs of thyroid hypofunction (Funahashi et al. 1980). In an additional intermediate-duration study with tributyltin oxide, treatment of Wistar rats with doses of approximately 4 mg/kg/day significantly decreased serum levels of T4 and TSH, and increased LH (Krajnc et al. 1984). No significant changes were measured in the concentrations of follicle-stimulating
3. HEALTH EFFECTS

hormone (FSH) and corticosterone. Release of TSH after administration of thyrotropin-releasing hormone (TRH) was slightly reduced at 4 mg/kg/day, but releases of both LH and FSH were enhanced. Light microscopy revealed flattening of the epithelial lining of the thyroid follicles at 4 mg/kg/day, but not at lower doses. In the pituitary, treatment with 4 mg/kg/day tributyltin oxide reduced the number of TSH-immunoreactive cells and the staining intensity, increased the number of cells staining for LH, and had no significant effect in the staining for GH-, FSH-, or ACTH-producing cells. Krajnc et al. (1984) concluded that their results suggested that treatment with tributyltin oxide for 6 weeks did not stimulate the pituitary-adrenal axis.

In a 2-generation reproductive toxicity study in female Wistar rats, there was suggestive evidence that tributyltin chloride may alter developmental landmarks controlled by sex hormones. Doses of 10 mg/kg/day significantly delayed the day of eye opening in F2 pups (Ogata et al. 2001). Anogenital distance was significantly increased in F1 and F2 females on Pneds 1 and 4 and on Pnd 1 in F1 pups at 2 mg/kg/day. The day of vaginal opening was significantly delayed (6 days) with 10 mg/kg/day in F1 and F2 groups. Analysis of the estrous cycles between Pneds 71 and 92 showed no alterations in F1 rats, but the number of cycles was significantly decreased in F2 rats. Also, the percentage of normal cycles was decreased F1 and F2 rats dosed with 10 mg/kg/day.

A study of similar design with tributyltin chloride was conducted to evaluate the development of reproductive parameters in male Wistar rats (Omura et al. 2001). The doses tested were 0.4, 2, and 10 mg/kg/day. Anogenital distance (measured on Pneds 1 and 4) was not significantly altered in F1 or F2 males and neither was the day of testes descent. The day of eye opening was significantly delayed in mid- and high-dose F1 rats and in high-dose F2 rats. Effects on the weight of the sex organs included: decreased absolute testis weight in all F1 groups (dose-related); decrease absolute epididymis weight in low- and high-dose F1 groups; decrease absolute testis and epididymis weight in high-dose F2 groups and in relative prostate weight in mid- and high-dose F2 groups. The only sperm parameters that were significantly altered were sperm count in high-dose F2 rats and spermatid count in mid- and high-dose F2 rats and high-dose F1 rats. Histological examination of the testes revealed minimal alterations in high-dose F1 rats, but were more frequent and severe in F2 rats and were considered abnormal in this group. These effects consisted of vacuolization of the seminiferous epithelium, spermatid retention, and delayed spermiation. Serum testosterone was increased and estradiol was decreased in high-dose F1 rats; serum estradiol was decreased and LH was increased in high-dose F2 rats.
3. HEALTH EFFECTS

The information available is insufficient to ascertain whether organotins cause endocrine disruption in laboratory mammals, but the studies of Ogata et al. (2001) and Omura et al. (2001) suggest that tributyltin may have such a property. In addition, assays in vitro support this hypothesis. A brief summary of some recent in vitro studies is presented below.

A commonly used test of potential endocrine-disruption activity is the assay of aromatase activity. Aromatase cytochrome P-450 is an enzyme that catalyzes the conversion of androgens to estrogens. Because estrogens are involved in processes including development of female secondary characteristics, regulation of bone density, menstruation cycle, and spermatogenesis, interference with their metabolism can have widespread consequences. Using human term placenta as source of enzymes, Heidrich et al. (2001) evaluated the aromatase activity of a series of organotins. The results showed that tributyltin chloride was a partial competitive inhibitor of aromatase activity. Dibutyltin dichloride was a less potent inhibitor, whereas tetrabutyltin and monobutyltin trichloride had no significant effect. In contrast, tributyltin had only moderate inhibitory activity toward 3β-HSD type I activity, an enzyme that converts dehydroepiandrosterone to androstenedione. None of the other butyltins tested inhibited 3β-HSD type I activity. Cooke (2002) found that tributyltin chloride and dibutyltin dichloride inhibited aromatase activity (a commercial preparation), but not monobutyltin or mono-, di-, or trioctyltins.

Tributyltin chloride inhibited human 5α-reductase type 1 and 5α-reductase type 2 (Doering et al. 2002), enzymes that mediate the activation of androgens, suggesting that this organotin could potentially disturb normal male reproductive physiology. 5α-Reductase type 2 also was inhibited by dibutyltin dichloride and neither enzyme was affected by monobutyltin trichloride or by tetrabutyltin, which suggested that at least two butyl groups bound to tin are required for the interaction with these enzymes. Triphenyltin chloride also was found to be a significant inhibitor of human sex steroid hormone metabolism by interacting with critical cysteine residues of the enzymes (Lo et al. 2003). McVey and Cooke (2003) examined the effects of organotins on the activity of 3β-hydroxysteroid dehydrogenase (3β-HSD), 17-hydroxylase (17-OHase), and 17β-hydroxysteroid dehydrogenase (17β-HSD), enzymes that catalyze steps in the synthesis of steroids. In microsomes from rat testes, tributyltin chloride inhibited 17-OHase and 3β-HSD, whereas monoocytltin trichloride inhibited only 3β-HSD. 17β-HSD activity was unaffected by mono-, di-, or tributyltin, or mono-, di-, or trioctyltin. Triphenyltin chloride, tributyltin chloride, and dibutyltin dichloride suppressed testosterone production in Leydig cells in vitro from neonatal pig testes by a yet unknown mechanism (Nakajima et al. 2003).
3. HEALTH EFFECTS

3.7 CHILDREN’S SUSCEPTIBILITY

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Relevant animal and *in vitro* models are also discussed.

Children are not small adults. They differ from adults in their exposures and may differ in their susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.

Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less susceptible than adults to health effects, and the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical periods of structural and functional development during both prenatal and postnatal life and a particular structure or function will be most sensitive to disruption during its critical period(s). Damage may not be evident until a later stage of development. There are often differences in pharmacokinetics and metabolism between children and adults. For example, absorption may be different in neonates because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of their bodies as extracellular water and their brains and livers are proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth and development, levels of particular enzymes may be higher or lower than those of adults, and sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the child more or less susceptible also depends on whether the relevant enzymes are involved in activation of the parent compound to its toxic form or in detoxification. There may also be differences in excretion, particularly in newborns who all have a low glomerular filtration rate and have not developed efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).
3. HEALTH EFFECTS

Children and adults may differ in their capacity to repair damage from chemical insults. Children also have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly relevant to cancer.

Certain characteristics of the developing human may increase exposure or susceptibility, whereas others may decrease susceptibility to the same chemical. For example, although infants breathe more air per kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their alveoli being less developed, which results in a disproportionately smaller surface area for alveolar absorption (NRC 1993).

No studies were located that specifically addressed exposure to inorganic tin in children. Data in adults regarding exposure to inorganic tin are derived from occupational exposure settings (a nonrelevant exposure scenario for children) and from ingesting food items contaminated with tin. This has produced nausea, vomiting, and diarrhea (WHO 1980, 2003) and it is expected that children would experience the same types of effects if exposed to high amounts of inorganic tin in the same manner. In a small number of studies available, exposure of rodents to inorganic tin during gestation did not result in embryotoxicity or teratogenicity (FDA 1972; Theuer et al. 1971).

No specific information was found regarding exposure of children to organotins. The only information that involves exposure to children is that from a report by Wax and Dockstader (1995) indicating that all members of a family of five, including three children, complained of nausea, vomiting, headache, sore throat, burning nose, and wheezing 24 hours after a room in their home had been painted with a paint containing tributyltin oxide for mildew control.

Studies in animals indicate that tributyltins, dibutyltins, and dioctyltins are mainly immunotoxic, whereas trimethyltins and triethyltins are neurotoxic. No studies of immunotoxicity in humans exposed to organotins have been conducted. A study in rats observed that the immunological effects produced by dibutyltin dichloride were more pronounced in rats exposed in the developmental phase of the lymphoid system (Seinen et al. 1977b). The neurotoxic effects of trimethyltin, triethyltin, and triphenyltin observed in experimental animals have been observed in adult humans accidentally exposed to these substances (Colosio et al. 1991; Feldman et al. 1993; Fortemps et al. 1978; Lin et al. 1998; Ross et al. 1981; Wu et al. 1990; Yanofsky et al. 1991) and it is reasonable to assume that similar types of effects would occur in children acutely exposed to high amounts of these substances. Studies with trimethyltin in rats showed that the development of lesions in the developing hippocampus is age-dependent and the most vulnerable
age period is between Pnds 9 and 15 (Chang 1984a, 1984b). Organotins are also known to be skin and eye irritants in adult humans (Goh 1985; Lyle 1958; Sheldon 1975) and similar effects would be expected in exposed children.

There are no developmental studies of organotins in humans. However, studies in animals have shown that triphenyltin, dibutyltin, and tributyltin administered to rodents during pregnancy induce adverse developmental effects and that the severity of the effects depends of the specific day(s) of gestation when treatment occurs (Baroncelli et al. 1995; Ema et al. 1991a, 1991b, 1992, 1995b, 1997b; Faqi et al. 1997; Farr et al. 2001; Harazono et al. 1998; Noda et al. 1991a, 1991b). The most commonly seen malformations are facial malformations, particularly cleft plate. These studies also showed that organotins can induce adverse reproductive effects such as pre- and postimplantation losses, resorptions, and fetal deaths. One key issue not yet resolved is whether these effects occur secondary to maternal toxicity or can occur in the absence of maternal toxicity.

Perinatal administration of organotins can cause neurodevelopmental (neurochemical and behavioral) effects in animals, which vary with the age at treatment and can persist until adulthood. This has been studied mostly with triethyltin and trimethyltin with the chemicals administered parenterally (Barone 1993; Barone et al. 1995; Freeman et al. 1994; Miller and O’Callaghan 1984; O’Callaghan and Miller 1988a; Reiter et al. 1981; Stanton 1991; Stanton et al. 1991).

There is no information regarding the pharmacokinetics of tin and tin compounds in children. Studies in animals have shown that both inorganic tin (Theuer et al. 1971) and organotin compounds (Nakamura et al. 1993; Noda et al. 1994) can cross the placenta and reach the developing organism. There are no data on tin and tin compounds in human breast milk and no animal studies that have conclusively demonstrated transfer of tin and tin compounds to the offspring via maternal milk. Recently, Cooke et al. (2004) found negligible transfer of tributyltin and dibutyltin from rats dosed during lactation with up to 2.5 mg tributyltin/kg/day to the pups via the milk.

In two multi-generation studies in rats, exposure to tributyltin chloride induced slight alterations in developmental landmarks in male and female animals, suggesting the possibility that this substance possesses endocrine modulatory properties in mammals (Ogata et al. 2001; Omura et al. 2001). However, no comprehensive testing has been done with tributyltin or other organotins in laboratory mammals. Tests in vitro indicate that organotins can affect the activities of enzymes involved in the synthesis of
male and female sex hormones, which could affect the balance of androgens and estrogens in the body of developing mammals (Cooke 2002; Doering et al. 2002; Heidrich et al. 2001; McVey and Cooke 2003).

### 3.8 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).

Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers as tools of exposure in the general population is very limited. A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in readily obtainable body fluid(s) or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures from more than one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to tin and tin compounds are discussed in Section 3.8.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that, depending on magnitude, can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by tin and tin compounds are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.10 “Populations that are Unusually Susceptible.”

3.8.1 Biomarkers Used to Identify or Quantify Exposure to Tin and Tin Compounds

Absorbed inorganic tin distributes to soft tissues and bone (see Sections 3.4.2.2 and 3.4.2.4). Elimination of inorganic tin from blood and other soft tissues is relatively rapid (half-time, 1–3 days in monkeys); therefore, acute exposure may be detectable as an elevation in blood tin levels only for a few days (see Section 3.4.4.4). Blood measurements may be suitable for detecting exposures of intermediate or chronic duration. Models that would support quantitative estimates of exposure, based on blood tin levels, have not been developed. Inorganic tin is retained in bone for much longer periods (half-time, 2–3 months in monkeys); however, noninvasive methods for measuring elevations in bone tin levels are not available. Absorbed inorganic tin is excreted primarily in urine (see Section 3.4.4.4); therefore, measurements of urinary tin may allow detection of long-term exposures to tin; however, models for translating this information into quantitative estimates of exposure have not been developed.

Detection of exposures to specific organotin compounds requires measurements of the specific compound (and metabolites). Organic tin compounds (alkyltin compounds) appear to be eliminated relatively rapidly from blood and other soft tissues (half-times, 2–15 days in rats); therefore, detection of exposure from measurements of alkyltin compounds in blood would require measurements made within a few days of an acute exposure (see Section 3.4.4.4). Models for estimating exposure levels from blood measurements have not been developed. Since absorbed alkyltin compounds are excreted in urine, urinary measurements may provide a means for detecting exposures. Methods for determining tin and tin compounds in biological materials are discussed in Section 7.1.

3.8.2 Biomarkers Used to Characterize Effects Caused by Tin and Tin Compounds

There are no specific biomarkers of effects for inorganic tin compounds. Certain organotin compounds do produce more specific effects than inorganic tin compounds. For example, studies in animals have shown that trimethyltin and triethyltin are primarily neurotoxic and affect specific areas or morphological substrates in the central nervous system (Aschner and Aschner 1992; Chang 1990). The structural
alterations observed in the brain from intoxicated animals (hippocampal lesions, intramyelinic edema) have also been observed in humans acutely exposed to high amounts of trimethyltin and triethyltin (Feldman et al. 1993; Foncin and Gruner 1979; Kreyberg et al. 1992; Yanofsky et al. 1991). Certain behavioral alterations seen in intoxicated animals, such as memory deficits and aggressive behavior, also have been observed in humans acutely exposed to high amounts of trimethyltin. While the neurological effects induced by these substances cannot be considered specific biomarkers of exposure for this group of chemicals, their manifestation can direct trained professionals to investigate potential exposure. Studies with other organotins, such as tributyltin, dibutyltin, and dioctyltin, in animals have reported effects on the bile duct and liver, immune system (thymus and lymphoid organs), kidneys, and blood, but these effects are not specific for organotin compounds.

3.9 INTERACTIONS WITH OTHER CHEMICALS

Tin is an element that affects the metabolism of various essential minerals such as zinc, copper, and iron by mechanisms not totally elucidated, but that may involve effects on absorption and retention. For example, Yamaguchi et al. (1979) reported that the increase in serum calcium concentration that occurred in rats following administration of a single oral dose of calcium chloride was significantly inhibited by previous administration of tin as stannous chloride (30 mg/kg every 12 hours for 3 days). Since calcium in the duodenal mucosa was reduced and the activity of alkaline phosphatase was also reduced in the mucosa, Yamaguchi et al. (1979) suggested that tin inhibited the duodenal active transport of calcium. In a study in volunteers, consumption of a diet that provided approximately 5 times more tin (0.65 mg Sn/kg/day) than a control diet (0.14 mg Sn/kg/day) for 20 days had no significant effect on fecal losses, urinary losses, apparent retention, and serum levels of calcium (Johnson and Greger 1982).

Administration of tin (as stannous chloride) in the diet (200 ppm for 21 days) to rats resulted in reduced concentration of zinc in the tibias, reduced retention of zinc in the kidneys, and increased amounts of zinc in the feces (Greger and Johnson 1981). In addition, the copper content of the kidneys and liver of the animals fed the diet with added tin was significantly lower than in rats fed a control diet. Also in the Greger and Johnson (1981) study, tin had no effect on the retention of iron in the kidneys or in fecal losses of iron, but the concentration of iron in the livers from treated rats was significantly higher than in livers from control rats. The effect on zinc appeared to be, at least in part, due to reduced absorption of zinc since food intake was not depressed in the treated rats. In contrast, the effect of tin on copper status seemed to be caused by a different mechanism based on the fact that the tin diet did not increase fecal excretion of copper. Greger and Johnson (1981) suggested that the increase in liver iron could indicate an
improvement in the iron nutritional status of the rats or impairment in the rat’s abilities to mobilize iron from the liver. They further hypothesized that the effect of tin on iron metabolism may have been a reflection of the effect of tin on copper metabolism because ceruloplasmin, a copper metalloenzyme, is one enzyme involved in mobilization of iron from the liver. In a subsequent study, the same group of investigators showed that feeding rats diets containing >500 ppm tin reduced plasma copper levels to 13% of those in control rats and also depressed copper levels in kidneys and liver (Johnson and Greger 1985). Similar results regarding the effects of tin on copper and zinc metabolism were reported by Rader et al. (1990). The results of these studies are consistent with the findings of De Groot (1973), who observed that supplementation of a high-tin diet with copper and iron could reduce signs of anemia in rats, but could not correct the reduced growth, and reduced growth is a common symptom of zinc deficiency (Rader et al. 1990). Tin was also found to interact with zinc metabolism in humans; individuals fed diets with excess tin lost significantly more zinc in their feces and less zinc in the urine than those fed a control diet (Johnson et al. 1982).

In a study in rats, Noda et al. (1994) examined the effect of pretreatment of pregnant animals with carbon tetrachloride on the teratogenic activity of dibutyltin dichloride. Pregnant rats were treated subcutaneously with carbon tetrachloride on Gds 6 and 7 and orally with various dose levels of dibutyltin dichloride on Gd 8; sacrifices were conducted on Gd 20. Pretreatment with carbon tetrachloride significantly increased the incidence of external and skeletal malformations caused by the organotin alone. Moreover, pretreatment with carbon tetrachloride increased the concentration of dibutyltin in embryos, maternal liver, and blood. Carbon tetrachloride caused maternal hepatotoxicity (increased serum transaminases) and decreased the activity of hepatic microsomal drug-metabolizing enzymes, suggesting that dibutyltin itself (and not a metabolite) was teratogenic.

Makita et al. (2003, 2004) studied the effects of the simultaneous administration of tributyltin chloride and \( p,p' \)-DDE on developmental end points in rats. Rats were treated orally with tributyltin chloride/kg/day alone (2 mg/kg/day) or tributyltin chloride plus \( p,p' \)-DDE (10 mg/kg/day) during gestation and lactation. Developmental parameters examined in the pups at various times up to 6 weeks of age included gender and gross malformations, body and sex organ weights, anogenital distance, eye opening, nipple retention (in males), vaginal opening, vaginal opening, preputial separation, and serum testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Tributyltin significantly depressed growth rate of the pups from Pnd 7 to 28, but simultaneous administration of \( p,p' \)-DDE prevented this effect. Sex organs’ weights were not affected by tributyltin, except for prostate weight which was decreased, but this decrease also was prevented by administration of \( p,p' \)-DDE. Ovary weight
was increased in the combination group relative to the tributyltin alone group. Serum testosterone was not affected in any group and serum LH was reduced in the tributyltin group, but not in the combination group. Tributyltin did not affect anogenital distance, nipple retention, or vaginal opening, but delayed eye opening (not observed in the combination group). The mechanism of interaction between tributyltin and \( p,p' \)-DDE is unknown.

3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

A susceptible population will exhibit a different or enhanced response to tin and tin compounds than will most persons exposed to the same level of tin and tin compounds in the environment. Reasons may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters result in reduced detoxification or excretion of tin and tin compounds, or compromised function of organs affected by tin and tin compounds. Populations who are at greater risk due to their unusually high exposure to tin and tin compounds are discussed in Section 6.7, Populations with Potentially High Exposures.

There are no specific populations that have been identified as being unusually susceptible to inorganic tin compounds with respect to health effects. However, studies in animals and humans indicate that inorganic tin affects the metabolism of various essential trace elements. For example, levels of dietary tin much higher than those in normal diets reduce zinc absorption, which reduces growth, and reduces plasma copper levels, and may lead to anemia. Therefore, children or adults who consume diets already poor in these minerals may be at higher risk of developing signs of lack of zinc or copper if their dietary tin is excessive (as in a canned-food-based diet). However, it is important to note that >90% of tin-lined cans used for food today are lacquered.

No population has been identified that is unusually susceptible to the effects of exposure to organotin compounds.

3.11 METHODS FOR REDUCING TOXIC EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to tin and tin compounds. However, because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to tin and tin compounds. When specific exposures have occurred, poison control centers and medical
toxicologists should be consulted for medical advice. No texts were found that provided specific information about treatment following exposures to tin and tin compounds.

Human exposure to tin may occur by inhalation, ingestion, or dermal contact (see Chapter 6). Gastrointestinal effects have been observed following ingestion of inorganic tin compounds and inhalation, ingestion or dermal exposure to some organotin compounds may cause neurological effects (see Section 3.2). Inorganic tin salts and organotins are reported to be skin and eye irritants (WHO 1980). The information below has been extracted from HSDB (2003).

### 3.11.1 Reducing Peak Absorption Following Exposure

Usually, it is unnecessary to induce emesis in cases of ingestion of inorganic tin compounds, and induced emesis may be dangerous in patients who have ingested caustic tin compounds such as stannic chloride. Emesis is contraindicated following ingestion of trimethyltin. Immediate dilution with 4–8 ounces of milk or water is recommended after oral exposure, as well as administration of activated charcoal slurry (240 mL water/30 g charcoal). Following inhalation exposure, the patient should be moved to fresh air. In cases of dermal exposure, contaminated clothing should be removed and the exposed area should be washed thoroughly with soap and water. Irrigation with copious amounts of tepid water (or preferably a physiologically-balanced eye wash solution) for at least 15 minutes is recommended in cases of eye exposure. Gastric lavage can be considered after ingestion of a potentially life-threatening amount of a tin compound if it can be performed soon after ingestion (generally within 1 hour). Caution should be used to protect the airway by placement in Trendelburg and left lateral decubitus position or by endotracheal intubation.

### 3.11.2 Reducing Body Burden

No specific information was located to reduce the body burden of tin and compounds following exposure.

### 3.11.3 Interfering with the Mechanism of Action for Toxic Effects

Information summarized in HSDB (2003) describes standard measures to support vital functions following exposure. There are specific measures to interfere with the mechanism of toxicity of tin and compounds. Because the toxicity of dialkyltins is related to reactions with biological dithiol groups, BAL
(2,3-dimercaptopropanol) has been suggested as an antidote, based on studies in animals, but it was not effective against trialkyltins or tetraalkyltins. DMPS (2,3-dimercaptopropane-1-sulfonic acid) and DMSA (meso-2,3-dimercaptosuccinic acid) were effective in reducing the bile duct, pancreas, and liver lesions in rats, but were less effective against thymus atrophy (Merkord et al. 2000).

3.12 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of tin and tin compounds is available. Where adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of tin and tin compounds.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

3.12.1 Existing Information on Health Effects of Tin and Tin Compounds

The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to tin and tin compounds are summarized in Figures 3-11 and 3-12. The purpose of this figure is to illustrate the existing information concerning the health effects of tin and tin compounds. Each dot in the figure indicates that one or more studies provide information associated with that particular effect. The dot does not necessarily imply anything about the quality of the study or studies, nor should missing information in this figure be interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.
Figure 3-11. Existing Information on Health Effects of Inorganic Tin Compounds

- **Human**
  - Inhalation
  - Oral
  - Dermal

- **Animal**
  - Inhalation
  - Oral
  - Dermal

- **Systemic**
  - Death
  - Acute
  - Intermediate
  - Chronic
  - Immunologic/Lymphoretic
  - Neurologic
  - Reproductive
  - Developmental
  - Genotoxic
  - Cancer

○ Existing Studies
Figure 3-12. Existing Information on Health Effects of Organotin Compounds

- **Human**
  - Inhalation: Death (Intermediate, Chronic), Immunologic/Lymphoretic, Neurologic, Reproductive, Developmental, Genotoxic, Cancer
  - Oral: Death (Intermediate, Chronic), Neurologic, Reproductive, Developmental, Genotoxic, Cancer
  - Dermal: Death (Intermediate, Chronic), Immunologic/Lymphoretic, Neurologic, Reproductive, Developmental, Genotoxic, Cancer

- **Animal**
  - Inhalation: Death (Intermediate, Chronic), Immunologic/Lymphoretic, Neurologic, Reproductive, Developmental, Genotoxic, Cancer
  - Oral: Death (Intermediate, Chronic), Neurologic, Reproductive, Developmental, Genotoxic, Cancer
  - Dermal: Death (Intermediate, Chronic), Immunologic/Lymphoretic, Neurologic, Reproductive, Developmental, Genotoxic, Cancer

- ● Existing Studies

TIN AND TIN COMPOUNDS

3. HEALTH EFFECTS
Figure 3-11 provides the information for inorganic tin compounds. There are case reports that describe acute and chronic effects of inhaled inorganic tin compounds on humans. There are also reports of humans that developed health effects after oral exposure to food and drink from tin cans. No other studies were located regarding health effects in humans after inhalation, oral, or dermal routes of exposure. The most relevant route of exposure to inorganic tin for humans is the oral route.

The health effects of inorganic tin compounds have been chiefly studied in animals after oral exposure, as shown in Figure 3-11. The figure also shows that no inhalation studies and only a few dermal studies were located regarding health effects from inorganic tin compounds.

Figure 3-12 provides health effects information on humans and animals after exposure to organotin compounds. The database for these compounds as a class is much more complete than for the inorganic tin compounds. There are case reports that describe deaths and other effects associated with inhalation, oral, and dermal routes of exposure. In addition to acute-duration inhalation studies and acute and intermediate dermal studies, there are reports of neurobehavioral effects in humans after inhalation, oral, and dermal exposures. The main route of exposure to organotins for humans is the oral route.

The extent of the database on health effects in animals resulting from exposure to organotin compounds is shown in Figure 3-12. Except for genotoxic studies, there are oral studies that describe all the other toxicological end points considered in this profile. By contrast, the information is more limited for the inhalation and dermal routes of exposure.

3.12.2 Identification of Data Needs

Acute-Duration Exposure. There are no data in humans following acute inhalation exposure to inorganic tin and the data in animals are limited mostly to death (Igarashi 1959; Schweinfurth and Gunzel 1987). Therefore, an acute-duration inhalation MRL was not derived for inorganic tin. For organic tin compounds, limited acute inhalation data exist for death in humans (Rey et al. 1984) and in animals (Igarashi 1959; Schweinfurth and Gunzel 1987), systemic effects in humans (Rey et al. 1984; Saary and House 2002; Wax and Dockstader 1995) and in animals (Igarashi 1959), and neurological effects in humans (Feldman et al. 1993; Rey et al. 1984; Ross et al. 1981; Saary and House 2002; Yanofsky et al. 1991). The information provided in these studies is inadequate for derivation of acute-duration inhalation MRLs for inorganic tin or organotins largely because of lack of quantitative data. Oral exposure is the main route of exposure to inorganic tin for humans. The available acute oral data for inorganic tin
provide information on lethality in animals (NTP 1982), on reproductive/developmental effects in rodents (FDA 1972), and on systemic effects in humans (Boogaard et al. 2003; WHO 1980, 2003). In the case of organotins, data exist for lethality in humans (Kreyberg et al. 1992; WHO 1980) and in animals (WHO 1980), systemic effects in humans (Lin and Hsueh 1993; Lin et al. 1998; WHO 1980; Wu et al. 1990) and in animals (Barnes and Magee 1958; Pelikan and Cerny 1970; Raffray and Cohen 1993; Funahashi et al. 1980; Seinen et al. 1977a; Takagi et al. 1992; Ueno et al. 1994, 1995, 1997, 2003a, 2003b), immunological effects in animals (Seinen et al. 1977a; Smialowicz et al. 1989, 1990; Snoeij et al. 1985), neurological effects in humans (Kreyberg et al. 1992; Lin et al. 1998; WHO 1980; Wu et al. 1990) and in animals (Baroncelli et al. 1990, 1995; Brown et al. 1984; Chang and Dyer 1983; Chang et al. 1983; Davis et al. 1987; Ema et al. 1991a; Magee et al. 1957; Squibb et al. 1980), and reproductive and developmental effects in animals (Ema and Harazono 2000; Ema et al. 1991b, 1992, 1997b, 1999b, 1999c, 2003; Farr et al. 2001; Harazono and Ema 2003; Noda et al. 1991a, 1992b). Again, the data for inorganic tin were insufficient for derivation of an acute oral MRL. The data for organotins were either insufficient or inadequate in that no NOAELs were available and most LOAELs were serious LOAELs, thus precluding derivation of acute oral MRLs. Acute dermal data were limited to a lethal human case (NIOSH 1976) and several reports in animals (Smith 1978) exposed to organotins, information on hepatic effects in humans (Colosio et al. 1991), and dermal and ocular effects in humans and animals (Barnes and Stoner 1958; Goh 1985; Klimmer 1969; Lyle 1958; Sheldon 1975). Excessive acute exposure to inorganic tin is unlikely to occur unless there is consumption of unusually high amounts of canned foods in a short period of time. Further acute studies with inorganic tin are unlikely to provide new key information. The decision to expand the database for acute exposure to some organotin compounds should be based on the results of a case-by-case evaluation of the likelihood of potential exposure to high concentrations of these substances for people living near waste sites. It is unlikely that the general population will be acutely exposed to high amounts of organotins.

Intermediate-Duration Exposure. There are currently no data concerning the effects of inorganic tin or organotin compounds on humans for this exposure duration for the inhalation, oral, or dermal routes of exposure. No data were available regarding effects in animals after intermediate-duration exposure to inorganic tin by the inhalation route. Studies of inorganic tin in rodents, primarily rats and mice, treated orally demonstrated effects in the gastrointestinal tract, the blood, the kidney, the liver, and bile ducts (Chmielnicka et al. 1993; De Groot et al. 1973; Dreef-van der Meulen et al. 1974; Janssen et al. 1985; NTP 1982; Schroeder et al. 1968). Very limited information was located regarding reproductive and developmental effects of inorganic tin compounds in animals (Theuer et al. 1971). The study by De Groot et al. (1973) with stannous chloride was used to derive an intermediate-duration oral MRL for
3. HEALTH EFFECTS

inorganic tin. Few studies were located that tested organotin compounds by the inhalation route in animals. These studies provided some information on respiratory, hepatic, renal, and reproductive effects but lacked enough detail to be considered for MRL derivation (Gohlke et al. 1969; Igarashi 1959; Iwamoto 1960). Intermediate-duration oral exposure studies with organotins provide information on lethality in various species (Magee et al. 1957; NCI 1978b; Seinen et al. 1977b) and on a variety of end points (hematological, body weight, endocrine, hepatic, renal, immunological, neurological, reproductive, and developmental in rodents (Adeeko et al. 2003; Barnes and Magee 1958; Bouldin et al. 1981; Bressa et al. 1991; Carthew et al. 1992; Cooke et al. 2004; Dacasto et al. 1994a; Funahashi et al. 1990; Gaunt et al. 1968; Graham and Gonatas 1973; Jang et al. 1986; Krajnc et al. 1984; Noland et al. 1982; Ogata et al. 2001; Omura et al. 2001; Purves et al. 1991; Seinen and Willems 1976; Seinen et al. 1977a, 1977b; Smith 1973; Snoeij et al. 1985; Tryphonas et al. 2004; Verdier et al. 1991; Vos et al. 1990). Most of these studies tested dibutyltin, diocetyltn, tributyltin, triethyltin, trimethyltin, and/or triphenyltin. Adequate information was available for derivation of an intermediate-duration oral MRL for dibutyltin dichloride based on altered humoral immune responses in rats (Seinen et al. 1977b) and for tributyltin oxide, also based on immunotoxicity (Vos et al. 1990). Information regarding effects following intermediate-duration dermal exposure was restricted to a study by Sheldon (1975), who described skin alterations in rabbits during a 90-day exposure period. Oral exposure is the main route of exposure to inorganic tin for humans; therefore, inhalation and dermal exposure studies seem unnecessary. Also, further oral studies are unlikely to provide new information. The effects of some organotins (i.e., trimethyltin, triethyltin, tributyltin, dibutyltin) are well characterized. Still, the information available for trimethyltin and triethyltin was inadequate for MRL derivation, largely because of the steepness of the dose-response curve for these compounds. The decision to conduct additional intermediate-duration studies designed to define NOAELs should rest on results of monitoring studies for these compounds in the environment and on the identification of populations potentially exposed to them.

Chronic-Duration Exposure and Cancer. Data on chronic exposure to inorganic tin were limited to cases of occupational exposures in which the main effects were respiratory effects (Cutter et al. 1949; Dundon and Hughes 1950; Pendergrass and Pryde 1948; Stewart and Lassiter 2001). Inhalation is assumed to have been the main route of exposure in these cases. Affected individuals showed a benign form of pneumoconiosis, or stannosis. Information regarding health effects in animals following chronic-duration exposure to inorganic tin is restricted to a 2-year oral bioassay in rats and mice (NTP 1982), a 42-month oral study in rats (Schroeder et al. 1968), and an 18-month oral study in mice (Schroeder and Balassa 1967), all with stannous chloride. While there were no compound-related nonneoplastic effects in the NTP (1982) study in rats and mice, Schroeder et al. (1968) described hepatic and renal effects as
well as decreased longevity in rats exposed to doses approximately 100 times lower than those tested by NTP (1982). There is no apparent explanation for this discrepancy except that the NTP (1982) study was a dietary study, while Schroeder et al. (1968) administered the compound in the drinking water. Studies comparing the bioavailability of tin in solid food vs. water may provide useful information. No chronic oral MRL was derived for inorganic tin because the lowest dose from Schroeder et al. (1968) was a serious LOAEL. The need to conduct inhalation and dermal chronic-duration studies with inorganic tin is less clear since the main route of exposure for humans to inorganic tin is the oral route. No data were located regarding health effects in humans following chronic exposure to organotin compounds. Long-term bioassays have been conducted for dibutyltin diacetate in rats and mice (NCI 1978a), triphenyltin hydroxide in rats and mice (NCI 1978b; Tennekes et al. 1989a, 1989b), and tributyltin oxide in rats (Wester et al. 1990). In addition, an 18-month study of the immunotoxicity of tributyltin oxide in rats is available and was used as basis for deriving a chronic-duration oral MRL for tributyltin oxide (Vos et al. 1990). No chronic oral MRL was derived for dibutyltin because a relative low dose in the NCI (1978a) study caused significant early mortality in rats. For the same reason, no chronic oral MRL was derived for triphenyltin (Tennekes et al. 1989b). Research to produce chronic oral data for other organotins that may be present in hazardous waste sites and represent a potential source of exposure for those living in the vicinity may be warranted. However, a comprehensive evaluation of 90-day studies should be conducted first. Environmental monitoring information suggests that the inhalation and dermal routes of exposure to organotins are much less relevant to humans than the oral route and, therefore, may be given lower priority.

There is no information regarding cancer in humans exposed to inorganic tin or organic tin compounds. An oral bioassay for stannous chloride in rats and mice provided no evidence of carcinogenicity at the levels tested (NTP 1982). Similar negative results were found for dibutyltin diacetate in rats and mice, although technical problems did not allow for a complete evaluation of uterine tumors in female rats (NCI 1978a). A bioassay for triphenyltin hydroxide in rats and mice also gave negative results (NCI 1978b), but studies with higher doses did find triphenyltin hydroxide to induce pituitary and testicular tumors in rats (Tennekes et al. 1989b) and hepatocellular carcinomas in mice (Tennekes et al. 1989a). A bioassay with tributyltin oxide in rats yielded questionable results (Wester et al. 1990), which led the EPA (IRIS 2005) to assign this chemical to a group for which “there is inadequate information to assess carcinogenic potential.” Since the observed tumors were considered to have high incidence in the strain of rat used (Wistar), it may be necessary to repeat the study in a different strain of rat. An oral bioassay seems more relevant than inhalation or dermal studies since these two routes of exposure are less relevant for humans. Further studies concerning the fates of the organic and tin moieties from these compounds and the
contribution of each moiety to mechanisms of carcinogenicity are needed in order to evaluate the role of tin in the tumorigenic response.

Genotoxicity. There are no human data regarding the genotoxic potential of inorganic tin or organotin compounds after inhalation, oral, or dermal exposures. The limited in vitro data for inorganic tin consist mostly of studies with stannous chloride and stannic chloride. The results in prokaryotic organisms have been mostly negative (Hamasaki et al. 1993; Nishioka 1975), but the opposite has been observed in tests conducted with mammalian cells (Dantas et al. 2002; Ganguly et al. 1992; Gulati et al. 1989). Further studies are unlikely to add new key information. Tests of many organotin compounds in *S. typhimurium* gave predominantly negative results (Hamasaki et al. 1993) and tests conducted in mammalian cells in vitro also gave predominantly negative results (Chao et al. 1999; Davis et al. 1987; Oshiro et al. 1991; Sasaki et al. 1993). Studies of organotin compounds in vivo, mostly in mice, have given mixed results (Chao et al. 1999; Davis et al. 1987; Ganguly 1994; Yamada and Sasaki 1993). Further genotoxicity studies with organotin compounds do not seem warranted at this time.

Reproductive Toxicity. No studies were located regarding reproductive effects of inorganic tin in humans following inhalation, oral, or dermal exposure or in animals following inhalation or dermal exposure. The only information available regarding oral exposure of animals to inorganic tin is that from Theuer et al. (1971), FDA (1972), and De Groot et al. (1973). FDA (1972) reported no reproductive effects (number of corpora lutea and of implantation and resorption sites) in rats, mice, and hamsters administered up to 0.31 mg tin/kg/day (as stannous chloride) during gestation (Gds 6–15 for rats and mice, Gds 6–10 for hamsters) (FDA 1972). Theuer et al. (1971) reported that administration of tin, as tin fluoride or sodium pentachlorostannite, to rats in the diet during gestation had no significant effect on the number of resorptions or placental weight. De Groot et al. (1973) observed moderate testicular degeneration in rats dosed for 9 weeks with approximately 315 mg tin/kg/day. Most rats in this group were moribund and had to be sacrificed; therefore, the biological significance of the testicular finding is unclear. The limited data available suggest that the reproductive system is not a target for inorganic tin toxicity at the levels commonly found in the environment. No data were available regarding reproductive effects in humans following exposure to organotin compounds by any route or in animals after dermal exposure. Reduced fertility was reported in female rats following inhalation exposure to a mixture of tributyltin bromide and dibutyltin dibromide for periods ranging from a few weeks to a few months (Iwamoto 1960). Numerous studies in rodents have examined the effects of organotins (mostly dibutyltin, tributyltin, and triphenyltin) on reproductive parameters such as pregnancy rates, pre- and postimplantation loss, and fetal deaths following dosing during pregnancy (Adeeko et al. 2003; Ema and
Harazono 2000; Ema et al. 1991b, 1992, 1999c; Faqi et al. 1997; Harazono et al. 1998; Noda et al. 1991a, 1992b) and found that the highest incidence of resorptions and postimplantation losses occurred when the chemicals were administered on Gds 7–9 (Ema et al. 1992, 1997a, 1999a). Most long-term studies have not reported histopathological alterations in reproductive organs from rats or mice (NCI 1978a, 1978b; Wester et al. 1990) with the exception of Tennekes et al. (1989b), who reported an increase in Leydig cell hyperplasia and tubular atrophy of the testes in rats treated with triphenyltin. The mechanism by which some organotins affect reproduction is not known, but there is evidence that suppression of uterine decidualization may be a cause of preimplantation losses (Ema and Miyawaki 2002; Ema et al. 1999b; Harazono and Ema 2003). It would be helpful to elucidate whether effects such as pre- and postimplantation loss occur secondary to maternal toxicity or can happen independent of maternal toxicity. Since direct effects on reproductive organs do not seem to have an important role (except for the findings of Tennekes et al. 1989b), further research should focus on the effects of organotins on the endocrine control of reproductive functions in adult animals and on the hormonally-controlled development of reproductive organs in animals exposed in utero and early in life. Numerous studies in vitro have shown that organotins can affect the activities of enzymes involved in the synthesis of steroid hormones, with potentially widespread consequences (i.e., Cooke 2002; Doering et al. 2002; Heidrich et al. 2001; McVey and Cooke 2003). Additional tests to evaluate the potential endocrine disrupting ability of organotins in mammals should be conducted. Pilot studies in primates would be valuable to reduce the uncertainty of extrapolating observations in animals to human health.

Developmental Toxicity. No studies were located regarding developmental effects of inorganic tin in humans following inhalation, oral, or dermal exposure, or in animals following inhalation or dermal exposure. Limited oral data on inorganic tin showed that treatment of rats, mice, and hamsters with up to 31 mg tin/kg/day by gavage in water during gestation (Gds 6–15 for mice and rats, Gds 6–10 for hamsters) has no significant effect on fetal weight, the number of live of dead fetuses, or the incidence of external and internal malformations (FDA 1972). Also, tin, in the form of tin fluoride or sodium pentachlorostannite, administered to rats during pregnancy had no significant effect on average fetal weight or the number of live fetuses per litter (Theuer et al. 1971). This study also showed that tin from inorganic compounds can cross the placenta and reach the fetus. There are no studies of developmental effects in humans following inhalation, oral, or dermal exposure to organotins. Several studies in animals, mostly rats and mice, have shown that oral exposure to some organotin compounds (mostly tributyltin, dibutyltin, and triphenyltin) during pregnancy induces external and skeletal malformations, the most common of which were cleft jaw and ankyloglossia (Ema and Harazono 2000; Ema et al. 1991b, 1992; Faqi et al. 1997; Harazono et al. 1998; Noda et al. 1991a, 1992b) and found that the highest
3. HEALTH EFFECTS

incidence of malformations occurred when the chemicals were administered on Gds 7–9 (Ema et al. 1992). Limited data in rats indicate that dibutyltin can cross the placenta and reach the embryo (Nakamura et al. 1993; Noda et al. 1994). A study in rats that included maternal exposure to tributyltin chloride during lactation showed that little, if any, tributyltin or dibutyltin is transferred to the suckling pups via the maternal milk (Cooke et al. 2004). A companion paper reported subtle alterations in immunological parameters in pups from rats that were exposed during pregnancy during lactation, and then the pups were exposed directly until 90 days of age (Tryphonas et al. 2004). As with reproductive effects, the role of maternal toxicity in the manifestation of adverse developmental effects is not totally clear. The mechanism responsible for the teratogenic activity of organotins is not known and studies should continue to investigate the events at the molecular level that may be affected. The use of in vitro systems (i.e., cultured rat embryos) may be preferable to studies in the whole animal, as the experimental conditions in the former are easier to manipulate than in the latter. Two studies in rats exposed to tributyltin chloride suggested that perinatal exposure can affect some developmental landmarks (Ogata et al. 2001; Omura et al. 2001). Whether this is a result of endocrine disrupting ability of these compounds or from other mechanisms is important to know. Triethyltins and trimethyltins are neurotoxic to humans and animals and have been extensively used as tools to investigate the relationship between localized lesions within the central nervous system and behavioral alterations. Continued research in this area is important to determine susceptible developmental periods during which alterations of neuronal structures will cause long-lasting effects or accelerate specific aspects of the normal aging processes.

Immunotoxicity. There currently is no information available in humans or animals suggesting that the immune system is a major target of inorganic tin toxicity, or that the immune system is a target of organic tin toxicity in humans. However, there is considerable information on the immunotoxic effects of some organotins administered to animals orally or by injection, and from in vitro tests systems. Studies have compared various organotins for several animal species (Seinen et al. 1977a, 1977b; Snoeij et al. 1985). The immunotoxic effect is characterized by reduced thymus weight and size and lymphocyte depletion (Krajnc et al. 1984; Seinen and Willems 1976; Seinen et al. 1977a, 1977b; Smialowicz et al. 1989, 1990; Snoeij et al. 1985). While dialkyltins appear to interfere directly with the proliferation of lymphocytes, tributyltin oxide has a direct action on lymphocytes in the thymus (Boyer 1989). The results of a study that reported alterations in the humoral immune response in rats exposed orally to dibutyltin dichloride were used as basis for derivation of an intermediate-duration oral MRL for dibutyltin dichloride (Seinen et al. 1977b). Long-term studies with tributyltin oxide in rats showed alterations in parameters of specific and nonspecific resistance (Vos et al. 1990). The results from this study were used as the basis for derivation of an intermediate- and a chronic-duration oral MRL for tributyltin oxide. It is
reasonably to assume that similar effects would occur in animals exposed to sufficiently high amounts of organotins by the inhalation and dermal routes. Future research should continue to focus on determining the basis for interspecies differences including pharmacokinetic differences, and differences at the cellular and molecular levels. It would be valuable to determine whether primates exhibit responses similar to rodents and if so, whether subtle alterations in immune parameters alter resistance to challenges with pathogens. A recent study evaluated immunocompetence in rats exposed during gestation and as juveniles and found subtle alterations of unknown toxicological significance (Tryphonas et al. 2004). Replication of these findings would be valuable.

**Neurotoxicity.** There are no studies in humans regarding neurotoxic effects after inhalation, oral, or dermal exposure to inorganic tin compounds. Limited animal data suggest that oral exposures to high concentrations of inorganic tins may induce effects on the central nervous system (WHO 1980), but the nervous system is not a sensitive target for inorganic tin toxicity.

Neurotoxic effects have been reported in humans after inhalation (Feldman et al. 1993; Rey et al. 1984; Ross et al. 1981; Saary and House 2002; Yanofsky et al. 1991), oral (Foncin and Gruner 1979; Kreyberg et al. 1992; Lin et al. 1998; Wu et al. 1990), and dermal (Colosio et al. 1991) exposure to organotins and in animals after oral exposure (i.e., Bouldin et al. 1981; Brown et al. 1984; Eto et al. 1971; Graham and Gonatas 1973; Magee et al. 1957; Snoeij et al. 1985; Squibb et al. 1980) to these compounds. Among the organotins, trimethyltin and triethyltin have been the most widely studied in acute- and intermediate-duration oral studies. These organotins are highly toxic and their effects are well characterized and are expected to occur across routes of exposure. Trimethyltin induces neuronal necrosis, particularly in the hippocampal region, whereas triethyltin produces intramyelinic edema (Chang 1990). Case studies of humans acutely exposed (accidentally or intentionally) to high amounts of trimethyltin or triethyltin and studies in animals reported morphological changes in the central nervous system as well as behavioral changes that may persist for a long time after the poisoning episode. One typical manifestation of trimethyltin intoxication in both humans and animals is aggressive behavior. Both trimethyltin and triethyltin have become important research tools for the study of brain function, in particular, to examine the association between damage to specific brain structures, such as the hippocampus or brain cell groups and behavioral alterations. Additional studies using nerve cells in vitro can provide more information on possible mechanisms of action of these organotins at the cellular and molecular levels. Also, studies on the effects of tin compounds on glial function, both during neurodevelopment and adulthood, would be useful. Studies of the potential effects of long-term exposure to low levels of trimethyltin or triethyltin, as it may occur near a waste site that contains these substances, may provide valuable information.
Epidemiological and Human Dosimetry Studies. The general population is exposed to inorganic tin compounds through consumption of contaminated food, in industrial settings, and potentially at hazardous waste sites through contact with contaminated air, water, and soil. Organotin compounds are also used in agricultural and other uses with potential exposure of people by different routes, although the main route of exposure is also the oral route. Only limited case reports of human exposure and no retrospective or prospective epidemiological studies are available. Occupational studies of inorganic tin exposure provide information mostly on respiratory effects in workers exposed chronically (Cutter et al. 1949; Dundon and Hughes 1950). In contrast, the neurotoxic effects of some organotins are well documented in workers and members of the general population exposed by all routes (Colosio et al. 1991; Feldman et al. 1993; Kreyberg et al. 1992; Lin et al. 1998; Rey et al. 1984; Ross et al. 1981; WHO 1980; Wu et al. 1990; Yanofsky et al. 1991). These cases have generally involved accidental or intentional exposure to high amounts of organotins. Should populations with past or ongoing exposure to organotins be identified, emphasis should be placed on the evaluation of organs and systems that have appeared to be particularly sensitive in animal studies. For example, evaluation of immunocompetence should have high priority in people exposed to tributyltin, dibutyltin, or dioctyltin, whereas neurobehavioral tests should be conducted in those known to have been exposed or are exposed to trimethyltin or triethyltin.

Biomarkers of Exposure and Effect.

Exposure. The development of models that would support quantitative estimates of exposure to tin and tin compounds based on blood or urine levels of tin, or a specific organotin or metabolite, would be valuable.

Effect. There are no biomarkers of effect specific for tin or tin compounds. Research to identify reliable biomarkers for exposure to tin and tin compounds in humans would be useful in order to evaluate the prevalence and magnitude of exposure in an at-risk population.

Absorption, Distribution, Metabolism, and Excretion. The toxicokinetics of tin compounds have not been adequately characterized to support the development of predictive PBPK models in humans (see Section 3.4). Existing models are based entirely on observations in animals (ICRP 2001). No quantitative estimates of absorption of inhaled inorganic or organotin compounds are available, for either humans or animals. Two balance studies of dietary exposures to inorganic tin provide estimates of
gastrointestinal absorption in humans that suggest considerable interindividual variability and, possibly, dose dependence (Calloway and McMullen 1966; Johnson and Greger 1982). Estimates of gastrointestinal absorption of organotin compounds in humans are not available. Studies in animals suggest that redox state (i.e., Sn[II] vs. Sn[IV]) (Hiles 1974) and number of alkyl moieties affect gastrointestinal absorption of tin compounds (Bridges et al. 1967; Kimmel et al. 1977; Mushak et al. 1982; Ohhira and Matsui 1993a; Ueno et al. 1994) thus, studies in humans that address these potential variables would be particularly useful. Information on the distribution of absorbed tin compounds in humans derives from analyses of human cadaver tissues (Kehoe et al. 1940; Schroeder et al. 1964). These studies, together with studies conducted in animals, suggest that the major sites of deposition of tin in humans appear to be similar to those in animals exposed to inorganic tin compounds; however, they provide no information on the distribution of specific inorganic or organotin compounds in humans. Quantitative estimates of the elimination rates of absorbed tin in humans are not available. Studies in animals indicate that elimination rates vary with chemical form and across species, for given tin compounds (Bridges et al. 1967; Brown 1984; Furchner and Drake 1976; Kimmel et al. 1977; Ueno et al. 1994).

Available information on the toxicokinetics in animals, while providing abundant information on the distribution and elimination kinetics of tin, do not provide adequate information for extrapolation of doses from one route of exposure to another (e.g., oral-to-dermal, oral-to-inhalation), for which health effects studies are lacking. The major information deficit, in this regard, is insufficient characterization of the extents and rates of absorption of tin from major potential routes of exposure (i.e., no information is available for the inhalation and dermal routes) and insufficient characterization of the effects of dose on gastrointestinal absorption.

**Comparative Toxicokinetics.** As noted in Section 3.5.2, information on the toxicokinetics of tin compounds in humans is sufficiently limited to preclude comparisons with other species (see Section 3.4). Studies in animals are also insufficient for comparisons of the absorption of tin compounds across species, from inhalation, oral, or dermal routes (see Section 3.4.1). Several studies have compared rates of elimination of tin, administered in various inorganic forms or as organotin compounds, in various animal species (Furchner and Drake 1976; Hiles 1974; NTP 1982). These studies demonstrate species differences in elimination kinetics that may be germane to extrapolations to humans. For example, the elimination kinetics of absorbed inorganic tin occurs more slowly in Rhesus monkeys than in rodents; this difference appears to be the result of a larger fraction of the tin body burden associated with the slowest kinetic compartment (presumably bone) in monkeys (Furchner and Drake 1976). Organotin compounds, in particular methyltin and ethyltin, accumulate in red blood cells to a much greater extent in rats than in
other species, including nonhuman primates (Brown 1984; Rose 1969; Rose and Aldridge 1968). Species differences to the hepatotoxic effects of some organotins have been described. Comparative studies with tributyltin and dibutyltin in rats, mice and guinea pigs showed the susceptibilities for liver toxicity followed the order: mice > rats > guinea pigs (Ueno et al. 2003b). Kinetic studies showed that the differences in susceptibility appeared to be partly due to differences in metabolism of tributyltin and in the distribution of dibutyltin within cell organelles. These observations suggest that a more complete characterization of inter-species variability in the toxicokinetics of tin would be useful for extrapolating doses across species, in particular, from rats to other species, including humans.

Information is available to support the development of models of toxicokinetics of various tin compounds in rodents and nonhuman primates (e.g., Rhesus monkey, marmoset); however, the current lack of observations on the toxicokinetics of tin compounds in humans makes evaluation of such models for applications to predicting the toxicokinetics of tin in humans highly uncertain. Useful types of observations in humans to support toxicokinetic model development would include: (1) quantifying extent and rates of absorption of tin compounds in humans from the inhalation, oral, and dermal pathways; (2) quantifying the relative contribution of various excretory routes to elimination of tin compounds in humans, including bile, urine, feces, and milk; (3) time course for the concentrations of tin in blood and blood plasma (or other tissues) following a single dose or during repeated exposures; (4) observing of blood:tissue and/or plasma:tissue concentration ratios for tin; and (5) identifying pathways and rates of metabolism of tin compounds.

**Methods for Reducing Toxic Effects.** Recommended methods for the mitigation of effects of acute exposure to tin compounds include standard treatments and measures to support vital functions (HSDB 2003). No information was located concerning mitigation of effects of lower-level or longer-term exposure to tin. This, in part, may reflect the fact that no population has been identified as having been subjected or currently undergoing exposure to excessive amounts of tin and compounds. Attempts to propose studies of specific methods to reduce possible adverse effects do not appear warranted at this time.

**Children’s Susceptibility.** Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.
There are no studies that specifically addressed exposure to inorganic tin in children. Workers exposed to tin in the air experienced respiratory effects (Cutter et al. 1949; Dundon and Hughes 1950; Pendergrass and Pryde 1948) and ingestion of excessive inorganic tin caused gastrointestinal effects (WHO 1980, 2003). It is reasonable to assume that children exposed in similar manners will experience similar effects. Dermal contact with some organotins such as tributyltin can cause skin irritation and exposure by any route to trimethyltin or triethyltin can cause serious neurological effects. There is no reason to believe that children exposed to these chemicals would exhibit a different response. There is no information on whether the developmental process is altered in humans exposed to tin and compounds. Limited evidence with tributyltin chloride in rats suggests that this substance may alter developmental events controlled by hormones (Ogata et al. 2001; Omura et al. 2001), but further studies are necessary on this issue. The possibility that organotin compounds may have endocrine-disrupting ability in mammals has not been systematically studied.

There are no data to evaluate whether pharmacokinetics of tin and tin compounds in children are different from adults. There is limited information indicating that inorganic tin can cross the placenta (Theuer et al. 1971), and also that dibutyltin can do so and reach the fetus (Nakamura et al. 1993; Noda et al. 1994). Administration of dibutyltin and other organotins, such as tributyltin and triphenyltin, to pregnant rodents has caused malformations in the fetuses (Ema et al. 1991a, 1991b, 1992, 1995b, 1997b; Faqi et al. 1997; Farr et al. 2001; Harazono et al. 1998; Noda et al. 1991a, 1991b), indirectly suggesting that organotins (or metabolites) other than dibutyltin also can cross the placenta. There are no studies on whether tin compounds can be transferred from mother to offspring through maternal milk. Cross-fostering studies can provide important information regarding the role of in utero vs. lactation exposure to tin compounds in normal development. There is evidence that acute perinatal exposure to some organotins results in altered behavioral responses in rodents tested as adults (i.e., Barone et al. 1995; Reiter et al. 1981; Ruppert et al. 1983). Research efforts should continue to focus on the possible underlying mechanisms that are responsible for such long-lasting postexposure toxicities. There are no data to permit an evaluation of whether metabolism of tin and compounds is different in children than in adults.

Research into the development of sensitive and specific biomarkers of exposures and effects for tin compounds would be valuable for both adults and children. There are no data on the interactions of tin with other chemicals in children; however, studies in humans and in animals have shown that dietary tin can influence the metabolism of zinc (Greger and Johnson 1981; Johnson and Greger 1982; Rader et al. 1990), which is essential for normal growth. There are no pediatric-specific methods to reduce peak absorption for tin and compounds, to reduce body burdens, or to interfere with the mechanisms of action.
Based on the information available, it is reasonable to assume that the supportive methods recommended for maintaining vital functions in adults will also be applicable to children.

Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: Exposures of Children.

### 3.12.3 Ongoing Studies

The following ongoing studies concerning health effects associated with tin and tin compounds were identified in the Federal Research in Progress database (FEDRIP 2004).

Dr. W.D. Atchison, from Michigan State University, East Lansing, Michigan, plans to examine the process by which environmental chemicals, such as some organotins, can destroy distinct populations of neurons in the brain, especially during development. Specifically, Dr. Atchison will study the effect of trimethyltin on the generation of mechanical tension in developing hippocampal pyramidal neurons in primary culture, or transformed neuronal cells. This research is sponsored by the National Institute of Environmental Health Sciences.

Dr. M.L. Billingsley, from Penn State University, Hershey, Pennsylvania, plans to use molecular biologic approaches to address specific mechanisms that may explain the selective actions of organotin toxicants. The first aim will be to investigate the normal function of stannin (a protein isolated from organotin-sensitive tissues) and to use targeted gene disruptions to determine the consequences of loss of stannin on the elaboration of organotin toxicity. The second aim will use *in vivo* antisense disruption of stannin expression to determine whether this protein is needed for the elaboration of organotin toxicity. This research is sponsored by the National Institute of Environmental Health Sciences.

Dr. A.Z. Mason, from California State University, Long Beach, California, proposes to determine the sub-lethal model of toxicity of tributyltin (TBT) and assess whether it and other toxicological analogues could constitute an environmental hazard to humans. A series of *in vivo* and *in vitro* experiments using the TBT-sensitive mollusk, *Nucella emarginata*, and human prostate cancer and hepatoma cell lines have been designed to specifically test each of the identified mechanisms of action and determine if TBT acts via perturbing aromatase activity, androgen conjugation, and elimination or by potentiation gonadotropin neuropeptide release. This research is sponsored by the National Institute of General Medical Sciences.
3. HEALTH EFFECTS

Dr. K.R. Pennypacker, from the University of South Florida, Tampa, Florida, proposes that brain injury leads to activation of NF-kB (nuclear factor kB) in neurons surviving injury and that this activation induces the transcription of growth factors that have a decisive role in promoting cell survival. NF-kB expression and activity in the rat hippocampus in response to injury caused by excitotoxicity (kainite), ischemia (middlecerebral arterial occlusion), and neurotoxicity (trimethyltin) will be examined to determine whether activation of NF-kB is a common event in injury to the brain. This research is sponsored by the National Institute of Neurological Disorders and Stroke.

Dr. C.R. Rice, of Mississippi State University, Mississippi State, Mississippi, plans to evaluate the immunotoxicity of mixtures of halogenated hydrocarbons (a co-planar PCB) and organotin (TBT) using channel catfish and mice as comparative vertebrate models, using the guidelines of the National Toxicology Program. Early studies will be devoted to establishing dose-dependent indices of toxicity that will be used to monitor the relative immunotoxicity of a co-planar PCB and TBT. Subsequent research will be devoted to evaluating the effects of the co-planar PCB and TBT, alone and in combination, on innate and antigen-specific immune parameters. This research is sponsored by the Department of Agriculture.
4. CHEMICAL AND PHYSICAL INFORMATION

4.1 CHEMICAL IDENTITY

Tin is a naturally occurring element that appears in group 14 (4A) of the periodic table at the boundary between the metals and nonmetals. Tin can form various compounds, both inorganic and organic. Inorganic tin compounds do not contain a tin-carbon bond, whereas organotin compounds contain at least one tin-carbon bond (Kroschwitz and Howe-Grant 1997; Lide 2000). The divalent and tetravalent oxidation states can be designated using the names stannous and stannic, respectively, in the name of the compound. Another commonly encountered nomenclature system, the Stock Oxidation-Number system, denotes the oxidation state in Roman numerals in parentheses following the metal’s name: tin(II) and tin(IV) (Smith 1996). Table 4-1 lists common synonyms and other pertinent identification information for tin and representative inorganic and organic tin compounds.

4.2 PHYSICAL AND CHEMICAL PROPERTIES

Tin is a silver-white metal that is malleable and somewhat ductile. It has a highly crystalline structure and exists in two allotropic forms at normal pressures. Gray or α tin exists below 13.2 °C and has a cubic structure. At 13.2 °C, gray tin is converted to white or β tin, which has a tetragonal structure. In compounds, tin can exist in the +2 or +4 oxidation state. Industrially important organotin compounds include the dimethyltin, dibutyltin, tributyltin, dioctyltin, triphenyltin, and tricyclohexyltin families. Organotin compounds that are industrially important contain tin in the +4 oxidation state (Kroschwitz and Howe-Grant 1997; Lide 2000). Table 4-2 lists important physical and chemical properties of tin and representative inorganic and organic tin compounds.
Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tin</th>
<th>Tin(II) chloride</th>
<th>Tin(IV) oxide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Metallic tin; silver matt powder; tin flake</td>
<td>Stannous chloride; tin dichloride; tin protochloride</td>
<td>Stannic oxide; tin oxide; stannic anhydride</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>Sn</td>
<td>SnCl₂</td>
<td>SnO₂</td>
</tr>
<tr>
<td>Chemical structure</td>
<td>Sn</td>
<td>SnCl₂</td>
<td>SnO₂</td>
</tr>
<tr>
<td>Identification numbers:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAS registry</td>
<td>7440-31-5</td>
<td>7772-99-8</td>
<td>18282-10-5</td>
</tr>
<tr>
<td>NIOSH RTECS</td>
<td>XP7320000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>XP8700000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>XQ4000000&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>EPA hazardous waste</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>DOT/UN/NA/IMCO shipping</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>HSDB</td>
<td>5035</td>
<td>582</td>
<td>5064</td>
</tr>
<tr>
<td>NCI</td>
<td>No data</td>
<td>C02722</td>
<td>No data</td>
</tr>
<tr>
<td>EINECS</td>
<td>231-141-8</td>
<td>231-868-0</td>
<td>242-159-0</td>
</tr>
</tbody>
</table>
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tin(II) fluoroborate</th>
<th>Tin(II) fluoride</th>
<th>Monomethyltin trichloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Tetrafluoroborate(1-), tin(2+) (2:1); tin bis(tetrafluoroborate)</td>
<td>Stannous fluoride; easygel; fluoristan; Gel-Kam; Gel-Tin</td>
<td>Trichloromethyl stannane; methyltin trichloride</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>SnB$_2$F$_8$</td>
<td>SnF$_2$</td>
<td>CH$_3$Cl$_3$Sn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td>Sn(BF$_4$)$_2$</td>
<td>SnF$_2$</td>
<td>H$_2$C—Sn·Cl</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cl</td>
</tr>
<tr>
<td>Identification numbers:</td>
<td>CAS registry 13814-97-6</td>
<td>7783-47-3</td>
<td>993-16-8</td>
</tr>
<tr>
<td></td>
<td>NIOSH RTECS No data</td>
<td>XQ3450000$^b$</td>
<td>WH8585500$^b$</td>
</tr>
<tr>
<td></td>
<td>EPA hazardous waste No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td>DOT/UN/NA/ IMCO shipping No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td>HSDB No data</td>
<td>783</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td>NCI No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td>EINECS 237-487-6</td>
<td>231-999-3</td>
<td>213-608-8</td>
</tr>
</tbody>
</table>
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Dimethyltin dichloride</th>
<th>Trimethyltin chloride</th>
<th>Monobutyltin trichloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Dichlorodimethyl stannane; Cotin 210</td>
<td>Chlorotrimethyl stannane; chlorotrimethyltin; trimethylchlorotin</td>
<td>Mono-n-butyltin trichloride; butyltrichloro stannane</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C₂H₆Cl₂Sn</td>
<td>C₃H₉ClSn</td>
<td>C₄H₉Cl₃Sn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td>Cl⁻H₃C⁻Sn⁻Cl⁻H₃C</td>
<td>H₃C⁻Sn⁻Cl⁻H₃C</td>
<td>Cl⁻Sn⁻Cl⁻Cl⁻Sn⁻Cl⁻Cl⁻Cl⁻</td>
</tr>
<tr>
<td>Identification numbers:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAS registry</td>
<td>753-73-1</td>
<td>1066-45-1</td>
<td>1118-46-3</td>
</tr>
<tr>
<td>NIOSH RTECS</td>
<td>WH7245000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>WH6850000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>WH678000&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>EPA hazardous waste</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>DOT/UN/NA/ IMCO shipping</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>HSDB</td>
<td>No data</td>
<td>6413</td>
<td>6073</td>
</tr>
<tr>
<td>NCI</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>EINECS</td>
<td>212-039-2</td>
<td>213-917-8</td>
<td>214-263-6</td>
</tr>
</tbody>
</table>
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Dibutyltin dichloride</th>
<th>Tributyltin chloride</th>
<th>Monobutyltin hydride</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synonyms</strong></td>
<td>Dibutyltin chloride; dichlorodibutyltin; dichlorodibutylstannane</td>
<td>Chlorotributylstannane; tributyltin chloride</td>
<td>n-Butyltin; butyltin trihydride</td>
</tr>
<tr>
<td><strong>Trade name</strong></td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td><strong>Chemical formula</strong></td>
<td>$\text{C}<em>8\text{H}</em>{18}\text{Cl}_2\text{Sn}$</td>
<td>$\text{C}<em>{12}\text{H}</em>{27}\text{ClSn}$</td>
<td>$\text{C}<em>4\text{H}</em>{12}\text{Sn}$</td>
</tr>
<tr>
<td><strong>Chemical structure</strong></td>
<td><img src="image" alt="Chemical Structure" /></td>
<td><img src="image" alt="Chemical Structure" /></td>
<td><img src="image" alt="Chemical Structure" /></td>
</tr>
</tbody>
</table>

Identification numbers:
- **CAS registry**: 683-18-1, 1461-22-9, 2406-65-7
- **NIOSH RTECS**: WH7100000\(^b\), WH6820000\(^b\), No data
- **EPA hazardous waste**: No data, No data, No data
- **DOT/UN/NA/IMCO shipping**: No data, No data, No data
- **HSDB**: 6071, No data, No data
- **NCI**: No data, No data, No data
- **EINECS**: 211-670-0, 215-958-7, No data
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Monobutyltin ion</th>
<th>Dibutyltin hydride</th>
<th>Tributyltin hydride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>No data</td>
<td>Di-n-butyltin; dibutylstannane; dibutyltin dihydride</td>
<td>Tributylstannane; tributyltin; Tributylstannic hydride</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C₄H₈Sn</td>
<td>C₈H₂₀Sn</td>
<td>C₁₂H₂₈Sn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td><img src="structure1.png" alt="Structure" /></td>
<td><img src="structure2.png" alt="Structure" /></td>
<td><img src="structure3.png" alt="Structure" /></td>
</tr>
</tbody>
</table>

Identification numbers:

- CAS registry 78763-54-9 1002-53-5 688-73-3
- NIOSH RTECS No data WH6883600b WH8675000b
- EPA hazardous waste No data No data No data
- DOT/UN/NA/IMCO shipping No data No data No data
- HSDB No data No data 6362
- NCI No data No data No data
- EINECS No data No data 211-704-4
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tetrabutyltin</th>
<th>Bis(tributyltin) oxide</th>
<th>Triethyltin bromide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Tetrabutylstannane</td>
<td>Lastanox Q; Biomet TBTO; Bromotriethyl-stannoxide</td>
<td>No data</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>TBTO&lt;sup&gt;c&lt;/sup&gt;</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C&lt;sub&gt;16&lt;/sub&gt;H&lt;sub&gt;36&lt;/sub&gt;Sn</td>
<td>C&lt;sub&gt;24&lt;/sub&gt;H&lt;sub&gt;54&lt;/sub&gt;OSn&lt;sub&gt;2&lt;/sub&gt;</td>
<td>C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;15&lt;/sub&gt;BrSn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td><img src="image1" alt="Chemical structure" /></td>
<td><img src="image2" alt="Chemical structure" /></td>
<td><img src="image3" alt="Chemical structure" /></td>
</tr>
<tr>
<td>Identification numbers:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAS registry</td>
<td>1461-25-2</td>
<td>56-35-9</td>
<td>2767-54-6</td>
</tr>
<tr>
<td>NIOSH RTECS</td>
<td>WH8605000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>JN8750000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>WH6740000&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>EPA hazardous waste</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>DOT/UN/NA/IMCO shipping</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>HSDB</td>
<td>6074</td>
<td>6505</td>
<td>No data</td>
</tr>
<tr>
<td>NCI</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>EINECS</td>
<td>215-960-8</td>
<td>200-268-0</td>
<td>220-443-5</td>
</tr>
</tbody>
</table>
### Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Triphenyltin</th>
<th>Triphenyltin hydroxide</th>
<th>Triphenyltin chloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Fentin [ISO]; triphenylstannylium</td>
<td>Fentin hydroxide; hydroxytriphenyl stannane</td>
<td>Chlorotriphenyltin; triphenylchlorostannane; Aquatin; fentin chloride</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C$<em>{18}$H$</em>{15}$Sn</td>
<td>C$<em>{18}$H$</em>{16}$OSn</td>
<td>C$<em>{18}$H$</em>{15}$ClSn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td><img src="image1.png" alt="Triphenyltin" /></td>
<td><img src="image2.png" alt="Triphenyltin hydroxide" /></td>
<td><img src="image3.png" alt="Triphenyltin chloride" /></td>
</tr>
</tbody>
</table>

Identification numbers:

- **CAS registry**: 668-34-8, 76-87-9, 639-58-7
- **NIOSH RTECS**: No data, WH8575000$^b$, WH6860000$^b$
- **EPA hazardous waste**: No data, No data, No data
- **DOT/UN/NA/IMCO shipping**: No data, No data, No data
- **HSDB**: No data, 1784, 6404
- **NCI**: No data, C00260, No data
- **EINECS**: No data, 200-990-6, 211-358-4
### Table 4-1. Chemical Identity of Tin and Tin Compounds^a^  

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mono-n-octyltin trichloride</th>
<th>Di-n-octyltin dichloride</th>
<th>Triocetylltin stannane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Trichlorooctylstannane; n-octyltin trichloride</td>
<td>Dichlorodiocytin; DOTC; Stannane, dichlorodiocytlin</td>
<td>No data</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C₈H₁₇Cl₃Sn</td>
<td>C₁₆H₃₄Cl₂Sn</td>
<td>C₂₄H₅₂Sn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td><img src="image" alt="Structure" /></td>
<td><img src="image" alt="Structure" /></td>
<td><img src="image" alt="Structure" /></td>
</tr>
</tbody>
</table>

Identification numbers:
- CAS registry: 3091-25-6, 3542-36-7, 869-59-0
- NIOSH RTECS: WH8590000^b^, WH724700^b^, No data
- EPA hazardous waste: No data, No data, No data
- DOT/UN/NA/ IMCO shipping: No data, No data, No data
- HSDB: No data, No data, No data
- NCI: No data, No data, No data
- EINECS: 221-435-4, 222-583-2, No data
Table 4-1. Chemical Identity of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tri-n-octyltin chloride</th>
<th>Tetra-n-octylstannane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synonyms</td>
<td>Chlorotrioctyl-stannane</td>
<td>Tetraoctylstannane</td>
</tr>
<tr>
<td>Trade name</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Chemical formula</td>
<td>C_{24}H_{51}ClSn</td>
<td>C_{32}H_{68}Sn</td>
</tr>
<tr>
<td>Chemical structure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Identification numbers:

- **CAS registry**: 2587-76-0                        3590-84-9
- **NIOSH RTECS**: WH6855000<sup>b</sup>                WH8635500<sup>b</sup>
- **EPA hazardous waste**: No data                   No data
- **DOT/UN/NA/IMCO shipping**: No data                No data
- **HSDB**: No data                                    No data
- **NCI**: No data                                     No data
- **EINECS**: 219-969-8                                222-733-7

<sup>a</sup>All information obtained from HSDB 2003 and ChemID 2003, except where noted.

<sup>b</sup>RTECS 2003

CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EINECS = European Inventory of Existing Chemical Substances; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances
### Table 4-2. Physical and Chemical Properties of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Property</th>
<th>Tin</th>
<th>Tin(II) chloride</th>
<th>Tin(IV) oxide</th>
<th>Tin(II) fluoride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>118.69</td>
<td>189.60</td>
<td>150.71</td>
<td>156.71</td>
</tr>
<tr>
<td>Color</td>
<td>Silver-white</td>
<td>White</td>
<td>White</td>
<td>White</td>
</tr>
<tr>
<td>Physical state</td>
<td>Solid</td>
<td>Solid</td>
<td>Solid</td>
<td>Solid</td>
</tr>
<tr>
<td>Melting point</td>
<td>231.9 °C</td>
<td>246 °C</td>
<td>1,630 °C</td>
<td>213 °C</td>
</tr>
<tr>
<td>Boiling point</td>
<td>2,507 °C</td>
<td>623 °C</td>
<td>Sublimes 1,800–1,900 °C</td>
<td>850 °C</td>
</tr>
<tr>
<td>Density (g/cm³)</td>
<td>7.265 (white)</td>
<td>3.90</td>
<td>6.95</td>
<td>4.57 at 25 °C</td>
</tr>
<tr>
<td>Odor</td>
<td>Odorless</td>
<td>Odorless</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>Insoluble</td>
<td>90 g/100 g water at 20 °C</td>
<td>Insoluble</td>
<td>30–39% in water at 20 °C</td>
</tr>
<tr>
<td>Other solvents</td>
<td>Soluble in hydrochloric acid, sulfuric acid, aqua regia, alkali, slightly soluble in dilute nitric acid</td>
<td>Very soluble in hydrochloric acid; soluble in alcohol, ethyl acetate, glacial acetic acid, sodium hydroxide solution</td>
<td>Insoluble in alcohol, cold acids; slowly soluble in hot concentrated potassium or sodium hydroxide solution</td>
<td>Practically insoluble in ethanol, ether, and chloroform</td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Log octanol/water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Log Koc</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>8x10⁻³ mm Hg at 1,224 °C</td>
<td>25 mm Hg at 427.9 °C</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Henry’s law constant</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Flashpoint</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Flammability limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>
**Table 4-2. Physical and Chemical Properties of Tin and Tin Compounds**

<table>
<thead>
<tr>
<th>Property</th>
<th>Monomethyltin trichloride</th>
<th>Dimethyltin dichloride</th>
<th>Trimethyltin chloride</th>
<th>Monobutyltin trichloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>240.08&lt;sup&gt;b&lt;/sup&gt;</td>
<td>219.67&lt;sup&gt;b&lt;/sup&gt;</td>
<td>199.26</td>
<td>282.17</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Colorless&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Colorless</td>
<td>Colorless</td>
</tr>
<tr>
<td>Physical state</td>
<td>Solid&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Solid&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Solid</td>
<td>Liquid</td>
</tr>
<tr>
<td>Melting point</td>
<td>43 °C&lt;sup&gt;b&lt;/sup&gt;</td>
<td>90 °C (107 °C)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>37.5 °C</td>
<td>-63 °C</td>
</tr>
<tr>
<td>Boiling point</td>
<td>171 °C&lt;sup&gt;b&lt;/sup&gt;</td>
<td>185–190 °C&lt;sup&gt;b&lt;/sup&gt;</td>
<td>154–156 °C</td>
<td>102 °C at 12 mm Hg</td>
</tr>
<tr>
<td>Density (g/cm³)</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>1.71 at 25 °C</td>
</tr>
<tr>
<td>Odor</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>Soluble in cold water&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Soluble in cold water&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Miscible with water</td>
<td>Sparingly soluble in water</td>
</tr>
<tr>
<td>Other solvents</td>
<td>Soluble in organic solvents&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Soluble in organic solvents&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Soluble in organic solvents</td>
<td>Soluble in organic solvents</td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log octanol/water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Log K&lt;sub&gt;oc&lt;/sub&gt;</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Henry’s law constant</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Flashpoint</td>
<td>105 °F (40 °C)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>No data</td>
<td>207 °F (97 °C)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>No data</td>
</tr>
<tr>
<td>Flammability limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>
### Table 4-2. Physical and Chemical Properties of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Property</th>
<th>Dibutyltin dichloride</th>
<th>Bis(tributyltin) oxide</th>
<th>Tributyltin chloride</th>
<th>Tributyltin hydride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>303.85</td>
<td>596.11</td>
<td>325.49d</td>
<td>291.09</td>
</tr>
<tr>
<td>Color</td>
<td>White</td>
<td>Slightly yellow</td>
<td>Colorlessd</td>
<td>No data</td>
</tr>
<tr>
<td>Physical state</td>
<td>Solid</td>
<td>Liquid</td>
<td>Liquidd</td>
<td>Liquid</td>
</tr>
<tr>
<td>Melting point</td>
<td>43 °C</td>
<td>&lt;-45 °C&lt;sup&gt;e&lt;/sup&gt;</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Boiling point</td>
<td>135 °C at 10mmHg</td>
<td>180°C at 2 mm Hg</td>
<td>145–147 °C at 5 mm Hg&lt;sup&gt;e&lt;/sup&gt;</td>
<td>112.5-113.5 °C at 8 mm Hg</td>
</tr>
<tr>
<td>Density (g/cm&lt;sup&gt;3&lt;/sup&gt;)</td>
<td>1.36 at 24 °C</td>
<td>1.17 at 25 °C</td>
<td>1.20&lt;sup&gt;o&lt;/sup&gt;</td>
<td>1.103 at 20 °C</td>
</tr>
<tr>
<td>Odor</td>
<td>No data</td>
<td>Weak odor</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>Insoluble in cold water</td>
<td>4 mg/L at pH 7, 20 °C</td>
<td>Insoluble in cold water&lt;sup&gt;d&lt;/sup&gt;</td>
<td>No data</td>
</tr>
<tr>
<td>Other solvents</td>
<td>Soluble in ether benzene, alcohol</td>
<td>Miscible with organic solvents</td>
<td>Soluble in oxygenated, chlorinated and aromatic solvents&lt;sup&gt;d&lt;/sup&gt;</td>
<td>No data</td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log octanol/water</td>
<td>0.97</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Log K&lt;sub&gt;oc&lt;/sub&gt;</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>2 mm Hg at 100 °C</td>
<td>7.5x10&lt;sup&gt;-6&lt;/sup&gt; mm Hg at 20 °C&lt;sup&gt;f&lt;/sup&gt;</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Henry's law constant</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Flashpoint</td>
<td>335 °F (168 °C)</td>
<td>&gt;212 °F (100 °C)</td>
<td>&gt;230 °F (110 °C)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>104 °F (40 °C)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Flammability limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>
### Table 4-2. Physical and Chemical Properties of Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Property</th>
<th>Tetrabutyltin</th>
<th>Triethyltin bromide</th>
<th>Triphenyltin hydroxide</th>
<th>Triphenyltin chloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>347.16</td>
<td>285.79(^b)</td>
<td>367.03</td>
<td>385.48</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless or slightly yellow</td>
<td>Colorless(^b)</td>
<td>White</td>
<td>White</td>
</tr>
<tr>
<td>Physical state</td>
<td>Oily liquid</td>
<td>Liquid(^b)</td>
<td>Solid</td>
<td>Solid</td>
</tr>
<tr>
<td>Melting point</td>
<td>-97 °C</td>
<td>-13.5 °C(^b)</td>
<td>119 °C</td>
<td>103.5 °C</td>
</tr>
<tr>
<td>Boiling point</td>
<td>145 °C at 10 mm Hg</td>
<td>223–224 °C(^b)</td>
<td>No data</td>
<td>240 °C at 13.5 mmHg</td>
</tr>
<tr>
<td>Density (g/cm(^3))</td>
<td>1.054 at 20 °C</td>
<td>1.630 g/mL(^b)</td>
<td>1.54 at 20 °C</td>
<td>No data</td>
</tr>
<tr>
<td>Odor</td>
<td>Distinct, characteristic</td>
<td>No data</td>
<td>Odorless</td>
<td>No data</td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>Insoluble in water</td>
<td>Very slightly soluble in cold water(^b)</td>
<td>1.2 mg/L at 20 °C</td>
<td>40 mg/L at 20 °C</td>
</tr>
<tr>
<td>Other solvents</td>
<td>Soluble in organic solvents</td>
<td>Soluble in organic solvents(^b)</td>
<td>Slightly soluble in toluene, alcohol</td>
<td>Moderately soluble in organic solvents</td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log octanol/water</td>
<td>No data</td>
<td>No data</td>
<td>3.53</td>
<td>4.19</td>
</tr>
<tr>
<td>Log (K_{oc})</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data</td>
<td>No data</td>
<td>3.53×10(^{-7}) mm Hg at 25 °C</td>
<td>No data</td>
</tr>
<tr>
<td>Henry’s law constant</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Flashpoint</td>
<td>225 °F (107 °C)(^c)</td>
<td>211 °F (99 °C)(^c)</td>
<td>211 °F (99 °C)(^c)</td>
<td>No data</td>
</tr>
<tr>
<td>Flammability limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Property</td>
<td>Tetraoctylstannane</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molecular weight</td>
<td>571.59&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Color</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical state</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting point</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling point</td>
<td>268 °C at 10 mm Hg&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Density (g/cm&lt;sup&gt;3&lt;/sup&gt;)</td>
<td>0.9605&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odor</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odor threshold:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Air</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solubility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other solvents</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition coefficients:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log octanol/water</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log K&lt;sub&gt;oc&lt;/sub&gt;</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henry’s law constant</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flashpoint</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flammability limits</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Explosive limits</td>
<td>No data</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>All information obtained from HSDB 2003, except where noted.
<sup>b</sup>Weast 1980
<sup>c</sup>Aldrich 2003-2004
<sup>d</sup>Ashford 1994
<sup>e</sup>Lewis 1997
<sup>f</sup>Blunden et al. 1984
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.1 PRODUCTION

No information is available in the TRI database on facilities that manufacture or process tin or tin compounds because these chemicals are not required to be reported under Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986) (EPA 1997).

The earth's crust contains about 2–3 ppm tin, comprising 0.0006% of the earth's crust (Budavari 2001; Bulten and Meinema 1991). The most important tin containing mineral is cassiterite, SnO₂. Other tin minerals are stannite, teallite, cylindrite, and canfieldite. After tin-containing ores are mined, they undergo further separation processing resulting in concentrates containing 70–77% tin by weight, which is almost pure cassiterite, and are ready for smelting (Gaver 1997).

The world's largest producer of tin in 2003 was Indonesia (33% of the world total), followed by China (24%), Peru (19%), Bolivia (7%), Brazil (7%), and Australia (3%). Of the 20 countries that mine tin, these six account for 93% of the world total of 2.09x10⁵ metric tons. Tin has not been mined in the United States since 1993. Production of tin stopped in 1989 at the only U.S. tin smelter at Texas City, Texas. However, the United States is believed to be the world's largest producer of secondary tin. In 2003, about 11,000 metric tons of tin from old and new scrap were recycled at 3 detinning plants and 70 secondary nonferrous-metal processing plants. The Defense Logistics Agency, which manages the National Defense Stockpile, sold 8,876 metric tons of pig tin from the stockpile in 2003. The Steel Recycling Institute stated that the steel can (tin-plated) recycling rate in the United States in 2003 was 60%. Tin is recovered, in addition to steel, in can recycling (Carlin 2003b, 2004). Production of organotin compounds was 5,000 tons in 1955 and approximately 35,000 tons in 1985 (Fent 1996). More recent production numbers for organotin compounds could not be located. Thirty one organotin compounds (e.g., bis(tributyltin) oxide, triphenyltin hydroxide, dibutyltin dichloride) are included on the U.S. High Production Volume (HPV) chemicals lists for 1990 and 1994. HPV chemicals are those that are manufactured in or imported into the United States in quantities ≥one million pounds per year (EPA 2004). Current U.S. manufacturers of selected tin compounds are given in Table 5-1.
Table 5-1. Current U.S. Manufacturers of Selected Tin Compounds

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inorganic tin compounds</strong></td>
<td></td>
</tr>
<tr>
<td>Tin(II) chloride</td>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division, Carrollton, Kentucky</td>
</tr>
<tr>
<td>Tin(II) fluoride</td>
<td>Ozark Fluorine Specialties, Inc., Tulsa, Oklahoma</td>
</tr>
<tr>
<td>Tin(IV) oxide</td>
<td>Engelhard Corporation, Appearance and Performance - Technologies, Elyria, Ohio</td>
</tr>
<tr>
<td></td>
<td>Ferro Corporation, Coatings, Colors, and Ceramics Group - Electronic Materials Division, Penn Yan, New York</td>
</tr>
<tr>
<td>Tin(II) fluoroborate</td>
<td>Atootech USA Inc., Rock Hill, South Carolina</td>
</tr>
<tr>
<td></td>
<td>General Chemical Corporation, Claymont, Delaware</td>
</tr>
<tr>
<td></td>
<td>OMG Fidelity, Inc., Newark, New Jersey</td>
</tr>
<tr>
<td></td>
<td>Solvay Fluorides Inc., St. Louis, Missouri</td>
</tr>
<tr>
<td><strong>Methyltin compounds</strong></td>
<td></td>
</tr>
<tr>
<td>Dimethyltin dineodecanoate</td>
<td>Gelest, Inc., Tullytown, Pennsylvania</td>
</tr>
<tr>
<td>Tetramethyltin</td>
<td></td>
</tr>
<tr>
<td>Clariant Life Science Molecules (America) Inc.</td>
<td>Gainesville, Florida</td>
</tr>
<tr>
<td>Gelest, Inc.</td>
<td>Tullytown, Pennsylvania</td>
</tr>
<tr>
<td><strong>Butyltin compounds</strong></td>
<td></td>
</tr>
<tr>
<td>Dibutyltin acetylacetonate</td>
<td>MacKenzie Company, Bush, Louisiana</td>
</tr>
<tr>
<td>Dibutyltin bis(2,4-pentanedionate)</td>
<td>Gelest, Inc., Tullytown, Pennsylvania</td>
</tr>
<tr>
<td>Dibutyltin bis(2-ethylhexanoate); Dibutyltin bis(iso-octyl) maleate; Dibutyltin bis(iso-octyl mercaptoacetate); Dibutyltin bis(isopropyl maleate); Dibutyltin bis(n-lauryl mercaptide); Dibutyltin dibutoxide; Dibutyltin dimethoxide; Dibutyltin disalicylate; Dibutyltin mercaptopropionate; Dibutyltin sulfide; Tributyltin fluoride</td>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division, Carrollton, Kentucky</td>
</tr>
<tr>
<td>Dibutyltin chloride; Dibutyltin oxide; Bis(tributyltin) oxide</td>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division, Axis, Alabama; Carrollton, Kentucky</td>
</tr>
<tr>
<td>Dibutyltin diacetate</td>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division, Carrollton, Kentucky</td>
</tr>
<tr>
<td></td>
<td>Ferro Corporation Performance and Fine Chemicals Group - Polymer Additive Division, Walton Hills, Ohio</td>
</tr>
<tr>
<td>Dibutyltin difluoride</td>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division, Carrollton, Kentucky</td>
</tr>
<tr>
<td></td>
<td>Atootech USA Inc., Rock Hill, South Carolina</td>
</tr>
</tbody>
</table>
### Table 5-1. Current U.S. Manufacturers of Selected Tin Compounds

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dibutyltin dilaurate</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky</td>
</tr>
<tr>
<td>Ferro Corporation Performance and Fine Chemicals Group - Polymer Additives Division</td>
<td>Walton Hills, Ohio</td>
</tr>
<tr>
<td>Johnson Matthey, Inc. Alfa Aesar</td>
<td>Ward Hill, Massachusetts</td>
</tr>
<tr>
<td>Dibutyltin maleate</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky</td>
</tr>
<tr>
<td>Ferro Corporation Performance and Fine Chemicals Group - Polymer Additive Division</td>
<td>Walton Hill, Ohio</td>
</tr>
<tr>
<td>Tributyltin chloride</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Axis, Alabama; Carrollton, Kentucky</td>
</tr>
<tr>
<td>Tributyltin hydride</td>
<td></td>
</tr>
<tr>
<td>Gelest, Inc.</td>
<td>Tullytown, Pennsylvania</td>
</tr>
<tr>
<td>Johnson Matthey, Inc. Alfa Aesar</td>
<td>Ward Hill, Massachusetts</td>
</tr>
<tr>
<td>Sigma-Aldrich Fine Chemicals</td>
<td>Plant location not specified</td>
</tr>
<tr>
<td>Tetrabutyltin</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Axis, Alabama</td>
</tr>
<tr>
<td>Octyltin compounds</td>
<td></td>
</tr>
<tr>
<td>Dioctyltin S,S'-bis(isooctylmercaptoacetate); Dioctyltin dichloride; Dioctyltin maleate</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky</td>
</tr>
<tr>
<td>Diocytlin dilaurate</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky</td>
</tr>
<tr>
<td>Gelest, Inc.</td>
<td>Tullytown, Pennsylvania</td>
</tr>
<tr>
<td>Diocytlin oxide</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky; Axis, Alabama</td>
</tr>
<tr>
<td>Tetraoctyltin</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Axis, Alabama</td>
</tr>
<tr>
<td>Phenyltin compounds</td>
<td></td>
</tr>
<tr>
<td>Diphenyltin chloride; Diphenyltin oxide; Triphenyltin fluoride</td>
<td></td>
</tr>
<tr>
<td>ATOFINA Chemicals, Inc. Specialty Chemicals Division</td>
<td>Carrollton, Kentucky</td>
</tr>
</tbody>
</table>

*Derived from SRI 2004. SRI reports production of chemicals produced in commercial quantities (defined as exceeding 5,000 pounds or $10,000 in value annually) by the companies listed.*
### 5.2 IMPORT/EXPORT

U.S. consumption of primary and secondary tin was 34,000 and 5,830 metric tons, respectively, in 2002, and is estimated as 36,000 and 8,460 metric tons, respectively, for 2003. U.S. imports of refined tin in 2002 totaled 42,200 metric tons and were mainly from Peru, followed by China, Bolivia, Brazil, and Indonesia. Tin imports for 2003 are estimated at 37,000 metric tons. Major imports of tin include unwrought metal, waste and scrap, and unwrought tin alloys. Tin exports of refined tin were 2,940 metric tons in 2002, and are estimated at 4,020 metric tons for 2003 (Carlin 2004). U.S. imports for consumption of dibutyltin oxide, tetrabutyltin, and other organotin compounds were approximately 447, 611, and 2,070 metric tons, respectively in 2003, and were approximately 266, 649, and 1,680 metric tons, respectively, through August 2004 (ITA 2004).

### 5.3 USE

The major uses of tin in 2003 were: cans and containers, 27%; electrical, 23%; construction, 10%; transportation, 10%; and others 30% (Carlin 2004). Tinplate is used in food packaging, aerosol containers, and decorative applications. Various tin alloys are important, including bronze and pewter. Tin readily forms alloys with other metals and imparts hardness and strength. Tin is an important component of solders, since it wets the base metal by alloying with it (Gaver 1997).

Inorganic tin compounds are used in the glass industry, where they are added to strengthen the glass. Inorganic tin compounds also serve as the base for the formulation of colors, as catalysts, and in perfumes and soaps (WHO 1980). Tin(IV) oxide (SnO₂) is used in the ceramics and glass industries, as well as a polishing agent and as a catalyst (Kroschwitz and Howe-Grant 1997). It is also used to produce milky or colored glass and in the formulation of fingernail polish (Windholz 1983). Tin(IV) chloride (SnCl₄) is often used as the starting material for the production of organotin compounds. Tin(II) fluoride (SnF₂) is added to toothpastes as an anticaries agent. Tin(II) chloride (SnCl₂) is the most important inorganic tin compound. It is used as an industrial reducing agent and in tin electroplating. Tin(II) chloride is also used as a food additive, (e.g., as a preservative and a color-retention agent). Tin(II) fluoroborate (Sn(BF₄)₂), which is not isolated as a solid but is only found in solution, is an important chemical in electroplating. The consumption of inorganic tin compounds is lower than that of organotin compounds (Graf 1996; Kroschwitz and Howe-Grant 1997).
Examples of commercially important organotin compounds include tetraorganotins (R₄Sn), triorganotins (R₃SnX), diorganotins (R₂SnX₂), and monoorganotins (RSnX₃). The organotin compounds of commercial importance have R groups equal to methyl, butyl, octyl, cyclohexyl, phenyl, or neophyl. The anionic X groups are commonly halides, oxide, hydroxide, carboxylates, or mercaptides. Tetraorganotin compounds are mainly used in the production of tri-, di-, and monoorganotin compounds. Tri- and diorganotin compounds are the most important classes of organotin compounds. Triorganotin compounds are used as industrial biocides, agricultural chemicals, wood preservatives, and marine antifouling agents. Diorganotin compounds are used as polyvinyl chloride (PVC) stabilizers and as polyurethane foam and esterification catalysts. Monoorganotin compounds are also used as PVC stabilizers, as well as in the treatment of glass (Batt 2004; Kroschwitz and Howe-Grant 1997).

The major commercial applications for which organotin compounds are used are as PVC heat stabilizers, biocides, catalysts, agrochemicals, and glass coatings, accounting for approximately 20,000 tons of tin consumption per year (Batt 2004). The major use of organotin compounds is for heat stabilization of PVC, which represents approximately two-thirds of the global consumption (Sadiki and Williams 1999). It was estimated that in 1981, the U.S. consumption of organotin compounds as PVC stabilizers was 10,650 tons, approximately 27% of the world market (Kroschwitz and Howe-Grant 1997). Organotin compounds used as PVC stabilizers include butyl-, octyl-, and methyltin compounds. Octyl- and methyltin compounds are used in PVC for food packaging. In the United States, the organotin compounds that are used predominantly as PVC stabilizers are methyltins (about 50% of the market) and butyltins (40%), with octyltin compounds making up the remainder. In Asia, methyltins (50%) and octyltins (40%) and in Europe, octyltins (60%) and butyltins (30%) are the most widely used organotin compounds as PVC stabilizers (Leaversuch 1999). Tributyltin compounds are also used as slimicides on masonry, as disinfectants, and as biocides for cooling systems, power station cooling towers, pulp and paper mills, breweries, leather processing, and textile mills (WHO 1990).

The use of triorganotin compounds as marine antifoulants has been restricted by the Organotin Antifouling Paints Control Act (June 16, 1988), which limits the type of vessel on which these paints can be used, and limits the use of tributyltin paints to those that have laboratory tested release rates of \( \leq 4 \, \mu g/cm^2/day \) (Cardwell et al. 1999a). France was the first country to adopt restrictions in 1982, and now the majority of industrialized countries have adopted restrictions on the use of tributyltin containing paints on vessels <25 meters in length, and include, in addition to France and the United States, the United Kingdom, Canada, New Zealand, Australia, and the European Union (Birchenough et al. 2002). On October 5, 2001, the International Maritime Organization (IMO) adopted the International Convention
on the Control of Harmful Anti-fouling Systems on Ships, which prohibits the use of harmful organotin compounds in anti-fouling paints on ships and established a mechanism to prevent the potential future use of other harmful substances as anti-fouling systems (IMO 2004).

### 5.4 DISPOSAL

Tin-containing wastes in the form of salts, slags, and muds are generated as a result of smelting, refining, and detinning processes. Solid wastes containing tin are generated by both domestic and industrial users of containers. Tin-containing wastes may be incinerated or disposed of in landfills (WHO 1980).

Inorganic and organic tin compounds may be disposed of in sealed containers in a secured sanitary landfill (NIOSH/OSHA 1981).

Tin is not listed as a hazardous waste constituent by the EPA and therefore, its disposal is not restricted by federal land disposal restrictions. No data were located regarding the amounts of tin disposed of by any means or trends in the disposal of tin.
6. POTENTIAL FOR HUMAN EXPOSURE

6.1 OVERVIEW

Tin and organotin compounds have been identified in at least 214 and 8 sites, respectively, of the 1,662 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2004). However, the number of sites evaluated for tin and organotin compounds is not known. The frequency of these sites can be seen in Figures 6-1 and 6-2, respectively. All sites where tin and organotin compounds were found are located in the United States.

Tin occurs naturally in the earth's crust with a concentration of approximately 2–3 ppm (Budavari 2001). Tin compounds are found in various environmental media in both inorganic and organic forms. Tin may be released to the environment from natural and anthropogenic sources. Tin is a component of many soils and inorganic tin compounds may be released in dusts from wind storms, roads, and agricultural activities. Releases of tin to environmental media may occur from the production and use of tin and tin compounds. Gases, dusts, and fumes containing tin may be released from smelting and refining processes, industrial uses of tin, waste incineration, and burning of fossil fuels (Byrd and Andreae 1986; Senesi et al. 1999; WHO 1980). In general, organotin compounds are released to the environment from anthropogenic sources; however, methyltin compounds can be produced in the environment by biomethylation of inorganic tin and can occur naturally (Fent 1996). Antifouling paints containing tributyltin are applied as a finish coat to the immersed sections of boats and floating structures. As the paint releases tributyltin into the water, it creates an environment that repels the organisms that may attach to the surface of submerged objects. Use of antifouling paints represents the major source of tributyltin into the coastal environment (Alzieu 1998). The use of tributyltin compounds as slimicides on masonry, disinfectants, and biocides for cooling systems, power station cooling towers, pulp and paper mills, breweries, leather processing, and textile mills (WHO 1990) may result in their release to the environment. Triphenyltin enters the environment directly from its use as a pesticide. To a lesser extent, organotin compounds may also enter the environment by leaching to soil and groundwater from consumer products containing organotin compounds disposed of in landfills (Fent 1996).

Tin may exist in either divalent (Sn\(^{2+}\)) or tetravalent (Sn\(^{4+}\)) cationic (positively charged) ions at environmental conditions. Tin(II) dominates in reduced (oxygen-poor) water, and will readily precipitate as a sulfide (SnS) or as a hydroxide (Sn(OH)\(_2\)) in alkaline water. Tin(IV) readily hydrolyzes, and can precipitate as a hydroxide. In general, tin(IV) would be expected to be the only stable ionic species in the
Figure 6-1. Frequency of NPL Sites with Tin Contamination

Derived from HazDat 2005
Figure 6-2. Frequency of NPL Sites with Organotin Contamination

Derived from HazDat 2005
weathering cycle (Wedepohl et al. 1978). Tin in water may partition to soils and sediments. Cations such as Sn$^{2+}$ and Sn$^{4+}$ will generally be adsorbed by soils to some extent, which reduces their mobility. Tin is generally regarded as being relatively immobile in the environment (Gerritse et al. 1982; WHO 1980).

Organotin compounds are generally only sparingly soluble in water and are likely to partition to soils and sediments. Most commercially used organotin compounds are relatively immobile in environmental media due to their low vapor pressures, low water solubilities, and high affinities for soil and organic sediments (Blunden et al. 1984). For example, nearly all of the tributyltin found in the water column is bound to suspended particles, with a small portion associated with dissolved organic matter and organic and inorganic ligands (Gadd 2000). Tributyltin that is associated with particles in the water column may settle out, which is an important process in its removal from the water column. Tributyltin sorption coefficients to sediments can range from 100 to 10,000 (Anderson et al. 2002). Degradation of organotin compounds involves breaking the tin-carbon bond and can occur in the environment by ultraviolet (UV) irradiation, or biological or chemical cleavage (Blunden et al. 1984). Rates of photodegradation and biodegradation of organotins in water are dependent upon environmental conditions. In sediment, organotins are generally persistent. Organotin compounds may be significantly bioconcentrated by aquatic organisms. Cleavage of the tin-carbon bond by hydrolysis is not a significant environmental fate process under environmental conditions (WHO 1990).

Occupational exposure to tin may be significant in some industrial environments. Ambient environmental levels of tin are generally quite low, except in the vicinity of pollution sources. Humans may be exposed to tin by inhalation, ingestion, or dermal absorption. However, typical human exposure to tin is primarily by ingestion of food. Tin-lined cans used to package food constitute the most important contribution to tin intake in the diet (Biégo et al. 1999). While there is evidence that tin is essential for the normal growth of rats, there is no evidence that tin is essential for other animals, including humans (WHO 1980). Exposure to organotin compounds may occur by the ingestion of seafood and contact with consumer products that contain organotin compounds. Household commodities made up of polyurethane, plastic polymers, and silicons contain butyltin concentrations in the parts per million range (Kannan et al. 1999). Mono- and dimethyltin and mono- and dibutyltin compounds have been detected in drinking water in Canada where polyvinyl chloride (PVC) pipes, containing these organotin compounds, are used in the distribution of drinking water (Sadiki and Williams 1996, 1999; Sadiki et al. 1996). Organotin compounds were detected in household dust in the United Kingdom (Santillo et al. 2003).
6.2 RELEASES TO THE ENVIRONMENT

The Toxics Release Inventory (TRI) data should be used with caution because only certain types of facilities are required to report (EPA 1997). Manufacturing and processing facilities are required to report information to the TRI only if they employ 10 or more full-time employees; if their facility is classified under Standard Industrial Classification (SIC) codes 20–39; and if their facility produces, imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar year (EPA 1997).

There is no information on releases of tin and tin compounds from manufacturing and processing facilities because these releases are not required to be reported (EPA 1997). However, releases of tin to environmental media may occur from the production and use of tin and tin compounds.

Tin and organotin compounds have been identified in a variety of environmental media (air, surface water, leachate, groundwater, soil, and sediment) collected at 214 and 8 sites, respectively, of the 1,662 current or former NPL hazardous waste sites (HazDat 2004).

6.2.1 Air

There is no information on releases of tin and tin compounds to the atmosphere from manufacturing and processing facilities because these releases are not required to be reported (EPA 1997).

Tin has been identified in air collected at 6 of the 214 current or former NPL hazardous waste sites where it was detected in some environmental media. No organotin compounds were found in air at the eight current or former NPL hazardous waste sites where organotin compounds were detected in some environmental media (HazDat 2004).

Tin may be released to the atmosphere from both natural and anthropogenic sources. Tin is a component of many soils and may be released in dusts from wind storms, roads, and agricultural activities. Gases, dusts, and fumes containing tin may be released from smelting and refining processes, industrial uses of tin, waste incineration, and burning of fossil fuels (Byrd and Andreae 1986; Senesi et al. 1999; WHO 1980). Davison et al. (1974) reported that the tin content of airborne fly ash from coal-burning power plants ranged from 7 to 19 μg/g. Worldwide emissions of tin to the atmosphere from coal and oil combustion, refuse incineration, and copper/nickel production facilities were estimated at 1,470–
10,810 metric tons in 1983 (Nriagu and Pacyna 1988). Organotin compounds may be released to air by agricultural spraying, volatilization, antifouling paint sprays, incineration of materials treated or stabilized with organotin compounds, and glass coating operations. Incineration of organotin containing material is unlikely to be a significant source of organotin compounds to air, since these compounds will be decomposed to inorganic tin during combustion (Blunden et al. 1984). Releases of organotin compounds to air are not significant due to their low vapor pressures and rapid photodegradation (Blunden et al. 1984; Fent 1996).

### 6.2.2 Water

There is no information on releases of tin and tin compounds to water from manufacturing and processing facilities because these releases are not required to be reported (EPA 1997).

Tin has been identified in groundwater and surface water at 78 and 36 sites, respectively, of the 214 NPL hazardous waste sites where it was detected in some environmental media. Organotin compounds were found in surface water at one of the eight current or former NPL hazardous waste sites where they were detected in some environmental media; organotin compounds were not found in groundwater at these sites (HazDat 2004).

Releases of tin to water may occur from industrial facilities smelting, refining, or using tin (WHO 1980). Antifouling paints containing tributyltin are applied as a finish coat to the immersed sections of boats and floating structures. As the paint releases tributyltin into the water, it creates an environment that repels the organisms that may attach to the surface of submerged objects. Use of antifouling paints represents the major source of tributyltin into the coastal environment. It has been estimated that one boat releases 1–10 μg tributyltin/cm² of hull surface daily to ensure antifouling protection. This corresponds to 0.2–2 g/day for a small sailboat and up to 50–500 g/day for an average sized merchant ship (Alzieu 1998). The use of triorganotin compounds as marine antifoulants has been restricted by the Organotin Antifouling Paints Control Act (June 16, 1988), which limits the type of vessel on which these paints can be used, and limits the use of tributyltin paints that have laboratory tested release rates of ≤4 μg/cm²/day (Cardwell et al. 1999a). Most industrialized countries, in addition to the United States, have adopted similar restrictions on the use of tributyltin containing paints. These countries include the United Kingdom, Canada, France, New Zealand, Australia, and the European Union (Birchenough et al. 2002).
Organotin compounds may also be released to water from overspray and land runoff from agricultural applications, industrial processes, and leaching from organotin-stabilized polyvinyl chloride (PVC) (Blunden et al. 1984). The use of tributyltin compounds as slimicides on masonry, disinfectants, and biocides for cooling systems, power station cooling towers, pulp and paper mills, breweries, leather processing, and textile mills may result in their release to the environment (WHO 1990). Triphenyltin acetate and triphenyltin hydroxide are used as fungicides, algicides, and molluscicides (WHO 1999). Timber treatment facilities can be a significant source of tributyltin in freshwater systems from seepage, accidental spills, and intentional releases. Minor sources of organotin compounds in freshwater can be seepage from landfill sites and agricultural runoff, due to the use of contaminated sewage sludge or organotin containing pesticides (Demora and Pelletier 1997). Monthly samples of influent, effluent, and sludges were collected from July 1990 to January 1991 from sewage treatment plants in five Canadian cities. Monobutyltin was detected in all influent samples. Dibutyl- and tributyltin were only detected infrequently, and octyltin species were not detected. A significant reduction, 40% on average, in the concentration of monomethyltin was found after passage through the sewage treatment plants, due to degradation and adsorption to sludge. No butyltin or octyltin species were found in five landfill leachate samples in southern Ontario, Canada (Chau et al. 1992).

### 6.2.3 Soil

There is no information on releases of tin and tin compounds to soil from manufacturing and processing facilities because these releases are not required to be reported (EPA 1997).

Tin has been identified in soil at 121 sites and in sediment at 49 sites collected from 214 NPL hazardous waste sites, where it was detected in some environmental media. Organotin compounds were found in sediment and soil at four sites and one site, respectively, of the eight current or former NPL hazardous waste sites where they were detected in some environmental media (HazDat 2004).

Tin may be released to soil from organotin pesticide usage and landfilling of tin-containing wastes, including used cans and organotin-containing plastics (WHO 1980). The application of pre-treated municipal sludge and urban refuse as soil amendments may also introduce tin to soils. Concentrations of tin in sewage sludges from countries in Europe and North America ranged from 40 to 700 mg/kg dry weight. Manures and poultry wastes contained tin at concentrations of 3.7–7.4 and 2.0–4.1 mg/kg dry weight, respectively. Other incidental point sources that may introduce tin to soil are corrosion of metal objects and dispersion of metallic ores during transport (Senesi et al. 1999). Organotin compounds may
be released to soil through agricultural applications and burial of organotin-containing waste material (Blunden et al. 1984). An estimated 5,200 tons of organotin compounds were released, primarily to landfills in the United States in 1976 (Laughlin and Linden 1985). No current data were found regarding releases of organotin compounds to soil.

6.3 ENVIRONMENTAL FATE

6.3.1 Transport and Partitioning

Tin may be transported in the atmosphere by the release of particulate matter derived from the combustion of fossil fuels and solid wastes. The vapor pressure of elemental tin is negligible (Cooper and Stranks 1966), and inorganic tin compounds are nonvolatile at environmental conditions. Airborne particles may travel long distances before deposition depending on the type of emitting source, physical form and properties (e.g., size, density), physical or chemical changes that may occur during transport, adsorption processes, and meteorological conditions (Senesi et al. 1999).

Tin may exist in either divalent (Sn$^{2+}$) or tetravalent (Sn$^{4+}$) cationic (positively charged) ions at environmental conditions. Tin(II) dominates in reduced (oxygen-poor) water, and will readily precipitate as a sulfide (SnS) or as a hydroxide (Sn(OH)$_2$) in alkaline water. Tin(IV) readily hydrolyzes, and can precipitate as a hydroxide. The solubility product of Sn(OH)$_4$ has been measured at approximately $10^{-56}$ g/L at 25 °C. In general, tin(IV) would be expected to be the only stable ionic species in the weathering cycle (Wedepohl et al. 1978).

Tin in water may partition to soils and sediments. Cations such as Sn$^{2+}$ and Sn$^{4+}$ will generally be adsorbed by soils to some extent, which reduces their mobility. Tin is generally regarded as being relatively immobile in the environment (Gerritse et al. 1982; WHO 1980). However, tin may be transported in water if it partitions to suspended sediments (Cooney 1988), but the significance of this mechanism has not been studied in detail. Transfer coefficients for tin in a soil-plant system were reported to be 0.01–0.1 (Senesi et al. 1999).

A bioconcentration factor (BCF) relates the concentration of a chemical in plants and animals to the concentration of the chemical in the medium in which they live. It was estimated that the BCFs of inorganic tin were 100, 1,000, and 3,000 for marine and freshwater plants, invertebrates, and fish, respectively (Thompson et al. 1972). Marine algae can bioconcentrate tin(IV) ion by a factor of 1,900 (Seidel et al. 1980).
Approximately 95% of tributyltin in the water column was found to be bound to suspended particles and the remainder was associated with dissolved organic matter and organic and inorganic ligands (Gadd 2000). Tributyltin that is associated with particles in the water column may settle out, which is an important process in the removal of tributyltin from the water column. Tributyltin sorption coefficients to sediments can range from 100 to 10,000 (Anderson et al. 2002). A partition coefficient of about 2,180 at 20 °C was calculated by Maguire et al. (1985) to estimate the adsorption of tributyltin ions by lake sediments. These investigations also concluded that the half-life of the desorption reaction was about 10 months, indicating that tributyltin can be strongly retained by sediments. The adsorption behavior of Sn⁴⁺ ion and eight organotin species (tri-, di-, and monobutyltin; tri-, di-, and monomethyltin; and tri- and diphenyltin) were studied in a water-sediment system using artificial seawater and estuarine sediment. Adsorption coefficients varied from 10⁰.⁵ to 10⁴.⁵ and showed the trend of Sn⁴⁺ > mono > di > tri in the same substituent series. Larger absorption coefficients were found for aromatic compounds than for aliphatic compounds (Sun et al. 1996). Sediment-water partition coefficients for tributyltin ranged from 240 to 65,000 in sediments of the coast of southwestern Spain. Similar values were found for monobutyltin. Dibutyltin was found to have higher affinity for sediment (Gomez-Ariza et al. 2001).

At ambient temperatures, the solubilities of organotin compounds range from 0.0001 to about 50 mg/L (Laughlin and Linden 1985; WHO 1980). Organotin compounds may partition from water to aquatic organisms. An octanol/water partition coefficient (K_{ow}) describes the partitioning of an organic chemical between octanol and water. Octanol is believed to best imitate the fatty structures in plant and animal tissues (Kenaga and Goring 1980). The K_{ow} of tributyltin at pH 6 was reported to be about 1,585 by Maguire et al. (1983). The most accurate K_{ow} for tributyltin in seawater was 5,500 (Laughlin and Linden 1985).

There is no evidence of biomagnification of tributyltin in marine ecosystems, but accumulation may occur, resulting in high tissue concentrations in some organisms (Meador 2000). Rüdel (2003) reported that, based on a review of the literature, the bioavailability of organotin compounds via the food chain appears to be of minor importance for tributyltin and triphenyltin when compared to uptake via the water phase. Measured BCF values for bis(tributyltin)oxide with marine oysters were found to range from 2,300 to 11,400 (Waldock and Thain 1983). A BCF of 30,000 was estimated by Maguire et al. (1984) for the bioconcentration of tributyltin cation by freshwater green algae. Seven-day BCF values were derived for dibutyltin dichloride, dibutyltin dilaurate, tributyltin chloride, bis(tributyltin) oxide, and triphenyltin chloride for muscle, liver, kidney, and vertebra tissue of round crucian carp. The BCF values ranged
from 12 in muscle to 5,012 in liver. For all organotin compounds, liver had the highest BCF values. The highest BCFs were found for the tributyltin compounds (Tsuda et al. 1986). BCF values for bis(tributyltin) oxide for red sea bream (*Pagrus major*), mullet (*Mugil cephalus*), and filefish (*Rudarius erodes*) were 9,400–11,000, 2,400–3,000, and 3,200–3,600, respectively, determined in an 8-week flow-through aquarium system. Larger BCF values were obtained when fish were reared in seawater containing lower concentrations of tributyltin. BCF values for triphenyltin chloride for *P. major* and *R. erodes* were 3,100–3,300 and 4,100, respectively, and were independent of the concentration of triphenyltin in the rearing water (Yamada and Takayanagi 1992). The log BCFs for tributyltin in fish from the Port of Osaka and the Yodo River, Japan were 3.6–4.2 and 2.9–3.5, respectively (Harino et al. 2000). After 50 days of exposure to water containing a constant concentration of tributyltin (500 ng/L), whole body concentrations in tilapia did not reach a plateau, and the 50-day BCF was 12,300. Enrichment of tributyltin was highest in the viscera, followed by gill, and then muscle (Hongxia et al. 1998). A BCF of 10,500 was found for tributyltin uptake from seawater in marine mussels (*Mugil graynus*) during the 56-day accumulation phase (Suzuki et al. 1998). BCFs were 17,000–350,000, 2,000–70,000, and 1,000–70,000 for tri-, di-, and monobutyltin, respectively, in mollusks living in southwest Spain, showing a decrease in BCF with decreasing lipophilicity for the butyltin compounds (Gomez-Ariza et al. 2001).

Bioconcentration as a function of pH was studied for triphenyltin and tributyltin in a freshwater sediment organism, *Chironomus ripaius*. At pH 5 and 8, respectively, the BCFs were 310 and 170 for tributyltin, and 680 and 510 for triphenyltin. While the difference in BCF at the two pHs was statistically significant for tributyltin, it was not for triphenyltin. This may be explained by the speciation differences for each of these compounds as pH varies. The acid dissociation constant (pKₐ) of tributyltin is 6.25, and at pH 5, the fraction of tributyltin hydroxide is approximately 5%, with the tributyltin cation as the predominant species in solution. The pKₐ for triphenyltin is 5.2, and at pH 5, approximately 40% is present as triphenyltin hydroxide with the remainder as triphenyltin cation. The differences in the observed pH dependence between triphenyltin and tributyltin may indicate that the neutral hydroxide species is the predominant form taken up by the organism. BCF values of 1,500 and 1,200 at pH 5 and 8, respectively, were determined for tetrabutyltin ion, which cannot undergo ionization and was used as a control compound. The difference between these BCF values for tetrabutyltin at pH 5 and 8 was not statistically significant (Looser et al. 1998).

Releases of organotin compounds to air from various surfaces are, in general, not significant due to their low vapor pressures and rapid photodegradation at surfaces (Fent 1996). It has been reported that
methylation of inorganic and organotin compounds, such as di- and tributyltin, are likely to occur in sediments, producing potentially volatile organotin compounds. This process may lead to mobilization of tin species into the water column and possibly into the atmosphere. However, there is currently no significant evidence of losses of organotin compounds to the atmosphere (Amouroux et al. 2000). There was no indication that tributyltin in water partitioned to the air during a 62-day period, whereas 20% of the water evaporated (Maguire et al. 1983).

6.3.2 Transformation and Degradation

6.3.2.1 Air

No information was located on the transformation or degradation of tin compounds in the atmosphere.

6.3.2.2 Water

Inorganic tin cannot be degraded in the environment, but may undergo oxidation-reduction, ligand exchange, and precipitation reactions (HSDB 2003). It has been established that inorganic tin can be transformed into organometallic forms by microbial methylation (Hallas et al. 1982). Inorganic tin may also be converted to stannane (H₄Sn) in extremely anaerobic (oxygen-poor) conditions by macroalgae (Donard and Weber 1988).

The speciation of organotin compounds is pH-dependent. At lower pHs, the cationic form will be the primary form, and as the pH is increased, the neutral hydroxide compounds will be the predominant species. In the environmentally relevant pH range (pH 5–9), the predominant organotin species will be the neutral hydroxide compounds (i.e., R₃SnOH, R₂Sn(OH)₂, and RSn(OH)₃). High concentrations of chloride favor the formation of chloro species. The pKₐ values for trimethyltin, triethyltin, tributyltin, and triphenyltin cations are approximately 6.60, 6.81, 6.25, and 5.2, respectively (Blunden et al. 1984; Fent 1996; Meador 2000).

Degradation of organotin compounds involves the breaking of the tin-carbon bond, which may occur by UV irradiation, or by biological or chemical cleavage (Blunden et al. 1984). In water, tributyltin can be degraded by photochemical and biological processes relatively rapidly; however, adsorption onto suspended particulate material in water followed by sedimentation is a key removal process (De Mora and Pelletier 1997). The half-life of tributyltin in seawater varies, depending on pH, temperature, turbidity,
and light; it is generally estimated to be in the range of 1 day to a few weeks (Alzieu 1998). Biodegradation is the major process in seawaters rich in suspended solids, but photolysis, in surface waters, exceeds biodegradation in clean seawater. Calculated half-lives range from 6 days in summer-time waters rich in suspended particles to 127 days in clean winter waters (Watanabe et al. 1992). Tributyltin can be degraded by microbial, microalgal, and fungal populations, as well as by some higher organisms, such as fish (Anderson et al. 2002). Cleavage of the tin-carbon bond by hydrolysis is not an important fate process under environmental conditions (WHO 1990).

### 6.3.2.3 Sediment and Soil

Inorganic tin cannot be degraded in the environment, but may undergo oxidation-reduction, ligand exchange, and precipitation reactions (HSDB 2003). Degradation of organotin compounds in sediments is much slower than in water, and half-lives have been estimated to be several years (Alzieu 1998). In addition to dealkylation of organotin compounds, methylation of tin and organotin compounds by chemical and/or biological means may occur. The contribution of methylation by biotic and abiotic mechanisms is not clear. This pathway may result in fully substituted and volatile tin compounds. Methylated butyltin compounds, such as tributylmethyltin and dibutyldimethyltin, have been found in contaminated harbor sediments and in surface waters (Amouroux et al. 2000; Cooney 1988). Methylation of tin in sediments was found to be positively correlated with increasing organic content in sediment and to follow predominately a biotic pathway (Hadjispyrou et al. 1998).

### 6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to tin and tin compounds depends in part on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of tin and tin compounds in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on tin and tin compounds levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring tin and tin compounds in a variety of environmental media are detailed in Chapter 7.

Environmental monitoring studies may report concentrations of organotin compounds in various environmental media in two formats, either as mass of tin per unit mass or volume of media, or as mass of
organotin ion per unit mass or volume of media. To convert mass on a tin basis to mass on an organotin cation basis, multiply by the ratio of the formula weight of the organotin cation to the atomic weight of tin. Conversions are provided in Table 6-1 for various organotin cations. For example, a tributyltin (TBT) concentration in sediment reported as 122 ng TBT/g would correspond to 50 ng Sn/g, since tributyltin ion has a mass that is 2.44 times greater than that of tin.

6.4.1 Air

Tin is detected in air infrequently and at low concentrations, except in the vicinity of industrial sources. Air concentrations in U.S. cities ranged from below the detection limit to 0.8 μg/m³ in several studies. Average concentrations are generally <0.1 μg/m³, with higher concentrations near some industrial facilities (EPA 1982a; WHO 1980). In some studies, tin was not detected in 40–>50% of samples. Atmospheric tin is associated with particulate matter, and peak concentrations were found on smaller respirable particles (1–3 μm) (WHO 1980). Samples of airborne inhalable particulate matter were collected in two urban/industrial areas in Illinois, southeast Chicago and East St. Louis, over a 2-year period. Average tin concentrations in the fine (<2.5 μm) and coarse (2.5–10 μm) particulate fractions were <0.007 and 0.012 μg /m³ for East St. Louis, respectively, and <0.007 μg /m³ for both the fine and course fractions in samples from southeast Chicago and a rural site in Bondville, Illinois (Sweet and Vermette 1993). The average tin concentration in highway tunnel exhaust aerosol in the Elbtunnel in Hamburg, Germany between August 1988 and January 1989 was 10.9 μg/m³ (Dannecker et al. 1990). Tin concentrations in the particulate matter in the ambient air at art glass manufacturing plants measured by personal samples from oven-charger and batch-mixer workers ranged from 0.1 to 3.5 μg/m³ from three plants that use arsenic as a fining agent (a fining agent is added to disperse air bubbles in glass). Tin was not detected in the particulate matter in the air at three other plants that use antimony compounds instead of arsenic (Apostoli et al. 1998). No monitoring data for concentrations of organotin compounds in air were found.

6.4.2 Water

Tin occurs in trace amounts in natural waters. However, it is seldom measured and only infrequently detected, since concentrations are often below the detection limit (NAS 1977; WHO 1980). In surface waters, tin was detected in only 3 of 59 samples from 15 U.S. and Canadian rivers at concentrations ranging from 1.3 to 2.1 μg/L, and not detected in 119 samples from 28 U.S. rivers. A mean tin concentration of 0.038 μg/L was reported for surface water in Maine (NAS 1977; WHO 1980).
### Table 6-1. Conversion Between Mass on a Tin Basis to Mass on an Organotin Cation Basis

<table>
<thead>
<tr>
<th>To convert from mass on a tin basis:</th>
<th>To:</th>
<th>Multiple by:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mass on a TBT cation basis</td>
<td>2.44</td>
</tr>
<tr>
<td></td>
<td>mass on a DBT cation basis</td>
<td>1.96</td>
</tr>
<tr>
<td></td>
<td>mass on a MBT cation basis</td>
<td>1.48</td>
</tr>
<tr>
<td></td>
<td>mass on a TMT cation basis</td>
<td>1.38</td>
</tr>
<tr>
<td></td>
<td>mass on a DMT cation basis</td>
<td>1.25</td>
</tr>
<tr>
<td></td>
<td>mass on a MMT cation basis</td>
<td>1.13</td>
</tr>
<tr>
<td></td>
<td>mass on a TPT cation basis</td>
<td>2.95</td>
</tr>
<tr>
<td></td>
<td>mass on a DPT cation basis</td>
<td>2.30</td>
</tr>
<tr>
<td></td>
<td>mass on a MPT cation basis</td>
<td>1.65</td>
</tr>
</tbody>
</table>

DBT = dibutyltin; DMT = dimethyltin; DPT = diphenyltin; MBT = monobutyltin; MMT = monomethyltin; MPT = monophenyltin; TBT = tributyltin; TMT = trimethyltin; TPT = triphenyltin
concentrations in public water supplies ranged from 1.1 to 2.2 μg/L in 42 U.S. cities and from 0.8 to 30 μg/L in 32 of 175 water supplies in Arizona (NAS 1977; WHO 1980). Tin concentrations in drinking water have been reported at <10 μg/L (WHO 2003). Tin is present in seawater at about 0.2–3 μg/L (NAS 1977; WHO 1980). Tin concentration in fresh snow from the French Alps collected in 1998 at different altitudes ranged from 157 to 436 pg/g (Veousseyre et al. 2001).

Concentrations of tributyltin (TBT) were found to range from 20 to 1,800 ng TBT/L in the Chesapeake Bay area, Maryland (Hall 1988). In surface waters from San Diego Bay, California in 1986–1989, tributyltin levels averaged 4.7–13 ng TBT/L in the north bay, 1.3–9.9 ng TBT/L in the south bay, 3.5–14 ng TBT/L in U.S. Navy pier regions, and 19–120 ng TBT/L in yacht harbors. Tributyltin concentrations in bottom waters in the San Diego Bay area ranged from 8.8 to 61 ng TBT/L. The mean tributyltin concentrations in regional surface waters from Pearl Harbor, Hawaii from 1986 to 1989 were: 0.0–6.8 ng TBT/L in channels; 0.0–4.9 ng TBT/L in outlying regions; 2.4–31 ng TBT/L in Southeast Loch; and 6.7–130 ng TBT/L in a small marina. Tributyltin concentrations in bottom waters in Pearl Harbor ranged from 0.0 to 9.7 ng TBT/L. In Honolulu harbor, surface and bottom water tributyltin concentrations were 4.8–580 and 2.6–170 ng TBT/L, respectively (Grovhoug et al. 1996). Tributyltin concentrations in surface water from the harbor area of Osaka City, Japan ranged from 2 to 33 ng TBT/L (Harino et al. 1998). Butyltin compounds were detected in 32 of the 63 seawater samples (0.5 m depth) that were collected from 18 areas along the Japanese coast from 1997 to 1999. Average butyltin concentrations were 4.6 ng MBT/L, 4.5 ng DBT/L, and 6.8 ng TBT/L from sampling stations for each of the four areas: the Pacific coast of northern Japan, the coast along the Sea of Japan, Tokyo Bay and the adjacent area, and western Japan. The highest concentrations in these four areas were found in western Japan with concentrations of 5.9 ng MBT/L, 6.9 ng DBT/L, and 20.1 ng TBT/L (Takeuchi et al. 2004).

The seasonal variations in tributyltin concentrations in marinas on Lake Ontario were studied from April to December 1998. The marinas were at Toronto, Mississauga, Oakville, Hamilton, and Fifty Point, Canada. Approximately 150–200 pleasure boats were in each marina in the summer. Tributyltin concentrations increased with increased boat activity, with a maximum concentration of 14 ng Sn/L reported in late August at Fifty Point. Concentrations of tributyltin varied at the marinas, peaking between June and September, but were always higher in the marinas compared to a reference site, Burlington, Canada, that was far from any marinas (Yang and Maguire 2000). Similar seasonal variations were seen in seawater collected from marinas and harbors from southwestern Spain. Tri-, di-, and monobutyltin concentrations were significantly higher in water collected in May and August compared to water collected in November and February. The highest concentrations were found in waters in enclosed
areas with poor water turnover. Tributyltin concentrations ranged from <0.5 to 31 ng Sn/L. Analysis for phenyltin compounds was performed, but none were found (Gomez-Ariza et al. 2001).

While many studies reported on the occurrence of organotin compounds in marine environments fewer studies reported the occurrence of organotin compounds in freshwater. A study investigating the levels of di- and tributyltin in fresh surface waters from nine sites across the United States found that, at most sites, di- and tributyltin were not detected (detection limits were 970 and 180 ng butyltin ion/L for dibutyltin and tributyltin, respectively). The highest dibutyltin concentrations were found in water sampled in 1998 from the Neuse River, North Carolina and Contentnea Creek, North Carolina at 140 and 160 ng DBT/L, respectively. Tributyltin was only detected in the Little Missouri River, North Dakota and Flat River, North Carolina at concentrations of 265 and 600 ng TBT/L, respectively (Jones-Lepp et al. 2004).

Bancon-Montigny et al. (2004) reported a monitoring study involving sampling along 11 rivers in southwest France from February to October 2001. Sites were chosen to represent specific industrial or agricultural activities. Organotin compounds were detected in most water samples; butyltin compounds were most frequently detected with concentrations generally ranging from below the detection limit (0.2 ng Sn/L) to 30 ng Sn/L. Phenyltin compounds were also detected at concentrations generally ranging from below the detection limit (0.2 ng Sn/L) to 20 ng Sn/L. High phenyltin concentrations were detected during the spring and the end of the summer and likely are derived from agricultural sources. Monophenyltin concentrations from over 400 up to 700 ng Sn/L were detected at four sampling sites. Octyltin compounds were detected as well; however, concentrations were generally lower, ranging from below the detection limit (0.2 ng Sn/L) to 15 ng Sn/L (Bancon-Montigny et al. 2004).

Mono- and dimethyltin and mono- and dibutyltin compounds have been detected in Canadian drinking water. Drinking water in Canada is distributed through PVC pipes stabilized with methyl- and butyltin compounds. Methyl- and butyltin compounds were detected at concentrations up to 22 and 43.6 ng Sn/L, respectively, in distributed water samples from six municipalities in Canada (Sadiki and Williams 1996). Tap water in 10 of 22 homes collected in February 1995 from five Canadian municipalities contained monomethyltin and dimethyltin compounds at concentrations of 0.5–257 and 0.5–6.5 ng Sn/L, respectively. No organotin compounds were detected in the tap water from the other 12 houses. No organotin compounds were detected in raw water or in water just after leaving the treatment plant, suggesting that the source of these organotin compounds was from some component of the distribution system (Sadiki et al. 1996). Canadian drinking water samples collected during the winter–spring 1996 from 28 sites and autumn 1996 from 21 sites were found to contain monomethyltin, dimethyltin, monobutyltin, and dibutyltin in ranges of <0.5–290.6, <0.5–49.1, <0.5–28.5, and <0.5–52.3 ng Sn/L,
respectively. These compounds were detected with a frequency of 84, 80, 16, and 12% in the winter–spring survey and 100, 57, 7, and 7% in the autumn survey, respectively. A summer 1996 survey of locations with the highest organotin concentrations in the winter–spring survey showed a decrease in mono- and dimethyltin concentration in 89% of the samples. This finding was consistent with laboratory studies that showed organotin release from PVC into water decreases after a few days. PVC pipe/tubing contains organotin compounds consistent with the organotin patterns found in the distributed water samples. Octyltin compounds, which are not used as stabilizers in the PVC used to distribute drinking water, were not detected in drinking water samples. Octyltin compounds are used instead as heat stabilizers in PVC for food packaging. Except for one treated water sample, no organotin compounds were detected in raw or treated water collected at the water treatment plant or in distributed water supplied through polyethylene pipes (Sadiki and Williams 1999).

Organotin compounds were measured in precipitation and fog in the forested catchment in Northeast Bavaria, Germany during 2001–2002. Mono-, di-, and tri methyl and butyl derivatives, as well as mono- and dioctyltin compounds were detected in precipitation samples collected in this study. The median total organotin concentrations in bulk precipitation, throughfall, and fog were 5.83, 14.6, and 57.1 ng Sn/L, respectively, over the year-long monitoring study. Monoalkyl tin compounds were the dominant species found in precipitation, with concentrations up to 192 ng Sn/L for monobutyltin in fog (Huang et al. 2004).

6.4.3 Sediment and Soil

Tin concentrations in soil are generally low, except in areas where tin containing minerals are present (Bulten and Meinema 1991). Tin concentrations in the earth's crust are approximately 2–3 mg/kg (Budavari 2001). Tin concentrations in soil can range from 2 to 200 mg/kg, but in areas of high tin deposits, levels of 1,000 mg/kg may occur (Schafer and Fembert 1984; WHO 1980). The mean background soil concentration in the United States is 0.89 mg/kg (Eckel and Langley 1988). Tin concentrations in topsoil (0–7.6 cm) from the western end of East St. Louis, Illinois ranged from <13 to 1,130 mg/kg. East St. Louis has a history of industrial facilities including smelters of ferrous and nonferrous metals, a coal-fired power plant, chemical producing companies, and petroleum refineries (Kaminski and Landsberger 2000a). Sediment cores collected in January 1996 from Central Park Lake in New York City, New York contained average tin concentrations ranging from 4.0 mg/kg at 44–47 cm depth to 67 mg/kg at 22–24 cm depth. The average tin concentration in surface sediments (0–2 cm depth) in Central Park Lake was 32 mg/kg. The similarities between the history of municipal solid waste incineration in New York City and the accumulation of trace metals in the Central Park Lake sediments
appear to be consistent with incineration being the major source of several metals to the New York City atmosphere (Chillrud et al. 1999). Tin concentrations in sediments from the Wah Chang Ditch and the northeast corner of Swan Lake, an area that received runoff from a Texas tin smelter during the 1940s and 1950s, were found to be as high as 8,000 mg/kg (Park and Presley 1997).

Organotin concentrations in sediment are summarized in Table 6-2. While tributyltin concentrations in water have declined since restrictions on tributyltin use in paints have been in place, concentrations of tributyltin in sediments have remained relatively high. Degradation of tributyltin in sediment is much slower than in the water column. Recent surveys of tributyltin concentrations in harbors and marinas in various countries show concentrations ranging from hundreds of parts per billion (μg/kg) to low parts per million (mg/kg) (Meador 2000). Tributyltin concentrations in sediment samples from the harbor area of Osaka City, Japan ranged from 0.002 to 0.966 mg TBT/kg dry weight (Harino et al. 1998). Sediment in southwestern Spain during November 1993–February 1994 and May–August 1994 were analyzed for the presence of butyl- and phenyltin compounds. No phenyltin species were found in sediment, but mono-, di-, and tributyltin were found at all stations sampled, with concentrations of tributyltin ranging from <0.0006 to 0.16 mg Sn/kg dry weight. Increased concentrations of organotin concentration during summer months were not observed in the sediment, as they were in water and biota, and may be due to vertical mixing of the sediment layers by natural and boating activities (Gomez-Ariza et al. 2001). Tri-, di-, and monobutyltin were detected in superficial sediment samples from five river estuaries (Deba, Urola, Oria, Oiartzun, and Bidasoa) of Gipuzkoa, North Spain at concentrations of 0.05–5.48, 0.15–0.71, and 0.86–2.87 mg Sn/kg dry weight, respectively. Except for one sampling point, monobutyltin, a degradation product of tributyltin, accounted for the largest percentage of total butyltin (>47%) (Arambarri et al. 2003). Sediments collected in November 1997 from three sites near Nuuk, Greenland contained tributyltin concentrations ranging from <0.001 to 0.171 mg Sn/kg dry weight (Jacobsen and Asmund 2000). Tributyltin concentrations were measured in sediment collected in 1997 and 1999 from transects along and perpendicular to the shipping lanes in the Sound (Øresund) and the Kattegat/Skagerrak region, an important shipping strait between Denmark and Sweden. Tributyltin concentrations ranged from 0.0015 to 0.0188 mg TBT/kg dry weight in the Sound and were below the detection limit (<0.001 mg TBT/kg dry weight) in the Kattegat region. A strong correlation was observed between tributyltin concentration and the organic fraction in sediment samples from the Sound (Strand et al. 2003).

Bancon-Montigny et al. (2004) reported a monitoring study involving sampling along 11 rivers in southwest France from February to October 2001. Sites were chosen to represent specific industrial or
### Table 6-2. Organotin Levels in Sediment

<table>
<thead>
<tr>
<th>Nature/location of sediment</th>
<th>Concentration of organotin compound</th>
<th>Units</th>
<th>Reported as</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central-west Greenland, near Nuuk Harbor, surface sediment</td>
<td>TBT</td>
<td>DBT</td>
<td>MBT</td>
<td>mg Sn/kg dw</td>
</tr>
<tr>
<td>Sandkaj</td>
<td>0.0097</td>
<td>0.0039</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Havnén</td>
<td>0.171</td>
<td>0.0096</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Hundeøen</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>St. Lawrence River in the Quebec City area, surface sediments</td>
<td>TBT</td>
<td>DBT</td>
<td>MBT</td>
<td>DPT</td>
</tr>
<tr>
<td>Portneuf</td>
<td>0.097</td>
<td>0.286</td>
<td>0.989</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sillery</td>
<td>0.146</td>
<td>0.165</td>
<td>0.087</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Quai Lévis</td>
<td>0.173</td>
<td>0.496</td>
<td>0.123</td>
<td>0.015</td>
</tr>
<tr>
<td>Bassin Louise</td>
<td>0.888</td>
<td>0.997</td>
<td>0.203</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Outside Bassin Louise</td>
<td>0.807</td>
<td>0.634</td>
<td>0.185</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>St. Charles River</td>
<td>0.330</td>
<td>0.579</td>
<td>0.165</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>St. Lawrence Marina</td>
<td>0.209</td>
<td>0.389</td>
<td>0.004</td>
<td>0.101</td>
</tr>
<tr>
<td>Île d’Orléans East</td>
<td>0.211</td>
<td>0.045</td>
<td>0.006</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Superficial sediments from five river estuaries (Deba, Urola, Oria, Oiatzun, and Bidasoa) of Gipuzkua, North Spain, October 2000</td>
<td>TBT</td>
<td>DBT</td>
<td>MBT</td>
<td>mg Sn/kg dw</td>
</tr>
<tr>
<td></td>
<td>0.05–5.48</td>
<td>0.15–0.71</td>
<td>0.86–2.87</td>
<td></td>
</tr>
<tr>
<td>Huelva coast, southwest Spain (November 1993–February 1994)</td>
<td>TBT</td>
<td>DBT</td>
<td>MBT</td>
<td>mg Sn/kg dw</td>
</tr>
<tr>
<td>Canela</td>
<td>0.0067</td>
<td>0.017</td>
<td>0.0032</td>
<td></td>
</tr>
<tr>
<td>Pinillos</td>
<td>0.0009</td>
<td>0.0026</td>
<td>0.0015</td>
<td></td>
</tr>
<tr>
<td>Carreras River</td>
<td>0.0140</td>
<td>0.080</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>Idla Cristina harbor</td>
<td>0.090</td>
<td>0.090</td>
<td>0.035</td>
<td></td>
</tr>
<tr>
<td>Cantil marina</td>
<td>0.100</td>
<td>0.270</td>
<td>0.080</td>
<td></td>
</tr>
<tr>
<td>Punta Caiman</td>
<td>0.0028</td>
<td>0.0037</td>
<td>0.0012</td>
<td></td>
</tr>
<tr>
<td>Isla Cristina breakwater (inner part)</td>
<td>&lt;0.0006</td>
<td>&lt;0.0007</td>
<td>0.0034</td>
<td></td>
</tr>
<tr>
<td>Terron harbor</td>
<td>28.0</td>
<td>46.0</td>
<td>45.0</td>
<td></td>
</tr>
<tr>
<td>Palo</td>
<td>2.0</td>
<td>3.6</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>Rompido marina</td>
<td>130.0</td>
<td>40.0</td>
<td>24.0</td>
<td></td>
</tr>
<tr>
<td>Pino</td>
<td>0.8</td>
<td>0.7</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Punta Umbria harbor</td>
<td>16.0</td>
<td>69.0</td>
<td>13.0</td>
<td></td>
</tr>
</tbody>
</table>
### Table 6-2. Organotin Levels in Sediment

<table>
<thead>
<tr>
<th>Nature/location of sediment</th>
<th>Concentration of organotin compound</th>
<th>Units</th>
<th>Reported as</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Six sites from the lowermost Tennessee River and Kentucky Lake, United States, surface sediments (0–5 cm)</td>
<td>MBT</td>
<td>DBT</td>
<td>TBT</td>
<td>mg/kg dw(^a)</td>
</tr>
<tr>
<td></td>
<td>&lt;0.003–</td>
<td>&lt;0.001–</td>
<td>0.0053– 0.320</td>
<td>0.014</td>
</tr>
<tr>
<td>Thirteen sites in the Sound (Øresund) between Denmark and Sweden, surface sediments, 1997</td>
<td>NR</td>
<td>NR</td>
<td>0.0015– 0.0188</td>
<td>mg/kg dw(^a)</td>
</tr>
<tr>
<td>Twenty-four sites from Coddington Cove, Newport, Rhode Island, United States, surface sediments (0–2 cm), 1993 and 1994</td>
<td>NR</td>
<td>NR</td>
<td>0.032–0.372 mg Sn/kg dw</td>
<td>Range</td>
</tr>
<tr>
<td>Eighteen sites from 11 rivers in southwest France, surface sediments, July 2001</td>
<td>0.016– 0.125</td>
<td>0.001– 0.087</td>
<td>0.0013– 0.089</td>
<td>mg Sn/kg dw</td>
</tr>
<tr>
<td>Eighteen sites from 11 rivers in southwest France, surface sediments, September 2001</td>
<td>0.001– 0.048</td>
<td>ND– 0.037</td>
<td>ND–0.020</td>
<td>mg Sn/kg dw</td>
</tr>
</tbody>
</table>

\(^a\)Concentration reported as mg butyltin ion/kg sediment.

DBT = dibutyltin; DPT = diphenyltin; dw = dry weight; MBT = monobutyltin; ND = not detected; NR = no data reported; SD = standard deviation; TBT = tributyltin; TPT = triphenyltin
agricultural activities. Mono-, di-, and tributyltin were present in nearly all surface sediment samples with concentrations ranging from 0.001 to 0.125, not detected to 0.087, and not detected to 0.089 mg Sn/kg dry weight, respectively. Mono-, di-, and triphenyltin and mono-, di-, and triocetyltn were also detected in some sediment samples, but with less frequency and generally at lower concentrations than the butyltin compounds (Bancon-Montigny et al. 2004).

Tri-, di-, and monobutyltin were detected in all sediment samples collected in the Quebec City harbor area of the St. Lawrence River with concentrations of 0.097–0.888, 0.045–0.997, and 0.004–0.989 mg Sn/kg dry weight, respectively. Diphenyltin was detected in two sites at concentrations of 0.015 and 0.101 mg Sn/kg dry weight. The organotin contamination found in this study was more comparable to levels reported for Canadian marine harbor sites than to freshwater harbor sites (Regoli et al. 2001). Tributyltin and dibutyltin concentrations in surface sediments (0–2 cm) collected in 1990 and 1992 from intertidal sites in Portland and Boothbay Harbor, Maine ranged from 0.024 to 12.4 mg TBT/kg and from 0.015 to 2.23 mg DBT/kg dry weight (Page et al. 1996). Tributyltin was detected in all 24 surface sediment (0–20 cm) samples collected from Coddington Cove, Newport, Rhode Island on November 3, 1993 and June 13, 1994; concentrations ranged from 0.032 to 0.372 mg Sn/kg dry weight with a mean concentration of 0.146 mg Sn/kg dry weight. Sediment cores of varying depth (up to 18 cm) were obtained from seven stations. Tributyltin was detected in all of these samples and ranged from 0.0073 to 0.225 mg Sn/kg dry weight. No consistent trends were observed in the tributyltin concentrations with depth, suggesting that mixing is an important process in the sediment column (Wade et al. 2004). Kentucky Lake constitutes the northernmost end of a shipping route for large barges and small ships between the Gulf of Mexico and the Ohio River. The lowermost Tennessee River receives industrial waste water from several industries in the Calvert City Industrial Complex. Total butyltin (BT) concentrations in the sediments of the lowermost Tennessee River and Kentucky Lake ranged from 0.0068 to 0.356 mg BT/kg dry weight (Loganathan et al. 1999).

6.4.4 Other Environmental Media

Tin and tributyltin concentrations found in foods are summarized in Tables 6-3 and 6-4, respectively. Tin concentrations of vegetables, fruits and fruit juices, nuts, dairy products, meat, fish, poultry, eggs, beverages, and other foods not packaged in metal cans are generally <2 mg/kg. Tin concentrations in pastas and breads have been reported to range from <0.003 to 0.03 mg/kg. Mean tin concentrations ranging from <1 to 1,000 mg/kg have been found in foods packaged in unlacquered or partially lacquered cans, while the average tin concentration in foods in lacquered cans has been reported to be 0–6.9 mg/kg.
6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Tin Levels in Food

<table>
<thead>
<tr>
<th>Food item</th>
<th>Concentration (mg/kg)</th>
<th>Reported as</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dietary intake in a French adult</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preserved foods in unlacquered cans</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tomatoes (n=3)</td>
<td>84 (46–156)</td>
<td>Mean, range</td>
</tr>
<tr>
<td>Artichoke (n=1)</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>Mushrooms (n=3)</td>
<td>34 (24–45)</td>
<td></td>
</tr>
<tr>
<td>Pineapples (n=5)</td>
<td>82 (44–136)</td>
<td></td>
</tr>
<tr>
<td>Fruit cocktail (n=2)</td>
<td>97 (88–107)</td>
<td></td>
</tr>
<tr>
<td>Peaches (n=3)</td>
<td>44 (27–71)</td>
<td></td>
</tr>
<tr>
<td>Pears (n=2)</td>
<td>47 (35–60)</td>
<td></td>
</tr>
<tr>
<td>Apricot (n=1)</td>
<td>114</td>
<td></td>
</tr>
<tr>
<td>Stewed fruit (n=1)</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Grapefruit (n=1)</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td><strong>Preserved foods in lacquered cans</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bean (n=1)</td>
<td>2.4</td>
<td>Mean, range</td>
</tr>
<tr>
<td>Tomatoes (n=2)</td>
<td>6.0 (3.2–8.8)</td>
<td></td>
</tr>
<tr>
<td>Asparagus (n=2)</td>
<td>3.9 (1.4–6.5)</td>
<td></td>
</tr>
<tr>
<td>Garden peas (n=1)</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Mushrooms (n=2)</td>
<td>6.9 (0.4–13.4)</td>
<td></td>
</tr>
<tr>
<td>Apricot (n=1)</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>Cherry (n=1)</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Strawberry (n=1)</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Papaya (n=1)</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>Meats (n=4)</td>
<td>4.5 (1.1–9.4)</td>
<td></td>
</tr>
<tr>
<td>Fishes (n=4)</td>
<td>0.7 (0.3–0.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Fresh foods</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carrots (n=4)</td>
<td>0.08 (0.07–0.09)</td>
<td>Mean, range</td>
</tr>
<tr>
<td>Cabbage (n=1)</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Endive (n=1)</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>Spinach (n=4)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Bean (n=1)</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Leek (n=1)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Potatoes (n=5)</td>
<td>0.1 (0.1–0.2)</td>
<td></td>
</tr>
<tr>
<td>Salad (n=4)</td>
<td>0.02 (0.01–0.03)</td>
<td></td>
</tr>
<tr>
<td>Tomatoes (n=4)</td>
<td>0.05 (0.04–0.06)</td>
<td></td>
</tr>
<tr>
<td>Lentils (n=2)</td>
<td>0.13 (0.09–0.17)</td>
<td></td>
</tr>
<tr>
<td>Bananas (n=3)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Oranges (n=3)</td>
<td>0.07 (0.06–0.08)</td>
<td></td>
</tr>
<tr>
<td>Pears (n=3)</td>
<td>0.07 (0.06–0.08)</td>
<td></td>
</tr>
<tr>
<td>Apples (n=4)</td>
<td>0.04 (0.02–0.07)</td>
<td></td>
</tr>
<tr>
<td>Apricots (n=2)</td>
<td>0.07 (0.06–0.08)</td>
<td></td>
</tr>
<tr>
<td>Alcoholic beverages (n=10)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
</tbody>
</table>
### Table 6-3. Tin Levels in Food

<table>
<thead>
<tr>
<th>Food item</th>
<th>Concentration (mg/kg)</th>
<th>Reported as</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mineral waters (n=5)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Nonalcoholic beverages (n=10)</td>
<td>0.04 (&lt;0.003–0.13)</td>
<td></td>
</tr>
<tr>
<td>Fishes and crustaceans (n=10)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Breads (n=6)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Pasta (n=12)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Meats (n=15)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Cooked pork meats (n=10)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Milk (n=10)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Dairy products (n=10)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Sugar (n=5)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Chocolate (n=1)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
<tr>
<td>Oil (n=4)</td>
<td>&lt;0.003</td>
<td></td>
</tr>
</tbody>
</table>

*aSource: Biego et al. 1999*
### Table 6-4. Tributyltin (TBT) Levels in Food

<table>
<thead>
<tr>
<th>Food item</th>
<th>Concentration (ng TBT/g) wet weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seafood from eight markets worldwide</strong></td>
<td><strong>Reported as mean</strong></td>
</tr>
<tr>
<td>Ulsan, Korea</td>
<td></td>
</tr>
<tr>
<td>Mussel, soft tissue</td>
<td>115</td>
</tr>
<tr>
<td>Shrimp, whole body</td>
<td>33</td>
</tr>
<tr>
<td>Squid, muscle</td>
<td>23</td>
</tr>
<tr>
<td>Shrimp, tail only</td>
<td>19</td>
</tr>
<tr>
<td>Chub mackerel, muscle</td>
<td>12</td>
</tr>
<tr>
<td>Flounder, muscle</td>
<td>9.4</td>
</tr>
<tr>
<td>Marseille, France</td>
<td></td>
</tr>
<tr>
<td>European squid, muscle</td>
<td>655</td>
</tr>
<tr>
<td>European squid, common cuttlefish, elegant</td>
<td>376</td>
</tr>
<tr>
<td>Mediterranean mussel, soft tissue</td>
<td>87</td>
</tr>
<tr>
<td>Red tuna, muscle</td>
<td>56</td>
</tr>
<tr>
<td>Common cuttlefish, muscle</td>
<td>14</td>
</tr>
<tr>
<td>Elegant cuttlefish, muscle</td>
<td>13</td>
</tr>
<tr>
<td>Green crab, muscle</td>
<td>3.6</td>
</tr>
<tr>
<td>Lemon sole, Senegalse sole, muscle</td>
<td>Not detected</td>
</tr>
<tr>
<td>Galveston, Texas, United States</td>
<td></td>
</tr>
<tr>
<td>Pacific oyster, American oyster, soft tissue</td>
<td>72</td>
</tr>
<tr>
<td>Squid, muscle</td>
<td>16</td>
</tr>
<tr>
<td>Shrimp, whole body</td>
<td>12</td>
</tr>
<tr>
<td>Shrimp, tail only</td>
<td>11</td>
</tr>
<tr>
<td>Southern flounder, tropical flounder, muscle</td>
<td>6</td>
</tr>
<tr>
<td>Oyster, soft tissue</td>
<td>4.6</td>
</tr>
<tr>
<td>Blue runners, Atlantic bonito, muscle</td>
<td>4.5</td>
</tr>
<tr>
<td>Singapore</td>
<td></td>
</tr>
<tr>
<td>Mackerel, muscle</td>
<td>23</td>
</tr>
<tr>
<td>Bigeye tuna, muscle</td>
<td>20</td>
</tr>
<tr>
<td>Mitre squid, muscle</td>
<td>12</td>
</tr>
<tr>
<td>Short-necked clam, soft tissue</td>
<td>5.6</td>
</tr>
<tr>
<td>Indian halibut, muscle</td>
<td>3.9</td>
</tr>
<tr>
<td>Crab, muscle</td>
<td>3.1</td>
</tr>
<tr>
<td>Silver pomfret, muscle</td>
<td>2.8</td>
</tr>
<tr>
<td>Stockholm, Sweden</td>
<td></td>
</tr>
<tr>
<td>Atlantic herring, muscle</td>
<td>36</td>
</tr>
<tr>
<td>Common mussel, blue mussel, soft tissue</td>
<td>22</td>
</tr>
<tr>
<td>European eel, muscle</td>
<td>2.8</td>
</tr>
<tr>
<td>Plaice, muscle</td>
<td>2.5</td>
</tr>
<tr>
<td>Atlantic salmon, muscle</td>
<td>Not detected</td>
</tr>
</tbody>
</table>
### Table 6-4. Tributyltin (TBT) Levels in Food

<table>
<thead>
<tr>
<th>Food item</th>
<th>Concentration (ng TBT/g) wet weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sydney, Australia</strong></td>
<td></td>
</tr>
<tr>
<td>Slimy mackerel, muscle</td>
<td>13</td>
</tr>
<tr>
<td>Sydney rock oyster, soft tissue</td>
<td>9.2</td>
</tr>
<tr>
<td>Butterfly fan lobster, muscle (tail)</td>
<td>7.2</td>
</tr>
<tr>
<td>Arrow squid, cuttlefish, muscle</td>
<td>7</td>
</tr>
<tr>
<td>Tiger flathead, muscle</td>
<td>6</td>
</tr>
<tr>
<td>Yellowtail kingfish, muscle</td>
<td>5.3</td>
</tr>
<tr>
<td>Largetooth flounder, muscle</td>
<td>4.2</td>
</tr>
<tr>
<td><strong>Halifax, Canada</strong></td>
<td></td>
</tr>
<tr>
<td>Longfin inshore squid, muscle</td>
<td>8.9</td>
</tr>
<tr>
<td>Cock shrimp, whole body</td>
<td>7.7</td>
</tr>
<tr>
<td>Common mussel, soft tissue</td>
<td>5.6</td>
</tr>
<tr>
<td>Witch flounder, muscle</td>
<td>2.7</td>
</tr>
<tr>
<td>Atlantic salmon, muscle</td>
<td>Not detected</td>
</tr>
<tr>
<td>Cock shrimp, tail only</td>
<td>Not detected</td>
</tr>
<tr>
<td><strong>London, England</strong></td>
<td></td>
</tr>
<tr>
<td>Oyster, soft tissue</td>
<td>43</td>
</tr>
<tr>
<td>Shrimp, muscle</td>
<td>13.9</td>
</tr>
<tr>
<td>Atlantic herring, muscle</td>
<td>11</td>
</tr>
<tr>
<td>Squid, muscle</td>
<td>7.9</td>
</tr>
<tr>
<td>Mackerel, muscle</td>
<td>7.3</td>
</tr>
<tr>
<td>Mussel, soft tissue</td>
<td>5.9</td>
</tr>
<tr>
<td><strong>Seafood from six markets in the United States</strong>[^b]</td>
<td>Reported as mean summer, winter</td>
</tr>
<tr>
<td>San Pedro, California</td>
<td></td>
</tr>
<tr>
<td>Bottom fish</td>
<td>7.1, 1.7</td>
</tr>
<tr>
<td>Crustaceans</td>
<td>1.2, 1.1</td>
</tr>
<tr>
<td>Mollusks</td>
<td>13, 1.5</td>
</tr>
<tr>
<td>Pensacola, Florida</td>
<td></td>
</tr>
<tr>
<td>Bottom fish</td>
<td>2.1, 1.4</td>
</tr>
<tr>
<td>Crustaceans</td>
<td>1.0, 1.4</td>
</tr>
<tr>
<td>Mollusks</td>
<td>2.0, no data</td>
</tr>
<tr>
<td>Chicago, Illinois</td>
<td></td>
</tr>
<tr>
<td>Freshwater fish</td>
<td>5.9, 3.2</td>
</tr>
<tr>
<td>Boston, Massachusetts</td>
<td></td>
</tr>
<tr>
<td>Bottom fish</td>
<td>1.3, 1.2</td>
</tr>
<tr>
<td>Mollusks</td>
<td>3.1, 0.70</td>
</tr>
<tr>
<td>Baltimore, Maryland</td>
<td></td>
</tr>
<tr>
<td>Bottom fish</td>
<td>1.3, 23</td>
</tr>
<tr>
<td>Crustaceans</td>
<td>1.2, 1.0</td>
</tr>
<tr>
<td>Mollusks</td>
<td>3.3, 0.54</td>
</tr>
</tbody>
</table>

[^b]: Reported as mean summer, winter
Table 6-4. Tributyltin (TBT) Levels in Food

<table>
<thead>
<tr>
<th>Food item</th>
<th>Concentration (ng TBT/g) wet weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle, Washington</td>
<td></td>
</tr>
<tr>
<td>Bottom fish</td>
<td>0.98, 1.0</td>
</tr>
<tr>
<td>Crustaceans</td>
<td>2.4, 1.2</td>
</tr>
<tr>
<td>Pen-reared fish</td>
<td>5.2, 14</td>
</tr>
</tbody>
</table>

*aKeithly et al. 1999  
*bCardwell et al. 1999b*
6. POTENTIAL FOR HUMAN EXPOSURE

Data from the Can Manufacturers Institute (CMI 1988) indicate that >90% of tin-lined cans used for food today are lacquered. Only light colored fruit and fruit juices are packed in unlacquered cans, since tin helps maintain the color of the fruit. Tin content in foods stored in opened metal cans increases over time, since tin can rapidly dissolve in the presence of oxygen. Acidic foods are more aggressive to the tin coating in metal cans, and canned acidic foods have higher tin contents. Tin concentrations of canned foods increase with storage time and temperature (WHO 2003).

Tin concentrations in various foods were determined in a dietary tin intake study for adults in France. Foods in lacquered cans generally were found to contain tin concentrations below 10 mg/kg, and tin concentrations ranged from 24 to 156 mg/kg in food from unlacquered cans. The average tin concentration in fresh foods was 0.03 mg/kg (Biégo et al. 1999). Canned vegetables and fruit products were found to have mean tin concentrations of 44 and 17 mg/kg fresh weight, respectively, in a 1994 total diet study in the United Kingdom (Ysart et al. 1999). A study of metal concentration in canned milk products in Lithuania showed that the content of tin in canned milk exceeded the concentration in raw milk, which, in 1990–1992, was on average 0.22 mg/kg. Mean tin concentrations in evaporated sterilized milk, concentrated sterilized milk, and sweetened condensed milk were 85, 89, and 40 mg/kg, respectively. Tin concentrations in canned milk were shown to increase during storage (Ramonaiytė 2001). Local and imported edible seaweeds obtained in British Columbia were found to contain tin in concentrations ranging from 0.01 to 0.46 mg/kg dry weight (van Netten et al. 2000).

Samples of fish, crustaceans, cephalopods (i.e., squid), and bivalve mollusks were purchased from markets in Stockholm, Sweden; London, England; Marseille, France; Singapore; Ulsan, Korea; Sydney, Australia; Galveston, United States; and Halifax, Canada during August and September 1997 and analyzed for tributyltin content. Average tributyltin concentrations for bivalves, pelagic fish, pelagic invertebrates, and flatfish were 40, 16, 7.4, and 4.6 μg TBT/kg, respectively. It was noted that the high concentrations in bivalves were expected. The lower concentrations of tributyltin found in flatfish were unexpected, since flatfish live on sediment and consume mostly benthic prey. Sediment is considered a sink for tributyltin in aquatic environments (Keithly et al. 1999). In a similar study, seafood was purchased in August 1989 and January 1990, representing a summer and winter sample, from Boston, Massachusetts; Baltimore, Maryland; Seattle, Washington; Pensacola, Florida; San Pedro, California; and Chicago, Illinois. These locations represented major fishing and aquaculture areas on the coasts of the United States and the Great Lakes. Categories of seafood sampled were bottom fish, crustacea, freshwater fish, mollusks, and maricultured fish. Tributyltin was detected in 35% of samples analyzed. Seafood purchased during the summer was found to have slightly higher tributyltin concentrations.
compared to seafood purchased in the winter in 10 of the 15 instances where the same or similar species were sampled from the same location during the summer and winter surveys. Elevated tributyltin concentrations in seafood sampled during the summer were believed to be consistent with increased recreational boat activity in the summer. Mean tributyltin summer concentrations for bottom fish, crustaceans, and mollusks were 0.98–7.1, 1.0–2.4, and 2.0–13 μg TBT/kg, respectively. Mean tributyltin winter concentrations for the same seafood categories were 1.0–23, 1.0–1.4, and 0.54–6.3 μg TBT/kg, respectively. The respective summer and winter mean concentrations of tributyltin were 5.9 and 3.2 μg TBT/kg in freshwater fish from Chicago, Illinois and 5.2 and 14 μg TBT/kg for pen-reared fish from Seattle, Washington (Cardwell et al. 1999b).

Tributyltin and triphenyltin concentrations were determined in foods in a market basket study. About 100 kinds of foods were purchased every year in 1990–1993 in Shiga Prefecture, Japan. Foods were divided into 13 groups: I, rice; II, cereals, grains, and potatoes; III, sugar and cakes; IV, fats and oils; V, bean products; VI, fruits; VII, green vegetables; VIII, other vegetables and seaweeds; IX, seasonal beverages; X, fish, mollusks, and crustaceans; XI, meats and eggs; XII, milk and dairy products; and XIII, cooked meats (curry and hash). Tributyltin and triphenyltin (TPT) were only detected in group X (fish, mollusks, and crustaceans) and group VIII (vegetables and seaweeds), with higher levels in group X (5.2 μg TBT and 0.4 μg TPT), than in group VIII (0.2 μg TBT and 0 μg TPT) (Tsuda et al. 1995). Twenty-two samples of gin, martini, cognac, red wine, and sherry that were stored in plastic containers, used in Canada for storage of alcoholic beverages, were analyzed for dioctyltin compounds, dioctyltin S,S'-bis(isooctyl mercaptoacetate). Beverages tested contained <40 μg/L tin. While these plastic containers contained up to 1,700 μg Sn/g, and these dioctyltin compounds were soluble in alcohol (64.7 and 150 μg/mL, respectively), there was no evidence of leaching in any samples analyzed (Méranger 1975).

Tin and organotin concentrations found in human tissues and fluids are summarized in Table 6-5. Tin was detected in nine human adipose tissue samples during the 1982 National Human Adipose Tissue Survey at concentrations ranging from 4.6 to 15 μg/g (Stanley 1986). Urine samples were selected from the available archived urine specimens from participants in the National Health and Nutrition Examination Survey (NHANES) III, conducted from 1988 to 1994. The 500 samples were chosen to represent a broad range of the U.S. population. Tin was detected in 89% of samples (detection limit, 0.1 μg/L) and had a 95th upper percentile concentration of 20.1 μg/L (Paschal et al. 1998). Tissue samples from various organs were obtained from 20 deceased individuals (15 men and 5 women), who, at the time of their death, lived in Terragona, Spain and the surrounding areas for at least 10 years. No known
### Table 6-5. Tin and Organotin Levels in Human Tissues and Fluids

<table>
<thead>
<tr>
<th>Human tissue or fluid</th>
<th>Concentration</th>
<th>Units</th>
<th>Reported as</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adipose tissue, (n=9)</td>
<td>4.6–15</td>
<td>μg/g</td>
<td>Range</td>
<td>Stanley 1986</td>
</tr>
<tr>
<td>Urine, NHANES, (n=500)</td>
<td>20.1</td>
<td>μg/L</td>
<td>95th upper percentile</td>
<td>Paschal et al. 1998</td>
</tr>
<tr>
<td>Urine (n=14) non-exposed men and women, Germany</td>
<td>1.8 (1.0–2.7)</td>
<td>μg/L</td>
<td>Mean (range)</td>
<td>Schramel et al. 1997</td>
</tr>
<tr>
<td>Terragona, Spain (n=20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>0.98 (0.28–4.57)</td>
<td>μg/g ww</td>
<td>Mean (range)</td>
<td>Llobet et al. 1998</td>
</tr>
<tr>
<td>Bone</td>
<td>6.18 (2.72–17.32)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>1.54 (0.68–3.04)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>4.44 (1.84–10.16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>1.74 (0.67–6.54)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Terragona, Spain (n=78)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>0.27 (0.23–0.74)</td>
<td>μg/g ww</td>
<td>Mean (range)</td>
<td>Garcia et al. 2001</td>
</tr>
<tr>
<td>Bone</td>
<td>0.47 (0.45–0.76)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>0.25 (0.23–0.43)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>0.16 (0.09–0.27)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>0.24 (0.23–0.31)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organotin compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood (n=32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central Michigan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monobutyltin</td>
<td>0.00817</td>
<td>μg/mLa</td>
<td>Mean</td>
<td>Kannan et al. 1999</td>
</tr>
<tr>
<td>Dibutyltin</td>
<td>0.00494</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tributyltin</td>
<td>0.00818</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland (n=9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total butyltin (MBT+DBT+TBT)</td>
<td>0.0024–0.0110</td>
<td>μg/g ww</td>
<td>Range</td>
<td>Kannan and Falandysz 1997</td>
</tr>
<tr>
<td>Denmark (n=18)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monobutyltin</td>
<td>0.0003–0.0047</td>
<td>μg/g ww</td>
<td>Range</td>
<td>Nielsen and Strand 2002</td>
</tr>
<tr>
<td>Dibutyltin</td>
<td>0.0008–0.0283</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tributyltin</td>
<td>&lt;0.0003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triphenyltin</td>
<td>&lt;0.003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan (n=4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monobutyltin</td>
<td>0.018 (0.012–0.022)</td>
<td>μg/g ww</td>
<td>Mean (range)</td>
<td>Takahashi et al. 1999</td>
</tr>
<tr>
<td>Dibutyltin</td>
<td>0.066 (0.045–0.078)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tributyltin</td>
<td>&lt;0.0020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*aConcentrations of organotins are reported in μg organotin species/g or mL.

DBT = dibutyltin; MBT = monobutyltin; TBT = tributyltin; ww = wet weight
occupational exposure to metals was found for these subjects based on a questionnaire sent to relatives. Tin concentrations were lowest in brain tissue and highest in bone at 0.98 and 6.18 μg/g wet weight, respectively. No significant differences in tin concentrations were noted based on gender or age (Llobet et al. 1998). In a similar study, samples of liver, lung, kidney, brain, and bone were collected from 78 adult subjects (57 men and 21 women) autopsied between 1997 and 1999 who at the time of death lived in Tarragona County, Spain or in the surroundings for the last 10 years. Autopsy records included data on gender, age, occupation, residence, and smoking and drinking habits. No occupational exposure to heavy metals was found in this group. Ages ranged from 36 to 76 years, 55% were considered smokers, and 24% were considered drinkers. An individual was considered a smoker if he or she smoked more than one pack of cigarettes per day for at least 1 year of his or her life. Men who consumed more than 280 g of alcohol per week (168 g for women) were considered drinkers. Place of residence was divided into three areas: (a) near the petrochemical industry, (b) near the petroleum refineries and municipal solid waste incinerator, and (c) urban area (downtown). For tin concentrations in the tissues studied, no significant differences between sex, smoking and drinking habits, or places of residence were found. One exception was in the kidney, where tin concentrations were slightly higher in drinkers (García et al. 2001).

Butyltin compounds were measured in human blood collected in July 1998 in central Michigan from 17 male and 15 female individuals. Mono-, di-, and tributyltin were detected in 53, 81, and 70% of the samples. Mono-, di-, and tributyltin concentrations ranged from below the detection limit to maximum concentrations of 0.027, 0.016, and 0.085 μg organotin ion/mL, respectively. Total butyltin concentrations ranged from below the detection limit to 0.101 μg BT/mL (Kannan et al. 1999). Human liver samples from nine individuals, aged 45–83, obtained from the Gdansk School of Medicine, Poland in March 1994, were found to contain total butyltin (mono-, di-, and tributyltin) concentrations ranging from 0.0024 to 0.011 μg BT/g wet weight (Kannan and Falandysz 1997). Four human liver samples obtained by autopsy in Ehime University Hospital, Japan in 1997 and 1998 were found to contain average concentrations of mono-, di-, tributyltin, and total butyltin of 0.018, 0.066, <0.002, and 0.084 μg organotin ion/g wet weight, respectively (Takahashi et al. 1999). Liver samples from 18 deceased Danish men aged 21–82 were collected from December 1999 to January 2000 at the Institute for Forensic Medicine, SDU, Odense University. Concentrations of tributyltin and triphenyltin were all below the detection limit, <0.0003 μg TBT/g and <0.003 μg TPT/g. Mean concentrations (and ranges) of mono- and dibutyltin were 0.0016 (0.0003–0.0047) μg MBT/g and 0.009 (0.0008–0.0283) μg DBT/g wet weight. A large interperson variability was noted for this sample with a more than 25-fold difference between the lowest and highest dibutyltin liver concentration (Nielsen and Strand 2002).
Ten individual indoor dust samples were collected from 10 regions from the United Kingdom in 2002. Samples were collected primarily from private households, but also included some businesses. Samples were analyzed for various chemicals including eight organotin compounds, mono-, di-, tri-, and tetrabutyltin, mono- and diocyltin, tricyclohexyltin, and triphenyltin. Mono-, di- and tributyltin, and mono- and dioclytin were found in all pooled regional samples, and mean concentrations were 1.375, 0.563, 0.1445, 0.4506, and 0.1292 μg organotin ion/g, respectively. Triphenyltin was found in only one pooled sample, at a concentration of 0.0069 μg TPT/g. Tetrabutyltin and trihexyltin were not detected. Detection limits were 0.001 μg organotin ion/g dry weight. Possible sources of these organotin compounds in the home may be from the use of butyl- and octyltin compounds as stabilizers in PVC. In addition, tributyltin is used as a fungicide and as treatment against dust-mites in carpets and textiles. Dust samples from Denmark, Finland, France, Spain, and Sweden showed similar patterns of organotin contents as found in the United Kingdom samples (Santillo et al. 2003).

Tin concentrations in the kidneys of mink collected from the Kootenay River and lower Fraser River in British Columbia, Canada were 6.25 and 5.5 μg/g dry weight. Tin concentrations in the livers of mink from the upper and lower Fraser River were 5.53 and 5.17 μg/g dry weight, respectively. Tin concentrations in the livers of otters were <4 μg/g dry weight collected from the Kootenay, lower and upper Columbia, and upper Fraser Rivers, and 2.67 μg/g from the lower Fraser River (Harding et al. 1998). Tin concentrations in mantle muscle and liver samples of juvenile Japanese common squid, *Todarodes pacificus*, collected from three locations in and near Japanese coasts, were 0.042–0.050 and 0.077–0.13 μg/g wet weight, respectively (Ichihashi et al. 2001).

Concentrations of butyltin (mono-, di-, and tributyltin) compounds were determined in the kidney and liver of 18 species of seabirds collected between the mid-1980s and mid-1990s from Japan, Korea, the North Pacific Ocean, and the southern Indian Ocean. The highest mean total butyltin concentrations were found in the kidney and liver of inland and coastal birds. The highest mean concentrations of butyltins (BT) were found in common cormorants from Lake Biwa, Japan at 0.300 and 0.280 μg BT/g wet weight, in kidney and liver, respectively. Among the open sea birds, the Laysan albatross from the North Pacific Ocean had the highest total butyltin concentrations in the liver at 0.043 μg BT/g wet weight (Guruge et al. 1997).

Concentrations of tributyltin and triphenyltin were measured in the muscle of 11 species of fish from the Port of Osaka and Yodo River, Japan. Concentrations of tributyltin and triphenyltin were found ranging
from 0.011 to 0.182 μg TBT/g and from <0.001 to 0.130 μg TPT/g wet weight. In addition, mono- and
dibutyltin and diphenyltin were detected in all samples. Monophenyltin was detected in all but one
sample from the Port of Osaka and none of the samples from the Yoda River (<0.001 μg MPT/g wet
weight). Concentrations of organotin compounds were higher in fish from sea areas than those from the
river (Harino et al. 2000). Ueno et al. (2004) determined butyltin concentrations in the liver of skipjack
Tuna (*Katsuwonus pelamis*) collected from Asian offshore waters, off-Seychelles (west African coast),
off-Brazil (west South American coast), and in open seas (North Pacific) during 1996–2001. High
concentrations of butyltins were found in skipjack tuna from offshore waters around Japan with
concentrations up to 0.400 μg BT/g wet weight. Tributyltin was detected at relatively higher
concentrations in all locations, with mean concentrations ranging from 0.0049 to 0.200 μg TBT/g wet
weight in the North Pacific and the East China Sea, respectively. Monobutyltin concentrations were
below the detection limit (0.0018 μg MBT/g) for four samples from the South China Sea, off-Indonesia,
off-Seychelles, and off-Brazil, and ranged up to 0.017 μg MBT/g wet weight in the East China Sea (Ueno
et al. 2004).

Concentrations of di- and tributyltin were studied in whole-body fish samples from six freshwater sites
across the United States (Jones-Lepp et al. 2004). Di- and tributyltin were not detected in 8 and 9 of the
13 fish samples, respectively, that were collected from these sites (detection limits were 0.00097 and
0.0018 μg/g for di- and tributyltin, respectively). The highest concentrations were reported in largemouth
bass (*Micropterus salmoides*) from Red Bank Creek, South Carolina at 0.221 μg DBT/g, and in
shorthead rosehorse (*Moxostoma macrolepidotum*) from the Little Missouri River, North Dakota at
0.389 μg TBT/g (Jones-Lepp et al. 2004).

Strand and Asmund (2003) studied the concentrations of butyltins in bivalves collected between 1999 and
2000 from six areas along the west coast of Greenland. The highest tributyltin concentration, 0.254 μg
TBT/g wet weight, was found in mussels (*Mytilus edulis*) sampled inside Nuuk harbor, the largest harbor
in West Greenland. Tributyltin could only be detected in two of the six areas outside of the harbor areas
at concentrations of 0.001 and 0.0027 μg TBT/g wet weight, in *Chlamys islandica* and *Nuculana pernula*,
respectively. Di- and monobutyltin concentrations ranged from <0.0005 to 0.025 and from <0.0005 to
0.0041 μg organotin ion/g wet weight, respectively, in *M. edulis* in the harbor sites. Di- and monobutyltin
were not detected in *C. islandica* from open water sites, and were detected in *N. pernula* from open water
at 0.0016 and 0.0012 μg organotin ion/g wet weight, respectively. Triphenyltin could not be detected in
any samples (<0.005 μg TPhT/g wet weight) (Strand and Asmund 2003). *M. edulis*, clams (*Mercenaria
mercenaria*), and fish (*Tautogolabrus adspersus*) collected in 1995 from Coddington Cove, Newport,
Rhode Island were found to contain tributyltin concentrations ranging from 0.0092 to 0.977 μg Sn/g wet weight. Tributyltin concentrations in lobsters from the same area were all below the detection limit (<0.006 μg Sn/g) (Wade et al. 2004). Tributyltin concentrations were measured in benthic mollusks (N. pernula, Nucula sulcata, Nucula tenuis, Artica islandica, Musculus niger, Cardium echinatum, Buccinum undatum, and Neptunea antiqua) collected in 1997 and 1999 from transects along and perpendicular to the shipping lanes in the Sound (Øresund) and the Kattegat/Skagerrak region, an important shipping strait between Denmark and Sweden. Di- and tributyltin were detected in all mollusk samples, and ranged from 0.011 to 0.267 μg DBT/g and from 0.0081 to 1.316 μg TBT/g dry weight (Strand et al 2003). Tributyltin was found in mussels (Mytilus galloprovincialis) from Portuguese coastal waters at concentrations of 0.011–0.789 μg Sn/g dry weight and was detected at all 17 sites sampled between May and July 2000. Mono- and dibutyl tin were also found in most samples with concentrations ranging from not quantifiable to 0.605 and from not quantifiable to 0.345 μg Sn/g dry weight, respectively. Di- and triphenyltin concentrations were not quantifiable in all but one sample, with a triphenyltin concentration of 0.016 μg Sn/g dry weight (Barroso et al. 2004).

Tributyltin, dibutyltin, and monobutyltin concentrations were determined in the liver, kidney, and brain tissues of adult southern sea otters (Enhydra lutris nereis) found dead along the coast of California during 1992–1996. The mean and range of liver, kidney, and brain concentrations for total butyltin compounds were 1.320 (0.040–9.2), 0.160 (0.004–0.43), and 0.061 (0.0027–0.14) μg BT/g wet weight, respectively. The accumulation of butyltin compounds in sea otters was explained by their bottom-feeding habit and a diet that consists exclusively of invertebrates such as mollusks and gastropods (Kannan et al. 1998a). Butyltin concentrations in the liver, kidney, and brain tissues of southern sea otters (E. lutris nereis) found dead on the California coast during 1992–1996 were 0.040–5.3, 0.004–0.265, and 0.0039–0.140 μg BT/g wet weight, respectively (Kannan et al. 2004).

Berge et al. (2004) studied the concentrations of organotin compounds in samples of harbor porpoise (Phocoena phocoena), common seal (Phoca vitulina), ringed seal (Phoca hispida), and glaucous gull (Larus hyperboreus) from Norwegian territories without any obvious point sources of tributyltin. Most samples were collected between 1998 and 2000; however, some of the porpoise samples were collected in 1988, which is prior to the restriction on the use of tributyltin on smaller boats. The highest concentrations of mono-, di-, and tributyltin were found in harbor porpoise samples in Northern Norway in 1988, especially in liver tissue with mean concentrations of 0.0345, 0.285, and 0.098 μg Sn/g wet weight, respectively. In general, mono-, di-, and tributyltin concentrations were lower in harbor porpoise tissues sampled in 1999 than in 1988. No phenyltins were found in ringed seals from Spitsbergen or in
glaucous gulls from Bear Island. Concentrations of phenyltins in blubber, kidney, and brain of common seals were below the detection limit (generally <0.001 μg Sn/g wet weight). Mono-, di-, and triphenyltin were detected in the liver, muscle, and kidney of harbor porpoises samples in 1999; mono- and diphenyltin were dominant in liver and muscle with mean concentrations of 0.0164 and 0.0192 μg Sn/g wet weight, respectively (Berge et al. 2004).

Ciesielski et al. (2004) measured the organotin concentrations in liver tissue of marine mammals found between 1999 and 2003 from the Polish coast of the Baltic Sea. The mammals studied included 14 harbor porpoises (P. phocoena), 2 striped dolphins (species not specified), 1 ringed seal (P. hispida), and 2 grey seals (Halichoerus grypus). Tributyltin was detected in all samples and ranged from 0.044 to 1.488 μg Sn/g dry weight in grey seal and striped dolphin, respectively. Dibutyltin was not detected in the two grey seal liver samples, but was detected in all other samples ranging from 0.071 to 3.295 μg Sn/g dry weight in ringed seal and striped dolphin, respectively. Monobutyltin was not detected in one of the grey seal samples, but was detected in all other samples ranging from 0.021 to 2.915 μg Sn/g dry weight for grey seal and striped dolphin, respectively (Ciesielski et al. 2004).

6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE

Human exposure to tin may occur by inhalation, ingestion, or dermal contact. However, exposure of the general population occurs primarily by ingestion of food (NAS 1977; WHO 1980). The daily intake from air is unlikely to exceed 0.5 μg based on concentrations of tin in air that have been estimated to be in the range of 0.002–0.03 μg/m³ (Biégo et al. 1999). Tinplate, which is steel coated with a thin layer of metallic tin, has been used to line cans for food. Some of these cans are also coated with a lacquer. While new canning techniques have decreased the amount of tin contamination of foods over the years, metal cans still are the main source of tin in the diet (WHO 2003). Tin(II) chloride is used as a food additive and has U.S. FDA Generally Regarded As Safe (GRAS) approval. It is used as a preservative for canned soda water, a color retention agent in canned asparagus, and a component in food packaging materials (Kroschwitz and Howe 1997). Tin exposure may occur from dental preparations, since tin(II) fluoride (0.41%) is an approved fluoride source in dentifrices (Pader 1993). In a laboratory study to determine the amount of tin and other metals leached into water from copper piping with four types of lead-free solders, which contain 94–95.5% tin, no significant leaching of tin was observed (Subramanian et al. 1991).
Estimates of daily dietary tin intake ranged from 1 mg, for diets consisting mainly of fresh meats, vegetables, and cereals, to 38 mg for diets including a high proportion of canned foods (Schafer and Femfert 1984; WHO 1980). The average daily tin intake of an adult in the United States was estimated at 4.003 mg (4 mg from food and 0.003 mg from air), and with undetectable levels contributed by drinking water (EPA 1987a; WHO 1980). Other estimates of human daily intake range from 0.2 to 17 mg (Klaassen et al. 1986; Krigman and Silverman 1984). Tin levels in drinking water have been reported at <0.010 mg/L. If daily intake of water is assumed to be 2 L/day, then intake of tin from water would be 0.012–0.020 mg/day (WHO 2003). The tin contents in fresh food or food packaged in lacquered or unlacquered cans were determined to estimate the daily tin intake in an adult in France. From this study, it was found that canned foods, while representing 6–7% of the daily consumed foods, represented >95% of the total tin intake. The estimated tin intake by an adult in France was determined to be 0.04 mg/kg body weight (Biégo et al. 1999). In a 1994 total diet study in the United Kingdom, the canned vegetables group and fruit product group contributed 66 and 31%, respectively, to the total average exposure of tin, which was estimated as 2.4 mg/day. From this study, an upper range exposure to tin of 7.9 mg/day was estimated. Population dietary exposure to tin from total diet studies in the United Kingdom from 1976 to 1994 ranged from 1.7 mg/day in 1985 to 5.4 mg/day in 1991 (Ysart et al. 1999).

Little is known about the extent of exposure of humans to butyltin compounds (Kannan et al. 1999). Occupational exposure represents the greatest exposure to tributyltin; nonoccupational exposure to tributyltin is usually slight, with diet as the most important means of exposure (Demora and Pelletier 1997). Dermal absorption is a significant route of occupational exposure for certain organotin compounds (Stewart and Lassiter 2001). Household commodities made of polyurethane, plastic polymers, and silicons contain butyltin concentrations in the ppm range. Butyltin compounds are also found in seafood (Cardwell et al. 1999b; Kannan et al. 1999; Keithly et al. 1999). The daily intakes of tributyltin and triphenyltin in Japan were estimated to be 4.7 and 0.7 μg in 1991 and 2.2 and 0.7 μg in 1992, respectively, based on a duplicate portion study. In this study, cooked meals were collected for 3 days from women in Shiga Prefecture, Japan in 1991 and 1992, and were homogenized and frozen. In a separate market basket study in Shiga Prefecture, Japan, daily intakes of tributyltin and triphenyltin in Japan were estimated to be 6.9 and 5.4 μg in 1991 and 6.7 and 1.3 μg in 1992, respectively. Of the food groups analyzed in the market basket study, 95% of the daily intakes of tributyltin and triphenyltin came from the fish, mollusks, and crustaceans food group (Tsuda et al. 1995). Human dietary exposure to butyltins by food in order of importance may be regarded as: marine food > animal-origin foods (dairy and meat) > farm products (rice, and sunflower and peanut oil) (Kannan et al. 1995). Other routes of exposure to organotin compounds may include leaching of organotin compounds from PVC and related compounds.
materials, which have led to contamination of food, drinking water, and municipal sewage sludges, as suggested in some studies. Dibutyltin and octyltin compounds have been found in some textiles products. It has been demonstrated that butyltin compounds in siliconized baking parchment can be transferred to food baked on this type of baking parchment (Takahashi et al. 1999). Organotin compounds were found in household dust in a U.K. study (Santillo et al. 2003).

Occupational exposures to tin may be substantial. Inhalation or dermal exposure to triphenyltin leachate, used in fungicides and insecticides, may occur during both manufacturing and application (NAS 1977; WHO 1980). Workers in the numerous industries producing or using inorganic tin or organotin compounds (Section 5.3) may also be exposed. NIOSH estimated that 730,000 workers in the United States were potentially exposed to tin in the workplace in 1980 (NOES 1989). The National Occupational Exposure Survey (NOES) database does not contain information on the frequency, concentration, or duration of exposure to workers to tin or any of its compounds. These surveys provide only estimates of number of workers potentially exposed to chemicals in the workplace.

6.6 EXPOSURES OF CHILDREN

This section focuses on exposures from conception to maturity at 18 years in humans. Differences from adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.

Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults. The developing human’s source of nutrition changes with age: from placental nourishment to breast milk or formula to the diet of older children who eat more of certain types of foods than adults. A child’s behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).

Exposure to tin and tin compounds for children will be similar to adults and will occur primarily through the diet. In a 7-day duplicate diet study of 97 pre-school aged (1.75–2.2 years) children from the Birmingham area in the United Kingdom, the average daily intake of tin was 1.78 mg/kg. In this study, mothers were asked to collect and weigh duplicate samples of all food and drink (including water) consumed by their children in and outside of the home. There was a significant correlation between the
amount of canned food consumed and the concentration of tin in the diet (Smart et al. 1987). Children living in institutional settings may be served more canned foods due to their ease of storage and economical price, and may be exposed to higher levels of tin than the general population (WHO 2003). In a joint World Health Organization (WHO) and International Atomic Energy Agency (IAEA) collaborative study published in 1989 on minor and trace elements in breast milk, median tin concentrations were 2.81 and 0.24 μg/L in breast milk from women in Guatemala and Zaire, respectively, 3 months after giving birth (WHO/IAEA 1989). No data were located regarding current concentrations of tin or tin compounds in human breast milk in the United States. Other possible exposures to tin by children may occur from the clothing of other household members with occupational exposure (Rinehart and Yanagisawa 1993).

6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

People eating a high percentage of their diet from canned foods will be exposed to higher amounts of tin than the general population. For example, people living in intuitional settings, such as nursing homes, boarding schools, or prisons, or people with lower incomes may be served or choose canned foods due to their ease of storage and economical price (WHO 2003).

Potentially high inhalation exposures to tin and its compounds may occur in the workplace or from agricultural uses of tin compounds. A study of the tin and lead concentrations in house dust from the homes of nine electrical-cable splicers employed by a large power company found higher tin concentrations in house dust from the splicers' homes compared to house dust from control homes. Tin concentrations in house dust from the homes of splicers and the controls were 117 and 14 ppm in laundry areas, and in other areas concentrations were 66 ppm and not detected (<10 ppm), respectively. In one of the control homes occupied by a person who soldered copper water pipes in his home using lead-tin solder, tin concentrations in dust were 5 times higher than levels found in dust from homes of either the control or splicer groups (Rinehart and Yanagisawa 1993). In a 1994 study of heavy metal exposure in a Bolivian smelter, personal breathing zone air samples were collected by 15 workers, representing 12 job categories during one shift according to NIOSH Method 7300. Tin exposure was below the occupational exposure criterion and was considered not hazardous (Sussell et al. 1996).
6.8 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of tin and tin compounds is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of tin and tin compounds.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.8.1 Identification of Data Needs

Physical and Chemical Properties. Table 4-2 and Section 4.2 summarize many of the relevant physical and chemical properties of tin and many of its compounds. There are adequate data for the physical and chemical properties of tin and inorganic tin compounds. The chemical behavior of most of the common organotin compounds in environmentally-relevant media is not well known. There is a need to measure the solubility and vapor pressure of the more important organotin compounds in order to provide a more reliable basis for predicting their fate in the environment.

Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit substance release and off-site transfer information to the EPA. The TRI, which contains this information for 2001, became available in May of 2004. This database is updated yearly and should provide a list of industrial production facilities and emissions.

Production volumes and uses of tin are well-documented (Carlin 2003b, 2004). While data were available on the uses of many organotin compounds, current production volumes could not be located. Data on releases, disposal practices, and possible environmental contamination from uses of tin and its compounds are limited. Since tin is not on the TRI and is not listed as an EPA hazardous waste
constituent, current data are not available on industrial releases or disposal practices. Information on releases or disposal practices, and current quantitative data on leaching of inorganic and organic forms of tin into foods from tin-lined cans and PVC packaging materials would be useful in assessing potential human exposure to tin compounds.

**Environmental Fate.** From the information available, it appears likely that both inorganic and organotin will partition to soils and sediments, and will not volatilize from water (Blunden et al. 1984; Cooney 1988; Fent 1996; Maguire et al. 1983, 1985; WHO 1980). Research on physical and biological processes in water and at sediment-water interfaces would be particularly helpful to more accurately predict the fate of tin compounds released to the environment. Methyltin compounds can be produced in the environment by biomethylation of inorganic tin (Fent 1996). It has been suggested that methylation of butyltin compounds in sediment may lead to mobilization of tin species into the water column and possibly to the atmosphere. However, there is currently no significant evidence of losses of organotin compounds to the atmosphere (Amouroux et al. 2000).

**Bioavailability from Environmental Media.** Inorganic tin is not well absorbed after inhalation, oral, and dermal exposure. Organotin compounds are somewhat better absorbed by both the inhalation and oral routes (Hiles 1974; Mori et al. 1984). Dermal absorption is a significant route of occupational exposure for certain organotin compounds (Stewart and Lassiter 2001). The daily intakes of tin from air, food, and water are small (WHO 1980). Further study of human intake of organotin compounds from food and water would also be useful. The pH may be an important consideration for the bioavailability of organotin compounds. Bioconcentration studies by Looser et al. (1998) indicated that as pH increases, uptake of organotin compounds increases.

**Food Chain Bioaccumulation.** It has been established that organotins can be bioconcentrated by aquatic organisms in marine environments (Gomez-Ariza et al. 2001; Harino et al. 2000; Hongxia et al. 1998; Laughlin and Linden 1985; Looser et al. 1998; Maguire et al. 1984; Meador 2000; Suzuki et al. 1998; Tsuda et al. 1986; Waldock and Thain 1983; Yamada and Takayanagi 1992). Similar information for terrestrial ecosystems would be useful. Inorganic tin compounds may also be bioconcentrated, but data are limited (Seidel et al. 1980; Thompson et al. 1972). There is no information available on the potential transfer of inorganic tin or organotin compounds from lower trophic levels to higher levels. This information would be useful because studies have shown that organotin can be bioconcentrated significantly.
6. POTENTIAL FOR HUMAN EXPOSURE

**Exposure Levels in Environmental Media.** Reliable monitoring data for the levels of tin and tin compounds in contaminated media at hazardous waste sites are needed so that the information obtained on levels of tin and tin compounds in the environment can be used in combination with the known body burden of tin and tin compounds to assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.

Data were obtained regarding tin levels in air (Dannecker et al. 1990; EPA 1982a, 1988c; NAS 1977; Sweet and Vermette 1993; WHO 1980). No monitoring data for concentrations of organotin compounds in air were found. Inorganic tin levels in water are limited to data obtained in the early 1980s (NAS 1977; WHO 1980) and more recent data were not found. Due to its use in marine paints, tributyltin levels, as well as di- and monobutyltin, levels are monitored in water (Gomez-Ariza et al. 2001; Grovhoug et al. 1996; Hall 1988; Harino et al. 1998; Sadiki and Williams 1996, 1999; Sadiki et al. 1996; Yang and Maguire 2000). There have only a few surveys reported that monitor the occurrence of organotin compounds in U.S. freshwaters (Bancon-Montigny et al. 2004; Jones-Lepp et al. 2004). Additional information on inorganic and organotin concentrations in all media, especially air, water, and soil at hazardous waste sites, determined by the most sensitive analytical methods, would be useful in evaluating human exposure to tin.

Several estimates concerning the human daily intake of tin have been reported (Biégo et al. 1999; EPA 1987c; Klaassen et al. 1986; Krigman and Silverman 1984; WHO 1980; Ysart et al. 1999). Data on the intake of organotin compounds from food are limited (Cardwell et al. 1999b; Keithly et al. 1999; Méranger 1975; Tsuda et al. 1995).

**Exposure Levels in Humans.** Tin has been detected in human adipose tissue (Stanley 1986), urine (Paschal et al. 1998; Schramel et al. 1997), and brain, bone, kidney, liver, and lung (García et al. 2001; Llobet et al. 1998). Butyltin compounds have been detected in blood (Kannan et al. 1999) and liver (Kannan and Falandysz 1997; Nielsen and Strand 2002; Takahashi et al. 1999). These reports are for populations without documented high exposures to tin and tin compounds and should represent background levels in human tissues. Biological monitoring data, especially for populations near hazardous waste sites, would help to assess human exposure to tin and tin compounds.

This information is necessary for assessing the need to conduct health studies on these populations.
6. POTENTIAL FOR HUMAN EXPOSURE

**Exposures of Children.** Very little data were found regarding the exposure of children to tin and tin compounds (Smart et al. 1987; WHO 2003; WHO/IAEA 1989). Like adults, the major route of exposure to tin will be through the diet, particularly a diet high in canned foods. Levels of tin and organotin compounds in the tissue and body fluids of children have not been found. Levels of tin in human breast milk have been reported (WHO/IAEA 1998); however, more recent tin concentrations in human breast milk have not been found.

Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data Needs: Children’s Susceptibility.

**Exposure Registries.** No exposure registries for tin and tin compounds were located. Tin and tin compounds are not currently substances for which a sub-registry has been established in the National Exposure Registry. Tin and tin compounds will be considered in the future when chemical selection is made for sub-registries to be established. The information that is amassed in the National Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be related to exposure to these substances.

### 6.8.2 Ongoing Studies

The Federal Research in Progress (FEDRIP 2004) database provides additional information obtainable from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1. These studies are summarized in Table 6-6.

The Organotin Environmental Programme (ORTEP) Association is an international non-profit organization of producers of organotin compounds established in 1978 by companies from the United States, Europe, and Japan. The goals of the ORTEP Association include the promotion and encouragement of the dissemination of scientific and technical information on the environmental effects of organotin compounds (ORTEP 2004). The International Tin Research Institute (ITRI) tin producers announced, in October 20, 2004, a project that will begin in January 2005 that will generate information to increase the understanding of the tin industry, and the applications of tin, as well as the interactions of tin with humans and the environment, including increased scientific understanding of the environmental fate of tin during its use and recycling (Tin Technology 2004).
### Table 6-6. Ongoing Studies on Organotin Compounds

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Affiliation</th>
<th>Research description</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eng G</td>
<td>University of the District of Columbia</td>
<td>Investigation of the environmental fate of triorganotins that leach in the aerobic and anaerobic sediments of D.C. waterways and determination of the toxicity of these compounds on the aquatic biota.</td>
<td>Department of Agriculture</td>
</tr>
<tr>
<td>Pannell KH</td>
<td>University of Texas at El Paso</td>
<td>The investigators propose to continue their initially successful study concerning the synthesis and biocidal evaluation of new organotin materials and compounds.</td>
<td>National Institutes of Health</td>
</tr>
</tbody>
</table>

\(^a\)FEDRIP 2004
7. ANALYTICAL METHODS

The purpose of this chapter is to describe the analytical methods that are available for detecting, measuring, and/or monitoring tin and tin compounds, their metabolites, and other biomarkers of exposure and effect to tin and tin compounds. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to identify well-established methods that are used as the standard methods of analysis. Many of the analytical methods used for environmental samples are the methods approved by federal agencies and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, analytical methods are included that modify previously used methods to obtain lower detection limits and/or to improve accuracy and precision.

Tin is usually determined as the total metal, but it may also be measured as specific organotin compounds. Flame atomic absorption analysis is the most widely used and straightforward method for determining tin; furnace atomic absorption analysis is used for very low analyte levels and inductively coupled plasma atomic emission analysis is used for multianalyte analyses that include tin.

The preferred separation technique for organotin compounds is gas chromatography (GC) due to its high resolution and detector versatility. Analysis of organotin compounds usually consists of four steps: (1) extraction; (2) formation of volatile derivative; (3) separation; and (4) detection and quantification. First, the organotin compounds must be extracted from the sample using organic solvents, ion exchange resins, or adsorption onto a solid support. For biological materials, a general clean-up step is needed, such as purification using Florisil, silica gel, alumina, or ion exchange resin. The extracted organotin compounds must then undergo derivatization to a volatile form to be able to separate them by GC. Derivatization methods include the formation of alkyl (methyl or pentyl) derivatives using a Grinard reagent, formation of ethyl derivatives using sodium tetraethylborate, or by formation of hydrides \( \text{R}_n\text{SnH}_{4-n} \) using sodium borohydride. Separation of these derivatives may be done using differences in their boiling points or by GC. Finally, detection and quantification can be performed using a flame photometric detector, atomic absorption spectroscopy (AAS), or mass spectrometry (MS) (Takeuchi et al. 2000; WHO 1990).

High performance liquid chromatography (HPLC) has also been used in the analysis of organotin compounds. The advantage of HPLC over GC is that no derivatization step is needed after extraction.
Most separations are based on ion exchange or reversed phase separations using gradient elution. AAS, inductively coupled plasma mass spectrometry (ICP-MS), and fluorometric detection can be used. HPLC coupled with AAS is commonly used for speciation of organotin compounds (Takeuchi et al. 2000).

### 7.1 BIOLOGICAL MATERIALS

Tin and its compounds can enter the human body through inhalation, ingestion, or penetration through the skin. Levels of tin and tin compounds in the body can be estimated by analysis of body fluids, excreta, or tissues. Methods for the determination of tin in biological materials are summarized in Table 7-1.

Normally, for determination in biological samples, the sample is digested in an oxidizing acid mixture followed by atomic spectrometric determination. Determination of organotin compounds in biological materials will require extraction, derivatization, separation, and detection, as described above. Human exposure to elemental tin and organotin compounds may be determined by analysis of blood or urine. Whole blood samples are typically analyzed by spectrophotometry and photometry. Urine samples may be acid digested to destroy organic matter and to oxidize tin to the tin(IV) state (Stewart and Lassiter 2001).

### 7.2 ENVIRONMENTAL SAMPLES

Methods for determination of tin in environmental samples are summarized in Table 7-2.

Tin is readily measured in multielement analyses of air, water, and solid waste samples by inductively coupled plasma-atomic emission spectroscopy (ICP-AES). For samples that are free of particulate matter, such as drinking water, direct aspiration atomic absorption spectroscopy, such as EPA Method 7870, may be used. Other samples, such as groundwater, industrial wastes, soils, sediments, sludges, and other solid wastes, require digestion prior to analysis to determine total and acid leachable metal (EPA 1992). EPA Method 3050B, which describes acid digestion of sediments, sludges, and soils, does not list tin as an analyte; however, it states other elements and matrices may be analyzed by this method if performance is demonstrated for that analyte in that matrix at the concentrations of interest (EPA 1996b).

The APHA methods using either a flame atomic absorption method (3111B) or electrochemical atomic absorption method (3113B) may be used for analysis of tin in water, depending on the sensitivity desired.
### Table 7-1. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Biological Materials

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total inorganic tin</td>
<td>Digestion of biological materials</td>
<td>Atomic spectrometric</td>
<td>No data</td>
<td>No data</td>
<td>Angerer and Schaller 1988</td>
</tr>
<tr>
<td>Urine</td>
<td>Digest in oxidizing acid, extract ketone as the cupferon chelate</td>
<td>Colorimetry</td>
<td>&lt;50 μg/L&lt;sup&gt;b&lt;/sup&gt;</td>
<td>98–106%</td>
<td>Baselt 1988</td>
</tr>
<tr>
<td>Urine</td>
<td>Extraction with polydithiocarbamate resin, which is ashed</td>
<td>ICP-AES</td>
<td>2 μg/L</td>
<td>100±10% recovery</td>
<td>Kneip and Crable 1988</td>
</tr>
<tr>
<td>Urine</td>
<td>Extract with resin, ash resin</td>
<td>ICP-AES</td>
<td>0.1 μg</td>
<td>100±10%</td>
<td>NIOSH 1984a</td>
</tr>
<tr>
<td>Food</td>
<td>Digest in oxidizing acid</td>
<td>AAS</td>
<td>No data</td>
<td>No data</td>
<td>AOAC 1990a</td>
</tr>
<tr>
<td>Urine</td>
<td>Extract with resin, ash resin</td>
<td>ICP-AES</td>
<td>0.1 μg/sample</td>
<td>100%</td>
<td>NIOSH 1994a</td>
</tr>
<tr>
<td>Blood</td>
<td>Wet ashing with nitric and perchloric acids</td>
<td>AAS</td>
<td>2.5 ng/mL</td>
<td>No data</td>
<td>Chiba et al. 1994</td>
</tr>
<tr>
<td>Urine</td>
<td>Acidified with nitric acid</td>
<td>ICP-MS</td>
<td>0.05 μg/L</td>
<td>95.5%</td>
<td>Schramel et al. 1997</td>
</tr>
<tr>
<td>Organotins and metabolites</td>
<td>Homogenized, hydrochloric acid added, extracted with ethyl acetate</td>
<td>HPLC/fluorescence&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.1–1 ng depending on the dialkytinspecies</td>
<td>91–100%</td>
<td>Yu and Arakawa 1983</td>
</tr>
<tr>
<td>Biological materials, tissue</td>
<td>Elution stepwise on silica gel column</td>
<td>AAS</td>
<td>1.5 ng Sn</td>
<td>72.7±9.3%</td>
<td>Iwai et al. 1981</td>
</tr>
<tr>
<td>Human liver</td>
<td>Acidified tissue extracted with 0.1% tropolone-acetone, derivatization with propyl magnesium bromide</td>
<td>GC-FPD</td>
<td>5 ng/g (TBT)</td>
<td>No data</td>
<td>Kannan and Falandysz 1997</td>
</tr>
<tr>
<td>Human liver</td>
<td>Homogenized with 0.1% tropolone-acetone/HCl, derivatized with propyl magnesium bromide</td>
<td>GC-FPD</td>
<td>4.0 ng/g(TBT)</td>
<td>No data</td>
<td>Takahashi et al. 1999</td>
</tr>
<tr>
<td>Human liver</td>
<td></td>
<td></td>
<td>3.0 ng/g (DBT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2.0 ng/g (MBT)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 7-1. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Biological Materials

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method method</th>
<th>Analytical method</th>
<th>Sample detection limit (ng/g)</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human liver</td>
<td>Acid digestion, derivatization with sodium tetraethylborate</td>
<td>GC-PFPD</td>
<td>0.3 (TBT) 3 (DBT, MBT)</td>
<td>No data</td>
<td>Nielson and Strand 2002</td>
</tr>
</tbody>
</table>

*a* A digestion procedure for metals in biological materials applicable to most metals, including tin.

*b* Estimated from sensitivity and linearity data.

*c* Fluorescence detection after derivitization with Morin reagent.

AAS = atomic absorption spectroscopy; DBT = dibutyltin; FPD = flame photometric detector; GC = gas chromatography; HCl = hydrochloric acid; HPLC = high performance liquid chromatography; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-MS = inductively coupled plasma mass spectrometry; MBT = monobutyltin; PFPD = pulsed flame photometric detector; TBT = tributyltin
### Table 7-2. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Environmental Samples

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total inorganic tin</td>
<td>Environmental</td>
<td>Digested in oxidizing acid</td>
<td>ICP-MS</td>
<td>0.04–50 ng/g</td>
<td>103±3%</td>
</tr>
<tr>
<td>Water</td>
<td>Generate hydride with sodium borohydride or electrolytically, sweep into silica cell heated to 700 °C</td>
<td>AAS</td>
<td>0.02 μg/L</td>
<td>No data</td>
<td>Rains 1982</td>
</tr>
<tr>
<td>Water (aqueous solution)</td>
<td>Generate hydride with sodium borohydride or electrolytically, sweep into silica cell heated to 700 °C</td>
<td>AAS</td>
<td>0.5 μg/L</td>
<td>No data</td>
<td>Thompson and Thomerson 1974</td>
</tr>
<tr>
<td>Water</td>
<td>Acidify with nitric acid</td>
<td>AAS (direct aspiration)</td>
<td>0.8 mg/L</td>
<td>No data</td>
<td>APHA 1998a</td>
</tr>
<tr>
<td>Water</td>
<td>Acidify with nitric acid</td>
<td>AAS (furnace technique)</td>
<td>5 μg/L</td>
<td>No data</td>
<td>APHA 1998b</td>
</tr>
<tr>
<td>Water</td>
<td>Acidify with nitric acid</td>
<td>ICP-AES</td>
<td>No data</td>
<td>No data</td>
<td>EPA 1986b, 1992, 1996b</td>
</tr>
<tr>
<td>Pesticide formulations</td>
<td>Form volatile organotin derivatives</td>
<td>GC-FID</td>
<td>No data</td>
<td>No data</td>
<td>Basters et al. 1978</td>
</tr>
<tr>
<td>Pesticide formulations</td>
<td>Derivatize butylmagnesium chloride, extract with toluene</td>
<td>GC-FID</td>
<td>No data</td>
<td>No data</td>
<td>AOAC 1990a</td>
</tr>
<tr>
<td>Air</td>
<td>Adsorbed onto Chromosorb 102 desorption with ethereal hydrochloric acid, methylated</td>
<td>GC-FID</td>
<td>0.05 μg/m³</td>
<td>93.3±9.3%</td>
<td>Zimmerli and Zimmermann 1980</td>
</tr>
<tr>
<td>Air</td>
<td>Adsorption on filter and XAD-2 resin, desorption</td>
<td>HPLC-AAS (furnace technique)</td>
<td>1 μg/sample</td>
<td>No data</td>
<td>NIOSH 1994b</td>
</tr>
<tr>
<td>Air</td>
<td>Adsorption on filter and XAS-2 resin, desorption, derivatization with sodium tetraethylborate</td>
<td>GC-FPD</td>
<td>0.01 μg</td>
<td>No data</td>
<td>NIOSH 2002</td>
</tr>
<tr>
<td>Water</td>
<td>Acidified, extracted with tropolone benzene, derivatized</td>
<td>GC-FPD</td>
<td>100 pg</td>
<td>96±4 to 103±8%</td>
<td>Maguire and Huneault 1981</td>
</tr>
</tbody>
</table>
### Table 7-2. Analytical Methods for Determining Inorganic Tin and Organotin Compounds in Environmental Samples

<table>
<thead>
<tr>
<th>Sample matrix</th>
<th>Preparation method</th>
<th>Analytical method</th>
<th>Sample detection limit</th>
<th>Percent recovery</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>Generate hydrides with sodium borohydride, separate hydrides by boiling point</td>
<td>AAS</td>
<td>2 ng</td>
<td>No data</td>
<td>Hodge et al. 1979</td>
</tr>
<tr>
<td>Water</td>
<td>Generate hydride derivatives</td>
<td>AAS</td>
<td>&lt;0.1 μg/L tributyltin</td>
<td>No data</td>
<td>Lee et al. 1989</td>
</tr>
<tr>
<td>Water</td>
<td>Extract in n-hexane, produce fluorescent morin derivative</td>
<td>Fluorescence</td>
<td>0.001–0.5 nmol/mL</td>
<td>91.3±0.6 to 99.7±0.5% recovery</td>
<td>Arakawa et al. 1983</td>
</tr>
<tr>
<td>Sediment</td>
<td>Organotin compounds are complexed with NaDCC and retained on a C&lt;sub&gt;80&lt;/sub&gt; column; complexes are eluted with EtOAc containing NaBPr&lt;sub&gt;4&lt;/sub&gt;</td>
<td>GC-MS</td>
<td>0.07 ng Sn/g (MBT); 0.09 ng Sn/g (DBT); 0.10 ng Sn/g (TBT)</td>
<td>80–90% (MBT); 85–95% (DBT and TBT)</td>
<td>Muñoz et al. 2004</td>
</tr>
</tbody>
</table>

<sup>a</sup>Tin not listed specifically as an analyte, but can be determined by ICP-AES.
<sup>b</sup>Method was validated with tetrabutyltin, tributyltin chloride, tricyclohexyltin hydroxide, and dibutyltin bis(isooctylmercaptoacetate).
<sup>c</sup>This method was developed for air monitoring of methyltin chlorides.

AAS = atomic absorption spectroscopy; DBT = dibutyltin; EtOAc = ethyl acetate; GC-FID = gas chromatography-flame ignition detector; GC-FPD = gas chromatography-flame photometric detector; GC-MS = gas chromatography mass spectrometry; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-MS = inductively coupled plasma-mass spectrometry; MBT = monobutyltin; NaBPr<sub>4</sub> = sodium tetra-n-propylborate; NaDCC = sodium diethylthiocarbamate; TBT = tributyltin
7. ANALYTICAL METHODS

While tin is not specifically listed as an analyte for the ICP-MS method (3125), it may also be used in most cases and has lower detection limits (APHA 1998a, 1998b, 1998c).

Organotin can be extracted from environmental samples and determined by AAS or GC methods, usually after derivatization and separation. NIOSH Method 5504 allows for analysis of organotin compounds (as tin) in air and was validated using tetrabutyltin, tributyltin chloride, tricyclohexyltin hydroxide, and dibutyltin bis(isoctylmercaptoacetate) (NIOSH 1994b). NIOSH Method 5526 was developed for air monitoring of monomethyltin trichloride, dimethyltin dichloride, and trimethyltin chloride (NIOSH 2002).

Muñoz et al. (2004) described a new method for the speciation of butyltin compounds where the compounds were complexed with sodium diethyldithiocarbamate and retained on a fullerene C\textsubscript{60} sorbent column. The neutral butyltin complexes were then eluted with ethyl acetate containing sodium tetra-$n$-propylborate as a derivatizing agent, and the eluent was then analyzed using GC/MS. By preconcentrating the organotin compounds on the C\textsubscript{60} sorbent, this method allows for determination of mono-, di-, and tributyltin in the ng/g range. Detection limits of 0.07, 0.09, and 0.10 ng Sn/g for mono-, di-, and tributyltin, respectively, were reported. Recoveries were reported to be 80–90% for monobutyltin and 85–95% for di- and tributyltin. Validation of this method was carried out by the analysis of a standard reference sediment (Muñoz et al. 2004).

7.3 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of tin and tin compounds is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of tin and tin compounds.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs

**Methods for Determining Biomarkers of Exposure and Effect.** Sensitive and selective methods are available for the detection and quantitative measurement of tin after the sample matrix in which it is contained has been properly treated. Atomic spectrometric techniques provide methods for the determination of tin with low detection limits that are highly specific are readily available (Angerer and Schaller 1988; AOAC 1984b; Kneip and Crable 1988; NIOSH 1984a). Methods for the determination of specific compounds that contain tin are more difficult and less well developed than are methods for the determination of total tin, but determination of specific tin compounds is an important concern because of the widespread use of organotin compounds as preservatives in industry and in other applications.

**Exposure.** Methods exist to determine inorganic and organic tin levels in environmental samples and human tissues. However, no methods have been identified that can be used to correlate the level and extent of exposure to tin and specific tin compounds with levels of tin in biological materials such as human tissues or fluids. It would be useful to have such methods to make these correlations; however, it is not likely that such a method will be developed.

**Effect.** No methods have been identified that can be used to directly associate levels of tin and specific tin compounds in biological samples with the onset of adverse health effects. If such methods were available, it would be possible to correlate the level or severity of effects with the level and extent of exposure.

**Methods for Determining Parent Compounds and Degradation Products in Environmental Media.** Methods for determining tin in water, air, and waste samples with excellent selectivity and sensitivity are well developed and undergoing constant improvement.

Sampling methodologies for very low level elemental pollutants such as tin continue to pose problems, including nonrepresentative samples, insufficient sample volumes, contamination, and labor-intensive, tedious extraction, and purification procedures (Green and LePape 1987).
7.3.2 Ongoing Studies

No ongoing studies involving analytical techniques of tin or tin compounds were found in a search of Federal Research in Progress (FEDRIP 2004).
8. REGULATIONS AND ADVISORIES

The international, national, and state regulations and guidelines regarding tin and tin compounds in air, water, and other media are summarized in Table 8-1.

ATSDR derived an intermediate-duration oral MRL for inorganic tin of 0.3 mg Sn/kg/day (as stannous chloride) based on a NOAEL of 32 mg/kg/day for hematological effects in rats in a 90-day feeding study (De Groot et al. 1973). An uncertainty factor of 100 was applied to the NOAEL (10 for animal to human extrapolation and 10 for human variability).

ATSDR derived an intermediate-duration oral MRL of 0.005 mg/kg/day for dibutyltin chloride based on a LOAEL of 5 mg/kg/day for immunological effects in rats in a 4–6-week feeding study (Seinen et al. 1977b). An uncertainty factor of 1,000 was applied to the LOAEL (10 for animal to human extrapolation, 10 for the use of a LOAEL, and 10 for human variability).

ATSDR derived an intermediate-duration oral MRL of 0.0003 mg/kg/day for tributyltin oxide based on a NOAEL of 0.025 mg/kg/day for immunological effects in rats in a 4.5–6-month dietary study in rats (Vos et al. 1990). An uncertainty factor of 100 was applied to the NOAEL (10 for animal to human extrapolation and 10 for human variability).

ATSDR derived a chronic-duration oral MRL of 0.0003 mg/kg/day for tributyltin oxide based on a NOAEL of 0.025 mg/kg/day for immunological effects in rats in an 18-month dietary study in rats (Vos et al. 1990). An uncertainty factor of 100 was applied to the NOAEL (10 for animal to human extrapolation and 10 for human variability).

EPA (IRIS 2005) derived an oral reference dose (RfD) of 0.0003 mg/kg/day for tributyltin oxide using a benchmark dose analysis of immunological effects in rats in an 18-month dietary study (Vos et al. 1990). A 10% relative change was chosen as the benchmark response (BMR).

EPA (IRIS 2005) has assigned tributyltin oxide to group D weight-of-evidence classification: not classifiable as to human carcinogenicity, or to a group for which there is “inadequate information to assess carcinogenic potential,” according to updated guidelines (EPA 2003g).
### Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTERNATIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IARC</td>
<td>Carcinogenicity classification</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>WHO</td>
<td>Drinking water guideline Tin and inorganic tin compounds</td>
<td>No numerical value based on low toxicity</td>
<td>WHO 1993</td>
</tr>
<tr>
<td><strong>NATIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulations and Guidelines:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Air:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACGIH</td>
<td>TLV (8-hour TWA) Tin (as Sn) Metal</td>
<td>2.0 mg/m³</td>
<td>ACGIH 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxide and inorganic compounds, except tin hydride</td>
<td>2.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organic compounds&lt;sup&gt;a&lt;/sup&gt; STEL</td>
<td>0.1 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.2 mg/m³</td>
<td></td>
</tr>
<tr>
<td>NIOSH</td>
<td>REL (10-hour TWA) Tin (as Sn) Inorganic compounds, except tin oxides</td>
<td>2.0 mg/m³</td>
<td>NIOSH 2003a, 2003b</td>
</tr>
<tr>
<td></td>
<td>IDLH</td>
<td>100 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organic compounds, except cyhexatin&lt;sup&gt;b&lt;/sup&gt; IDLH</td>
<td>0.1 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stannous oxide</td>
<td>25 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.0 mg/m³</td>
<td></td>
</tr>
<tr>
<td>OSHA</td>
<td>PEL (8-hour TWA) for general industry Tin (as Sn) Inorganic compounds, except oxides</td>
<td>2.0 mg/m³</td>
<td>OSHA 2003a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>29 CFR 1910.1000, Table Z-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organic compounds</td>
<td>0.1 mg/m³</td>
</tr>
<tr>
<td></td>
<td>PEL (8-hour TWA) for construction industry Tin (as Sn) Inorganic compounds, except oxides</td>
<td>2.0 mg/m³</td>
<td>OSHA 2003c</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>29 CFR 1926.55, Appendix A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organic compounds</td>
<td>0.1 mg/m³</td>
</tr>
<tr>
<td>OSHA</td>
<td>PEL (8-hour TWA) for shipyard industry Tin (as Sn) Inorganic compounds, except oxides</td>
<td>2.0 mg/m³</td>
<td>OSHA 2003b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>29 CFR 1915.1000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organic compounds</td>
<td>0.1 mg/m³</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tin oxide (as Sn) Total dust</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Respirable fraction</td>
<td>5.0 mg/m³</td>
</tr>
</tbody>
</table>
### Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATIONAL (cont.)</td>
<td>Occupational values</td>
<td></td>
<td>USNRC 2003</td>
</tr>
<tr>
<td>USNRC</td>
<td>Oral ingestion for Class D³</td>
<td></td>
<td>10 CFR 20,</td>
</tr>
<tr>
<td></td>
<td>$^{110}\text{Tin}$</td>
<td>ALI (μCi) 4.0x10³</td>
<td>Appendix B</td>
</tr>
<tr>
<td></td>
<td>$^{111}\text{Tin}$</td>
<td>7.0x10⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{113}\text{Tin}$ (LLI wall)⁴</td>
<td>2.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{113}\text{Tin}$</td>
<td>2.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{117m}\text{Tin}$ (LLI wall)⁴</td>
<td>2.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{117m}\text{Tin}$</td>
<td>2.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{119m}\text{Tin}$ (LLI wall)⁴</td>
<td>3.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{119m}\text{Tin}$</td>
<td>4.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121}\text{Tin}$ (LLI wall)⁴</td>
<td>6.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121}\text{Tin}$</td>
<td>6.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121m}\text{Tin}$ (LLI wall)⁴</td>
<td>3.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121m}\text{Tin}$</td>
<td>4.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{123}\text{Tin}$ (LLI wall)⁴</td>
<td>5.0x10²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{123}\text{Tin}$</td>
<td>6.0x10²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{123m}\text{Tin}$</td>
<td>5.0x10⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{125}\text{Tin}$ (LLI wall)⁴</td>
<td>4.0x10²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{125}\text{Tin}$</td>
<td>5.0x10²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{126}\text{Tin}$</td>
<td>3.0x10²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{127}\text{Tin}$</td>
<td>7.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{128}\text{Tin}$</td>
<td>9.0x10³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhalation² for Class D³</td>
<td>ALI (μCi) DAC (μCi/mL)</td>
<td>10 CFR 20,</td>
</tr>
<tr>
<td></td>
<td>$^{110}\text{Tin}$</td>
<td>1.0x10⁴ 5.0x10⁻⁶</td>
<td>Appendix B</td>
</tr>
<tr>
<td></td>
<td>$^{111}\text{Tin}$</td>
<td>2.0x10⁵ 9.0x10⁻⁵</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{113}\text{Tin}$</td>
<td>1.0x10⁴ 5.0x10⁻⁷</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{117m}\text{Tin}$ (bone and surf)⁴</td>
<td>1.0x10³ No data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{117m}\text{Tin}$</td>
<td>2.0x10³ 5.0x10⁻⁷</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{119m}\text{Tin}$</td>
<td>2.0x10³ 1.0x10⁻⁶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121}\text{Tin}$</td>
<td>2.0x10⁴ 6.0x10⁻⁶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{121m}\text{Tin}$</td>
<td>9.0x10² 4.0x10⁻⁷</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{123}\text{Tin}$</td>
<td>6.0x10² 3.0x10⁻⁷</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{123m}\text{Tin}$</td>
<td>1.0x10⁵ 5.0x10⁻⁵</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{125}\text{Tin}$</td>
<td>9.0x10² 4.0x10⁻⁷</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{126}\text{Tin}$</td>
<td>6.0x10¹ 2.0x10⁻⁸</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{127}\text{Tin}$</td>
<td>2.0x10⁴ 8.0x10⁻⁶</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$^{128}\text{Tin}$</td>
<td>3.0x10⁴ 1.0x10⁻⁵</td>
<td></td>
</tr>
</tbody>
</table>
### Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>USNRC</td>
<td>Occupational values</td>
<td></td>
<td>USNRC 2003</td>
</tr>
<tr>
<td></td>
<td><em>Inhalation⁶ for Class W¹</em></td>
<td>ALI (μCi)</td>
<td>10 CFR 20, Appendix B</td>
</tr>
<tr>
<td></td>
<td>¹¹⁰Tin</td>
<td>DAC (μCi/mL)</td>
<td>1.0x10⁴ 5.0x10⁻⁶</td>
</tr>
<tr>
<td></td>
<td>¹¹¹Tin</td>
<td></td>
<td>3.0x10⁵ 1.0x10⁻⁴</td>
</tr>
<tr>
<td></td>
<td>¹¹³Tin</td>
<td></td>
<td>5.0x10² 2.0x10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>¹¹⁷mTin</td>
<td></td>
<td>1.0x10³ 6.0x10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>¹¹⁹mTin</td>
<td></td>
<td>1.0x10³ 4.0x10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>¹²¹Tin</td>
<td></td>
<td>1.0x10⁴ 5.0x10⁻⁶</td>
</tr>
<tr>
<td></td>
<td>¹²¹mTin</td>
<td></td>
<td>5.0x10² 2.0x10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>¹²³Tin</td>
<td></td>
<td>2.0x10² 7.0x10⁻⁸</td>
</tr>
<tr>
<td></td>
<td>¹²³mTin</td>
<td></td>
<td>1.0x10⁵ 6.0x10⁻⁵</td>
</tr>
<tr>
<td></td>
<td>¹²⁵Tin</td>
<td></td>
<td>4.0x10² 1.0x10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>¹²⁶Tin</td>
<td></td>
<td>7.0x10¹ 3.0x10⁻⁸</td>
</tr>
<tr>
<td></td>
<td>¹²⁷Tin</td>
<td></td>
<td>2.0x10⁴ 8.0x10⁻⁶</td>
</tr>
<tr>
<td></td>
<td>¹²⁸Tin</td>
<td></td>
<td>4.0x10⁴ 1.0x10⁻⁵</td>
</tr>
<tr>
<td>b. Water</td>
<td><strong>Drinking water standards</strong></td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Food</td>
<td><strong>Direct food substances affirmed as GRAS in accordance with good</strong></td>
<td>Not to exceed 0.0015% calculated as tin for all food categories</td>
<td>FDA 2003a 21 CFR 184.1845</td>
</tr>
<tr>
<td></td>
<td><strong>manufacturing practices; stannous chloride (anhydrous and dehydrated)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Food additives permitted for direct addition to food for human</strong></td>
<td>Not to exceed 20 pmm calculated as tin</td>
<td>FDA 2003b 21 CFR 172.180</td>
</tr>
<tr>
<td></td>
<td><strong>consumption; stannous chloride (food additive) may be safely used</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>for color retention in asparagus packed in glass, with lids lined with an inert material</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Indirect food additives; adhesives; bis(tributyltin)oxide</strong></td>
<td>For use as a preservative only</td>
<td>FDA 2003d 21 CFR 175.105(c)(5)</td>
</tr>
<tr>
<td></td>
<td><strong>Indirect food additives; polymers; polyurethane resins</strong></td>
<td>Dibutyltin chloride</td>
<td>FDA 2003e 21 CFR 177.1680(b)</td>
</tr>
<tr>
<td></td>
<td><strong>Indirect food additives; resinous and polymeric coatings</strong></td>
<td>Stannous chloride</td>
<td>FDA 2003c 21 CFR 175.300</td>
</tr>
<tr>
<td></td>
<td><strong>Indirect food additives; rubber articles intended for repeated use; stannous chloride</strong></td>
<td>Activators (total not to exceed 5% by weight of rubber product)</td>
<td>FDA 2003f 21 CFR 177.2600(c)(4)</td>
</tr>
<tr>
<td></td>
<td><strong>Substances GRAS in accordance with good manufacturing or feeding practices; stannous chloride</strong></td>
<td>Not to exceed 0.0015% calculated as tin</td>
<td>FDA 2003g 21 CFR 582.3845</td>
</tr>
<tr>
<td>d. Other</td>
<td><strong>Carcinogenicity classification</strong></td>
<td>A⁴⁹</td>
<td>ACGIH 2003</td>
</tr>
<tr>
<td>ACGIH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td></td>
<td>D¹¹</td>
<td>IRIS 2005</td>
</tr>
</tbody>
</table>
# Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>RfD</td>
<td>Bis(tributyltin oxide)</td>
<td>3\times 10^{-4} mg/kg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bis(tributyltin oxide)</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td>RFC</td>
<td>Community right-to-know;</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>release reporting; effective date of reporting</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bis(tributyltin oxide)</td>
<td>01/01/95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Triphenyltin chloride</td>
<td>01/01/95</td>
</tr>
<tr>
<td></td>
<td>Emergency release notification</td>
<td>Tin</td>
<td>EPA 2003d</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>40 CFR 355, Appendix A</td>
</tr>
<tr>
<td></td>
<td>Extremely hazardous</td>
<td>Trimethyltin chloride</td>
<td>Reportable quantity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Threshold planning quantity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Triphenyltin chloride</td>
<td>Reportable quantity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Threshold planning quantity</td>
</tr>
<tr>
<td></td>
<td>Municipal solid waste landfills; hazardous constituent; tin (total)</td>
<td>Method</td>
<td>6010</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PQL</td>
</tr>
<tr>
<td></td>
<td>Notification requirements of releases</td>
<td>Tin</td>
<td>EPA 2003b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Standards for owners and operators of hazardous waste TSD facilities; groundwater monitoring; tin (total)</td>
<td>Method</td>
<td>7870</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PQL</td>
</tr>
<tr>
<td></td>
<td>Effluent concentrations for Class D&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Air (µCi/mL)</td>
<td>2.0x10^-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Water (µCi/mL)</td>
<td>5.0x10^-5</td>
</tr>
<tr>
<td>USNRC</td>
<td></td>
<td>11^0Tin</td>
<td>3.0x10^-7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11^1Tin</td>
<td>1.0x10^-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11^3Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>2.0x10^-9 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11^5Tin</td>
<td>3.0x10^-9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11^7Tin</td>
<td>3.0x10^-5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11^9Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>3.0x10^-9 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19^mTin</td>
<td>6.0x10^-5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^1Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>2.0x10^-8 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^1Tin</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^1Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>1.0x10^-9 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^1Tin</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^3Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>9.0x10^-10 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^3Tin</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^3Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>2.0x10^-7 7.0x10^-4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^5Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>1.0x10^-9 No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^5Tin</td>
<td>No data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^5Tin (LLI wall)&lt;sub&gt;d&lt;/sub&gt;</td>
<td>8.0x10^-11 4.0x10^-6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^7Tin</td>
<td>3.0x10^-8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^7Tin</td>
<td>9.0x10^-5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12^8Tin</td>
<td>4.0x10^-8</td>
</tr>
</tbody>
</table>

<sup>c</sup> Concentrations for Class D facilities are specified by the US Nuclear Regulatory Commission (USNRC) as USNRC 2003.

<sup>d</sup> The LLI (low-level inventory) wall concentration limits (PQLs) are specified by the USNRC.

---

305 TIN AND TIN COMPOUNDS

8. REGULATIONS AND ADVISORIES
Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL (cont.)</strong></td>
<td>Effluent concentrations for Class W&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td>USNRC 2003</td>
</tr>
<tr>
<td>USNRC</td>
<td></td>
<td>Air (μCi/mL)</td>
<td>10 CFR 20, Appendix B</td>
</tr>
<tr>
<td></td>
<td>110&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>2.0x10&lt;sup&gt;-8&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>111&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>4.0x10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>113&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>8.0x10&lt;sup&gt;-10&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>117&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>2.0x10&lt;sup&gt;-9&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>119&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>1.0x10&lt;sup&gt;-9&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>121&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>2.0x10&lt;sup&gt;-8&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>121&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>8.0x10&lt;sup&gt;-10&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>123&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>2.0x10&lt;sup&gt;-10&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>123&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>2.0x10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>125&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>5.0x10&lt;sup&gt;-10&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>126&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>9.0x10&lt;sup&gt;-11&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>127&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>3.0x10&lt;sup&gt;-8&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>128&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>5.0x10&lt;sup&gt;-8&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Release to sewers for Class D&lt;sup&gt;c&lt;/sup&gt;; USNRC 2003</td>
<td>monthly average concentration</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>110&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>5.0x10&lt;sup&gt;-4&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>111&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>1.0x10&lt;sup&gt;-2&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>113&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>3.0x10&lt;sup&gt;-4&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>117&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>3.0x10&lt;sup&gt;-4&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>119&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>6.0x10&lt;sup&gt;-4&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>121&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>8.0x10&lt;sup&gt;-5&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>121&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>5.0x10&lt;sup&gt;-3&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>123&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>9.0x10&lt;sup&gt;-5&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>123&lt;sup&gt;m&lt;/sup&gt;Tin</td>
<td>7.0x10&lt;sup&gt;-3&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>125&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>6.0x10&lt;sup&gt;-5&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>126&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>4.0x10&lt;sup&gt;-5&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>127&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>9.0x10&lt;sup&gt;-5&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>128&lt;sup&gt;T&lt;/sup&gt;In</td>
<td>1.0x10&lt;sup&gt;-3&lt;/sup&gt; μCi/mL</td>
</tr>
<tr>
<td><strong>STATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Air</td>
<td>No data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Water</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Florida</td>
<td>Drinking water guideline</td>
<td>HSDB 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tin</td>
<td>4.2 mg/L</td>
</tr>
<tr>
<td></td>
<td>Minnesota</td>
<td>Drinking water guideline</td>
<td>HSDB 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tin</td>
<td>4.0 mg/L</td>
</tr>
</tbody>
</table>
Table 8-1. Regulations and Guidelines Applicable to Tin and Tin Compounds

<table>
<thead>
<tr>
<th>Agency (cont.)</th>
<th>Description</th>
<th>Information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Food</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Other</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*aSkin notation: refers to the potential significant contribution to the overall exposure by the cutaneous route, including mucous membranes and the eyes, either by contact with vapors or, of probable greater significance, by direct skin contact with the substance.
*A class designation
*cClass D: refers to the retention (clearance half-times of <10 days) for all compounds except those given for W.
*dWhen an ALI is defined by the stochastic dose limit, this value alone, is given. When an ALI is determined by the non-stochastic dose limit to an organ, the organ or tissue to which the limit applies is shown, and the ALI for the stochastic limit is shown in parentheses. (Abbreviated organ or tissue designations are used: LLI wall = lower large intestine wall; St. wall = stomach wall; Blad wall = bladder wall; and Bone surf = bone surface.)
*eThe ALIs and DACs for inhalation are given for an aerosol with an activity median aerodynamic diameter (AMAD) of 1 μm and for class D and W of radioactive material, which refers to their retention (clearance half-times of <10 days and 10–100 days, respectively) in the pulmonary region of the lung.
*fClass W: refers to the retention (clearance half-times of 10–100 days) for sulfides, oxides, hydroxides, halides, nitrates, and stannic phosphate.
*gA4: not classifiable as a human carcinogen
*hD: not classifiable as to human carcinogenicity

ACGIH = American Conference of Governmental Industrial Hygienists; ALI = annual limits on intakes; CFR = Code of Federal Regulations; DAC = derived air concentration; EPA = Environmental Protection Agency; FDA = Food and Drug Administration; GRAS = generally recognized as safe; HSDB = Hazardous Substances Data Bank; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; LLI = lower large intestine; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; PQL = practical quantitation limit; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term exposure level; TLV = threshold limit values; TSD = treatment, storage, and disposal; TWA = time-weighted average; USNRC = Nuclear Regulatory Commission; WHO = World Health Organization
9. REFERENCES


* Cited in text
**9. REFERENCES**


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


320 TIN AND TIN COMPOUNDS

9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


*Iwamoto I. 1960. [Experimental studies on the influence of butyltin poisoning through the respiratory tract upon the reproductive function.] J Tokyo Med College 18:1351-1376. (Japanese)


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


343 TIN AND TIN COMPOUNDS

9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


*Pelikan Z, Cerny E. 1968. [The toxic effect of tri-n-butyl-tin compounds on white mice.] Arch Toxicol 23:283-292. (German)


9. REFERENCES


Pieters RHH, Bol M, Lam BW, et al. 1992. The organotin-induced thymus atrophy, characterized by depletion of CD4+CD8+ thymocytes, is preceded by a reduction of the immature CD4-CD8-TCRalphaß/low-CD2high thymoblast subset. Immunology 76:203-208.


9. REFERENCES


9. REFERENCES


9. REFERENCES


TIN AND TIN COMPOUNDS

9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


**9. REFERENCES**


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


9. REFERENCES


10. GLOSSARY

**Absorption**—The taking up of liquids by solids, or of gases by solids or liquids.

**Acute Exposure**—Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological Profiles.

**Adsorption**—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

**Adsorption Coefficient (K_{oc})**—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

**Adsorption Ratio (K_{d})**—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

**Benchmark Dose (BMD)**—Usually defined as the lower confidence limit on the dose that produces a specified magnitude of changes in a specified adverse response. For example, a BMD{\textsubscript{10}} would be the dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 10%. The BMD is determined by modeling the dose response curve in the region of the dose response relationship where biologically observable data are feasible.

**Benchmark Dose Model**—A statistical dose-response model applied to either experimental toxicological or epidemiological data to calculate a BMD.

**Bioconcentration Factor (BCF)**—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

**Biomarkers**—Broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility.

**Cancer Effect Level (CEL)**—The lowest dose of chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

**Carcinogen**—A chemical capable of inducing cancer.

**Case-Control Study**—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without outcome.

**Case Report**—Describes a single individual with a particular disease or exposure. These may suggest some potential topics for scientific research, but are not actual research studies.

**Case Series**—Describes the experience of a small number of individuals with the same disease or exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.

Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome. At least one exposed group is compared to one unexposed group.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at one point in time.

Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human health assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the adverse effects.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero death.

Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from the body or environmental media.

Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or irreversible health effects.

Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.

Incidence—The ratio of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In Vivo—Occurring within the living organism.

Lethal Concentration\textsubscript{LO} (LC\textsubscript{LO})—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration\textsubscript{50} (LC\textsubscript{50})—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose\textsubscript{LO} (LD\textsubscript{LO})—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose\textsubscript{50} (LD\textsubscript{50})—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time\textsubscript{50} (LT\textsubscript{50})—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific population.

Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified interval of time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a chemical.

No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Effects may be produced at this dose, but they are not considered to be adverse.

Octanol-Water Partition Coefficient ($K_{ow}$)—The equilibrium ratio of the concentrations of a chemical in $n$-octanol and water, in dilute solution.

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound and especially a pesticide that acts by inhibiting cholinesterase.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests.

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic endpoints. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

**Prevalence**—The number of cases of a disease or condition in a population at one point in time.

**Prospective Study**—A type of cohort study in which the pertinent observations are made on events occurring after the start of the study. A group is followed over time.

$q_1^*$—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the multistage procedure. The $q_1^*$ can be used to calculate an estimate of carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually $\mu g/L$ for water, mg/kg/day for food, and $\mu g/m^3$ for air).

**Recommended Exposure Limit (REL)**—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

**Reference Concentration (RfC)**—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation reference concentration is for continuous inhalation exposures and is appropriately expressed in units of mg/m$^3$ or ppm.

**Reference Dose (RfD)**—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level (NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nontreshold effects such as cancer.

**Reportable Quantity (RQ)**—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

**Reproductive Toxicity**—The occurrence of adverse effects on the reproductive system that may result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

**Retrospective Study**—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

**Risk**—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes continually. No more than four excursions are allowed per day, and there must be at least 60 minutes between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may not be exceeded.

Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

Teratogen—A chemical that causes structural defects that affect the development of an organism.

Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit (STEL), or as a ceiling limit (CL).

Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour workday or 40-hour workweek.

Toxic Dose\(_{50}\) (TD\(_{50}\))—A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.

Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.

Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic average of 10 and 1.

Xenobiotic—Any chemical that is foreign to the biological system.
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333.
MINIMAL RISK LEVEL WORKSHEET

Chemical Name: Tin
CAS Numbers: 7440-31-5
Date: April 2005
Profile Status: Final Post-Public Comment
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 13
Species: Rat

Minimal Risk Level: 0.3 [X] mg/kg/day [ ] ppm


Experimental design: The effect of stannous chloride was studied in male and female Wistar rats (10/sex/dose level) for 13 weeks at dietary levels of 0, 300, 1,000, 3,000, and 10,000 ppm. Using a conversion dietary factor of 0.05 kg food/kg body weight/day and the molecular weight of 118.69 for tin, it can be estimated that the diet provided approximate doses of 0, 9.5, 32, 95, or 315 mg Sn/kg/day. End points monitored included: survival, body weight, food intake, hematology (hemoglobin, hematocrit, total erythrocytes, total and differential leukocytes), serum chemistry (transaminases, alkaline phosphatase, bilirubin), urinalysis, organ weights (nine organs), and gross and microscopic pathology. Tin in the standard diet was not determined, but the concentrations of calcium, phosphorus, iron, copper, and zinc were known. The concentrations of these minerals were consistent with the concentrations in standard rat’s diets, except for the amount of zinc, which was about 50% of that found in the standard diet.

Effect noted in study and corresponding doses: The highest dietary level (315 mg Sn/kg/day) caused reduced food consumption and abdominal distension on week 1. At week 8, loss of body weight occurred in males and females, and one male died. At week 9 another three males died and the group was discontinued. Rats in the 95 mg/kg/day level showed poor appetite and abdominal distension the first 2 weeks; this was associated with decreased food consumption, but they kept growing. At termination, no significant differences in body weights were seen. Food consumption was low also at 32 mg/kg/day, but only on week 1. Hemoglobin concentration was significantly reduced starting at week 4 at 95 and 315 mg/kg/day (about 12 and 20%, respectively) and only at week 4 in 32 mg/kg/day males (3% reduction). Terminal hemoglobin and hematocrit were significantly reduced only in high-dose males (6 and 4%, respectively). Tin had no noticeable effect on osmotic resistance of the erythrocytes or on the number of reticulocytes. Serum alkaline phosphatase was significantly decreased at termination in both sexes but there was no significant effect on transaminases or in bilirubin. Terminal urine samples were unremarkable, as were relative organ weights. Rats from the high-dose group which had to be terminated early showed distended intestines, slight edema of the pancreas, and grayish-brown livers. There was moderate testicular degeneration, severe pancreatic atrophy, spongy white matter in the brain, acute bronchopneumonia, enteritis and liver changes characterized by homogeneous appearance of the liver cell cytoplasm and mild proliferation of the bile duct epithelium. In the other groups at termination, treatment-related effects included bile duct epithelium proliferation and homogeneous cytoplasm at 95 mg/kg/day. The 95 mg/kg/day dose level is considered a minimal LOAEL based on the unknown biological significance of a transient 12% reduction in hemoglobin concentration.

Dose and end point used for MRL derivation: 32 mg/kg/day; decreased hemoglobin concentration.

[X] NOAEL [ ] LOAEL
Uncertainty Factors used in MRL derivation:

[ ] 10 for use of a LOAEL  
[ ] 10 for extrapolation from animals to humans  
[X] 10 for human variability

Was a conversion factor used from ppm in food or water to a mg/body weight dose?  
Yes.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: NA

Was a conversion used from intermittent to continuous exposure?  
No

Other additional studies or pertinent information that lend support to this MRL: The effects of the administration of stannous chloride, stannous orthophosphate, stannous sulfate, and stannous tartrate at the same dietary levels as above in the diet of rats for 4 weeks are in agreement with the data from the 13-week study (De Groot et al. 1973). The LOAELs for body weight gain, depressed hemoglobin and hematocrit values, and liver histopathology at 4 weeks were seen with the 3,000 ppm diet in males. The NOAEL was the 1,000 ppm diet. With the orthophosphate and tartrate salts, the differences in hemoglobin and hematocrit were not significant with the 3,000 ppm diet, but were significant with the 10,000 ppm diet.

Janssen et al. (1985) reported a LOAEL of 7.9 mg/kg/day for significant decreases in hemoglobin in rats fed a diet containing stannous chloride for 28 days. However, the standard diet contained only 20% of the copper reported for the diet in the De Groot et al. (1973) study. The lower concentrations of these minerals may have made the rats in the Janssen et al. (1985) study more susceptible to the effects of tin on hematopoiesis. Transient hemolytic anemia was also reported in rabbits administered 10 mg tin/kg/day (as stannous chloride), the only dose level tested, by gavage for 4 months (Chmielnicka et al. 1993). However, no information was provided in that study regarding the trace mineral composition of the diet.

Agency Contact (Chemical Manager): Carolyn Harper, Ph.D.
MINIMAL RISK LEVEL WORKSHEET

Chemical Name: Dibutyltin dichloride  
CAS Number: 683-18-1  
Date: April 2005  
Profile Status: Final Post-Public Comment  
Route: [X] Oral  
Duration: [X] Intermediate  
Graph Key: 28  
Species: Rat  
Minimal Risk Level: 0.005 mg/kg/day  

Experimental design: Groups of male and female weanling Wistar rats (5–10/group) were fed diets containing 0, 50, or 150 ppm of the test material (>98% pure) for 4–6 weeks. Based on a body weight of 0.2 kg, it can be estimated that these levels provided doses of dibutyltin dichloride of approximately 0, 5, and 15 mg/kg/day (EPA 1988). End points examined included body weight and parameters of humoral and cellular immune responses. The humoral immune response was assessed by measuring formation of antibodies against SRBC and \textit{E. coli} lipopolysaccharide. Rats were immunized intraperitoneally with SRBC 5 days before termination of the experiments. The cellular immune response was assessed by examining allograft rejection (rats were grafted at week 7).

Effects noted in study and corresponding doses: Final body weight after 4 weeks of exposure was not significantly altered relative to controls, but it was 28% lower than controls in the high-dose group after 6 weeks of exposure. Allograft rejection time was significantly delayed in the high-dose group relative to controls. In the tests for humoral response, the number of antibody-producing cells per million spleen cells was not affected, but the number per whole spleen was significantly decreased in a dose-related manner. This response was associated with a decreased hemagglutination titer in the high-dose group. The antibody titers against \textit{E. coli} lipopolysaccharide were slightly but not significantly lower in treated groups than in controls. The dose of 5 mg/kg/day is the study LOAEL based on the reduction in hemagglutinating antibodies against SRBC.

Dose and end point used for MRL derivation: 5.0 mg/kg/day; immunological effects.

[X] LOAEL

Uncertainty Factors used in MRL derivation:

[X] 10 for use of a LOAEL  
[X] 10 for extrapolation from animals to humans  
[X] 10 for human variability

Was a conversion factor used from ppm in food or water to a mg/body weight dose?  
Yes. A food factor of 0.1 kg food/day/kg body weight was calculated using a body weight of 0.2 kg (from study) in an allometric equation (EPA 1988).

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: NA
Was a conversion used from intermittent to continuous exposure?
No

Other additional studies or pertinent information that lend support to this MRL: Limited additional information was available for dibutyltin dichloride from intermediate-duration studies. Gaunt et al. (1968) conducted a 90-day dietary general toxicity and histopathology study in rats and found no significant effects other than a slight reduction in hemoglobin with the highest dose tested (5.7 mg/kg/day); no effect was seen at 3.4 mg/kg/day. Although the Gaunt et al. (1968) study defined a NOAEL and, possibly a minimal LOAEL, the immunological alterations reported in the Seinen et al. (1977b) study are preferred as basis for the intermediate-duration oral MRL because of the known immunotoxic properties of dibutyltins (i.e., Seinen et al. 1977a) and tributyltins (dibutyltin is a metabolite of tributyltin; Matsuda et al. 1993; Ueno et al. 1994). In two acute-duration oral studies in rats, serious LOAEIs were described at or below the 5 mg/kg/day intermediate-duration LOAEL from Seinen et al. (1977b). In Ema et al. (1991b), 5 mg/kg/day was a serious developmental LOAEL and in Ema and Harazono (2000), 3.8 mg/kg/day was a serious reproductive LOAEL. However, in these two studies, the rats were treated with dibutyltin dichloride by gavage in oil, and the bolus administration may have contributed to the severity of the effects.

Agency Contact (Chemical Manager): Carolyn Harper, Ph.D.
**MINIMAL RISK LEVEL WORKSHEET**

<table>
<thead>
<tr>
<th>Chemical Name:</th>
<th>Tributyltin oxide</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS Number:</td>
<td>56-35-9</td>
</tr>
<tr>
<td>Date:</td>
<td>April 2005</td>
</tr>
<tr>
<td>Profile Status:</td>
<td>Final Post-Public Comment</td>
</tr>
<tr>
<td>Route:</td>
<td>[ ] Inhalation  [X] Oral</td>
</tr>
<tr>
<td>Duration:</td>
<td>[ ] Acute  [X] Intermediate  [ ] Chronic</td>
</tr>
<tr>
<td>Graph Key:</td>
<td>66</td>
</tr>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
</tbody>
</table>

**Minimal Risk Level:** 0.0003 [X] mg/kg/day  [ ] ppm


**Experimental design:** Groups of male Wistar rats were fed a diet containing 0, 0.5, 5, or 50 ppm tributyltin oxide (95.3% pure) for 4.5–6 months. This diet provided approximately 0, 0.025, 0.25, and 2.5 mg/kg/day of the tin compound. Parameters of specific resistance evaluated included IgM and IgG response to ovalbumin and delayed-type hypersensitivity (DTH) response to ovalbumin and tuberculin after 6 months of treatment; resistance to *Trichinella spiralis* infection after 5.5 months; mitogenic response of thymus and spleen cells after 4.5 months; and surface marker analysis of mesenteric lymph nodes after 6 months. Parameters of nonspecific resistance examined included clearance of *Listeria monocytogenes* from the spleen after injection at 5 months and natural cell-mediated cytotoxicity of spleen and peritoneal cells after 4.5 months.

**Effects noted in study and corresponding doses:** Neither body weight nor spleen weight were significantly altered after 4.5 months of treatment, but thymus weight was reduced by 17% relative to controls in the high-dose group. Neither the IgM nor IgG response to ovalbumin and *T. spiralis* were altered after 5.5 months of exposure. The immunoglobulin E (IgE) responses to *T. spiralis*, as determined by the passive cutaneous anaphylaxis reaction, were suppressed in a dose-related manner (significant in the mid- and high-dose groups). The DTH reactions to ovalbumin and tuberculin were not significantly altered after 6 months of dosing. There was an increase in the number of larvae *T. spiralis* in muscle after infection in the mid- and high-dose groups after 5.5 months of exposure to the tin compound. No significant effect was observed on the response of spleen cells to T- and B-mitogens after 4.5 months. The cell surface marker analysis of mesenteric lymph node cells showed a reduction in the relative count of T-lymphocytes and an increase in the percentage of B-lymphocytes in the mid- and high-dose groups after 6 months of treatment. The *in vivo* clearance of *L. monocytogenes* was impaired in the high-dose group after 5 months of treatment. Treatment with tributyltin oxide did not induce a consistent effect on the natural killer cell activity of spleen and peritoneal cells after 4.5 months of exposure (decreased in the low- and high-dose groups, and increased in the mid-dose group). Based on the depression of IgE titers and increased *T. spiralis* in muscle after 5.5 months of exposure to tributyltin oxide, the study LOAEL is 0.25 mg/kg/day and the NOAEL is 0.025 mg/kg/day.

**Dose and end point used for MRL derivation:** 0.025 mg/kg/day; immunological effects.

[X] NOAEL  [ ] LOAEL
App 2

1. **Uncertainty Factors used in MRL derivation:**

- [ ] 10 for use of a LOAEL
- [X] 10 for extrapolation from animals to humans
- [X] 10 for human variability

2. **Was a conversion factor used from ppm in food or water to a mg/body weight dose?**
   Yes, conversions were done by the study authors.

3. **If an inhalation study in animals, list conversion factors used in determining human equivalent dose:** NA

4. **Was a conversion used from intermittent to continuous exposure?**
   No

**Other additional studies or pertinent information that lend support to this MRL:** Numerous studies in animals have demonstrated that the main target for some alkyltin compounds, tributyltin among them, is the immune system, particularly the thymus (Boyer 1989; Seinen et al. 1977a, 1977b; Snoeij et al. 1985). Therefore, it is expected that additional intermediate-duration studies, which did not focus on the immune system, identified higher NOAELs. For example, a 4-week dietary study with tributyltin oxide in rats observed slight hematological abnormalities at 0.25 mg/kg/day and hepatic and body weight NOAELs at 1 mg/kg/day (Krajnc et al. 1984). That same study found a 17% in thymus weight at 1 mg/kg/day and a 35% decrease at 4 mg/kg/day. An additional study with tributyltin oxide reported reduced natural killer cell activity in rats at 1 mg/kg/day following 6 weeks of treatment (Van Loveren et al. 1990). In yet another rat study, Verdier et al. (1991) reported slight impairment in host resistance to L. monocytogenes following exposure to tributyltin oxide for 28 days at 5 mg/kg/day, but not at 1 mg/kg/day.

The NOAEL of 0.025 mg/kg/day of Vos et al. (1990) is supported by recent developmental studies with tributyltin chloride that evaluated systemic and immunologic parameters in the offspring of rats exposed to tributyltin chloride in utero (Gds 8-21), through the mother’s milk, and directly as young adults until the age of 90 days (Cooke et al. 2004; Tryphonas et al. 2004). The doses tested were 0, 0.025, 0.25, and 2.5 mg/kg/day. Neither body weights nor food consumption was affected in the dams. No effects were observed on litter size, pup weight at birth, sex ratio, or survival until weaning. Growth of the treated pups after weaning was slightly reduced (<10%) relative to controls and analysis of food consumption and weight gain showed that male pups converted feed into weight gain less effectively than females. No effects were seen on the weights of pup’s brain, kidney or adrenals, but there was a decrease in absolute and relative liver weight in 60-day-old females at 0.025 and 2.5 mg/kg/day, a decrease in absolute and relative liver weight in 90-day-old males at 2.5 mg/kg/day, decrease in absolute spleen weight in 30-day-old males at 2.5 mg/kg/day and in relative spleen weight in 60-day-old females at 2.5 mg/kg/day, and a decrease in relative thymus weight in 60-day-old females at 0.25 and 2.5 mg/kg/day and in absolute thymus weight in 30-day-old males at 2.5 mg/kg/day. No consistent treatment-related gross or microscopic lesions were observed in dams and pups. Clinical chemistry changes of potential biological importance included a decrease in serum amylose in 90-day-old males at 0.25 and 2.5 mg/kg/day and decreased T4, also in 90-day-old males at 2.5 mg/kg/day. Based on the changes in pup's organ weights and in clinical chemistry parameters, the 0.25 mg/kg/day dose is a LOAEL and 0.025 mg/kg/day a NOAEL. The reduced weight gain of the pups is not considered adverse because the difference with controls was less than 10%.

In the study of immunological parameters (Tryphonas et al. 2004), the only significant change in serum immunoglobulin levels that appeared dose-related was an increase in IgG at 0.25 and 2.5 mg/kg/day in 90-day-old males. Flow cytometric analysis of splenocytes showed a significant increase mean percent and absolute NK cell numbers in high-dose 30-day-old males and females, a decrease in the percentage,
but not in absolute numbers of CD4+8+ T cells in 60-day-old females, and an increase in the percentage of NK cells in 90-day-old males. The anti-SRBC IgM response was not affected by exposure to tributyltin. No significant alterations were observed in the lymphoproliferative activity of splenocytes in response to mitogen stimulation. The delayed-type hypersensitivity response (DTH) was not affected in 60-day-old females, but 90-day-old males showed a significant trend toward a decrease in DTH response with increasing doses of tributyltin. The assays for *L. monocytogenes* infectivity and NK cell activity did not give dose-related responses. Cytokine levels in serum were not affected. Gross examination of lymphoid tissues was unremarkable. The most consistent histological finding was mild to moderate cortical atrophy of the thymus, characterized by decreased numbers of cortical lymphocytes at 2.5 mg/kg/day at all ages.

*Agency Contact (Chemical Manager):* Carolyn Harper, Ph.D.
MINIMAL RISK LEVEL WORKSHEET

Chemical Name: Tributyltin oxide  
CAS Number: 56-35-9  
Date: April 2005  
Profile Status: Final Post-Public Comment  
Route: [ ] Inhalation  [X] Oral  
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic  
Graph Key: 79  
Species: Rat

Minimal Risk Level: 0.0003 [X] mg/kg/day  [ ] ppm


Experimental design: Groups of male Wistar rats were fed a diet containing 0, 0.5, 5, or 50 ppm tributyltin oxide (95.3\% pure) for 18 months. This diet provided approximately 0, 0.025, 0.25, and 2.5 mg/kg/day of the test material. Parameters of specific resistance evaluated included IgM and IgG response to sheep red blood cells (SRBC) after 16 months; IgM and IgG response to ovalbumin and the delayed-type hypersensitivity (DTH) response to ovalbumin and tuberculin after 15 months of treatment; resistance to \textit{T. spiralis} infection after 16.5 months; mitogenic response of thymus and spleen cells after 16.5 months; and surface marker analysis of mesenteric lymph nodes after 18 months. Parameters of nonspecific resistance examined included clearance of \textit{L. monocytogenes} from the spleen after injection at 17 months and natural cell-mediated cytotoxicity of spleen and peritoneal cells after 16 months.

Effects noted in study and corresponding doses: No information was provided regarding body weight or weight of the thymus and spleen at termination. Exposure to tributyltin oxide did not affect the primary IgM or the secondary response to SRBC after 16 months of dosing. Neither the IgM nor IgG response to ovalbumin and \textit{T. spiralis} were altered after 15 months of treatment, but the IgE responses to \textit{T. spiralis}, as determined by the passive cutaneous anaphylaxis reaction, was suppressed in a dose-related manner (significant in the mid- and high-dose groups). The DTH reactions to ovalbumin and tuberculin were not significantly altered after 16 months of dosing. There was an increase in the number of larvae \textit{T. spiralis} in muscle after infection in the mid- and high-dose groups after 16.5 months of exposure to the test material. No significant effect was observed on the response of spleen cells to T- and B-mitogens after 16 months. The cell surface marker analysis of mesenteric lymph node cells showed a reduction in the relative count of T-lymphocytes and an increase in the percentage of B-lymphocytes in the mid- and high-dose groups after 18 months of treatment. The \textit{in vivo} clearance of \textit{L. monocytogenes} was impaired in the high-dose group after 17 months of treatment. Treatment with tributyltin oxide for 16 months significantly reduced the natural killer cell activity of spleen and peritoneal cells, but there was no dose-response relationship. Based on the depression of IgE titers and increased \textit{T. spiralis} in muscle after 16.5 months of exposure to tributyltin oxide, the study LOAEL is 0.25 mg/kg/day and the NOAEL is 0.025 mg/kg/day.

Dose and end point used for MRL derivation: 0.025 mg/kg/day; immunological effects.

[X] NOAEL  [ ] LOAEL
Uncertainty Factors used in MRL derivation:

- [ ] 10 for use of a LOAEL
- [X] 10 for extrapolation from animals to humans
- [X] 10 for human variability

Was a conversion factor used from ppm in food or water to a mg/body weight dose?
Yes, conversions were done by the study authors.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: NA

Was a conversion used from intermittent to continuous exposure?
No

Other additional studies or pertinent information that lend support to this MRL: The findings from the intermediate-duration portion of the Vos et al. (1990) study support the longer-term observations. A 2-year bioassay with tributyltin oxide in rats described hepatic, renal, endocrine, and body weight effects with a dose level of 2.1 mg/kg/day and NOAELs for these effects are approximately 0.2 mg/kg/day (Wester et al. 1990). In that study there also were changes in immunoglobulin levels at 2.1 mg/kg/day throughout the study, namely: increase in IgA after 12 and 24 months, decrease in IgG in females after 3 and 13 months, and increase in IgM after 3, 12, and 24 months. No additional chronic-duration studies were located for tributyltin oxide.

Agency Contact (Chemical Manager): Carolyn Harper, Ph.D.
APPENDIX B. USER’S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

Chapter 3

Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.
LEGEND

See Sample LSE Table 3-1 (page B-6)

(1) **Route of Exposure.** One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.

(2) **Exposure Period.** Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.

(3) **Health Effect.** The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).

(4) **Key to Figure.** Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).

(5) **Species.** The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.

(6) **Exposure Frequency/Duration.** The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).

(7) **System.** This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.

(8) **NOAEL.** A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").
LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.

Reference. The complete reference citation is given in Chapter 9 of the profile.

CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.

Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

LEGEND

See Sample Figure 3-1 (page B-7)

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

Exposure Period. The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.

Health Effect. These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.

Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.

NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).

CEL. Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.
(18) **Estimated Upper-Bound Human Cancer Risk Levels.** This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels ($q_1^*$).

(19) **Key to LSE Figure.** The Key explains the abbreviations and symbols used in the figure.
### Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation

<table>
<thead>
<tr>
<th>Key to figure&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Species</th>
<th>System</th>
<th>NOAEL (ppm)</th>
<th>LOAEL (effect)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Less serious (ppm)</td>
<td>Serious (ppm)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>INTERMEDIATE EXPOSURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 d/wk</td>
<td>6 hr/d</td>
</tr>
<tr>
<td></td>
<td>Systemic</td>
<td></td>
<td></td>
<td>5 d/wk</td>
<td>6 hr/d</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>Rat</td>
<td>Resp</td>
<td>3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10 (hyperplasia)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nitschke et al. 1981</td>
</tr>
<tr>
<td>CHRONIC EXPOSURE</td>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>Rat</td>
<td></td>
<td>20</td>
<td>(CEL, multiple organs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wong et al. 1982</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>Rat</td>
<td>89–104 wk</td>
<td>10</td>
<td>(CEL, lung tumors, nasal tumors)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>NTP 1982</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>Mouse</td>
<td>79–103 wk</td>
<td>10</td>
<td>(CEL, lung tumors, hemangiosarcomas)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 d/wk</td>
<td></td>
<td>NTP 1982</td>
</tr>
</tbody>
</table>

<sup>a</sup> The number corresponds to entries in Figure 3-1.

<sup>b</sup> Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10<sup>-3</sup> ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
**Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation**

**Acute (<14 days)**
- Systemic
  - Death
  - Respiratory
  - Hematological

**Intermediate (15-364 days)**
- Systemic
  - Death
  - Hematological
  - Hepatic
  - Reproductive
  - Cancer

*Doses represent the lowest dose tested in each study that produced a tumorigenic response and do not imply the existence of a threshold for the cancer endpoint.*

---

**Legend:**
- k-Monkey
- g-Guinea Pig
- r-Rat
- h-Rabbit
- m-Mouse
- ◆ Cancer: Effect Level Animals
- ◈ LOAEL: More Serious Animals
- ◇ LOAEL: Less Serious Animals
- ◊ NOAEL: Animals
- ▲ Minimal Risk Level for effects other than Cancer
### APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>American Conference of Governmental Industrial Hygienists</td>
</tr>
<tr>
<td>ACOEM</td>
<td>American College of Occupational and Environmental Medicine</td>
</tr>
<tr>
<td>ADI</td>
<td>acceptable daily intake</td>
</tr>
<tr>
<td>ADME</td>
<td>absorption, distribution, metabolism, and excretion</td>
</tr>
<tr>
<td>AED</td>
<td>atomic emission detection</td>
</tr>
<tr>
<td>AFID</td>
<td>alkali flame ionization detector</td>
</tr>
<tr>
<td>AFOSH</td>
<td>Air Force Office of Safety and Health</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukemia</td>
</tr>
<tr>
<td>AOAC</td>
<td>Association of Official Analytical Chemists</td>
</tr>
<tr>
<td>AOEC</td>
<td>Association of Occupational and Environmental Clinics</td>
</tr>
<tr>
<td>AP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>APHA</td>
<td>American Public Health Association</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>atm</td>
<td>atmosphere</td>
</tr>
<tr>
<td>ATSDR</td>
<td>Agency for Toxic Substances and Disease Registry</td>
</tr>
<tr>
<td>AWQC</td>
<td>Ambient Water Quality Criteria</td>
</tr>
<tr>
<td>BAT</td>
<td>best available technology</td>
</tr>
<tr>
<td>BCF</td>
<td>bioconcentration factor</td>
</tr>
<tr>
<td>BEI</td>
<td>Biological Exposure Index</td>
</tr>
<tr>
<td>BMD</td>
<td>benchmark dose</td>
</tr>
<tr>
<td>BMR</td>
<td>benchmark response</td>
</tr>
<tr>
<td>BSC</td>
<td>Board of Scientific Counselors</td>
</tr>
<tr>
<td>C</td>
<td>centigrade</td>
</tr>
<tr>
<td>CAA</td>
<td>Clean Air Act</td>
</tr>
<tr>
<td>CAG</td>
<td>Cancer Assessment Group of the U.S. Environmental Protection Agency</td>
</tr>
<tr>
<td>CAS</td>
<td>Chemical Abstract Services</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CEL</td>
<td>cancer effect level</td>
</tr>
<tr>
<td>CELDS</td>
<td>Computer-Environmental Legislative Data System</td>
</tr>
<tr>
<td>CERCLA</td>
<td>Comprehensive Environmental Response, Compensation, and Liability Act</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>Ci</td>
<td>curie</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL</td>
<td>ceiling limit value</td>
</tr>
<tr>
<td>CLP</td>
<td>Contract Laboratory Program</td>
</tr>
<tr>
<td>cm</td>
<td>centimeter</td>
</tr>
<tr>
<td>CML</td>
<td>chronic myeloid leukemia</td>
</tr>
<tr>
<td>CPSC</td>
<td>Consumer Products Safety Commission</td>
</tr>
<tr>
<td>CWA</td>
<td>Clean Water Act</td>
</tr>
<tr>
<td>DHEW</td>
<td>Department of Health, Education, and Welfare</td>
</tr>
<tr>
<td>DHHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOE</td>
<td>Department of Energy</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DOL</td>
<td>Department of Labor</td>
</tr>
<tr>
<td>DOT</td>
<td>Department of Transportation</td>
</tr>
</tbody>
</table>
NA/IMCO

DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F₁ first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koon organic carbon partition coefficient
K o/w octanol-water partition coefficient
L liter
LC liquid chromatography
LC₅₀ lethal concentration, 50% kill
LCLo lethal concentration, low
LD₅₀ lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT₂₀ lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCLG</td>
<td>maximum contaminant level goal</td>
</tr>
<tr>
<td>MF</td>
<td>modifying factor</td>
</tr>
<tr>
<td>MFO</td>
<td>mixed function oxidase</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>mm</td>
<td>millimeter</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeters of mercury</td>
</tr>
<tr>
<td>mmol</td>
<td>millimole</td>
</tr>
<tr>
<td>mppcf</td>
<td>millions of particles per cubic foot</td>
</tr>
<tr>
<td>MRL</td>
<td>Minimal Risk Level</td>
</tr>
<tr>
<td>MS</td>
<td>mass spectrometry</td>
</tr>
<tr>
<td>NAAQS</td>
<td>National Ambient Air Quality Standard</td>
</tr>
<tr>
<td>NAS</td>
<td>National Academy of Science</td>
</tr>
<tr>
<td>NATICH</td>
<td>National Air Toxics Information Clearinghouse</td>
</tr>
<tr>
<td>NATO</td>
<td>North Atlantic Treaty Organization</td>
</tr>
<tr>
<td>NCE</td>
<td>normochromatic erythrocytes</td>
</tr>
<tr>
<td>NCEH</td>
<td>National Center for Environmental Health</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>ND</td>
<td>not detected</td>
</tr>
<tr>
<td>NFPA</td>
<td>National Fire Protection Association</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NIEHS</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>NIOSH</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>NIOSHTIC</td>
<td>NIOSH's Computerized Information Retrieval System</td>
</tr>
<tr>
<td>NLM</td>
<td>National Library of Medicine</td>
</tr>
<tr>
<td>nm</td>
<td>nanometer</td>
</tr>
<tr>
<td>nmol</td>
<td>nanomole</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>NOES</td>
<td>National Occupational Exposure Survey</td>
</tr>
<tr>
<td>NOHS</td>
<td>National Occupational Hazard Survey</td>
</tr>
<tr>
<td>NPD</td>
<td>nitrogen phosphorus detection</td>
</tr>
<tr>
<td>NPDES</td>
<td>National Pollutant Discharge Elimination System</td>
</tr>
<tr>
<td>NPL</td>
<td>National Priorities List</td>
</tr>
<tr>
<td>NR</td>
<td>not reported</td>
</tr>
<tr>
<td>NRC</td>
<td>National Research Council</td>
</tr>
<tr>
<td>NS</td>
<td>not specified</td>
</tr>
<tr>
<td>NSPS</td>
<td>New Source Performance Standards</td>
</tr>
<tr>
<td>NTIS</td>
<td>National Technical Information Service</td>
</tr>
<tr>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>ODW</td>
<td>Office of Drinking Water, EPA</td>
</tr>
<tr>
<td>OERR</td>
<td>Office of Emergency and Remedial Response, EPA</td>
</tr>
<tr>
<td>OHM/TADS</td>
<td>Oil and Hazardous Materials/Technical Assistance Data System</td>
</tr>
<tr>
<td>OPP</td>
<td>Office of Pesticide Programs, EPA</td>
</tr>
<tr>
<td>OPPT</td>
<td>Office of Pollution Prevention and Toxics, EPA</td>
</tr>
<tr>
<td>OPPTS</td>
<td>Office of Prevention, Pesticides and Toxic Substances, EPA</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>OSHA</td>
<td>Occupational Safety and Health Administration</td>
</tr>
<tr>
<td>OSW</td>
<td>Office of Solid Waste, EPA</td>
</tr>
<tr>
<td>OTS</td>
<td>Office of Toxic Substances</td>
</tr>
<tr>
<td>OW</td>
<td>Office of Water</td>
</tr>
</tbody>
</table>
OWRS  Office of Water Regulations and Standards, EPA
PAH  polycyclic aromatic hydrocarbon
PBPD  physiologically based pharmacodynamic
PBPK  physiologically based pharmacokinetic
PCE  polychromatic erythrocytes
PEL  permissible exposure limit
pg  picogram
PHS  Public Health Service
PID  photo ionization detector
pmol  picomole
PMR  proportionate mortality ratio
ppb  parts per billion
ppm  parts per million
ppt  parts per trillion
PSNS  pretreatment standards for new sources
RBC  red blood cell
REL  recommended exposure level/limit
RfC  reference concentration
RfD  reference dose
RNA  ribonucleic acid
RQ  reportable quantity
RTECS  Registry of Toxic Effects of Chemical Substances
SARA  Superfund Amendments and Reauthorization Act
SCE  sister chromatid exchange
SGOT  serum glutamic oxaloacetic transaminase
SGPT  serum glutamic pyruvic transaminase
SIC  standard industrial classification
SIM  selected ion monitoring
SMCL  secondary maximum contaminant level
SMR  standardized mortality ratio
SNARL  suggested no adverse response level
SPEGL  Short-Term Public Emergency Guidance Level
STEL  short term exposure limit
STORET  Storage and Retrieval
TD50  toxic dose, 50% specific toxic effect
TLV  threshold limit value
TOC  total organic carbon
TPQ  threshold planning quantity
TRI  Toxics Release Inventory
TSCA  Toxic Substances Control Act
TWA  time-weighted average
UF  uncertainty factor
U.S.  United States
USDA  United States Department of Agriculture
USGS  United States Geological Survey
VOC  volatile organic compound
WBC  white blood cell
WHO  World Health Organization
greater than
greater than or equal to
equal to
less than
less than or equal to
percent
alpha
beta
gamma
delta
micrometer
microgram
cancer slope factor
negative
positive
weakly positive result
weakly negative result
APPENDIX D. INDEX

AAS ................................................................. 291, 292, 293, 294, 295, 296, 297
absorbed dose .................................................. 204
active transport .................................................. 205
adipose tissue .................................................. 176, 276, 288
adrenal gland ................................................... 151
adrenals .......................................................... 127, 147
adsorbed .......................................................... 252, 256
adsorption ......................................................... 255, 256, 257, 259, 291
aerobic .............................................................. 290
alanine aminotransferase (see ALT) .................. 123
ALT ................................................................. 123, 155
ambient air .................................................... 261
anaerobic .......................................................... 259, 290
anemia .............................................................. 5, 13, 16, 118, 206, 207
antandrogenic .................................................. 196
antifouling agent ............................................. 247
aspartate aminotransferase (see AST) .............. 123
AST ................................................................. 123, 155
atomic absorption spectroscopy (see AAS) ........ 291, 292, 294, 296
bioavailability .................................................. 215, 257, 287
bioconcentration .............................................. 256, 257
bioconcentration factor ................................... 256
biodegradation .................................................. 252, 260
biomarker .......................................................... 203, 204, 220, 223, 291
blood cell count ............................................. 119
body weight effects ......................................... 130
breast milk ...................................................... 7, 175, 202, 284, 285, 289
cancer ............................................................ 5, 6, 13, 36, 149, 150, 158, 196, 201, 215, 224
carcinogen .......................................................... 307
carcinogenic .................................................... 13, 14, 16, 23, 24, 150, 151, 152, 215, 301
carcinogenicity ................................................ 6, 13, 151, 152, 158, 215, 301, 307
carcinomas ...................................................... 149, 215
cardiovascular .................................................. 30, 115, 155
cardiovascular effects ...................................... 115
chromosomal aberrations .................................. 161, 167
clearance .......................................................... 21, 22, 134, 185, 307
cleft palate ...................................................... 15, 145, 148
crustaceans ....................................................... 12, 271, 275, 276, 283
death ............................................................... 15, 23, 25, 112, 136, 152, 193, 212, 276, 278
deoxyribonucleic acid (see DNA) ..................... 162, 168
dermal effects .................................................. 33, 129, 156
desorption ........................................................ 257, 295
DNA ............................................................... 161, 162, 167, 168, 193, 203
dopamine ........................................................ 139, 147
elimination half-time ........................................ 182, 183, 185
elimination rate ............................................... 221
diabetes ............................................................ 15, 126, 127, 128, 195, 196, 197, 199, 202, 214, 217, 218, 223
<table>
<thead>
<tr>
<th>Term</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>endocrine effects</td>
<td>126</td>
</tr>
<tr>
<td>erythema</td>
<td>156</td>
</tr>
<tr>
<td>estrogen receptor</td>
<td>196</td>
</tr>
<tr>
<td>estrogenic</td>
<td>196</td>
</tr>
<tr>
<td>fetus</td>
<td>6, 174, 196, 200, 217, 223</td>
</tr>
<tr>
<td>fractional absorption</td>
<td>169</td>
</tr>
<tr>
<td>FSH</td>
<td>127, 197, 198, 206</td>
</tr>
<tr>
<td>gas chromatography (see GC)</td>
<td>291, 294, 296</td>
</tr>
<tr>
<td>gastrointestinal effects</td>
<td>5, 31, 116, 117, 223</td>
</tr>
<tr>
<td>GC</td>
<td>291, 293, 294, 295, 296, 297</td>
</tr>
<tr>
<td>general population</td>
<td>12, 15, 173, 203, 213, 220, 282, 285</td>
</tr>
<tr>
<td>genotoxic</td>
<td>13, 23, 161, 167, 212, 216</td>
</tr>
<tr>
<td>genotoxicity</td>
<td>161, 216</td>
</tr>
<tr>
<td>groundwater</td>
<td>249, 253, 254, 292, 305</td>
</tr>
<tr>
<td>half-life</td>
<td>203, 257, 259</td>
</tr>
<tr>
<td>hematological effects</td>
<td>13, 14, 16, 17, 32, 118, 119, 301</td>
</tr>
<tr>
<td>hepatic effects</td>
<td>32, 120, 121, 122, 125, 155, 213</td>
</tr>
<tr>
<td>high performance liquid chromatography (see HPLC)</td>
<td>294</td>
</tr>
<tr>
<td>hippocampus</td>
<td>15, 136, 138, 147, 159, 177, 191, 192, 201, 219, 225</td>
</tr>
<tr>
<td>HPLC</td>
<td>291, 293, 294, 295</td>
</tr>
<tr>
<td>hydrolysis</td>
<td>252, 260</td>
</tr>
<tr>
<td>ICP</td>
<td>292, 293, 294, 295, 296, 297</td>
</tr>
<tr>
<td>immune system</td>
<td>5, 19, 205, 218</td>
</tr>
<tr>
<td>immunological</td>
<td>14, 19, 21, 22, 23, 34, 131, 132, 135, 147, 151, 157, 201, 213, 214, 218, 301</td>
</tr>
<tr>
<td>immunological effects</td>
<td>14, 19, 21, 22, 34, 131, 132, 135, 201, 213, 214, 218, 301</td>
</tr>
<tr>
<td>inductively coupled plasma (see ICP)</td>
<td>291, 292, 294, 296</td>
</tr>
<tr>
<td>K&lt;sub&gt;ow&lt;/sub&gt;</td>
<td>257</td>
</tr>
<tr>
<td>LD&lt;sub&gt;50&lt;/sub&gt;</td>
<td>113, 114, 152</td>
</tr>
<tr>
<td>leukemia</td>
<td>161</td>
</tr>
<tr>
<td>limbic system</td>
<td>15, 191</td>
</tr>
<tr>
<td>lymphoreticular</td>
<td>132, 157</td>
</tr>
<tr>
<td>mass spectrometry (see MS)</td>
<td>291, 292, 294, 296</td>
</tr>
<tr>
<td>methylation</td>
<td>259, 260, 287</td>
</tr>
<tr>
<td>micronuclei</td>
<td>161, 167</td>
</tr>
<tr>
<td>milk</td>
<td>147, 202, 208, 218, 222, 223, 275, 276, 285, 289</td>
</tr>
<tr>
<td>MS</td>
<td>291, 292, 293, 294, 295, 296, 297</td>
</tr>
<tr>
<td>musculoskeletal effects</td>
<td>30, 120</td>
</tr>
<tr>
<td>myelin</td>
<td>14, 137, 189, 190, 193</td>
</tr>
<tr>
<td>neonatal</td>
<td>137, 170, 175, 176, 199</td>
</tr>
<tr>
<td>neurobehavioral</td>
<td>34, 196, 212, 220</td>
</tr>
<tr>
<td>neurochemical</td>
<td>202</td>
</tr>
<tr>
<td>neurodevelopmental</td>
<td>146, 202</td>
</tr>
<tr>
<td>norepinephrine</td>
<td>192</td>
</tr>
<tr>
<td>nuclear</td>
<td>225</td>
</tr>
<tr>
<td>ocular effects</td>
<td>33, 114, 129, 152, 157, 213</td>
</tr>
<tr>
<td>partition coefficients</td>
<td>257</td>
</tr>
<tr>
<td>pharmacodynamic</td>
<td>184</td>
</tr>
<tr>
<td>pharmacokinetic</td>
<td>13, 184, 185, 186, 200, 202, 219, 223</td>
</tr>
<tr>
<td>photolysis</td>
<td>260</td>
</tr>
<tr>
<td>pKa</td>
<td>258, 259</td>
</tr>
<tr>
<td>placenta</td>
<td>6, 199, 202, 217, 223</td>
</tr>
</tbody>
</table>
pyriform cortex ........................................................................................................................... 15, 138, 139
renal effects......................................................................................................................... 32, 124, 125, 126, 155, 214
retention ....................................................................................................................... 16, 123, 146, 170, 171, 178, 180, 189, 198, 205, 206, 246, 282, 304, 307
salivation ............................................................................................................................. 139
solubility .................................................................................................................................. 256, 286
spermatogonia .................................................................................................................. 142, 197
T3 ...................................................................................................................................................... 128, 196
T4 ...................................................................................................................................................... 127, 147, 196, 197
thymocytes ...................................................................................................................... 14, 193, 194
thyroid ............................................................................................................................................. 126, 127, 128, 149, 193, 196, 197
thyroxine ............................................................................................................................................. 21, 127
toxicokinetic .................................................................................................................. 23, 194, 220, 221, 222
tremors ...................................................................................................................................... 113, 138, 139
triiodothyronine .................................................................................................................. 196
TSH ...................................................................................................................................................... 127, 197
tumors ............................................................................................................................................. 149, 150, 151, 194, 215
UV ...................................................................................................................................................... 252, 259
vapor pressure ................................................................................................................. 252, 254, 256, 258, 286
volatilization ....................................................................................................................... 254
weanling ............................................................................................................................................. 19